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Introduction into Mitochondria and Mitochondrial Disease
Mitochondrial disorders are the most common cause of inherited metabolic disease, 
with an estimated prevalence of 1 in 5,000 to 1 in 8,500 live births.1,2 The genetic and 
consequently the biochemical background of these diseases varies widely, as do the 
clinical signs and symptoms.3 The clinical spectrum varies from neonatal fatal lactic 
acidosis, to paediatric multi-system diseases and adult oligo-system disorders, to 
dormant (asymptomatic) carriers. To date, no cure is available, but new substances 
aimed at providing a less poor disease outcome are under development.4 To judge the 
effectiveness of these compounds, clinical studies need to be executed. Previously, a 
Cochrane review on treatment studies in patients with mitochondrial disease stated 
that the quality of many of the previously performed studies is low.5 One of the main 
problems arising in these low quality studies includes the heterogeneity of the, often 
small-numbered, study population and the lack of sufficiently sensitive end points.
This thesis aims to select and validate both clinical and laboratory outcome measures 
for mitochondrial disease in children. In this introductory chapter, we illustrate the 
heterogeneity and complexity of mitochondrial medicine by providing information on 
the molecular background underlying mitochondrial disease and describing the hetero-
geneous phenotype. To illustrate the infancy of this field in clinical trial methodology, we 
will provide a short history on treatment studies in mitochondrial disease.
The Heterogeneity of Mitochondrial Disease
Three main characteristics of mitochondrial medicine are responsible for the 
complexity and heterogeneity of mitochondrial disease. First of all, mutations 
in any of the ~1,100 proteins involved in mitochondrial assembly, structure, 
function and maintenance may be involved in the pathogenesis of a mitochon-
drial disease. Furthermore, in case of a mutation in the mitochondrial DNA, the 
percentage in which the mutation is present (i.e. heteroplasmy) may vary between 
tissues or even within tissues. Finally, although mitochondria are present in all 
cells except for the erythrocytes, not all tissues seem to be equally sensitive to 
the failing mitochondria which can only partly explained by differences in tissue 
distribution of affected proteins.
Mitochondrial structure and function
Mitochondria are found in almost every cell in a varying number per cell type. For example, 
a human liver cell may contain 1,000-2,000 mitochondria per cell; whereas a mature 
erythrocyte contains none.6 Mitochondria exist, at least in dividing cells in culture and in 
neurons, in a dynamic mitochondrial network, showing constant fusion and fission.7 
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Mitochondria contain outer and inner membranes that are both composed of a phos-
pholipid bilayer and proteins (Figure 1). The outer mitochondrial membrane encloses 
the entire organelle and has a phospholipid:protein ratio of 1:1. It contains protein 
import machineries, protein channels that allow diffusion of small molecules into the 
mitochondrial inter-membranous space. The inner mitochondrial membrane has a 
very high (4:1) protein to phospholipid ratio and contains numerous proteins such as 
the respiratory chain complexes, adenosine triphosphate (ATP) synthase and protein 
and metabolite import machineries.8 The inner mitochondrial membrane is compart-
mentalised into numerous cristae, which greatly expand the surface area of the inner 
mitochondrial membrane, increasing the number of energy generating proteins and 
thereby the ability to produce ATP.9 This characteristic architecture of the mitochondrial 
inner membrane is thought to be maintained by the interaction of the mitochondrial 
contact site and cristae organising system which is closely related to both inner and 
outer mitochondrial membrane.10 The mitochondrial matrix is the space enclosed by the 
inner mitochondrial membrane. The matrix contains a highly-concentrated mixture of 
hundreds of enzymes, mitochondrial ribosomes, transfer (t)RNAs and several copies of 
mitochondrial DNA (mtDNA),11 which are double-stranded circular DNAs. 
Figure 1. 
Artist impression of a mitochondrion.
Mitochondria are involved in several metabolic processes such as haem synthesis, heat 
production, the storage and signalling of calcium ions, programmed cell death and 
steroid synthesis.12 The most prominent role of mitochondria, in the context of this 
thesis, however is to provide the cell with energy in the form of ATP.11 
ATP production from glucose occurs via glycolysis, the tricarboxylic acid (TCA) or Krebs 
cycle, the respiratory chain, and ATP synthase (the latter two are also known as the 
oxidative phosphorylation (OXPHOS) system; Figure 2 and 3). First, glucose is oxidised 
to pyruvate through glycolysis, which generates 2 ATPs. Then, pyruvate is actively 
transported into the mitochondrial matrix, where it is converted to acetyl-CoA via the 
pyruvate dehydrogenase complex (PDHC). Acetyl-CoA is substrate for the TCA cycle, 
which forms energy-rich metabolites such as flavin adenine dinucleotide, reduced form 
20
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(FADH), nicotinamide adenine dinucleotide, reduced form (NADH) and ATP.8 In the mito-
chondrial matrix, the electrons from the TCA cycle are transmitted through NADH to 
Complex I and subsequently to Coenzyme Q (CoQ10). Some electrons are transferred 
also via FADH and Complex II to CoQ10. CoQ10 transports the electrons to Complex III 
and via cytochrome c they move to Complex IV where they are ultimately transferred to 
molecular oxygen to form water. The energy released by the electron transport is used, 
by Complex I, III and IV, to pump protons into the inter-membrane space, building up 
a proton gradient across the inner mitochondrial membrane. Complex V or F0-F1 ATP 
synthase uses this proton gradient for phosphorylation of ADP to ATP.11 Part of the ATP 
is used by mitochondria themselves while the majority is transported into the cytosol. 
Transport of ATP to the cytosol is executed by the ADP/ATP transporter (or adenine 
nucleotide transporter, ANT).13
Figure 3.  
Artist impression of the oxidative phosphorylation system. From left to right Complex I, II, III, IV and V. 
Figure 2.  
Energy production. Glucose is converted to acetyl-CoA by glycolysis and PDHC. Acetyl-CoA is used in the TCA 
cycle to produced NADH and FADH, which can be used by the electron transport chain to build up a proton 
gradient across the mitochondrial inner membrane. 
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Molecular background of mitochondrial disease
The OXPHOS system (Complex I-V; Figure 3) is under dual genetic control, with the 
exception of Complex II, which is only encoded by nuclear genes. The mitochondrial 
DNA (mtDNA, Figure 4) encodes for 13 of the 168 structural polypeptides comprising 
the OXPHOS complexes (subunits of complexes I, III, IV and V), plus 2 ribosomal and 
22 transfer RNAs required for the partially autonomous mitochondrial translational 
apparatus.14 To date, over 260 pathogenic mutations and 120 large-scale rearrange-
ments have been identified in the mitochondrial genome and more than 170 in nuclear 
genes.4 The number of the latter has been steadily increasing since the introduction of 
whole-exome/whole-genome sequencing.15
Figure 4. 
Mitochondrial DNA. The small, circular mtDNA.
Inheritance of mtDNA mutations has three distinct characteristics: maternal uniparental 
inheritance, heteroplasmy and the threshold effect (Figure 5).11 Since mitochondria in 
the sperm cell are actively destroyed by ubiquitination during fertilisation, mtDNA and 
therefore mtDNA mutations are exclusively transmitted through the mother, to poten-
tially all her offspring. Since multiple copies of mtDNA are present per cell and mutant 
mtDNA often co-exists in the cell with normal mtDNA, the mutation may be present in 
various proportions (heteroplasmy) per mitochondrion and per cell. A high heteroplasmy 
percentage, as compared to wild-type mtDNA, may lead to biochemical alterations16 
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and signs and symptoms when exceeding a certain threshold. There is no consensus 
regarding the mutation load causing mitochondrial dysfunction or the possibility of 
tissue specifi city of this threshold, which also diff ers per mutation. Mitotic segregation, 
the random distribution of the mutation between daughter cells during mitosis, causes 
heteroplasmy to vary between organs. This variation between tissues not only compli-
cates the diagnostics,17,18 but also results in a heterogeneous involvement of organs.
 
Figure 5.  
Hallmarks of mitochondrial inheritance. When cells proliferate, random distribution of mtDNA across daughter 
cells (mitotic segregation, A) occurs. For the expression of a phenotype of mitochondrial dysfunction, the hetero-
plasmy percentage has to exceed a certain threshold (B). Pedigree illus-trating maternal inheritance (C). Since 
mitochondria are inherited via the oocyte, all children of mothers will be at risk of having the mtDNA mutation, 
whereas the son will not pass the mutation to his children. 
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Most of the genes involved in mitochondrial function and maintenance have been relo-
cated to the nuclear genome since pro-mitochondria entered the eukaryotic cell approx-
imately 1.5 billions of years ago. Therefore, mutations in nuclear DNA may directly affect 
components of the oxidative phosphorylation system, by hits in assembly genes, genes 
encoding proteins involved in mtDNA integrity, replication or mtDNA translation, but 
also in proteins involved in other functions of the mitochondrion, such as membrane 
lipid composition, mitochondrial quality control and mitochondrial dynamics. 
How to accomplish the diagnosis of a mitochondrial disorder
The diagnosis of a mitochondrial disease requires the merging of clinical, biochem-
ical and genetic data. Since mitochondria are present in virtually all cells, the clinical 
diagnostic work-up for a suspected mitochondrial disease includes thorough clinical 
evaluation, followed by medical history taking which always should include a detailed 
family history. All commonly affected organs should be screened (physical examination, 
imaging and electrophysiology) to obtain evidence of the level of multi-organ involve-
ment. The presence of suspicious or highly suspicious symptoms (Figure 6) indicates 
the clinical probability of a mitochondrial disease. Additional blood, urine and cerebral 
spinal fluid metabolic investigations may assist in discriminating mitochondrial disorders 
from other multi-system disorders, although none of the routinely applied biomarkers 
are 100% specific. Slightly to highly elevated lactate and alanine concentrations in 
blood and/or CSF are indicative of a mitochondrial disease.19 Of importance, normal 
blood lactate concentrations do not rule out a mitochondrial disease.20 The value of two 
recently discovered biomarkers, fibroblast growth factor 21 (FGF21) and growth and 
differentiation factor 15 (GDF15), will be studied in more depth in this thesis. 
Next to the clinical and metabolic investigations, the contemporary step in the estab-
lishment of a mitochondrial disease is the measurement of the maximal activity of the 
mitochondrial energy generating system. Mostly, skeletal muscle tissue is used for diag-
nostic purposes since muscle is a mitochondria-rich tissue and in most patients the 
skeletal muscles are affected. In patients with predominant liver or heart involvement, a 
biopsy of the affected tissue might be more informative. Cultured fibroblasts of patients 
are also analysed in routine diagnostics.23 To obtain a muscle sample, a needle biopsy 
of the vastus lateralis dextra muscle is performed in adults while in children preferably a 
surgically removed muscle biopsy is performed under general anaesthesia. 
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An alternative to this invasive procedure is the percutaneous conchotome muscle 
biopsy of the musculus tibialis anterior, which can be performed under local anaes-
thesia. Geographical breakdown determines whether the sample can be investigated 
immediately, often termed ’fresh’, or should be shipped to a well-equipped mitochondrial 
centre in frozen condition. Because the reliability of the measurements is higher in fresh 
muscle tissue and the activity of the whole energy generating system can be measured 
only in fresh muscle cells, it is recommended to analyse a fresh biopsy.24,25 Mitochon-
drial function can be measured applying various strategies; for example, radioactivity 
based assays to measure the CO2 production in the presence of diff erent substrates, 
substrate based-oxygen consumption assays and spectrophotometric analysis of ATP 
and enzymes and enzyme complexes.23,24 Following an enzyme defi ciency diagnosis, 
genetic analysis to confi rm the biochemical fi ndings is warranted. 
Figure 6. 
Suspicious and highly suspicious symptoms of mitochondrial disease. In light grey the suspicious symp-
toms, in dark grey the highly suspicious symptoms.
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In case of a clear mitochondrial syndrome or maternal relatives with a known mtDNA 
mutation, primary sequencing of the gene suspected to be mutated is recommended. 
In some conditions, like the m.3243A>G mutation, urine DNA analysis is more sensi-
tive compared to blood analysis.26,27 The order of the initial investigations (biochemical 
versus genetic) is currently changing with more rapid and cheaper genetic diagnostics. 
The biochemical verification of observed genetic alterations, however, is expected to 
become even more important to confirm the pathogenicity of a (new) mitochondrial 
disease mutation or mutations in genes of unknown function.
The phenotype of mitochondrial disorders
Mitochondrial disorders are often said to present ’at any age, with any symptom of 
any organ and in any mode of inheritance’.28 In general, mitochondrial diseases are 
progressive diseases and a substantial number of children with mitochondrial disease 
dies before puberty. Children presenting at early age generally have the worst prog-
nosis: of those presenting before the age of 6 months, about one third survives beyond 
their second birthday.29,30 Children with cardiac involvement, about 17 - 58% in of all 
paediatric cases,31-33 have highest morbidity with about 50% of children dying before 
the age of 12 years.31 The rate of the decline is unpredictable, even in patients with the 
same genetic background. There is no clear correlation between the clinical and the 
biochemical or genetic phenotype.31,34
Mitochondrial disorders can be classified based on the molecular defect, the biochem-
ical deficiency or the clinical signs and symptoms. The problem with classification 
based on molecular defect, is that some defects are very rare and that two patients 
with the same genetic defect, even those within the same family, may have a completely 
different phenotype and disease course.34 Classification based on biochemical deficien-
cies creates larger groups compared to the stratification based on molecular defects, 
but the lack of correlation to the clinical phenotype remains. Patients can also be classi-
fied based on well-defined mitochondrial syndromes. However, classification based on 
syndromes also creates small groups with a wide variety in underlying disease causes.35
In daily practice, most affected children don’t present with a full-blown syndrome, but 
mostly with a non-specific multi-system phenotype involving tissues requiring most en
ergy, such as the brain, retina, heart, kidney, and skeletal muscle.4 Roughly, two main 
clinical phenotypes can be observed: mitochondrial encephalopathy (with mainly central 
nervous system involvement) and mitochondrial myopathy (mainly muscle involvement). 
However in practice, most children have a combination of both phenotypes, either or 
not in combination with other affected organs or tissues (Figure 7). With the discovery 
of mutations in ’non-classical’ mitochondrial pathways, the phenotype associated with 
mitochondrial disease is rapidly expanding to cover dysmorphias, haematological and 
endocrine abnormalities, and many more.15 
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In some, but certainly not all patients, a specific mitochondrial syndrome can be 
observed. Sometimes, the clinical syndrome may give an indication on the genetic 
cause of the disease, as may be the case in patients with the m.3243A>G mutation 
associated with for example mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes (MELAS) or maternally inherited diabetes mellitus and deafness 
(MIDD). 
Figure 7.   
Multi-system involvement of mitochondrial disorders. In patients with mitochondrial disorders, the most 
commonly affected organs include (top down): brain, eye, ear, heart, liver, gastrointestinal system, nerves and 
skeletal muscle. 
Mitochondrial myopathy 
Mitochondrial myopathy is a heterogeneous entity with variable severity, aetiology and 
prognosis. Most patients present in early childhood with hypotonia and motor retar-
dation. At later age, symptoms of proximal myopathy leading to a positive Gower’s 
sign, exercise intolerance, ptosis and external ophthalmoplegia may become apparent. 
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Despite fatigue and sometimes mild concentration problems, intelligence is typically 
normal. Some patients may be severely limited in their daily activities and fully depen-
dent on wheelchairs and help from caretakers, while others manage to live a reasonably 
normal life despite their reduced physical capacities.29 Some patients develop multi-
system disease symptoms later in life, including cardiomyopathy, optic atrophy, or senso-
rineural deafness. 
Mitochondrial encephalopathy 
Patients with mitochondrial encephalopathy also present with a very heterogeneous 
phenotype, ranging from early fatal epilepsy syndromes to migraine and dementia at 
later age. Children typically present with psychomotor retardation and failure to thrive, 
either or not in combination with other neurological features such as hypotonia, spaticity 
and epilepsy.30 Depression, behaviour problems, and psychosis may complicate the 
course of the disease.36 Brain magnetic resonance imaging (MRI) may show specific or 
non-specific abnormalities,37 but most patients only have functional defects. Typically, 
patients are severely mentally retarded, attend a special school and remain dependent 
on caretakers.29 
Leigh syndrome
The prototype of mitochondrial encephalomyopathy is Leigh syndrome (Figure 8). The 
diagnosis of ’Leigh syndrome’ is made on a distinctive MRI picture with a symmet-
rical distribution of hyperintensities in the basal ganglia, either or not in combination 
with brainstem, thalamus, diencephalon, cerebellum and spinal cord lesions.38 Patients 
usually present within the first months or years of life with psychomotor retarda-
tion in combination with signs of brainstem or extrapyramidal dysfunction and lactic 
academia.38,39 Symptoms include neurological symptoms (muscle weakness, hypo-
tonia, dystonia, respiratory impairment, lethargy, ophthalmoparesis, optic atrophy, 
ataxia, dysphagia, cranial nerve palsies, and polyneuropathy) sometimes in combination 
with cardiomyopathy, diarrhoea, vomiting, anaemia or renal problems.38 Death occurs 
usually before adulthood as a consequence of respiratory failure caused by on-going 
brainstem dysfunction either or not in combination with increasing muscle dysfunc-
tion.38 From a functional perspective, these children are mostly wheelchair-bound and 
severely dependent on their caretakers. For examples, see Box 1. 
Box 1: Description of three cases with Leigh syndrome 
Rick is a 12-year-old boy suffering from Leigh syndrome due a homozygous mutation in MTFMT. 
His developmental age is approximately 2 years. He is sociable and able to communicate in short 
sentences. He is able to follow simple and single commands but his cooperation, attention span 
and understanding are limited. His neurological examination shows strabismus, decreased facial 
expression, proximal muscle weakness and mild spasticity in his legs. He has nocturnal ventilation 
and is not able to go to school due to tiredness. 
28
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Jack is a 12-year-old boy with Leigh syndrome due to a homozygous mutation in NDUFS7. He 
is able to communicate via eye movements but not through speech. Except for some involuntary 
movements of the face and his left arm, he is not able move. He has severe contractures of his 
joints and a mixed picture of atonia and spasticity. He is fed through a gastrostomy and has to be 
ventilated 24 hours a day because of central hypoventilation. 
Peter was 2 years old and carries a heterozygous mutation in NDUFS7. During an infectious 
episode at the age of 15 months, he was diagnosed with Leigh syndrome, based on a severe 
hypotonia and a characteristic MRI picture. After this period, his condition improved and he deve-
loped normally. The only abnormal sign on physical examination was an intention tremor. At the 
age of 28 months, his condition deteriorated acutely and he was admitted because of hypoventi-
lation. A week after the admission, he died from a central apnoea.
Figure 8.  
Leigh syndrome. Cartoon depicting symptoms that can be observed in patients with Leigh syndrome.
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The m.3243A>G mutation
Another mitochondrial disease entity illustrating the heterogeneity of mitochondrial 
disorders, are those caused by the 3243A>G nucleotide change in the mitochondrial 
DNA transfer RNA of Leucine (Figure 9). This point-mutation, classically known as the 
MELAS mutation, actually has a much wider spectrum of clinical phenotypes. Whereas 
high heteroplasmy levels are indeed associated with mitochondrial encephalopathy, 
lactic acidosis and stroke-like episodes (MELAS) syndrome, low to moderate hetero-
plasmy levels are associated with a huge variety of other phenotypes.40,41 Examples 
hereof include mitochondrial inherited diabetes and deafness (MIDD), cardiomyopathy, 
macular abnormalities, and myopathy. Where some patients may only become aware of 
the cause of their mild complaints through the diagnosis of a maternal family member, 
other patients present in early infancy and remain dependent on their caretakers life-
long. For examples, see Box 2. 
Box 2: Description of three cases with a m.3243A>G mutation.
Ralph is a 32-year-old man who started suffering from progressive hearing loss at the age of 
15 years. He had a history of slow motor and cognitive development. Six years after his first 
symptoms, he suffered from his first stroke-like episode with confusion, headache, and aphasia, 
followed by two stroke-like episodes at the age of 31 and 34 years of age. After the first stro-
ke-like-episode, his cognitive abilities declined and he suffered from epilepsy and migraine. At 
the age of 28 years, a severe hypertrophic cardiomyopathy with cardiac failure was detected, 
which only slowly improved after medication. A few years later, at the age of 30 years, he was 
admitted because of a severe diabetic ketoacidosis as a consequence of a diabetes de novo. The 
m.3243A>G mutation (>90% in muscle and 60% in leucocytes) was found as an explanation for 
his complaints. At this moment, Ralph is severely impaired in his activities of daily living and suffers 
from psychotic episodes. 
Rose, the 34-year-old sister of Ralph, was found to carry the m.3243A>G mutation (heterop-
lasmy percentage 40%) when her brother was diagnosed with MELAS syndrome. She suffers from 
migraine headaches, insulindependent diabetes mellitus, moderate deafness, and constipation. 
She has a very mild hypertrophic cardiomyopathy, but has no cardiac complaints. At physical 
examination, muscle atrophy and decreased muscle power are found. Her retina shows some 
hyperpigmentation. She contemplates prenatal genetic diagnostics for having a child on her own. 
The 60-years-old mother of Rose and Ralph has a heteroplasmy level of 20%. Her hearing is 
normal, and she has no diabetes mellitus, cardiomyopathy or myopathic complaints. 
Tom is the 9-year-old nephew of Ralph. Despite that he is not very good at school gymnastics and 
it took him 3.5 years to get his first swimming certificate, he has no complaints so far.
30
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Figure 9. 
Symptoms that can be observed in patients with the m.3243A>G mutation. A) MELAS syndrome; B) MIDD. Note 
the overlap between MIDD and MELAS syndrome.
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Mitochondrial Medicine: the long Road to Treatment
The term mitochondrion was proposed by Benda in 1898 to describe a group of 
subcellular organelles with faint, threadlike granules.42 The widely accepted endosym-
biont theory states that these small organelles resulted from the primordial ingestion of 
the energy-efficient and oxygen-detoxifying prokaryotic bacteria-like protomitochondria 
by prokaryotic cells.43 The importance of these organelles in metabolic function was 
only defined in the early 20th century through a series of experiments describing the role 
of these organelles in oxidative phosphorylation.44 
The first described patient with a mitochondrial disease was a young Swedish woman 
with severe hypermetabolism with electron microscopically abnormal mitochondria 
and loose coupling of oxidation and phosphorylation on examination of the muscle, 
reported by Ernster and Luft in 1962.45 This paper introduced the concept of mito-
chondrial medicine and numerous biochemical and histochemical assays allowing 
detection of mitochondrial function were developed and used to diagnose patients 
with mitochondrial disorders. Soon, the heterogeneity and multi-system nature of respi-
ratory chain disorders became clear and Shapira introduced the term ’mitochondrial 
encephalomyopathies’ to indicate disorders in which the oxidative phosphorylation was 
hampered.46 Several clinical syndromes were defined, such as MELAS and MERRF 
(myoclonus epilepsy with ragged red fibres) syndrome.
Although mitochondrial DNA (mtDNA) was first described in 1967, it was not until 
1988 that the first disease-causing mutation in this small molecule was discovered. The 
group of Harding and colleagues found the first large-scale single deletions in mtDNA in 
patients with mitochondrial myopathies,47 quickly followed by the discovery of a single 
gene mutation in mtDNA causing LHON.48 That first discovery was soon followed by 
many others and the mitochondrial disease ’molecular era’ had come.49 In the next 
decade, when approximately 100 mutations in mtDNA were listed, the first mutation in 
nuclear DNA was described in the small and nuclear encoded second complex of the 
respiratory chain, followed by the first mutation in Complex I by the Nijmegen group.50,51 
Increased knowledge about the structure, function and pathology of the OXPHOS 
system has led to some obvious intervention strategies. In 1989, the first patients with 
a primary coenzyme Q10 (CoQ10) biosynthesis defect was described. The first descrip-
tion reported some improvement in fatigue and alertness on CoQ10 supplementation 
(150 mg)52 whereas later studies report full recovery (up to 300 mg).31 Since then, only 
~75 cases have been described in literature, despite the systematic screening for these 
defects in muscle biopsies.53 More recently, allogeneic haematopoietic stem cell trans-
plantation and thereby reintroduction of the thymidine phosphorylase enzyme, was 
shown to be able to lower the toxic and disease causing thymidine and deoxyuridine 
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levels in blood in patients with mitochondrial neuro-gastro-intestinal encephalopathy 
(MNGIE).54,55 The promising results of successful allogeneic haematopoietic stem cell 
transplantation are however hampered by the high mortality rate of the procedure. 
Finally, stroke-like episodes in patients with MELAS syndrome were suggested to be 
caused by endothelial dysfunction.56 Since endothelial function is regulated by nitric 
oxide, a precursor of nitric oxide, L-arginine, was infused. This resulted in improve-
ment of headache and nausea during stroke-like episodes, prevention of stroke-like 
episodes when used prophylactically and in an increased total body maximal aerobic 
capacity.55-59 Unfortunately, all of these observations are non-blinded and performed in 
just a handful of patients. 
The above mentioned strategies only apply to a small proportion of all subjects with 
mitochondrial disease. Various new strategies, which may improve the lives of many 
more mitochondrial disease patients in the future, are under investigation. These strat-
egies include: i) prevention of transmission of gene defects to offspring; ii) replacement 
or repair of defective genes (gene therapy); iii) altering the balance between wild-type 
and mutated mtDNA; iv) controlled regulation of specific transcriptional regulators; v) 
inhibition of autophagy; and vi) metabolic manipulation.60 
Preventing transmission of known disease-causing mutations and/or known respira-
tory chain enzyme defects, by prenatal biochemical/genetic or pre-implantation genetic 
diagnostics or oocyte donation, is part of daily care.61,62 Mitochondrial donation, allowing 
women with mtDNA mutations to have children with their own nuclear DNA but with 
healthy mitochondria, has been approved by the House of Lords of the United Kingdom 
in 2015, is still in its infancy. 
Gene therapy, covering both the second and the third strategy, aims at i) targeted re-ex-
pression of the mutated gene to correct single mutations in either nuclear or mtDNA; 
ii) at manipulation of the heteroplasmy percentage using zinc fingers or transcription 
Activator-Like Effector Nucleases; or iii) at overexpression of proteins involved in the 
stability of mt-tRNA in case of mutations in genes encoding mt-tRNAs. Clinical trials 
testing the effectiveness of gene therapy, mostly in (non-mitochondrial) ocular disorders, 
are currently running.
The expression and amount of mitochondrial OXPHOS proteins (approach iv) can be 
influenced by e.g. transcription regulation or endurance training.63 For example, pathways 
controlling mitochondrial biogenesis can be targeted via peroxisome proliferator-activated 
receptor gamma (PPARγ) coactivators (PGC family), which activates several transcrip-
tion factors regulating the expression of OXPHOS genes. Both NAD-dependent protein 
deacetylase sirtuin 1 (SIRT1) and 5’adenosine monophosphate-activated protein kinase 
(AMPK), enzymes regulating the activity of PGC1α, the most well characterised enzyme 
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of the PGC family, are drugable enzymes. In a mouse model for mitochondrial disease, 
the upregulation of mitochondrial biogenesis by these activators showed improvement 
of both biochemical and clinical parameters.64,65 However, because of a lack of spec-
ificity of the consequences of transcription regulation, it is highly likely that more side 
effects apart from the already recognised hepatic steatosis will occur.66 Healthy subjects 
receiving the AMPK activator R118 showed altered mental status, hemodynamic insta-
bility and increased blood lactate concentrations, which was thought to be caused by 
mitochondrial dysfunction instead of increased mitochondrial function.67
Activation of autophagy (approach v), the recycling of degraded cellular organelles 
to warrant their quality, can be inhibited by rapamycin (sirolimus). The administra-
tion of rapamycin to a mouse model for mitochondrial disease both delayed disease 
progression and fatal outcome, and corrected several of the biochemical abnormalities 
observed in this mouse model.68 Also for this strategy, the long-term effects on organ-
elle quality are unknown and more investigations are indicated to elucidate the long 
term effect and side effects of rapamycin. 
Metabolic manipulation by the ketogenic diet aims at stimulating mitochondrial β-ox-
idation and providing ketones as an alternative substrate for brain, heart and skeletal 
muscle. This approach has shown variable effects in mice69,70 but was poorly tolerated 
by patients with mitochondrial myopathy, who uniformly showed severe muscle pain 
with elevated creatine kinase followed by progressive increase of serum myoglobin 
values.71 
The sixth approach also aims at counteracting specific derangements in cellular homeo-
stasis caused by mitochondrial dysfunction.4,60,72 Well-characterised alterations include 
increased reactive oxygen species production, altered redox-metabolism, alterations in 
the mitochondrial network architecture, diminished mitochondrial membrane potential 
and altered cellular mitochondrial calcium handling.
The most frequently studied consequence of mitochondrial dysfunction is an increased 
production of reactive oxygen species or radicals (ROS). ROS are a physiological 
by-product of metabolism and play an important physiological role in protein expression 
and regulation via various signalling pathways.73 If ROS production becomes higher 
than can be counterbalanced by the cell’s own anti-oxidant system,74,75 damage to 
proteins, lipids and DNA may occur, which is thought to have harmful effects on cellular 
and mitochondrial (ultra)structure, activity and matrix protein diffusion.3,74-77 To what 
extent ROS are involved in the pathophysiology of mitochondrial disease is still under 
debate.74,75 Despite the on-going controversies of ROS’ role in mitochondrial disease 
pathology, much effort is devoted to studying the effects of lowering (scavenging) ROS 
in mitochondrial disease models and patients. The clinically most well-studied scavenger 
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is CoQ10, which acts as an electron transporter in the mitochondrial respiratory chain 
where it transports electrons from Complex I and II to Complex III.78 The results of CoQ10 
supplementation in mitochondrial disorders other than CoQ10 biosynthesis defects are 
less convincing.79 A synthetic CoQ derivative, Idebenone (hydroxydecyl benzoquinone), 
is well studied in Leber Hereditary Optic Neuropathy (LHON),80,81 a mitochondrial disease 
that causes blindness in young adults as well as in Friedreich’s ataxia, a progressive, 
multi-system neurodegenerative disorder.82,83 On both diseases, no significant effect of 
idebenone was observed. EPI-743, another CoQ10 analogue combined with vitamin E, 
was shown to be safe in several open-label safety studies.73,74,84 These safety studies 
also report reversion of vision loss in six patients with LHON85,86 and improvement of 
gross motor function and general mitochondrial disease severity in 22 children with 
mitochondrial disease.84 The same company is currently testing another drug candi-
date, EPI-589, in a phase 1B.87 Bendavia, a drug targeted at cardiolipin within the 
inner mitochondrial membrane, also aims at reducing ROS production. The topical 
solution containing Bendavia, Ocuvia, was designed to treat ocular disorders such 
as LHON. Safety studies for both drugs are currently ongoing.87 Khondrion, located 
in Nijmegen, has developed KH176, a drug influencing ROS-redox metabolism, which 
showed a favourable safety profile in recent phase 1 study.87
Since no cure for most mitochondrial disorders is available yet, present day manage-
ment is focussed on secondary prevention, symptomatic treatment, rehabilitation, and 
psychological support. The management of a patient with a mitochondrial disease 
includes life-long advices regarding nutrition, medication, exercise, and recurrence risk 
as well as screening for common treatable complications of mitochondrial disease, 
such as cardiomyopathy, renal failure, and cardiac conduction defects. All of these 
preventive interventions still rely on empirical data and expert opinions. 

Problem definition
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Patients, their relatives and physicians are desperate to find any treatment that helps 
to cure or alleviate mitochondrial diseases. Until 1990, when the first randomised, 
placebo controlled clinical trial in mitochondrial diseases was performed,88 the ‘treat-
ment’ of patients was mostly based on rationally selected vitamins of which anecdotal 
evidence of effectiveness was available. These open-label studies typically involved 
a heterogeneous group of just a handful of patients reporting improved quality of life 
with the use of these vitamins. Since there were no obvious side effects, the need 
for evidence regarding their efficacy was never high on the agenda. In 2006, the first 
critical systematic review of the literature stated that most of the studies in patients with 
mitochondrial disease had inadequate trial design or a non-conclusive outcome.89 A 
few years later the number of trials had doubled, but the percentage of well designed 
and reported randomised clinical trials remained stable and extremely low (12 out of 
1,335 studies).5 This was the starting point for a more critical attitude towards open-
label studies in small groups and for the discussion on how to improve the quality of 
future studies.
Designing a clinical study to prove treatment effects in patients, and especially children, 
with mitochondrial disorders is challenging for many reasons (Box 3). Mitochondrial 
disorders are rare, heterogeneous diseases involving multiple organs and the clinical 
disease course is unpredictable, variable and often oscillating. Although the variability 
in affected organs and degree of handicap (illustrated by the cases in Box 1 and 2) 
may warrant grouping of patients into homogeneous clinical cohorts, both the external 
validation of the results of the trial and the potential to detect clinical benefit for a small 
group of patients with specific biochemical or genetic abnormalities are hampered when 
setting very strict inclusion criteria. Lastly, the unpredictable disease course requires 
such large cohorts that patient recruitment will be impossible despite the participation 
of multiple centres. 
Box 3: Hurdles in proving treatment effects in patients with mitochondrial disease
Rare disorders
Clinically, biochemically and genetically heterogeneous disorders
Clinical heterogeneity within one genetic entity, both in mtDNA and nDNA mutations
Unpredictable, variable and sometimes oscillating natural disease course
Multi-system disease with variable involvement of organs
Patients are often very disabled and unable to perform functional tests 
Abilities of patients vary widely 
Child-specific aspects
Children are developing and growing
Outcome measures for children mostly have a limited age range
Paediatric patients are often unable to communicate
Children have a shorter attention span and are less likely to follow the instructions completely
The cooperation required for some tests is highly dependent on the level of enthusiasm for the test
and the mental abilities of the child
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The use of robust end points relevant to and feasible for a large proportion of patients 
with mitochondrial disease may assist in widening the inclusion criteria of the trial and 
therefore increase its feasibility and the generalizability of the results. The end points 
that have been used so far have rarely been validated and do not always measure 
symptoms and complaints experienced by or relevant to the patient. Therefore, we 
sought to improve this aspect of clinical trial design by looking for reproducible, sensi-
tive and responsive clinical biomarkers indicative of disease severity.
Outcome measure selection for trials in patients with mitochondrial disease
In medicine, outcome measures are defined as instruments providing information about 
certain disease aspects, such as disease severity, response to therapy or remission 
of the disease.90 It is said that ‘Clinical trials are only as credible as their end points’,91 
since the success of the trial is based on the change in the primary end point. At this 
moment, the selection of outcome measures for clinical trials evaluating interventions 
with new drugs in patients with mitochondrial disorders is inefficient and not systemati-
cally addressed. As only those trials in which end points are assessed with valid instru-
ments provide meaningful data, the selection of a robust instrument for the targeted 
population should have the highest priority. Since the mitochondrial disease field has 
paid little attention to the selection of outcome measures, the selection and use of 
robust instruments will - as we expect - lead to an enormous increase in the quality of 
trials and significance of data. Here, I will elaborate on the strategy to identify and select 
instruments measuring clinically relevant aspects of health in children with mitochond-
rial disorders.
Identification of available instruments
Surely, the improvement in health and disability after the intended treatment should 
be experienced by and relevant to the patient. This is endorsed by regulatory authori-
ties such as the US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA), preferring the inclusion of clinically meaningful outcomes in clinical trials. 
How can we identify these relevant aspects of health to patients with mitochondrial 
disease? 
According to the World Health Organisation (WHO), health is a multi-dimensional 
construct: ‘a state of complete physical, mental and social well-being and not merely 
the absence of disease or infirmity’. Forty-six years after the rather non-specific but 
holistic definition of health, the WHO developed a framework for thinking about health 
in chronic conditions, taking into account the bio psychosocial aspect of human func-
tioning.92 This framework, the International Classification of Functioning, Disability 
and Health (ICF, Figure 10) with a separate version for children and youth (ICF-CY), 
comprises four dimensions: i) body functions; ii) body structure; iii) activities and parti-
cipation; and iv) environmental factors. 
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In the ICF-model, the severity of the experienced disability is seen as a dynamic, inter-
active process among the interconnected components of functioning in contextual 
factors.93 For example, an increase in muscle strength may not correlate with the daily 
functioning94 and may be irrelevant to a patient not able to adequately coordinate move-
ments. To systematically identify the complaints and limitation relevant to all, or at least 
a large majority of patients with mitochondrial disorders, the framework provided by the 
ICF may be of major assistance. 
Figure 10.  
The International Classification of Functioning, Disability and Health (ICF) framework. The structure 
of the ICF (left), filled out as an example for the symptoms, limitations and disabilities that can be observed 
in patients with mitochondrial disease (right). Note the interplay between the health condition on physical 
function, activity and participation on one side, and the influence of environmental and personal factors on the 
other. 
Health condition
Body Functions 
& 
Body Structure
Activities Participation
Environmental 
factors
Personal
factors
Mitochondrial disease
Psychomotor 
retardation, 
dystonia, 
constipation,
short stature, 
fatigue, muscle 
cramps, epilepsy, 
vomiting, etc. 
Unable to sit,
dress, play, 
feed, speak
Unable to go 
to school and 
participate in 
activities of the 
household
Availability of 
wheelchai, health 
care and financial 
resources       
Coping
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Selection of instruments
When the relevant aspects of the disease are known, instruments measuring the func-
tional and structural consequences of mitochondrial disease can be identified, as well 
as functional tests measuring the consequences of the disease on activities and parti-
cipation. The ICF-framework fails to identify two groups of instruments, namely those 
measuring quality of life and biomarkers. The latter should be indicative of disease 
severity and should change with disease progression or regression to be applicable as 
an outcome measure in clinical trials.
 
Subsequent selection of the most adequate instrument should be based on the internal 
properties of the instrument in the intended population. Validation studies seek to 
explore these internal properties of a certain instrument, including feasibility, reliability, 
validity and responsiveness (Table 1 and Figure 11).95-99 The reliability (precision) of an 
instrument is the extent to which scores for patients who have not changed are the 
same for repeated measurements under several conditions, using different sets of items 
from the same multi-item measurement instrument (internal consistency), over time 
(test-retest), by different raters on the same occasion (inter-rater) and by the same rater 
on different occasions (intra-rater).99 The test-retest reliability of an outcome measure 
is determined by the variability in the subject, in the observer, and in the measurement 
itself. In practice, it is difficult to separate these sources of error. In inter- and intra-rater 
experiments, the variation is mainly related to the observer and the measurement itself. 
The validity (accuracy) of a measurement instrument answers the question whether an 
instrument measures the concept it is supposed to measure.99 The validation process 
consists of a series of studies. First, feasibility, face validity (‘looks like’ measuring what 
it is supposed to measure) and content validity (measures useful items) are assessed for 
the targeted patient group. If the instrument passes through the first validity tests, crite-
rion validity is assessed by correlating the measure with a gold standard. A high correla-
tion means that the instrument demonstrates the real value of the construct measured. 
Since for many disorders no gold standard is available, correlation with other well-vali-
dated measures is often performed (construct validity). Construct validity can be broken 
down into two subcategories: convergent validity, agreement with previous instruments 
rating the same aspect of disease and divergent validity, whether this instrument is 
not correlated to instrument with which there is a lack of relationship. The responsive-
ness of an instrument measures the ability to detect changes over time. Usually, the 
relationship between the evaluated instrument and other end points is evaluated in a 
treatment setting. Since we don’t have effective treatment yet, responsiveness will be 
difficult to determine. The assessment of an instrument should approximately follow this 
sequence, since unfeasible and unreliable instruments need no assessment of validity. 
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Table 1. Internal properties of an instrument: explanation.
Figure 11. 
Illustration of reliability (precision) and validity (accuracy). A) Both accuracy and precision; B) accuracy 
only; C) precision only; D) Neither accuracy nor precision.
Reliability = the likelihood that a measurement reﬂ ects the true value of the measurement instead of random 
error
Interna consistency Consistency of subitems in measuring the same concept
Intra-rater reliability Repeatability by the same rater on diff erent occasions
Inter-rater reliability Reproducibility between observers on the same occasion
Test-retest reliability Reproducibility within the same subject over time
Validity = generalizability of interpretation, measures a stable concept
Face validity Looks like measuring the right construct
Content validity Relevance and comprehensiveness of items in measuring the construct
Criterion validityw Refl ection of value of the construct (i.e. gold standard)
Construct validity Refl ection of the dimensionality of the construct measured
Cross-cultural validity Performance of items of a translated or culturally adapted instrument
Responsiveness = the ability to detect change over time in the construct measured
Criterion responsiveness Detection of change of the construct (i.e. gold standard)
Construct responsiveness Detection of the change in a derivative of the construct 
Responsiveness = the ability to detect change over time in the construct measured
Discriminative ability Discriminative ability between healthy and diseased persons
Floor eff ect Discriminative ability in low scores
Ceiling eff ect Discriminative ability in high scores
Smallest detectable change Smallest change in score that can be measured in an individual
Minimum important change Smallest change in score patients perceive as important
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It is highly unlikely that the perfect instrument, which is feasible, highly relevant and 100% 
precise and accurate in all children with any mitochondrial disorder exists. However, the 
systematic appraisal of available instruments and the subsequent selection of most 
robust instruments based on data instead of gut feeling will certainly increase the quality 
of the information obtained by future clinical trials.
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Scope of this thesis
At the time this project was started, little attention had been paid to the methodological 
quality of clinical studies in mitochondrial disorders. Clinical management was mainly 
directed by non-blind studies in small, heterogeneous cohorts, using poorly exam-
ined and/or clinically insignificant outcome measures. In an international collaboration, 
we united in our combat for high-quality research in this challenging field. One of the 
recommendations to improve the design of future clinical trials was to use validated and 
clinically meaningful end points. Since experience with the validation of end points for 
mitochondrial disease field was lacking, this project had been started.
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Aims of this thesis
The main aim of this thesis was to contribute to the knowledge on which outcome 
measures to use in future trials in children with mitochondrial disorders. 
This aim led to the following research goals: 
I. Explore which the symptoms and disabilities associated with mitochondrial disease 
should be measured in clinical trials from a patients’ and doctors’ perspective.
II. Systematically select instruments from literature that could be used to cover these 
symptoms and disabilities.
III. Validate these instruments in patients with mitochondrial disorders.
IV. Develop new instruments for domains that seem important but are not covered.
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Outline of this thesis
The first part of this thesis aims to select clinically relevant and robust outcome measures 
for children with mitochondrial disorders for the validation studies in part three. The first 
chapter evaluates the methodological quality of the treatment studies in mitochondrial 
disease so far. It concludes with recommendations to improve the quality of future 
clinical trials. In the second chapter, we describe the complaints and disabilities in 
mitochondrial disorders from a patient and parent perspective. The most frequent and 
most burdensome symptoms described in this chapter are used in the third chapter 
to select end points measuring these symptoms and limitations from literature. Using a 
systematic selection procedure to review the available information obtained in more or 
less similar disorders, we generate a toolbox of clinically relevant and robust outcome 
measures. 
The second part aims at determining which selection (genetic or biochemical entity or 
clinical syndrome) should be used to define inclusion criteria for the validation studies. 
Part two assesses natural history in two patient cohorts: patients with a mutation in one 
of the nuclear genes encoding subunits or assembly proteins for Complex I (Chapter 4) 
and in carriers of the m.3243A>G mutation (Chapter 5). 
The third part of this thesis describes the results of several validation studies using the 
instruments from the toolbox composed in chapter three. The first three studies are 
exploratory studies in the paediatric population. In the sixth chapter, we describe the 
feasibility of 3D accelerometers in measuring daily physical activity in children with mito-
chondrial disease. In chapter 7, we describe the feasibility, reliability and validity of the 
(motor-)assisted 6-minute cycling test in children with mitochondrial and neuromuscular 
disorders. Since the available instrument to determine general mitochondrial disease 
severity in children was in our opinion not suitable for clinical trials, we developed the 
International Paediatric Mitochondrial Disease Scale, which assesses the severity of 
mitochondrial disease related complaints and disabilities from a subjective, objective 
and functional perspective. Chapter 8 describes the process of the development, 
the initial reliability and validity studies and the results of the international validation 
study. The last three chapters of the third part describe studies in a large cohort of 
m.3243A>G carriers, who have been included in a national follow-up in our centre since 
2010 (see Chapter 5). In the ninth chapter of this thesis, we describe the feasibility of 
2-dimensional strain echocardiography, a technique to quantify the deformation of the 
myocardium non-invasively. The value of two potential biomarkers (fibroblast growth 
factor 21 (FGF21) and growth and differentiation factor 15 (GDF15)) in determining and 
monitoring disease progression in m.3243A>G carriers is studied in Chapter 10 and 11. 
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Goal
To select clinically relevant and robust outcome measures for in children with 
mitochondrial disease from literature.
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Mitochondrial dysfunction is a common cause of inherited multi-system disease that 
often involves the nervous system. Despite major advances in our understanding of the 
pathophysiology of mitochondrial diseases, clinical management of these conditions 
remains largely supportive. Using a systematic approach, we identified 1,039 publica-
tions on treatments for mitochondrial diseases, only 35 of which included observations 
on more than five patients. Reports of a positive outcome on the basis of a biomarker of 
unproven clinical significance were more common in non-randomised and non-blinded 
studies, suggesting a publication bias toward positive but poorly executed studies. 
Although trial design is improving, there is a critical need to develop new biomarkers 
of mitochondrial disease. In this article, we make recommendations for the design of 
future treatment trials in mitochondrial diseases. Patients and physicians should no 
longer rely on potentially biased data, with the associated costs and risks.
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Introduction
Rare diseases affect 7% of the population and, owing to neurological involvement, 
many individuals with such disorders will present to a neurologist.1 The vast majority 
of rare diseases are genetically inherited, and most have no available treatment, as 
identification of effective therapeutic agents for rare diseases is a difficult process. 
The patient population for rare disorders is usually small and distributed over a wide 
geographical area, often crossing administrative boundaries. Such factors limit studies 
of natural history, and can hinder the identification of appropriate, clinically relevant and 
validated disease end points. Given that the target population in rare disease is small, 
financial incentives for pharmaceutical companies to develop and test novel treatments 
are lacking. Thankfully, this lack of incentive is mitigated by legislation and national 
plans for such diseases,2 which have kindled increasing interest from pharmaceutical 
corporations in these niche areas. Interest in therapeutic research in rare diseases is 
also is driven by the hope that medicines for ‘orphan diseases’ might be useful for 
morecommon ailments.
Mitochondrial disorders - a group of rare inherited diseases of energy metabolism - 
often present with neurological features, and provide an excellent illustration of the 
problems associated with treatment development for rare diseases. Despite an 
increase over the past two decades in the number of published studies reporting treat-
ment effects in mitochondrial disease (Figure 1A), a recent systematic review of the 
literature found no evidence of an effective intervention for any mitochondrial disorder.3 
Thanks to advances in molecular diagnostics, however, a growing number of patients 
with mitochondrial disorders are being identified, and the pressure to find a cure has 
consequently continued to mount. Mitochondrial disorders are now considered among 
the most common inherited diseases and, given their relentlessly progressive nature, 
often worsening over many decades, these disorders cause substantial morbidity. 
Although mitochondrial disorders can be caused by many different genetic defects of 
both nuclear and mitochondrial DNA (mtDNA), they share common pathogenic path-
ways that are potentially amenable to intervention. Here, we critically evaluate proposed 
treatments for mitochondrial diseases, highlighting the danger of relying on openlabel 
studies, and making recommendations for future trials aimed at developing new thera-
pies for these devastating diseases. 
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Figure 1.
Trials of treatments for mitochondrial disease. A) Publications listed on MEDLINE in 5 year intervals show 
that the number of trials has increased over time (the dip at 2008–2012 is probably attributable to ascer-
tainment before the end of 2012 on an exponential curve; see Box 1 for search and methodological details); 
B) Scatter plot of the negative log of all p values listed in included studies (higher numbers indicate a more 
statistically signifi cant result, −log(p)>1.3 = p <0.05). Lower-quality studies had higher reported statistical 
signifi cances; C) Scatter plot and trend line show improvement of study quality over time; D) Scatter plot of 
the negative log of all clinically relevant p values in the included studies. Lower-quality studies report greater 
statistical signifi cance for these end points, which were all non-signifi cant in high-quality studies.
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Proposed treatments
Mitochondrial disorders are primarily due to a biochemical defect of ATP synthesis. ATP 
is required for all active cellular processes, and the majority is generated by mitochon-
drial oxidative phosphorylation (OXPHOS), which facilitates the transfer of electrons 
between the respiratory chain enzyme complexes. For the most part, early attempts to 
develop treatments for mitochondrial disorders have focused on enhancing respiratory 
chain function (Table 1).
Table 1.  
Treatments evaluated in patients with mitochondrial diseases. 
Agent Specific mechanism(s) of action Highest level of clinical study in 
humans
Reference
Increase of substrate supply to respiratory chain
Carnitine Fatty acid transfer for citric acid 
cycle intermediates
Case report 71
Niacin Precursor for NADH, which trans-
fers electrons from intermediates to 
the respiratory chain
Case report 72
Thiamine Enhancement of pyruvate dehydro-
genase to decarboxylate pyruvate 
for oxidation
Case report 73
Dichloroacetate Inhibition of pyruvate dehydroge-
nase kinase to increase availability 
of pyruvate for oxidation
Randomised, placebo-controlled 
cross-over trial in MELAS due to 
m.3243A>G mutation (negative 
outcome)
34
Augmentation of respiratory chain components
Riboflavin Precursor for flavin adenine dinu-
cleotide, an electron carrier bound 
to complexes I and II
Open-label study in complex I defici-
ency (positive outcome)
8
Coenzyme Q10 Electron carrier from complexes I 
and II to complex III
Randomised, placebo-controlled 
cross-over trial (negative outcome)
32
Idebenone Analogue of coenzyme Q10 Randomised, placebo-controlled trial 
in Leber hereditary optic neuropathy 
(negative outcome)
36
EPI-743 Analogue of vitamin E Open-label study in Leigh 
syndrome and Leber hereditary 
optic neuropathy (positive outcome)
39,47
Bypass of respiratory chain components
Succinate Citric acid cycle intermediate 
which donates electrons directly 
to complexes I and II, thus partially 
bypassing complex I
Case report 12
Vitamins C and K Bypass of complex III Case report 13
Energy buffering
Creatine ATP storage in muscles via the 
creatine phosphokinase system
Randomised, placebo-controlled 
cross-over trials in mitochondrial 
myopathies (negative outcomes in 
two trials, positive surrogate end 
points in one trial)
35,52,73
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Supplements aimed at increasing respiratory chain substrate availability include carni-
tine (which facilitates the transfer of fatty acids, thereby increasing the availability of 
metabolites from the citric acid cycle),4 niacin (the precursor to NADH, which transfers 
electrons from intermediate metabolites to the respiratory chain),5 and thiamine (which 
enhances pyruvate dehydrogenase activity and, therefore, the availability of decar-
boxylase pyruvate for oxidation).6 A synthetic agent, dichloroacetate - an inhibitor of 
pyruvate dehydrogenase kinase - has also been used for treatment of mitochondrial 
disorders on the rationale that this compound increases the availability of pyruvate for 
oxidation.7
Attempts to enhance electron transfer within the respiratory chain have included 
supplementation with riboflavin (the precursor for flavin adenine dinucleotide (FAD), an 
electron carrier bound to complexes I and II),8 and coenzyme Q10 (CoQ10, also known 
as ubiquinone, which is an electron carrier from Complexes I and II to Complex III).9 
Synthetic agents based on CoQ10 and vitamin E - such as the drugs idebenone and EPI 
743 - have also been designed to increase the penetration of an electron carrier into 
mitochondria and/or central nervous system tissue.10,11
Alternative strategies to treat mitochondrial diseases include biochemical ‘bypass’ 
of specific respiratory chain complexes, such as with the use of succinate (a citric 
Antioxidant activity
Cysteine Increases muscle availability of 
glutathione peroxidase
Randomised, placebo-controlled 
cross-over trial in progressive 
external ophthalmoplegia (negative 
outcome)
14
Lipoic acid β-ketoacid dehydrogenase cofactor 
with antioxidant properties
Case report; randomised, 
placebo-controlled cross-over 
trial (with creatine and coenzyme 
Q10; negative outcomes in various 
mitochondrial myopathies)
66,46
Dimethylglycine Antioxidant activity Randomised, placebo-controlled 
cross-over trial in Saguenay 
Lac-St-Jean cytochrome c oxidase 
deficiency (negative outcome)
15
Oxidative capacity adaptations
Aerobic exercise 
training
Reversal of deconditioning and/or 
mitochondrial adaptation to improve 
oxidative capacity
Randomised, non-blinded 
controlled trial in mitochondrial 
myopathies (positive outcome)
17,51,65,75
Resistance exercise 
training
Myofibre regeneration and 
presumed gene shifting
Open-label study (positive outcome) 76,77
Nitric oxide meta-
bolism
L-arginine Substrate for nitric oxide synthase Open-label placebo-controlled 
trial in MELAS due to m.3243A>G 
mutation (positive outcome)
18
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acid cycle intermediate that donates electrons directly to FAD, thus partially bypassing 
Complex I)12 and a combination of vitamins C and K (in order to bypass Complex III).13 
Other treatments have focused on the reduction of toxic metabolites through antioxi-
dant activity, and specific agents with this effect include cysteine, vitamins C and E, 
lipoic acid, and dimethylglycine.14,15 Another approach is ‘energy buffering’; that is, the 
use of creatine to increase ATP storage through the creatine phosphokinase system.16 
Finally, exercise therapy is thought to produce adaptations in mitochondria that improve 
oxidative capacity and/or reduce muscle deconditioning.17 Exceptions to the above 
categories include the use of L-arginine in patients with stroke-like episodes (in light 
of the vasoactive effects of this compound that are mediated through the nitric oxide 
pathway),18 and corticosteroids.19 Several other experimental treatments are in the 
preclinical phase of development, and have not been tried in patients to date.20
Although the first case report of a treatment benefit in mitochondrial disease was 
published in 1981, the first trial was not published until 1990,21 and the vast majo-
rity of proposed therapies have not been tested in controlled trials. Not surprisingly, 
both patients and physicians are desperate to find any treatment that helps and, in the 
absence of hardcore evidence, clinical practice continues to be shaped by studies that 
involve fewer than five patients - often anecdotal evidence and case reports. Despite 
lack of proven efficacy, many ‘traditional’ treatments (such as CoQ10, thiamine and 
carnitine) are used widely,22 in part owing to the low incidence of adverse effects with 
these therapies. After a prolonged period with no new therapies, however, recent results 
from openlabel studies of new agents have generated interest from patients and patient 
support groups.23,24 Given the inherent difficulties of conducting randomised clinical 
trials for rare diseases, should we settle for these openlabel data? 
Reliability of evidence
To address the reliability of current evidence of efficacy for mitochondrial therapies, 
we objectively evaluated all of the published data on treatments for mitochondrial 
disease. Our aim was to determine whether less rigorous studies (that is, non-rando-
mised, non-blinded studies) can reliably inform clinical decision-making in mitochond-
rial medicine. A systematic review, performed on 23rd October 2012, yielded 1,039 
publications spanning a 47-year period (Box 1). Titles and abstracts were reviewed 
to include only studies describing treatment effects in mitochondrial diseases in five 
or more patients, which led to identification of a total of 35 studies.8,14,15,17,18,21,25–52 The 
methodological quality of each study was independently evaluated by three authors 
using the Jadad scale (Box 2, Supplementary Document 1).53 Studies are awarded 
a score on this scale on the basis of three factors: randomisation (up to 2 points if a 
valid randomisation procedure was specified), blinding (up to 2 points if a valid blinding 
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procedure was specified), and participant-withdrawal characteristics (1 point if withdra-
wals were correctly documented). The final score ranges from 0-5, with high values 
denoting good-quality studies and lower scores indicating poor-quality studies. 
Box 1: Systematic review methods. 
We identified studies of English-language publications on MEDLINE using OvidSP via the follo-
wing searches: ‘mitochondrial disease OR mitochondrial disorder OR mitochondrial myopathy OR 
Leber optic neuropathy OR Leber optic neuropathy OR Leigh syndrome OR Leigh syndrome OR 
congenital lactic acidosis OR progressive external ophthalmoplegia OR Kearns Sayre syndrome 
OR mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS)’ and 
‘treatment OR therapy OR coenzyme Q10 OR idebenone OR EPI 743 OR creatine OR carnitine 
OR vitamin OR exercise OR arginine OR dichloroacetate’. Our search, performed on 23rd October 
2012, yielded 1,039 results. Titles and abstracts were reviewed, and 49 original research studies 
in humans that tested a therapeutic agent in patients with mitochondrial disorders were identified. 
After exclusion of studies involving fewer than five patients, a total of 35 studies remained; the full-
length articles for these articles were reviewed in detail. For trials with a single primary end point, 
these end points were selected as the relevant end point: only three trials met this criterion. 15,34,36 
For all other trials, which had multiple end points, we selected end points that involved clinically 
important measures: in the case of multi-system disorders, these end points included quality of life 
measurements, combined scores such as the GATE or Newcastle scores, or measurements that 
clearly indicated relevance to patient symptomatology. In the case of mitochondrial myopathies, 
we included global measures of muscle strength (Medical Research Council scales), functional 
muscle tests (walking tests) or other standardised neurological examination results as applicable. 
In the case of Leber hereditary optic neuropathy, we included improvement in visual acuity as the 
relevant end point. In the case of one study,2 the p value was not provided in the manuscript for 
treatment effect, and this was calculated ourselves using a grouped two-tailed Student t-test.
Box 2: Jadad scoring. The Jadad scores (minimum score 0, maximum score 5) for identified 
studies were determined by three independent reviewers. When authors disagreed the studies 
were re-reviewed and discussed until the most appropriate scoring was agreed upon. Points were 
allocated as follows:
Randomisation
+1 if study described as randomised
−1 if an inappropriate method of randomisation was described
+1 if an appropriate method of randomisation was described
Blinding
+1 if the study was described as double-blind
−1 if an inappropriate method of blinding was described
+1 if an appropriate method of double-blinding was described
Withdrawals
+1 if participant withdrawals were accounted for
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Study trends
On the basis of our analysis, several trends with regard to the studies on mitochond-
rial treatment were observed. First, non-randomised and non-blinded studies were 
substantially more likely to report statistically significant results with lower p values (that 
is, a higher level of significance) than were randomised and blinded studies (Figure 
1B). Notably, a trend towards improved study design has been observed over the past 
decade (Figure 1C). Second, studies with a low Jadad score were more likely to report 
a clinically relevant, statistically significant outcome, whereas none of the clinically- 
relevant primary end points (Supplementary Document 2) were statistically significant 
in high-quality studies (Figure 1D). The inevitable subjectivity of many direct clinical 
measures (such as muscle strength), together with the well-recognized placebo effect, 
can often account for positive results in clinical trials. These two factors are particularly 
problematic in open-label (non-blinded) studies, making them more vulnerable to bias. 
Furthermore, open-label trials involving young children can reveal ‘improvements’ in 
outcome that are due to normal growth and development, as has been demonstrated 
in studies of other neuromuscular disorders.54 
Publication bias
Although some treatment effects seen in open-label studies could be important, overall 
our findings strongly suggest a publication bias towards small, non-blinded studies that 
report positive effects of treatments for mitochondrial disease, despite the fact that the 
findings are not supported by larger randomised studies. This issue of lack of reprodu-
cibility is likely to reflect the ‘winner’s curse’, whereby small studies that are carried out 
without a clearly defined end point, and without a predefined statistical analysis plan, 
are likely to yield a positive result, particularly if non-blinded and non-randomised. For 
example, CoQ10 and carnitine were studied on several occasions and, in both cases, 
positive open-labelled studies preceded negative randomised controlled trials (most 
pertinently observed in a single study with both open-label and blinded phases). The 
positive outcome in the open-label studies was partly due to the use of non-validated 
surrogate disease markers in the early studies, and was compounded by a lack of 
blinding and/or randomisation. The higher-quality trials showed no treatment effect, 
despite using much higher doses of the drugs.32
In spite of these negative data, both CoQ10 and carnitine continue to be prescribed 
in major treatment centres, and these prescriptions are then renewed indefinitely by 
other practitioners. Consequently, some drugs have been ‘grandfathered’ into prescri-
bing practice on the basis of pre-existing positive open-label data - these drugs seem 
to be exempt from refutation with high-quality evidence. Paradoxically, the apparent 
safety of most of these agents has contributed to the problem: the balance of low risk 
of adverse events with a possible benefit of treatment has motivated continued 
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prescriptions. Hopefully, the CoQ10 issue will be fi nally resolved, one way or another, 
following the publication of results from an ongoing randomised double-blind multi-
centre trial of this treatment.55
Recommendations for future trials
As well as their role in proving effi  cacy, large randomised trials are of critical importance 
with regard to patient safety. Dichloroacetate is no longer prescribed in adults with 
MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) 
because the drug caused onset or worsening of peripheral neuropathy in 17 of 19 
patients, resulting in premature termination of the randomised controlled trial.34 Acute 
neuropathy had been previously documented following dichloroacetate treatment in 
individual MELAS cases, but in some patients this eff ect was attributed to the mitochon-
drial disorder rather than the drug. Direct linkage of the neuropathic eff ect to the treat-
ment became possible only when a large number of patients (n = 30) were studied in 
a trial of high-quality design. Notably, nine of 10 trials with a high-quality design (Jadad 
score ≥3) included reports on adverse events, whereas these outcomes were reported 
in only 15 of 25 trials scoring ≤2 on the Jadad scale (Figure 2).
Figure 2.
Adverse outcome reporting improves with study quality. Graph showing proportion of studies in each 
Jadad-score group that did and did not report adverse outcomes.
Small numbers of participants do not preclude a high-quality result, provided that the 
randomisation is appropriate. Selection bias during recruitment can easily contribute to 
misleading fi ndings, particularly if the natural history of the disease is poorly understood. 
A mitochondrial disorder such as Leigh syndrome is particularly vulnerable to such bias 
as the severity of this disease fl uctuates markedly over time in an unpredictable manner. 
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In studies of such cases, regression to the mean during spontaneous recovery of a 
patient could be misinterpreted as a positive therapeutic response, particularly when 
numerous end points are used, thereby increasing the chance of a false-positive result. 
Even for complex multi-system diseases, therefore, a trial should have a simple design, 
and aim to evaluate a predefined primary end point that is clinically relevant (Box 3). 
Other end points, such as biomarkers or physiological measurements, remain critically 
important to confirm that the agent is an effector of its target mechanism, but should 
not be used to prove clinical efficacy unless the end point is clinically relevant.
Box 3: Recommendations for treatment trials in mitochondrial diseases.
• Mitochondrial disorders are heterogeneous, and often have a complex multi-system pheno-
type that fluctuates over time in an unpredictable manner, which presents a major challenge 
for the design and interpretation of clinical trial data.
• Small studies should focus on patients with a similar genotype and phenotype, and ideally 
those at a similar stage of the disease; for rare mitochondrial disease this usually requires 
international collaboration.
• Simple trial designs are often the best, using validated, clinically meaningful and pre-specified 
primary end points. End points should be chosen that are most relevant to the genotype or 
phenotype in question. 
• A key issue is the identification of biomarkers that are indicative of clinically relevant outcomes, 
which will require multi-disciplinary collaboration and patient involvement.
• Open-label trials are prone to bias through unanticipated placebo effects and subjective 
clinical measurements. These studies are important as a first step in evaluating treatments, 
but they must be considered preliminary, and should not shape routine clinical practice.
• Open-label studies should be published only if they have a small number of defined pre-
 specified end points and a clear predefined statistical analysis plan, and are publically regis-
tered on ClinicalTrials.gov before recruitment commences. The results of these studies should 
not be considered as preliminary evidence for the benefit and safety of an intervention, but 
merely serve as a signal to proceed with further evaluation in appropriately controlled trials.
• Large multi-centre randomised controlled trials have been carried out for mitochondrial 
disease, and several others are in progress. These trials establish proof of principle that data 
of the highest quality can be produced to underpin mitochondrial medicine, facilitated by 
international consortia.
• Off-licence prescription of medicines or food supplements could have value in a compassio-
nate context, but the lack of objective efficacy should be made clear to patients and families, 
who should be ad-vised that prescribing may stop if a high-quality negative trial is published.
Open trial results should be considered preliminary at best and, if positive, be followed 
up with a randomised study. Such a trial could be targeted to a specific phenotypic or 
genetic group on the basis of data from a pilot open-label study. On the other hand, nega-
tive results from potentially underpowered studies in patients with fluctuating phenotypes 
and genetically heterogeneous diseases may mask minor therapeutic benefits. Small 
treatment effects are important when no other treatments are available (Box 3).
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A novel approach
One approach to addressing the difficulties in obtaining high-quality evidence for rare 
disorders is exemplified by Health Canada’s conditional approval to prescribe idebe-
none in Friedreich ataxia. Approval was provided under the condition that enhanced 
postmarketing surveillance took place under the Notice of Compliance with Condi-
tions policy.56 The original approval for this trial was based on evidence of treatment 
benefit from a single randomised controlled trial.57 When no efficacy was demonstrated 
in the subsequent randomised trial for the primary or secondary end points,58 Health 
Canada issued an open letter to physicians on 20th January 2010 to draw attention 
to the negative results. When further trials of idebenone in Freidrich ataxia were also 
negative59 and systematic reviews concluded that there was no evidence of efficacy,60 
Santhera Pharmaceuticals announced on 27th February 2013 that the agent would be 
withdrawn from the market after consultation with Health Canada.61 This system of drug 
approval enabled a balanced approach to the problem: a potentially valuable drug was 
made available at the earliest opportunity on the basis of high-quality evidence, with the 
possibility of later withdrawal if further trial data were not positive.
Critical issues for the future
For the reasons described above, drug development in mitochondrial disorders has 
been highly problematic. Tightening of safety and efficacy standards is well-recognized 
to have led to an increase in the costs of developing novel agents for these disorders. 
Consequently, despite increasing investment in research and development, the number 
of drugs successfully brought to market each year continues to decrease.62 To address 
this issue, the FDA introduced the Critical Path Initiative, which provides recommenda-
tions to help reconcile society’s high safety expectations for novel drugs with the phar-
maceutical industry’s limited capacity to produce these treatments given the increasing 
costs.62 A key component of these recommendations is multidisciplinary collaboration 
to identify biomarkers that correspond with clinical benefit and/or adverse reactions, in 
order to identify suitable or unsuitable compounds at an early phase of testing.
Mitochondrial disorders have no shortage of potential biomarkers, ranging from bioche-
mical measurements (such as lactate, pyruvate, alanine, citrulline, creatine kinase, 
organic acid quantification and antioxidant levels), physiological measurements (inclu-
ding cardiac dimensions and/or output, visual parameters, and various measurements 
of aerobic or anaerobic exercise capacity or muscle power), genetic measurements 
(mtDNA deletion/mutation burden or copy number), and imaging (magnetic resonance 
spectroscopy (MRS) of brain or muscle). To date, none of the biomarkers that have 
been altered by treatments in high-quality studies have been shown to correlate closely 
with a clinical outcome (namely, lactate,23,30,32,46,49 pyruvate,29 alanine,29 antioxidant 
levels,14,46 and MRS findings in the brain29).
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Future studies would be greatly aided by the discovery of a clinically valid biomarker or 
outcome measure.63,64 These biomarkers may not be specific for mitochondrial disease 
per se; for example, a measure of cardiac, visual or auditory function could be useful in 
patients with an m.3243A>G mutation in the MTTL1 gene - one of the most common 
mutations associated with MELAS. Agreement on an accepted biomarker would enable 
its use for ‘screening’ of new treatments in small exploratory experimental medicine 
studies (phase Ib or phase II), potentially revealing major adverse effects, or showing 
that an agent is ineffective at an early stage. Notably, a positive result from such early 
studies should only be used to inform planning for a randomised placebo-controlled 
trial (phase III), and would not provide evidence of clinical efficacy. A major pitfall of this 
approach is the risk that a new treatment could be rejected prematurely because it did 
not influence a selected biomarker (type II error, false negative). Again, this risk could 
be mitigated with the use of an accepted, sensitive, well-characterised biomarker that 
correlates with disease severity.
Finally, efficacy (phase III) studies are not without their challenges. Without detailed 
natural history data, it may not be possible to identify a sensitive and reliable primary 
trial end point that is directly related to disability. The end point may be different for 
each mitochondrial subphenotype, and the aim of the study will also be critical: will 
the treatment prevent progression (such as in Leber hereditary optic neuropathy34), 
reduce the frequency of relapses (for example, with L-arginine in MELAS18), or reverse 
a functional deficit (as in exercise studies17,51,65)? Ultimately, the aim of these studies will 
be to improve quality of life (QoL), but demonstrating a significant change with crude 
QoL questionnaires will be challenging in a study with perhaps a few hundred patients 
at most.
Practically speaking, recent work has shown that the most common mitochondrial 
syndromes are sufficiently prevalent to allow multi-centre trials to achieve adequate 
enrolment,66 and prior trials have demonstrated effective multi-centre collaboration 
across multiple national jurisdictions.36,49 Nevertheless, to study all treatments using 
this approach will not be possible. For some subgroups of mitochondrial disease, small 
studies will be the only way forward. We believe that such studies can be highly valu-
able, provided that a high-quality study design is employed (Box 3). In short, the ‘big 
pharma’ model (specifically, phase III trials) may not be possible, so other approaches 
should be employed if we are to make headway. The past should not be forgotten, 
however, and new treatments should be compared with both placebo and current best 
standard of care. Inevitably, this approach could involve incorporation of drugs into the 
trial that are already grandfathered into clinical practice, even if their adoption has a 
weak evidence basis.
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Conclusions
The increase in publications of trials of mitochondrial treatments over the past decade 
has been mirrored by a trend towards improved study design (Figure 1). These metho-
dological advances have been underpinned by disease registries and multi-centre 
collaborations (such as the North American and European Mitochondrial Diseases 
Networks67–69), which provide proof of principle that rigorous testing of mitochondrial 
medicines is possible, even for this heterogeneous group of rare disorders. In general, 
rare disorders with incidence above five per 100,000 individuals are more likely to have 
orphan drugs approved for their treatment.70 Cause for optimism exists, therefore, that 
novel treatments will continue to be trialled for mitochondrial disease.
Notably, however, premature use of a new treatment can have far-reaching conse-
quences that are quite separate from the high cost and potential adverse effects. Inef-
fective medicines undermine patient confidence in both medical practitioners and the 
medical research community, who may be accused of exploiting patients and their 
families for commercial gain. Such lack of trust will blunt enthusiasm for future clinical 
trials. We therefore urge judicious use of off-licence medicines on a named-patient basis 
(also known as ‘expanded access’ or ‘special access’ programmes in North America). 
The hope of short-term benefit must be counterbalanced by the chance of causing 
longer-term damage, in part through the ‘opportunity cost’ of off-licence prescribing 
for a specific patient, which delays the more rigorous evaluation of newer treatments. 
The root cause of the problem is likely to be multi-faceted, with academics motivated 
by publicationlinked career advancement, industry being driven by financial incentives, 
and patients and families driven by their immediate needs for disease improvement and 
health. 
Resolution of these potentially conflicting issues will not be easy, but all stakeholders 
must work together to ensure efficient progress. Critical issues involve the identifica-
tion of disease biomarkers that correspond to the clinical outcome of the patient, the 
use of multi-centre collaborations to include adequate patient populations for study, 
and multidisciplinary collaborations to identify novel agents with novel mechanisms, 
with innovative and accurate study design using clinically relevant primary end points. 
Leading mitochondrial physicians should set an example, avoiding overemphasis on 
the theoretical benefits of unproven treatments; patient groups can better educate their 
members to engage in high-quality research and controlled trials; and both should work 
collaboratively with industry in well-powered, multi-centre randomised controlled trials. 
Only by doing this will we make headway in developing treatments for these currently 
incurable diseases.
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Since some drug intervention effects are only experienced by the patient, organisa-
tions such as the Food and Drug Administration prefer clinically meaningful outcome 
measures. Here, we evaluated which symptoms and limitations in daily life are most 
burdensome to paediatric patients with mitochondrial disorders and their parents, 
using two questionnaires. In a study of 78 patients, the most burdensome complaints 
included fatigue, behaviour and speech disturbances, epilepsy, and muscle weakness 
and a high degree of limitations in daily activities was found. Importantly, there was a 
discrepancy between what symptoms metabolic paediatricians estimated would be 
most burdensome compared to the patients’/caretakers’ opinion. To include feasible 
and relevant outcome measures in intervention studies, the experience and opinions of 
patients and caretakers should therefore be heard.
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Introduction
Mitochondrial diseases are the most prevalent inherited metabolic diseases, with an 
incidence of approximately 1:5,000 live births.1 Currently, there is no cure for mito-
chondrial diseases but there are some promising results of pharmacological interven-
tions in cells and animals2-5 and in some mitochondrial disorders.6,7 A recent Cochrane 
review states that while the number of trials in patients with mitochondrial disorders has 
doubled since 2006,8 the percentage of trials with an adequate trial design remained 
stable but extremely low (12 out of 1,335 studies).9 Therefore, more awareness on 
how to perform scientifically sound clinical trials and joint ventures to find solutions for 
the many difficulties associated with these heterogeneous and complex disorders is of 
major importance. 
The careful and systematic selection of outcome measures is necessary for scientifically 
sound clinical trials (Figure 1). The US Food and Drug Administration (FDA) stresses that 
it is required to include outcome measures of importance to patients in every trial. Since 
the doctors’ opinion of the severity of symptoms and disabilities does not necessary 
agree with that of the patients,10-12 we studied which symptoms and limitations are the 
most burdensome to paediatric patients with mitochondrial disorders and their parents 
and whether this corresponds to the estimation of their doctors’ opinion. 
Mitochondrial diseases are complex and heterogeneous multi-system disorders mostly 
affecting the function and sometimes the structure of the brain, muscles and heart.13 
Because of the complexity of these disorders, it seems difficult to determine which 
symptoms to measure during a clinical trial. We asked patients and their parents about 
the symptoms that they experience as most bothersome and most wanted to change 
during future treatment. To identify and classify symptoms and disabilities we used the 
International Classification of Functioning, Disability and Health for Children and Youth 
(ICF-CY) framework (Figure 2),14 developed by the World Health Organization (WHO). 
The ICF-CY checklist was used to inventory symptoms and disabilities in our patient 
population. 
This is, to our knowledge, the first study investigating which complaints and disabilities 
patients with mitochondrial disorders and their parents experience in daily life. 
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Figure 1. 
Flowchart for selecting outcome measure instruments used to determine disease severity and 
follow-up disease progression to be used in clinical trials for children with mitochondrial disorders. 
In the red box marked the position of this study in the flowchart. MD = mitochondrial disease; OM = outcome 
measure.
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All paediatric (<18 years) Dutch-speaking patients with a mitochondrial disorder, 
followed up regularly at the Nijmegen Centre for Mitochondrial Disorders, were included 
in this study. Patients were defined having a mitochondrial disorder when the fresh 
muscle biopsy showed one or more of the following: i) ATP production 10% under 
the lower limit of the control range;15 and/or ii) one or more enzyme complex deficien-
cies (under the limit of the control range); and/or iii) a confirmed pathogenic mitochon-
Figure 2. 
The International Classification of Functioning, Disability and Health for Children and Youth (ICF-CY) 
framework. The structure of the ICF-CY (left), filled out as an example for the symptoms, limitations and 
disabilities that can be observed in patients with mitochondrial disease (right). Note the interplay between the 
health condition on physical function, activity and participation on one side, and the influence of environmental 
and personal factors on the other. 
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drial DNA (mtDNA) or nuclear mutation; and/or iv) a mitochondrial syndrome (Leigh or 
MELAS syndrome, MNGIE, etc.).5 Patients were grouped as having myopathy, enceph-
alomyopathy, encephalopathy or mainly gastrointestinal involvement based on their 
most prominent symptom(s), if they did not fit the profile of a specific mitochondrial 
syndrome. 
We sent two questionnaires to all patients who met the inclusion criteria (Supplementary 
Document 3). The first questionnaire was designed to assess which symptoms were 
most burdensome to patients and their parents. It contained three domains: i) The pres-
ence of symptoms/complaints in the child; ii) Which three symptoms would (the parent 
expect) the child most like to change mostly; and iii) Which three symptoms would the 
parents themselves like to change? The symptoms and complaints list was composed 
of the most frequently observed symptoms in mitochondrial disease (literature search 
and subsequent agreement SK and JS). The items are listed in Figure 5. All five (trainee-) 
metabolic paediatricians involved in the care of these patients with mitochondrial disor-
ders at the Nijmegen Centre for Mitochondrial Disorders were asked to fill out the first 
questionnaire to assess which symptoms they felt are most burdensome to patients 
and their parents. The questionnaire was completed by every physician (both for the 
parents’ and for the patients’ perspective). They answered, keeping in mind the whole 
spectrum of mitochondrial disease patients seen in our centre, the questions: i) ‘Which 
three symptoms would (the parent expect) the child most like to change?’ (patient and/
or parent report); and ii) ‘Which three symptoms would the parents themselves like to 
change (parent report)?’ using the same list of symptoms patients/parents used. 
The second questionnaire assessed what impairment was experienced in body func-
tions and activities and participation in daily life. We used the ICF-CY to identify the 
areas of disability of patients with mitochondrial disorders. The ICF-CY comprises four 
dimensions: i) body functions; ii) body structure; iii) activities and participation; and iv) 
environmental factors (Workgroup ICF-CY 2003). We only used the body functions 
and activities and participation domains. For the activity domains, separate question-
naires for children under 3 years, from 3-6 years, from 7-12 years and from 13 to 18 
years were used (Supplementary Document 3). All dimensions include sub domains, 
which can be assessed using the ICF-CY checklist (e.g. ‘Does your son/daughter have 
any problems being alert and awake?’). We asked the patients or his/her parent(s) 
to indicate whether a function/activity was affected (0 = not) and, if present, to what 
extent (1-10 point Likert scale) this was a problem to them. Data of the basic tasks: 
eating, walking, talking, comprehension, going to school, forming and keeping social 
relationships and participating in family and community life were explored for differ-
ences among groups. 
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We separately analysed the results of these questionnaires for each age group requiring 
another ICF-CY list, for the most prevalent clinical syndromes (myopathy, encephalop-
athy, encephalomyopathy, gastrointestinal involvement and Leigh syndrome). We also 
separately analysed the results of the first questionnaire in patients rating more than 
the median amount of symptoms and those rating less than the median amount of 
symptoms. Burden is defined as the product of prevalence (i.e. percentage of people 
with ICF-CY domain score >0) and the median domain score of patient with non-zero 
values. The total scores were summed. Since the amount of questions differs per age 
group, percentages of the maximum score were given as well. Binary values such 
as the prevalence of the two most common and the two most burdensome symp-
toms was compared between different groups using the Chi-square test (or Fisher’s 
exact test, depending on the minimum expected cell count). If significant (groups were 
significantly different from each other) the standardised residuals were interpreted. All 
(ordinal) ICF-CY domain-parameters were assessed, but all deviated strongly from 
(log) normality. Therefore, median scores with ranges are given and between-group 
comparison was performed by the Wilcoxon non-parametric test (2 groups) or the 
Kruskall-Wallis non-parametric test (>2 groups). In case of significant Krusal-Wallis 
ANOVA analysis a posthoc test were performed using the Willcoxon-Mann Whitney 
U test with Bonferoni adjustment for the threshold of significance (i.e. 0.05/number of 
comparisons) is used. All data were analysed using PASW 18.0. p <0.05 was defined 
as being statistical significant. This study has been conducted in the Netherlands with 
approval from the regional Medical Research Ethics Committee.
Results 
Cohort description 
The questionnaires were sent to 143 patients and their parents. Seventy-eight (54.5%) of 
patients and their parents responded positively, of which five patients aged under three 
years (6.4%), 26 patients aged 3-6 years (33.3%), 32 patients aged 7-12 years (41.0%) 
and 15 patients were older than 13 years (19.3%). Of the 58 patients of whom gender 
was noted, 35 (58.6%) were boys. Twenty patients (25.6%) returned the questionnaire 
anonymously. In the non-anonymous group, consisting of 58 patients (74.4%), biochem-
ical diagnosis was noted. Twenty patients (34.4%) had only decreased ATP production, 
11 patients (18.9%) had a Complex I deficiency, three patients (5.2%) had a Complex 
III deficiency, one patient (1.3%) had a Complex V deficiency and 17 patients (29.3%) 
had a combined enzyme deficiency. In 12 out of 58 patients (20.7%), the genetic defect 
causing the mitochondrial dysfunction was found (4 patients with the m.3243A>G, one 
patient with a combined m.3243A>G and a mutation in the POLG gene, one patient 
with a mutation in the AGK gene, and one patient each with m.13781T>C, m.8993T>G, 
m.6489C>A, m.8363G>A and m.13513>A, mutations and one patient with a combined 
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Figure 3.
Flowchart of our study. 143 patients followed up in our centre were sent two questionnaires, 78 patients 
responded positively of which 20 patients returned the questionnaire anonymously. Of the remaining 58 
patients the muscle biopsy showed: mitochondrial enzyme complex deficiencies in 32 patients, decreased 
ATP production (< 90% of lowest reference value) in 20 patients and in 5 patients, the diagnosis was based on 
mtDNA or MRI analysis; 12 had a genetic diagnosis.
Questionnaires sent to 143 patients 
followed up at our center with
- ATP production ≤  90%
- ≥  1 mitochondrial enzyme complex 
deficiency
- a pathogenic mutation in nDNA or 
mtDNA, and/or
- a mitochondrial syndrome
78 returned 
questionnaires
65 patients did not 
respond
58 patients with 
known biochemical/
genetic diagnosis in 
muscle
20 patients returned 
questionnaire 
anonymously
21 patients with ATP 
production >10% 
decreased
32 patients with 
mitochondrial 
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5 patients with 
diagnosis based on 
mtDNA analysis or 
MRI  
12 patients with known genetic defect
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m.3460G>A mutation and 16q23.3 deletion). One patient had a normal biopsy and no 
mutation in mitochondrial DNA, but did have Leigh syndrome (as evidenced from MRI) 
with dystonia, epilepsy, tetraplegia therefore fulfi lling our criterion iv (Figure 3). For an 
overview of all patient details (Figure 4). 
Figure 4. 
Patient description. A) Gender; B) Age category; C) Biochemical abnormalities in muscle biopsy; D) Genetic 
defects; and E) Clinical phenotype. AGK = acylglycerol kinase; ATP = adenosine triphosphate; CPEO = chronic 
progressive external ophthalmoplegia, KSS = Kearns Sayre syndrome; MELAS = mitochondrial encephalop-
athy, lactic acidosis and stroke-like episodes. 
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Symptoms
Seventy-eight patients and parents responded to our request to indicate the presence 
of signs and symptoms of their children. In patients aged 0-3 years, the most prevalent 
symptoms were developmental delay and balance problems (both 4 out of 5 patients) 
and constipation, fatigue, hypotonia, muscle weakness, intellectual disability, coordina-
tion problems and growth retardation (3 out of 5 patients). In patients aged 3-6 years, 
the most prevalent symptoms were balance problems (65.4%) and developmental 
delay, speech and language problems, hypotonia, coordination problems and fatigue 
and lack of energy (all 57.7%). In patients aged 7-12 years, the most prevalent symptoms 
were developmental delay (65.6%), fatigue and lack of energy (65.6 % and 68.8% respec-
tively), hypotonia (65.6%), and problems relating to others (59.4%). In patients aged above 
13 years, the most prevalent symptoms were lack of energy and fatigue (86.7% and 
73.3% respectively), concentration problems, and muscle weakness (both 60%). There 
was no difference in the prevalence of fatigue, lack of energy, speech and language 
problems and behavioural problems among the different age groups (Figure 5). 
Symptoms (parents expect) children would like to change
Ninety-one percent (71 out of 78) of the parents and their children filled out the ques-
tionnaire concerning what three symptoms and complaints (parents expect) the child 
would like to change. Six patients and their parents scored only one item, ten patients 
and their parents filled in two items, and one patient/parent filled in five symptoms. Of the 
children aged 0-3 years, 1 parent gave no answers and two parents gave all the same 
answers as their children. Since this indicates the imaginable difficulties estimating the 
opinion of their young child, we excluded these answers from the analysis. In children 
aged 3-6 years, the most burdensome symptoms (according to the patient or their 
parents’ estimation) include: speech and language problems (30.8%), fatigue and lack of 
energy (26.8% and 19.2%, respectively), and developmental delay (26.9%). In children 
aged 7-12 years, the most burdensome symptoms (according to the patient or their 
parents’ estimation) were fatigue and lack of energy (31.3% and 25%, respectively), 
decreased muscle power, and epilepsy (both 25%). In children aged over 13 years, 
the most burdensome symptoms (according to the patient or their parents’ estimation) 
were fatigue and lack of energy (26.7% and 53.3%, respectively), frequent infections, 
muscle weakness and hypotonia, muscle pain and speech and language problems (all 
13.3%; Figure 5A). There was no difference in the burden of fatigue, lack of energy and 
speech and language problems among children within the different age groups or with 
more or less than the median amount of symptoms. 
Figure 5: Presence and burden of symptoms in mitochondrial disease as rated by patients and their 
parents. Presence of physical complaints, as reported by parents, in our cohort of patients with mitochondrial 
disorders, indicated by the percentage behind the complaint (%). The red (upper) bar indicates the percentage 
of parents rating this symptom in the top 3 of most burdensome symptoms. The blue (lower) bar indicates the 
percentage of children (> 3 years) rating this symptom amongst the most burdensome symptoms.
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Symptoms parents would like to change
Ninety-five percent (74 out of 78) of the parents filled in the questionnaire about what 
three symptoms they would like to change. Four parents scored only one item, twelve 
parents filled in two items, two filled in four items, and one filled in nine items. The latter 
questionnaire was excluded from the analysis. 
Parents of children aged 0-3 years rated muscle weakness (3 out of 5 patients), devel-
opmental delay, speech and language problems and frequent infections (all 2 out of 5 
patients) as the most important symptoms they would like to change. In children aged 
3-6 years, the most burdensome symptoms to parents were speech and language 
impediments (30.8%), lack of energy (23.1%) and developmental delay and muscle 
weakness (both 19.2%). In children aged 7-12 years, parents would most like to change 
behavioural abnormalities (28.1%), fatigue and lack of energy (25% and 21.9% respec-
tively), developmental delay and problems in social interactions (both 15.6%). In chil-
dren aged over 13 years, the most burdensome symptoms to parents were behavioural 
problems (33.3%), fatigue and lack of energy (40% and 20%, respectively) and intellec-
tual problems (26.7%; Figure 5B and Table 1). There was no difference in the burden of 
fatigue, lack of energy, behaviour problems and speech and language problems among 
parents of children within the different age groups or with more or less than the median 
amount of symptoms.
Clinical syndromes
In patients with myopathy (n = 13), the most prevalent symptoms were hypotonia, 
muscle weakness (both 76.9%) and lack of energy and fatigue (both 69.2%). In 
patients with encephalopathy (n = 16), the most common problems include develop-
mental delay (93.8%), intellectual retardation and hypotonia (both 75%), problems in 
social interactions, and balance and coordination problems (all 68.8%). In children with 
encephalomyopathy (n = 17), the most common symptoms included balance problems 
(76.5%), fatigue and lack of energy, developmental delay and intellectual problems (all 
70.6%), hampered coordination and hypotonia (both 64.7%), concentration problems 
and speech and language deficiencies (both 58.8%). In children with primary gastro-
intestinal involvement (n = 4), the most common complaints include fatigue and lack 
of energy and fatigue (both 3 out of 4). The most common symptoms in patients with 
Leigh or Leigh/MELAS syndrome (n = 5) include speech and language deficiencies 
and difficulties with balance (both 4/5) and tiredness, intellectual disability, coordination 
problems, stiffness of arms and legs, epilepsy and constipation (all 3/5). 
Of the children with myopathy, (their parents estimated that) 46.2% would like to change 
(to their parents’ estimation) their fatigue, 38.5% would like to change muscle weakness 
and 23.1% would like to change lack of energy, developmental delay and coordination 
problems. (Parents of) children with encephalopathy (estimated that), 31.1% would like 
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to change vision problems, 25% would like to change epilepsy and 18.8% would like to 
change the developmental delay. Parents of children with encephalomyopathy reported 
that the (estimated) most burdensome symptoms for their children were: muscle weak-
ness (23.5%), vomiting, concentration problems, speech and language impediments, 
lack of muscle power and energy and epilepsy (all 17.6%). The children with gastro-
intestinal involvement would (to their parents’ estimation) like to change fatigue, lack 
of energy, concentration problems, depressed mood, and frequent infections (all 1/4). 
Parents of a child with Leigh syndrome expected that their child would like to his/her 
change speech abnormalities (2/5), developmental delay, diminished social interaction, 
intellectual disability, muscle weakness, epilepsy, dysphagia, and breathing abnormal-
ities (all 1/5). 
The parents of children with myopathy would like to change fatigue and frequent infec-
tions (30.8%), as well as behavioural problems, decreased muscle power, and lack 
of energy (23.1%). The parents of children with encephalopathy would like to change 
the developmental delay and epilepsy (both 31.3%) and vision, speech and language 
abnormalities, as well as behavioural and concentration problems (18.8%). The parents 
of children with encephalomyopathy found speech and language problems (35.5%), 
developmental delay (29.4%) and behavioural problems, muscle weakness, and 
frequent infections (all 23.5%) to be the most burdensome symptoms. The parents of 
children with primarily gastrointestinal involvement preferred to change fatigue (2/4), 
lack of energy, frequent infections, social interaction problems, speech and language 
abnormalities, concentration problems, depressed mood, and headache (all 1/4). The 
parents of children with Leigh syndrome would like to change speech and language 
impediments (3/5), and intellectual disability, developmental delay, epilepsy, muscle 
weakness, involuntary movements, breathing problems and dysphagia (1/5 each). There 
was no significantly different frequency of fatigue, lack of energy or behaviour or speech 
problems among the clinical entities. No differences were found in the percentage of 
children scoring speech problems, fatigue or lack of energy among the most burden-
some symptoms. From a parents’ perspective, no differences were found in behaviour, 
fatigue and lack of energy, but a significantly non-equal distribution was seen in speech 
and language impediments (significantly lower proportion of the parents of a child with 
myopathy that scored this symptom among the most burdensome symptoms, (stan-
dardised residuals -1.7) compared to parents of a child with another phenotype). 
Physicians’ perspective
All five paediatricians filled out the questionnaire concerning their views on the three 
most burdensome symptoms of patients with mitochondrial disorders. Four out of five 
paediatricians scored fatigue and lack of energy as one of the three the most important 
items children and parents would like to change, followed by muscle pain and muscle 
weakness (2 out of 5) in children and developmental delay and muscle weakness (2 out 
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Table 1.
Agreement on most burdensome symptoms among patients and their parents and paediatricians. Top 
10 symptoms rated by parents and patients with prevalence of patients/parents mentioning this symptom in 
the top-3 most burdensome complaints (% of whole group). Top 7/9 symptoms rated by paediatricians as 
most burdensome (number of paediatricians rating this symptom). One can observe the correct estimation 
of burden in fatigue, lack of energy, developmental delay and muscle weakness, the overestimation of the 
burden of muscle cramps and the underestimation of the burden caused by behaviour problems, speech and 
language impediments, epilepsy, hypotonia and frequent infections.
Patients (to parents' estimation) (%) Patients to paediatricians' estimation ( n = )
Lack of energy 27 Fatigue 4
Fatigue 27 Lack of energy 4
Muscle weakness 18 Muscle pain 2
Speech and language impediments 17 Muscle weakness 2
Developmental delay 14 Speech and language impediments 1
Epilepsy 13 Epilepsy 1
Hypotonia 10 Headache 1
Frequent infections 9
Concentration problems 9
Diminished interaction 8   
Parents (%) Parents to paediatricians' estimation ( n = )
Fatigue 26 Fatigue 3
Behavioral problems 23 Lack of energy 3
Lack of energy 22 Developmental delay 2
Speech and language impediments 21 Muscle weakness 2
Developmental delay 19 Muscle pain 1
Hypotonia 15 Speech and language problems 1
Muscle weakness 13 Epilepsy 1
Epilepsy 13 Diminished interaction 1
Frequent infections 13 Stiffness of limbs 1
Concentration problems 10   
of 5) in parents (Table 1). One can appreciate the correct estimation of burden in fatigue, 
lack of energy, developmental delay and muscle weakness. However, there was an 
overestimation of the burden of muscle cramps and an underestimation of the burden 
caused by behaviour problems, speech and language problems, epilepsy, hypotonia 
and frequent infections.
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Body Function, Activities and Participation 
All but two patients (76 patients) filled out the ICF-CY questionnaire about which limita-
tions patients experience in body functioning. Unfortunately, ten parents did not see the 
daily activities and participation questionnaire on the back of the paper and one only 
filled it out partially.
In the Body Function domain, the most burdensome complaints included clumsi-
ness and lack of coordination (calculated burden 6.6), body balance and control (6.3), 
muscles problems (6.3), eating (5.0), and tasks requiring thinking, making sounds and/
or saying words (both 4.7). These were also the most prevalent problems. The limita-
tions with the highest median severity score (so if present, most severely affected) 
include making sounds and saying words (9/10), clumsiness and lack of coordination, 
bodily balance and control, problems with muscles and eating (all 8/10; Table 2A).
In the Activities and Participation domain, the most burdensome complaints included: 
learning to write (calculated burden 8.3), learning to calculate (6.9), engaging in activ-
ities at school, in the neighbourhood and community (6.8), participating in employ-
ment preparedness programs (6.8), walking (6.6) and using the toilet (6.6). The most 
frequently affected domains include engaging in activities at school, in the neighbour-
hood and community (85%), learning to write (83%) and dressing one-self (81%). 
The domains with the highest median score include both learning to write and calcu-
late (both 10/1), learning to read (9.5/10), participating in employment preparedness 
programs, avoiding self-harm, problem solving (all 9/10), using the toilet and speaking 
(both 8.5/10) (Table 2B). 
Do you have any problems… Prevalence of 
patients with 
problems in this 
area (%)
Median score 
(1-10)
Burden 
...with clumsiness or coordinating parts of the body? 82 8 6.6
...with balance or body control? 79 8 6.3
...with muscles of the body, arms or legs? 76 8 6.1
...eating? 62 8 5.0
...with tasks requiring thinking? 67 7 4.7
...making sounds/ saying words? 52 9 4.7
...paying attention to something or someone? 63 6 3.8
Do you have tics, tremors or other unusual movements? 50 7 3.5
Table 2.
Prevalence and severity of impairment. A) Prevalence of problems in the ICF-FY Body Function domain and 
B) the Activities and Participation domain. Burden is calculated by multiplying the prevalence and the severity 
median. In Table 2B the age ranges in which the question is applicable are indicated. 
99
...getting the right amount of nutrients? 50 7 3.5
…with bowel movements? 52 6 3.1
...seeing things ?
…falling asleep or staying asleep? 50 6 3.0
…remembering or recalling something? 48 6 2.9
Do you experience pain more than other children of the 
same age?
40 7 2.8
...with stiffness of body, arms or legs? 46 6 2.8
...being alert and awake? 41 6 2.5
...with movement of wrists, elbows, shoulders or
   knees?
49 5 2.5
...controlling arm and leg movements? 48 5 2.4
...with sensitivity or irritation of skin? 42 5.5 2.3
...distinguishing sounds, shapes or smells? 33 7 2.3
...digesting food? 31 6 1.9
Are you allergic or hypersensitive to any food, plant or 
animal?
24 6 1.4
...hearing sounds ? 29 4.5 1.3
...breathing? 22 5 1.1
...with urination ? 18 5 0.9
...with how the heart functions? 17 4 0.7
Do you have any problems… Agerange to 
which question 
is applicable 
(years)
Prevalence of 
patients with 
problems in this 
area (%)
Median 
score 
(1-10)
Burden
…learning to write? 3-18 83 10 8.3
...learning to calculate? 3-18 69 10 6.9
…in engaging in activities in school, neighborhood 
   or community?
3-18 85 8 6.8
…participating in programs that prepare 
   for employment?
13-18 75 9 6.8
...walking? 0-18 78 8.5 6.6
...using the toilet? 3-18 73 9 6.6
...learning to read? 3-18 69 9.5 6.6
...dressing self? 3-18 81 8 6.5
...participating in the activities of the household? 3-18 77 8 6.2
...washing self? 3-18 77 8 6.2
...relating to others? 0-18 73 8 5.8
...eating? 3-18 72 8 5.8
...avoiding harm to self? 3-18 63 9 5.7
...playing with things? 0-12 70 8 5.6
...playing with others? 0-12 74 7.5 5.6
...speaking? 0-18 65 8.5 5.5
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Body Function, Activities and Participation per age group
In children aged under three years, the most prevalent problems include problems with 
getting the right amount of nutrients and skin abnormalities (5/5), problems with muscles, 
balance, eating, playing and sleeping as well as understanding the meaning of concepts 
such as amount, length, ‘the same’ and ‘different’ (4/5). The highest burden was expe-
rienced in eating (median 9/10), walking, and proper nutrition and muscles problems (all 
8/10), sitting and standing up, clumsiness, and balance problems (all 7/10). In children 
aged 3-6 years (n = 24), the most prevalent symptoms include clumsiness (85%), balance 
problems (81%), and difficulties in learning to write (77%), read and calculate as well as 
going to the toilet, dressing oneself, and participating in community activities (all 73%). 
The most severe limitations experienced were problems with literacy and mathematics 
(all 8/10), clumsiness (7/10), balance problems, participating in community activities 
and dressing oneself (all 6.5/10). In children aged 7-12 years (n = 32), the most prev-
alent symptoms include muscle problems (81%), balance problems and clumsiness 
(both 78%), problems with tasks requiring thinking and participating in household and 
community activities (all 69%) as well as problems washing and dressing oneself, playing 
with others, and learning to write (all 66%). The most burdensome domains include 
difficulties in learning to write (10/10) and mathematics (9/10), washing oneself, and 
going to the toilet alone, participating in communal activities, understanding concepts 
…with concepts such as amount, length, the same
   or different?
0-12 61 9 5.5
...performing multiple tasks or responding to 
   a command with multiple components?
0-18 68 8 5.4
...participating in (pre-)school education? 3-18 66 8 5.3
...using words, phrases or sentences? 0-12 65 8 5.2
...solving problems? 13-18 56 9 5.0
...sitting up or getting to stand? 0-18 61 7.5 4.6
...being consistent in behavior from day to day? 3-18 57 8 4.6
...with uncontrolled movements of arms or legs? 0-18 65 7 4.6
...using hands and arms? 0-18 59 7 4.1
...performing a single task or responding to a 
   single communication?
0-18 44 8 3.5
...following the requirements of a daily routine? 3-18 46 7.5 3.5
...mouthing, touching or tasting things? 0-12 43 8 3.4
...using gestures, pictures, or drawings to 
   communicate?
0-18 38 8 3.0
...understanding what others say? 0-18 42 7 2.9
…making contact 0-3 50 5 2.5
...understanding the meaning of gestures or pictures? 0-18 35 7 2.5
...making different vocal sounds? 0-18 24 8 1.9
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such as amount, length, ‘the same’ and ‘different’ and performing multiple tasks and/or 
responding to multiple comments (all 8/10). In children aged over 13 years (n = 15), the 
most prevalent problems include problems with learning to read and write, problems 
with muscles, participating in the activities of the community, and forming and keeping 
social relationships (all 87%) and problems with walking, sitting and standing, balance 
problems, and limitations in participating in the activities of the family (73%). The most 
burdensome domains include limitations in participating in employment preparedness 
programs (9/10), participating in the community activities, and forming and keeping 
social relationships (both 8/10).
Body Function, Activities and Participation per clinical diagnosis
In children with myopathy (n = 13), the most commonly affected domains included 
problems with muscles and clumsiness (both 85%), balance problems and limitation in 
participating in family activities (both 60%). The most burdensome domains included 
pain, dressing oneself, eating, playing with others and problems performing multiple 
tasks or responding to a command with multiple components (all 6/10) as well as 
problems with consistent behaviour (5.5/10). In children with encephalopathy (n = 16), 
the most common limitation include comprehension, clumsiness, and tasks requiring 
thinking (all 88%), problems with vision, balance and muscles and performing multiple 
tasks or responding to a command with multiple components (all 81%). The most 
burdensome domains include performing multiple tasks or responding to a command 
with multiple components, problem solving, speaking, washing oneself, going to the 
toilet, preventing harm to oneself, forming and keeping social relationships, going to 
school and participating in employment preparedness programs (all 10/10). In chil-
dren with encephalomyopathy (n = 17), the most prevalent problems include balance 
problems (94%), clumsiness (88%), muscle problems (76%) as well as problems with 
walking and tasks requiring thinking (65%). The most burdensome complaints included 
limitations in saying words and understanding gestures and learning to write (all 10/10) 
and problems with walking, talking and eating (9/10). In children with a gastrointestinal 
phenotype (n = 4), the most prevalent problems include problems hearing and sleeping 
(both 3 out of 4). The most burdensome complaints include problems with attending 
to school (8/10), making social contact (6/10), sleeping problems (5/10) and problems 
with eating and proper nutrition (both 4/10). In children with Leigh syndrome (n = 5), the 
most prevalent complaints include tics, tremors or other unusual movements, balance 
problems (both 5 out of 5), and speech impediments (4 out of 5 patients). The most 
burdensome complaints include clumsiness, vision problems, pain, breathing problems, 
skin abnormalities, difficulties learning to write, walk, dress and wash oneself (all 10/10). 
Analysis of the median score of eating, walking, talking, comprehension, attending 
school, forming and keeping social relationships and participating in family and commu-
nity life among age groups and clinical diagnosis, revealed that only 2 parameters reach 
statistical significance. An unequal distribution of the severity of speech impediments 
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was observed among the groups, though none of these reached significance in the 
posthoc test. Surprisingly, a lower prevalence and severity of problems with walking 
difficulties was observed in the group with myopathy, compared to patients with Leigh 
syndrome (p = 0.007; n = 10 and 3).
Total score on Body Functions and Activities and Participation
The sum score from the Body Functions domain had a median value of 78 (range 0 – 
179). The sum score of the Activities and Participation domain had a median value of 
102 (range 0 – 290). The total score had a mean of 176 with a range of 8 to 449. In 
children with myopathy, the median score for Body Functions was 56 (range 11 – 99), 
92 (range 0 – 177) for Activities and Participation and 164 (range 11 – 258) for the total 
score. In children with encephalopathy, the median score for Body Functions was 111 
(range 14 – 179), 200 (range 0 – 290) for Activities and Participation and 295 (range 
18 – 430) for the total score. In children with encephalomyopathy, the median score for 
Body Functions was 75 (range 6 – 167), 107 (range 0 – 282) for Activities and Partic-
ipation and 191 (range 26 – 449) for the total score. In children with Leigh syndrome, 
the median score for Body Functions was 88 (range 50 – 136), 114 (range 0 – 179) 
for Activities and Participation and 167 (range 50 – 295) for the total score. In children 
with mainly gastrointestinal involvement, the median score for Body Functions was 104 
(range 51 – 117), 17 (range 10 – 126) for Activities and Participation and 134 (range 
61 – 230) for the total score. No statistical difference in total sub domain scores and 
total score was observed among the different age groups or clinical groups (Table 3). 
Table 3.
Median percentage of maximum score on the Body Function and Acitivities and Participation domains 
among the different clinical groups.
Myopathy Encepha-
lopathy
Encepha-
lomyopathy
Gastro-
intestinal 
Leigh 
syndrome
Body Functions Median (%) 22 43 29 30 34
Activities & Participation Median (%) 32 71 54 6 44
Total Score Median (%) 29 55 34 19 32
Discussion
This is the first study investigating the signs, symptoms and limitations of mitochondrial 
disorders from both a patient and parent perspective. We found that the most burden-
some symptoms (according to parents) children experience include fatigue and lack 
of energy, epilepsy, muscle weakness, and speech and language impediments. For 
parents, behavioural problems, speech and language impediments, fatigue, hypotonia 
and developmental delay are amongst the most burdensome symptoms. From the 
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perspective of the multi-dimensional ICF-CY, we found a high disease burden in the 
areas of clumsiness and coordination problems, bodily balance and control, eating, 
muscle problems, tasks requiring thinking and making sounds or saying words (Body 
Functions domain) and difficulties in learning to write and calculate, engaging in social 
activities, participating in employment preparedness programs, walking and using the 
toilet (Activities and Participation domain). The range in limitations experienced in the 
Body Function and Activities and Participation domains varies from almost none to 
449 (with a maximum score of 550 for that age-group) is extremely high. Children with 
encephalopathy experienced the most (though not significantly more) limitations in daily 
life, followed by children with encephalomyopathy and Leigh syndrome. 
 
This study also shows that there is a discrepancy between what paediatricians felt were 
the most burdensome symptoms for patients, compared to the patients themselves. 
Although they adequately estimated the burden of fatigue, lack of energy, muscle weak-
ness and developmental delay, the importance of speech impediments, behavioural 
problems, frequent infections, epilepsy, and diminished interaction between patients 
and their parents was underestimated, while the importance of muscle cramps and 
muscle weakness was overestimated. This may suggests that patients and their 
parents are more hampered by limitations in interaction and daily activities, while physi-
cians are more focused on the physical symptoms of the disease. It is important to take 
this discrepancy into account when selecting outcome measures for clinical trials or 
when optimizing patient care. The consequence for the process of selecting outcome 
measures could for example be that patients and parents should be actively involved in 
the outcome measure selection process to assure that the domains most important to 
the patient are covered. 
The use of the proxy report in the indication of most severe symptoms rated by the 
child might have negatively influenced the reliability of our results. First of all, parents are 
also not fully able to determine the burden of disease of their child. In a recent study in 
patients with Duchenne muscular dystrophy, parents were able to adequately estimate 
the physical quality of life but underestimated the quality of life of their sons in three 
other domains, namely moods and emotions, self-perception and bullying.16 Secondly, 
the high percentage of ‘children’ rating behavioural problems as one of the main things 
they would like to change, probably indicates the difficulty of parents in separating their 
opinion from their child’s. 
This study provides a starting point for the mitochondrial disease field to determine 
which symptoms and disabilities should be covered in clinical trials. For example, since 
fatigue and lack of energy are the most common and most burdening symptoms in 
paediatric mitochondrial disease patients and their parents, it is important to validate 
or develop adequate outcome measures for these symptoms, such as the Checklist 
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Individual Strength and the PedsQL multi-dimensional fatigue scale for subjective 
fatigue17-22 and the accelerometer to measure daily physical activity.23,24 Given the high 
impact of mitochondrial diseases on the activities in daily life and the limited correlation 
between muscle power and functional abilities,25 we would advise to use a detailed 
questionnaire such as the Pediatric Evaluation of Disabilities Inventory (PEDI)26 for the 
assessment of patient important treatment effects. 
Moreover, the use of outcome measures measuring speech and language develop-
ment and behavioural problems may measure differences very important to parents. 
However, the results can also be applied into daily clinical practice, in the form of an 
intensive rehabilitation trajectory including the consultation of psychologists and speech 
therapists. In our personal experience, intelligence in children with severe language 
impairment is frequently underestimated and these children and their parents might 
benefit significantly from speech devices, for example. 
The heterogeneity within our patient cohort allows us to form a good impression of the 
wide variation of complaints, disabilities and abilities between patients with mitochon-
drial disorders. From the figures of this study, the challenges and limitations experi-
enced by the wide variety of patients with mitochondrial disorders seem quite homoge-
neous. However, the results of this study may not be applicable to small homogeneous 
cohorts of patients. Since clinical phenotypes and cultural differences vary between and 
within countries, we decided to only include Dutch patients and their paediatricians. We 
analysed several clinical phenotypes separately, to give an impression of complaints in 
homogeneous cohorts.
The FDA strongly advises to include outcome measures of importance to patients in 
every trial. Here, we investigated which symptoms are most burdensome to patients 
and their parents and which activities and participations in daily life are most restricted. 
These symptoms include not only the fatigue, lack of energy, muscle weakness and 
developmental delay, as correctly estimated by physicians, but also a high burden of 
behavioural, speech and language impediments was reported. This provides not only a 
starting point for the selection of outcome measures of importance to patients for future 
clinical trials, but also a significant concern and starting point for supportive therapy 
when caring of these patients.
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A clinical trial is only as reliable as its outcomes, therefore the careful and system-
atic selection of outcome measures is extremely important. Currently, the selection of 
outcome measures for clinical trials designed to evaluate new drugs in patients with 
mitochondrial disorders is inefficient and has not been addressed systematically. Given 
that meaningful data can be obtained only from trials in which outcomes are assessed 
using valid instruments, one should first focus on the validation of a set of selected 
instruments in the target population. The aim of this review is to systematically select a 
‘toolbox’ of robust outcome measures that are relevant to all patients. Using an exten-
sive search of published literature, we systematically compiled a toolbox with outcome 
measures based on a primary search for possible instruments. Subsequently, we 
reduced this toolbox using strict criteria that were adapted from the United States Food 
and Drug Administration. The result is a toolbox with clinically relevant and psychomet-
rically robust instruments for performing clinical research in children with mitochon-
drial disorders was compiled. In coming years, more experience using these outcome 
measures in children with various mitochondrial disease phenotypes must be obtained 
before reliable conclusions regarding the validity of these instruments can be drawn.
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Introduction
Mitochondrial diseases are the most prevalent inherited metabolic diseases, with an 
incidence of approximately 1 in 5,000 live births.1 Most individuals with mitochondrial 
diseases have a defect in the mitochondrial oxidative phosphorylation (OXPHOS) 
system, the final biochemical pathway in adenosine triphosphate (ATP) synthesis. 
Because mitochondria are present in nearly every cell, in principle, symptoms can 
arise from virtually every organ, although the most commonly affected organs are the 
brain, heart, and skeletal muscle.2 In general, two primary phenotypes – mitochon-
drial encephalopathy and mitochondrial myopathy – can be distinguished, although 
most children have a combination of both phenotypes, either with or without a multi-
system disease. In addition to wide variability in the pattern of the affected organs, the 
degree of disability also varies widely. While some patients can remain in a mainstream 
school and achieve normal milestones (e.g. obtaining a swimming certificate), others 
can barely interact with their environment. Although some rare exceptions exist3,4, there 
is currently no treatment for most mitochondrial diseases.
Table 1.
Hurdles in outcome measure selection and development in paediatric mitochondrial disease.
A recent Cochrane review stated that, although the number of trials has doubled since 
2006,5 the proportion of trials with an adequate trial design has remained extremely low 
(accounting for only 12 out of 1,335 studies).6 Assessing the effect of a given treatment 
in children with a mitochondrial disorder is difficult for many reasons (Table 1). The 
two major challenges in designing a clinical trial are: i) the wide heterogeneity within 
this group of disorders, which requires the outcome measures to be almost individu-
ally tailored; and ii) the unpredictable, variable, and oscillating clinical disease course, 
which can require impracticably large cohorts to adequately test the potential benefits 
Rare disorders, small groups for validation
Clinically, biochemically and genetically heterogeneous disorders
Clinical heterogeneity within one genetic entity, both in mtDNA and nDNA mutations
Unpredictable, variable and sometimes oscillating natural disease course
Multi-system disease with variable involvement of organs
Patients are often unable to communicate
Patients are often very disabled and unable to perform functional tests (floor effect)
The cooperation required for some tests may be impossible or unreliable in young children, or children with mental retarda-
tion or behavioural problems
Abilities of patients vary widely (floor and ceiling effect)
Outcome measure instruments mostly have a limited age range
Children are developing and growing
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Figure 1. 
Flowchart for selecting the outcome measure instruments to be used in clinical trials for children with 
mitochondrial disorders. Outcome measures are tests that are used to determine disease severity and to 
follow the progression of the disease. The position of this study is indicated by the red box. MD: mitochondrial 
disease; OM: outcome measure. 
General experience with 
natural disease course of 
mitochondrial disease 
patients
Study which complaints and 
disabilities are most 
burdensome to patients and 
their parents
Patient important 
symptoms and disabilities
Define symptoms and 
disabilites to be 
covered by OMsPreviously used OMs in 
other neuromuscular 
disorders
Previously used OMs in 
other paediatric 
disorders
Potential 
OMs
Inventory of potential 
OMs for these 
symptoms and 
disabilites
Select OMs to be 
validated
Agree on criteria 
for selection of OM
Assemble a group of both 
experts in mitochondrial 
disorders and in OM 
selection
Select symptoms and 
disabilities for which a 
new OM should be 
developed
Validate OM in 
targeted MD 
population
Selected OM New OM
Use OM in clinical 
trial
Systematic 
appreciation of 
available OMs
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Table 2. 
Consequences of the lack of consensus on outcome measures.
of a new therapy. A potential solution to these challenges is the careful selection or 
development of universally applicable and sensitive outcomes and outcome measures 
(Figure 1). 
In the field of mitochondrial diseases, a lack of consensus regarding which outcomes 
measures should be used in clinical trials has resulted in several problems (Table 2), 
including inefficient trial design and inconclusive trial results. The latter is of major 
concern to researchers and practitioners, not only because it can lead to the inefficient 
spending of limited resources, but also because it can be predicted in advance that 
some trials will yield inconclusive results, which is clearly not consistent with good 
clinical practice.
The aim of this review is to provide a systematically composed set of scientifically robust 
and clinically significant outcome measures for the entire disease spectrum of paediatric 
mitochondrial disorders. Because the phenotypes that are associated with mitochon-
drial disorders are highly heterogeneous, the selected outcome measures should ideally 
cover the complaints and disabilities that are most prevalent and prominent among chil-
dren with mitochondrial disorders and should not focus on one specific symptom seen 
only in a rare mitochondrial syndrome. This generalised approach requires a multi-di-
mensional framework that shifts the focus from the symptoms, aetiology, and patho-
physiology – all of which can vary from patient to patient – to the impact of physical 
and cognitive limitations experienced in daily life. To achieve this goal, we applied the 
widely used International Classification of Functioning, Disability and Health for Children 
and Youth (ICF-CY) framework (Figure 2), which was developed by the World Health 
Organization7 and is a multi-dimensional framework with a holistic and biopsychosocial 
vision of the consequences of disease.
Inefficient, duplication of effort with every trial/clinical study
Suboptimal selection of outcome measures for clinical trials
most test are not clinically relevant to the patient
most tests have not been validated before use in clinical trial
natural fluctuation (due to tiredness, growth and development) of test unknown
no empirical evidence of responsiveness to change, even if valid and reliable
Only scientifically sound tests and trials provide meaningful data
patients shouldn’t be burdened by unnecessary tests/trials (Good Clinical Practice) - primum non nocere!
inefficient spending of sparse resources
Only consensus on outcomes will allow future meta-analyses
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As described previously, the applicable domains to be covered were defined with a 
subsequent review of the available instruments.8–11 Because no previous study has 
investigated the robustness of outcome measures in a mitochondrial disease, we used 
the results of studies of other paediatric neuromuscular and central nervous system 
disorders.
Figure 2.
The International Classification of Functioning, Disability and Health for Children and Youth (ICF-CY) 
framework. The structure of the ICF-CY is shown on the (left). At the right, the framework is completed to 
show the symptoms, limitations, and disabilities that can be observed in patients with a mitochondrial disease. 
Note the interplay between the health condition on physical function, activity, and participation and the influ-
ence of environmental and personal factors.
Health condition
Body Functions 
& 
Body Structure
Activities Participation
Environmental 
factors
Personal
factors
Mitochondrial disease
Psychomotor 
retardation, 
epilepsy, short 
stature, dystonia, 
contractures, 
vomiting, fatigue
Unable to sit,
play, speak, 
walk, dress
Unable to go 
to school and 
participate in 
community
Availability of 
wheelchair
Coping
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Methods
Identification of disabilities that can occur in children with a mitochondrial 
disease 
We used the ICF-CY framework (Figure 2) to identify systematically the symptoms and 
disabilities that occur in the majority of patients who have a mitochondrial disorder. The 
ICF-CY comprises the following four dimensions: i) body functions; ii) body structure; iii) 
activities and participation; and iv) environmental and personal factors. Each of these 
dimensions includes several sub domains (e.g. walking is a sub domain in the activ-
ities and participation domain). We assessed the presence of abnormalities that are 
frequent among patients with a mitochondrial disease in all four domains (and their sub 
domains) based on a literature search and expert opinions (JS, SK, separate assess-
ments followed by mutual agreement). Because quality of life (QoL) in general was not 
included as a domain in the ICF-CY, we added health-related quality of life (parent and/
or patient reported) to the classification system. General mitochondrial disease severity 
was also included as a domain.
For all of the domains in this list (Table 3), outcome measure instruments were identified 
primarily by performing a thorough review of the published literature. In addition, three 
outcome measures were identified based on the experience of the authors. A flow chart 
detailing the selection process is presented in Figure 3. 
Outcome measure identification 
We searched PubMed for possible outcome measure instruments for each symptom 
using the following search strings for paediatrics: ((child*[tiab] OR schoolchild*[tiab] OR 
infan*[tiab] OR adolescen*[tiab] OR paediatri*[tiab] OR paediatr*[tiab] OR boy[tiab] OR 
boys[tiab] OR boyhood[tiab] OR girl[tiab] OR girls[tiab] OR girlhood[tiab] OR youth[tiab] 
OR youths[tiab] OR teen[tiab] OR teens [tiab] OR teenager*[tiab] OR preschool*[tiab])). 
In addition, we used the following search strings for outcome measures: ((‘outcome 
assessment (health care)’[MeSH Terms] OR (outcome[tiab] AND measur*[tiab]) OR Eval-
uation study [tiab] OR ‘Clinical Trial’ [Publication Type] OR ‘trial’[tiab] OR (‘rating scale 
[tiab] or rating [ti])). We used a combination of i) ‘the symptom’ (including synonyms), ii) 
the paediatric search string, and ii) the outcome measure search string.
Our initial search yielded more than 24,000 hits; therefore, we chose to review only 
the first 200 abstracts in each domain to identify outcome measure instruments. For 
the articles that explicitly focused on outcome measures, the full-text article and its 
inclusive references were explored, and instruments with good face validity were 
included (cross-referencing). In addition, outcome measures with good face validity that 
were listed on the TREAT-NMD Registry of Outcome Measures website (http://www.
researchrom.com) were included. If commonly used and valuable instruments were not 
detected by our search, we included these instruments separately. 
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Children are developing and 
grow
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Resear-
chRO
M
 
(n = )
Added 
by cross 
referencing 
(n = )
Total 
num
ber of 
instrum
ents
Instrum
ents 
excluded
(n = )
Instrum
ents 
included
(n = )
Instrum
ents 
included, 
but in other 
dom
ain
(n = )
Intellectual function
(intelligence or (intellectual ability*) 
or IQ
 or “intelligence quotient”)
3,168
200
12
2011
0
1
13
11
2
2
E
nergy and
 d
rive
(fatigue or tiredness or "lack of 
energy" or "daily physical activity")
706
200
14
2010
5
1
20
14
6
0
P
sychom
otor d
evelop
m
ent
(developm
ent and (m
otor or 
psychom
otor))
1,876
200
8
2011
0
1
9
6
3
0
A
ff
ective functions
(depression or "affective disorder")
4,487
200
9
2011
0
0
9
6
3
0
Speech and language
("language delay" or "language 
problem
s" or "speech delay" or 
"speech problem
s")
138
138
12
1980
0
1
13
10
3
0
H
eart contraction force
((heart or m
yocardi*) and (contrac-
tility or "contraction force"))
68
68
7
1976
0
1
8
6
2
1
Exercise tolerance
("exercise test" or "exercise tole-
rance" or endurance or "exercise 
intolerance")
1,327
200
10
2009
0
0
10
8
2
3
Insuffi
cient energy p
rod
uction
("ATP production" or "energy 
production" or "ATP synthesis")
2
2
0
1997
0
2
2
0
2
0
Accum
ulation of m
etabolites in 
the b
od
y
(((m
etabolite or m
etabolites) and 
accum
ulation) or (accum
ulation 
and "m
itochondrial dysfunction"))
0
0
0
-
0
2
3
0
3
0
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P
arental/fam
ily strain/stress
((parental or parenting) and (stress 
or strain))
1,087
200
9
2010
3
1
13
12
1
0
Q
uality of life
("quality of life")
4,345
200
9#
2012
2
2
13
8
5
1
G
eneral m
itochondrial tests
("m
itochondrial disease" or 
"m
itochondrial disorder")
24
24
1
2003
0
0
1
0
1
1
Total num
ber of articles
24,675
3,368
175
23
16
214
146
68
24
Figure 3.
Flowchart depicting how the toolbox was 
created. First, we inventoried which symp-
toms/limitations are commonly present in 
patients with a mitochondrial disorder. Next, 
the available instruments for these symptoms 
in children were identified based on a search 
of the published literature, cross-referencing, 
the research Registry of Outcome Measures 
database, and our own experience. We then 
assessed whether each instrument could be 
useful in a paediatric mitochondrial disease (face 
validity). Based on face validity, the instruments 
were then included or excluded from our 
review. From our own experience, three tests 
were added (magnetic resonance imaging, 
growth charts, and fibroblast growth factor 21). 
Finally, the 72 instruments that were selected 
for our review were extensively studied for 
their psychometric properties (Supplementary 
Document 3), from which we selected a core set 
of symptom-specific instruments for clinical trials 
in children with a mitochondrial disorder. ICF-CY, 
International Classification of Functioning, 
Disability and Health for Children and Youth.
Table 3.
Search strings and number of results. The 
selected symptoms/chapters from the ICF-CY 
are listed in bold, and the search string that 
was used is shown below each symptom/
chapter. The number of results obtained from 
PubMed using this symptom/domain search 
string in combination with the paediatric and 
outcome string is indicated at the right. Because 
only the first 200 abstracts were reviewed for 
each symptom, we list the year of the oldest 
article that was reviewed. If a scale had multiple 
scales for different age groups, only one scale 
was counted. The number of instruments that 
were found in addition to those identified by the 
PubMed search, and the number of additional 
instruments found on researchrom.com are 
listed; finally, the total number of instruments 
and the number of excluded and included 
instruments are indicated. Note: quality of life 
questionnaires specifically designed for an irrel-
evant disease (e.g. respiratory disease) are not 
included in this number.
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Inventory of which symptoms of the 
ICF-CY are affected
- Literature search
- Clinical experience
- Agreement authors
22 domains
Literature search
- 24.675 articles
- 3.368 abstract reviewed
Face validity?
- Used in children?
- Measures relevant symptom? 
- Follow -up/ assessment instrument?
Exclusion of 
instrument
( n = 146)
Inclusion of 
instrument
( n = 69)
Search for psychometric properties of 
instrument
- Pubmed search: review of 254 articles
- See Supplementary Document 4  
Pubmed search
175 different instruments
www.ResearchROM.com 
23 instruments extra
Cross referencing
17 extra instruments
Selection of outcome measure instruments
- the relevance of the outcome for patients in daily life - 
has been used in two or more similar diseases Or in 
mitochondrial disorders before
- good reliability and validity of the test in patients with 
similar diseases
- the test has been used for follow-up in one or more 
studies
- proposed feasibility in the target group
- estimated safety for the targeted population
-See Table  3
Common core set
Symptom specfic 
outcome 
measures
3 instruments (own 
experience )
V
A
L
I
D
A
T
I
O
N
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Outcome measure selection for inclusion in this review
From all of the outcome measures that our search yielded, only the outcome measures 
that had face validity were included in the review. Face validity was determined using 
the following criteria: i) previously used in children, and ii) measures symptoms that 
might be present in any phenotype of mitochondrial disorders, and iii) follow-up/assess-
ment instrument, not a diagnostic instrument or screening instrument for the general 
population.
Psychometric data collection
Very few outcome measure studies have been performed in patients with mitochondrial 
disorders, and consequently the psychometric properties of most tests that are given in 
this specific patient population are unknown. Therefore, we collected the psychometric 
data of validation studies in other, better-studied paediatric disorders. This search 
was performed using the paediatric search strings as described above combined with 
the name (including the abbreviation) of the test. Where applicable, we included data 
from similar disorders, including neuromuscular disorders such as Duchenne muscular 
dystrophy (DMD), spinal muscular atrophy (SMA), and Friedreich’s ataxia (FRDA), as 
well as encephalopathies such as cerebral palsy (CP), as these disorders include symp-
toms that are similar to mitochondrial disorders such as muscle weakness, coordi-
nation problems, spasticity or hypotonia, and a progressive disease course (with the 
exception of CP, although this disorder was still included, as it is the only common 
and well-studied central nervous system disorder with symptoms that are common to 
mitochondrial disorders). This approach probably provided the best indication of the 
methodological quality and robustness of the test in our population. If the data for these 
disorders were not available, data from other paediatric conditions were used. A total 
of 254 articles (Figure 2) were reviewed and yielded sufficient psychometric data for all 
instruments (Supplementary Document 4).
Outcome measure appreciation
Following the review of psychometric data, the outcome measures for our toolbox were 
selected. Because we wanted our toolbox to contain only the most scientifically robust 
instruments, the instruments were required to fulfil all of our established criteria. 
Given that these criteria are quite strict and because we wanted to retain our holistic and 
multi-dimensional approach, we also provided an additional set of tests containing the 
outcome measures that fulfilled four or five of our six criteria. To distinguish the instru-
ments based on whether they are robust or not, we used regular and italic typefaces. 
Therefore, each of the six following criteria (adapted from United States Food and Drug 
Administration12) should be satisfied: i) the outcome is relevant in daily life to a signifi-
cant proportion of the children with a mitochondrial disorder; ii) the test has been used 
in mitochondrial disorders or at least one disease with similar symptoms (e.g. DMD, 
SMA, FRDA, or CP); iii) there is high reliability and validity (inter- and intrarater reliability 
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and test–retest reliability >0.6 and correlation with other valid instrument measuring the 
same symptom >0.5) in patients with diseases with similar symptoms (e.g. DMD, SMA, 
FRDA, or CP); iv) the test has been used for follow-up in one or more studies (and has 
preferably been found to be sensitive to change); v) there is proposed feasibility in the 
target group; and vi) there is estimated safety for use in the target population.
Results
Agreement regarding disabilities in patients with mitochondrial disorders
Two authors (SK and JS, physicians who are involved in the care of patients with mito-
chondrial disorders) agreed to include the following ICF-CY sub domains: intellec-
tual function, energy and drive, psychomotor development, affective functions, heart 
contraction force, pulmonary function, insufficient energy production, accumulation of 
metabolites in the body, muscle power, muscle tone, muscle endurance, and control 
of voluntary movements (Domain I); structure of the central nervous system (Domain 
II); changing and maintaining body position, walking and moving and carrying, moving 
and handling objects, managing one’s own behaviour and self-care (Domain III); and 
parental stress (Domain IV). Additionally, QoL and general mitochondrial outcome 
scoring lists were included.
Identification and selection based on face validity
For each domain, we searched PubMed for outcome measures in children. For each 
symptom, we found 2 to 4,487 articles. Because we found a total of 24,675 articles, 
we reviewed only the first 200 abstracts for each domain. We therefore reviewed the 
abstracts of 3,368 (14%) articles and detected 175 outcome measure instruments. 
Based on the aforementioned criteria for face validity, 68 instruments were selected for 
a thorough review of their psychometric properties. Twenty-three additional instruments 
were extracted from the TREAT-NMD Registry of Outcome Measures website data-
base (http://www.researchrom.com) based on face validity, and 16 additional instru-
ments with good face validity were detected using cross-referencing. Three additional 
instruments were included based on our own experience (fibroblast growth factor 21, 
magnetic resonance imaging (MRI), and growth charts; Figure 3; Table 2). 
Psychometric properties of instruments
All 72 detected instruments with face validity were then explored individually for 
psychometric properties in children with or without disease. For some tests, extremely 
few psychometric data were available, whereas other tests were extensively validated. 
Only two of the 72 instruments, the Newcastle Paediatric Mitochondrial Disease Scale 
and the biomarker fibroblast growth factor 21, have been validated in patients with 
mitochondrial disorders, albeit in only one study each. We summarise all of our results, 
123
including reliability and validity, method of administration, time to administer, age refer-
ence, responsiveness, and strengths and weaknesses, in the Supplementary Docu-
ment 4.
Outcome measure toolbox for children with mitochondrial disorders
Table 4 shows the core set of outcome measures that is recommended for all children 
with a mitochondrial disorder as well as for children with a (predominant) myopathy (e.g. 
Kearns–Sayre syndrome) or encephalopathy (e.g. Leigh or mitochondrial encephalomy-
opathy, lactic acidosis, and stroke-like episodes (MELAS)). In our experience, most chil-
dren have a mixed phenotype; therefore, we recommend determining whether myop-
athy or pyramidal/extrapyramidal symptoms are the most disabling conditions and then 
selecting tests based on the abnormalities that are most prominent during the physical 
examination. We selected outcome measures for the common core set at the ICF-CY 
subdimensions energy and drive (e.g. accelerometer), psychomotor development (the 
Alberta Infant Motor Scale), neuromuscular function (e.g. the Medical Research Council 
Scale), cardiovascular and respiratory system (e.g. speckling tracking MRI), walking 
and moving (e.g. the 6-minute walking test), and changing and maintaining body posi-
tion (e.g. the Motor Function Measure). In addition, we selected the KIDSCREEN-52 
measurement to assess quality of life. Optional tests for specific groups of children 
were also selected from the various ICF-CY subdimensions and included a measure of 
general mitochondrial disease severity (the Newcastle Paediatric Mitochondrial Disease 
Scale) and a measure of growth state (growth charts). The recommended core set 
is based on the psychometric properties of the outcome measures (Supplementary 
Document 4), and the strict selection criteria that are described in the Methods section. 
Table 4. 
Suggested outcome measures for children with a mitochondrial disorder. Common core set (top), as 
well as optional tests for specific groups and purposes (bottom.). The instruments shown in italics met only 
four or five of the six selection criteria but were included to retain the holistic and multi-dimensional vision on 
the disease. Note: none of these instruments has been validated for follow-up in children with a mitochondrial 
disease. Election was based on relevance and feasibility in this patient group and strict criteria for psycho-
metric robustness. 
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126
Chapter 3  |  Towards the harmonisation of outcome measures in children with mitochondrial disorders
As shown in Table 4, age and disease severity should be taken into consideration when 
selecting an appropriate instrument as each instrument is applicable only to a specific 
age and/or disease severity range. Thus, some instruments – including questionnaires 
that measure QoL, performance and capacity of the activities of daily life and subjective 
fatigue – can be applied to all patients within the age group for that instrument. For 
other instruments, however, inclusion or exclusion should be based on the abilities of 
the patient. For example, for testing ambulatory children with relatively mild myopathy, 
robust instruments that measure exercise tolerance (e.g. maximum exercise tests or the 
6-min walking test) may be feasible. However, more severely affected (wheelchair-de-
pendent) children are unable to perform these tests. It is therefore worth developing or 
validating new outcome measures such as the three-dimensional accelerometer and 
the assisted 6-minute cycling test to assess exercise tolerance. Exercise tolerance is 
a domain that appears to be sensitive to small but relevant treatment effects. Another 
example is the selection of either the Gross Motor Function Measure (GMFM) or the 
Motor Function Measure (MFM), based on the presence of spastic or flaccid paresis 
respectively. Because cardiomyopathy is a life-limiting condition,12 and because altered 
myocardial function is present in many mitochondrial disorder patients,13–15 it seems 
reasonable to measure myocardial function during clinical trials using instruments that 
are sensitive to small changes in myocardial contractility, even though the clinical conse-
quences of small changes in myocardial function are currently unknown. Although age 
at death is commonly used as an outcome measure for lethal diseases, the wide vari-
ability in homogeneous biochemical and genetic entities such as Complex I deficiency16 
means that studies should include extremely large groups of patients; however, such 
large groups are not currently available. Because function does not always follow (abnor-
malities in) brain structure, the quantification of brain lesions based on MRI was not 
included in the core set. Moreover, because the spontaneous disappearance of lactate 
peaks on 1H-magnetic resonance spectroscopy has been described in progressive 
Leigh disease,17 this test was not appropriate for judging treatment effects.
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Discussion
This is the first study to systematically compose a toolbox containing robust and clinically 
relevant outcome measures that cover virtually the entire disease spectrum of paedi-
atric mitochondrial disorders. Assembling such a toolbox is challenging for mitochondrial 
disorders, particularly given the heterogeneity and unpredictability of these diseases. We 
therefore used the multi-dimensional ICF-CY framework to select the most commonly 
encountered disabilities. We then selected 14 general and 19 symptom specific psycho-
metrically sound and clinically relevant outcome measures by thoroughly reviewing the 
published literature. The results of this study will facilitate the efficient and universal 
selection of outcomes for use in future clinical trials, which will in turn improve the quality 
of future clinical trials involving children with mitochondrial disorders.
It should be noted that the instruments contained within our toolbox have not yet been 
validated for mitochondrial diseases. However, the validation of a new instrument is 
complicated by the lack of a criterion standard and the difficulties in defining homoge-
neous and representative cohorts. Moreover, growth, development, and variable coop-
eration require age-appropriate instruments and reference values. Therefore, additional 
experience using these instruments in this population is needed before a definitive 
toolbox can be created. After sufficient experience has been obtained, and using the 
multi-disciplinary expertise of outcome measure experts, statisticians and legal author-
ities, the next steps towards valid outcomes can be taken.11,18,19
The instruments in the toolbox were selected based on their applicability to the widest 
possible range of disabilities. Although this approach has major advantages for making 
comparisons between groups, the use of a generic instrument can cause reduced 
specificity, a floor and/or ceiling effect, and decreased sensitivity to small changes that 
may be clinically relevant to an individual patient. Moreover, many instruments are appli-
cable to patients within only a small age range, and few valid instruments for infants and 
toddlers exist. Therefore, it may be necessary to include highly sensitive quantifiable 
metho ds for measuring daily physical activity in severely disabled patients and exercise 
tests or muscle power tests in patients with more capabilities, as well as instrument 
sets for testing both younger and older children.
For all subjective tests, and particularly for questionnaires that assess general well-
being, one should consider that the supportive care and optimism associated with 
participating in a clinical trial can increase the participant’s well-being. One should there-
fore use caution when using these questionnaires in open-label studies. The reliability 
of a questionnaire in assessing the health-related quality of life for children with severe 
intellectual disability is unknown; however, in children with reasonable language skills 
and cognitive development (i.e. a developmental age of approximately 5 years), self- 
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report QoL questionnaires should also be used, as they can provide another perspec-
tive of the impact of the disease than parent questionnaires.
In our opinion, the feasibility of using the entire toolbox is quite good. Using the entire 
toolbox for a patient with myopathy will take approximately 2.5 hours, including more 
than 1 hour to complete the questionnaires. Because most patients will find these tests 
physically challenging, we recommend performing the tests in the same sequence, 
at the same time of day, and on the same day of the week while alternating between 
physical tests and questionnaires. Most of the tests in the toolbox can be performed by 
a physiotherapist. Finally, based on the capacities, limitations, and/or other complaints 
specific to the individual child, certain tests in the toolbox can be either skipped or 
included. In composing this toolbox, we used a few practical considerations that may 
influence the applicability of the results. First, we did not seek to provide outcome 
measures for all symptoms that may be present in the full disease spectrum of mito-
chondrial disorders; rather, we focused on the symptoms and limitations that are 
common to most patients. Moreover, the ICF-CY domains were selected based on a 
physician’s opinion, which can differ from the opinions of patients, policymakers, and 
certain specialists. 
Additional studies (e.g. using special focus groups) may reveal discrepancies between 
these groups with respect to their experiences and interests. In addition, although more 
than 24,000 articles were detected by our initial search, only the first 200 abstracts 
for each domain were reviewed; as a result, some instruments that are rarely used may 
have been missed. Thus, because of the lack of experience in mitochondrial disorders, 
it is not possible to determine the validity of these instruments in this population using 
previous studies in which disorders with similar symptoms were used to estimate the 
robustness of the instruments. However, it should be noted that the validity of a test 
used in patients with DMD or CP does not necessarily reflect the validity of the same 
test in mitochondrial disorders, as the phenotypes do not overlap completely, and 
mitochondrial disorders are often more complex in terms of multi-system involvement. 
Finally, the multi-dimensionality of the ICF-CY is not reflected in the common core set 
of our toolbox, as the tests (e.g. for participation or family stress) did not fulfil our 
extremely strict selection criteria. However, although imperfect, the approach used here 
will facilitate the selection of outcome measures for rare mitochondrial symptoms and 
other diseases. 
Although many clinical trials have been performed in patients with mitochondrial disor-
ders, most of these trials used an inadequate trial design and/or yielded a non-conclusive 
outcome.5,6 Because a growing number of compounds are beneficial in cell and animal 
models,2,20,21 we focused on selecting outcomes for clinical trials in humans.13–15 However, 
the systematic selection of a toolbox containing clinically relevant and psychometrically 
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robust instruments is just the beginning, and this study may serve as the starting point 
for further efforts to obtain international consensus regarding the outcome measures. 
International collaboration is necessary in order to gain insight into the feasibility and 
validity of these instruments in well-defined groups of patients with mitochondrial disor-
ders. Only after achieving this goal will clinical trial design be more efficient, and trials 
will harvest valid data that can ultimately be used in meta-analyses, thereby preventing 
unnecessary expenses and, most importantly, sparing patients from undergoing unnec-
essary research procedures.2
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Goal
To select inclusion criteria for the validation studies based on the clinical heteroge-
neity and natural disease course in two different cohorts of patients with mitochondrial 
disease. 
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Natural disease course and genotype-phenotype correlations in 
Complex I deficiency caused by nuclear gene defects: what we learned 
from 130 cases
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Mitochondrial Complex I is the largest multi-protein enzyme complex of the oxidative 
phosphorylation system. Seven subunits of this complex are encoded by the mitochond-
rial and the remainder by the nuclear genome. We review the natural disease course 
and signs and symptoms of 130 patients (four new cases and 126 from literature) with 
mutations in nuclear genes encoding structural Complex I proteins or those involved 
in its assembly. Complex I deficiency caused by a nuclear gene defect is usually a 
non-dysmorphic syndrome, characterised by severe multi-system organ involvement 
and a poor prognosis. Age at presentation may vary, but is generally within the first year 
of life. The most prevalent symptoms include hypotonia, nystagmus, respiratory abnor-
malities, pyramidal signs, dystonia, psychomotor retardation or regression, failure to 
thrive, and feeding problems. Characteristic symptoms include brainstem involvement, 
optic atrophy, and Leigh syndrome on MRI, either or not in combination with internal 
organ involvement and lactic acidemia. Virtually all children ultimately develop Leigh 
syndrome or leukoencephalopathy. Twenty-five percent of the patients died before the 
age of six months, more than half before the age of two and 75% before the age of ten 
years. Some patients showed recovery of certain skills or are still alive in their thirties. 
No clinical, biochemical, or genetic parameters indicating longer survival were found. 
No clear genotype-phenotype correlations were observed, however defects in some 
genes seem to be associated with a better or poorer prognosis, cardiomyopathy, Leigh 
syndrome or brainstem lesions. longer rely on potentially biased data, with the associ-
ated costs and risks.
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Introduction
Mammalian Complex I or NADH:ubiquinone oxidoreductase is the largest enzyme 
complex of the mitochondrial oxidative phosphorylation system.1 It consists of 45 
subunits, of which seven are encoded by the mitochondrial genome, and the remainder 
by the nuclear genome.1 Complex I has two modes of action: funnelling electrons to 
ubiquinone (co-enzyme Q) and redox driven proton translocation.2,3 These actions are 
carried out by three proposed functional modules, consisting of several subunits of 
Complex I: the N-module for NADH oxidation, the Q-module for ubiquinone reduc-
tion and the P-module for proton translocation.4 The complex has two arms, one 
embedded in the mitochondrial inner membrane (P-module) and one protruding into 
the mitochondrial matrix (N/Q-module), forming an L-shape. The proton gradient built 
up by Complex I to V is used by Complex V to synthesise ATP from ADP and inorganic 
phosphate. Fourteen highly conserved subunits can be distinguished, including the 
mitochondrial encoded ND1-6, 4L, and NDUFS1-3, NDUFS7-8 and NDUFV1-2.2 The 
assembly of Complex I is not fully elucidated yet, but more and more assembly factors 
are found.6-8 
Mutations in one of the nuclear encoded structural or assembly genes of Complex I 
have a dramatic effect on neurodevelopment and overall patient survival.9 The majority 
of the children with an isolated Complex I deficiency present with Leigh syndrome, a 
devastating neurodegenerative disease.9-11 These patients usually present within the 
first months of life with psychomotor retardation in combination with signs of brain-
stem or extrapyramidal dysfunction and lactic acidaemia.10,12 The disease has first been 
described by Denis Leigh who described the characteristic findings on neuropatholo-
gical postmortem examination with vacuolation of the neuropil and relative preserva-
tion of the neurons, associated with demyelination, gliosis and capillary proliferation,13 
seen on MRI as bilateral hyperintensities in the basal ganglia, brainstem, thalamus, 
diencephalon, cerebellum and spinal cord.10 Death occurs usually within the first years 
of life as a consequence of respiratory failure caused by ongoing brainstem dysfunc-
tion whether or not in combination with increasing muscle weakness.12 Other pheno-
types that have been described in patients with Complex I deficiency include neonatal 
cardiomyopathy,9,14-19 leukoencephalopathy,16,20-22 fatal infantile lactic acidosis11,23 and 
other undefined progressive or stable encephalomyopathies.11,24 The significance of 
the classification of symptoms into syndromes is still under debate.9 No obvious geno-
type-phenotype correlations have been identified to date and patients with mutations 
in the same gene may present with highly variable phenotypes.9,25 Also, the prognosis 
of nuclear encoded Complex I deficiency is quite variable, ranging from fatal neonatal 
disease11,23 to survival beyond three decades.26 For the patients and their families, it is 
important to get an evidence based indication of the prognosis for their child. 
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An accurate prognosis not only includes the age of death, but also the occurrence 
of symptoms such as epilepsy, visual disturbances, hearing problems, and brainstem 
symptoms, which may severely affect quality of life. The known presence of cardio-
myopathy or deterioration during infection may have implications for follow-up and 
preventive immunisations. Importantly, the prediction of the clinical course of Complex I 
deficiency is not only important for the patients and their families, it is also indispensable 
for establishing clinical trials. Before the effect of a drug can be tested, the natural 
history must be known, with the most debilitating and most prevalent symptoms iden-
tified. To date, we are not aware of any treatments or supplementation with vitamins, 
anti-oxidant or other compounds that positively influence the disease course of these 
patients.27
In this review, we provide detailed information regarding the prognosis of patients 
with nuclear encoded Complex I deficiency based on systematic literature search. We 
summarise the clinical details of all nuclear encoded Complex I patients described in the 
literature, as well as four new cases with known mutations in Complex I genes. To give a 
detailed overview of prevalence of clinical symptoms and their natural course in time we 
looked for genetic, biochemical and clinical predictors indicative for prognosis of patients 
and based on this provide advice to clinicians taking care of Complex I deficient patients.
Methods
Search strategy for literature study
We searched Pubmed for all the individual subunits and assembly factors of Complex 
I to identify cases of nuclear encoded Complex I deficiency. We excluded patients with 
combined gene deletions. We contacted all research groups describing living patients 
with nuclear gene mutations and Complex I deficiency presented in the literature to 
assess the current clinical condition and the disease course after the publication. 
In patients on whom limited clinical information was present, we also contacted the 
authors to ask for a more detailed clinical description. Siblings of patients presented in 
the articles on whom no biochemical or genetic analysis was performed, were excluded 
from this review.
New cases
We briefly described the clinical course of four new patients with known mutations in 
structural or assembly genes of Complex I.
Genetic, biochemical and clinical data
We entered all data of the literature search and the new cases in a database, including 
age at presentation, age of death, cause of death, current age if the patient is still 
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alive, their clinical condition, the causative gene mutation, the origin of the patient, the 
presence of consanguinity, and histological findings in the muscle biopsy.
The activity of Complex I in skeletal muscle and skin fibroblasts was expressed as the 
percentage of the lowest reference value, to make the results of the measurements 
uniform, despite the different methods and reference values used in different laboratory. 
For the other patients, Complex I deficiency was confirmed by other methods such as 
Blue Native Page. The maximum lactate, both in serum and cerebrospinal fluid (CSF) 
was noted and considered (arbitrary) mildly elevated above 2.1 mmol/l (noted as 1 
in the Supplementary Table), moderately elevated above 4.0 mmol/l (2) and severely 
elevated above 7.0 mmol/l (3). Alanine in serum was considered increased above 450 
μmol/l. The presence of tricarboxylic acid (TCA) cycle intermediates in urine was also 
noted.
Birth parameters were assessed, including the gestational age, birth weight and APGAR 
score. Low birth weight was defined as a birth weight lower than the 5th percentile 
for gestational age. The presence of dysmorphic features, macrocephaly, and micro-
cephaly was noted. The age at which the following symptoms were described, was 
noted: psychomotor retardation, (isolated) motor retardation, developmental regres-
sion, deterioration after infection, failure to thrive, feeding problems, encephalopathy, 
lethargy, irritability, pyramidal signs and symptoms, extrapyramidal signs and symp-
toms, dys-/hypertonia, hypotonia, muscle weakness, exercise intolerance, dystrophy, 
ataxia, neuropathy, epilepsy, myoclonic epilepsy, ptosis, ophthalmology, nystagmus, 
strabismus, optic atrophy/pale optic disc, retinitis pigmentosa, vision problems, hearing 
loss, respiratory abnormalities, temperature regulation abnormalities, tension regulation 
abnormalities, dysphagia, cardiomyopathy, gastrooesophageal reflux, vomiting, consti-
pation, hepatopathy, renal involvement, and osteoporosis. The presence and localisa-
tion (basal ganglia, midbrain, brainstem, spinal cord, or cerebellum) of Leigh syndrome 
on brain magnetic resonance imaging (MRI) was noted, as well as the presence of cere-
bral/cerebellar atrophy, leukoencephalopathy, and hypoplasia of the corpus callosum. 
We noted the percentage of patients (literature and new cases) known to have the 
clinical features described above, as well as the median age at which the symptoms 
were first noted. 
Complex I subunits
Several sequential and parallel steps within the assembly process can be distinguished; 
the step in which the subunit is incorporated in the holocomplex was grouped accor-
ding to Vogel et al.7 The functional modules of Complex I as described in the introduc-
tion were grouped according to Angerer et al.4 Brandt analysed whether the proteins 
were in the central core of the Complex or accessory to it; we grouped the subunits 
according to his analysis.2 
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Statistical analysis: 
All data were analysed using SPSS 16.0. Spearman’s rho was used to correlate non-pa-
rametric data. All data were described using the median and the range. The number of 
patients dying before a certain age was calculated as number of patients died before 
that age devided by the total number of patients who died + patients living beyond 
that age. Outcome variables were tested for normality if the data reflected a Gaussian 
distribution test. Group medians were compared using the Mann-Witney test, or the 
Kruskall Wallis test. Correlations were calculated using the Spearman rank coefficient. 
Kaplan Meier survival analyses were performed for the patients with mutations in the 
three functional modules,4 in assembly factors compared to structural genes, as well 
as for patients with mutations in central subunits or accessory subunits,2 and in early 
and late in assembly.7
Since the number of patients per gene was insufficient to perform statistical pattern 
analyses, we evaluated the clinical course for specific pattern in the individual genes 
and individual symptoms if four patients or more with mutations in these genes are 
known.
Case reports
The first patient was a boy with a homozygous deletion of exons 2-4 in NDUFAF2 
c.[128-?_510+?del];[128-?_510+?del]. He was the fourth child of first cousin parents 
of Lebanese descent. Three older siblings were healthy. Apart from maternal diabetes 
mellitus, the pregnancy was uncomplicated and he was born at 36 weeks gestation by 
Caesarean section with normal APGAR scores. He had bilateral single palmar creases. 
At six months of age, he was admitted to hospital due to a respiratory syncytial virus 
infection and psychomotor retardation was noted. Nystagmus was found, which had 
reportedly been present since age 4 months. An ophthalmological examination showed 
horizontal nystagmus, hypermetropia and decreased vision. In addition he had hearing 
impairment and used a hearing aid, and he was found to be developmentally delayed. 
At the age of nine months, he was admitted because of pneumonia. He developed 
epilepsy with generalised seizures and was treated with Phenobarbital; EEG was 
normal. Respiratory support was required due to apnoeas. He had episodes of swea-
ting and pooling of secretions was also noted. Cerebral MRI showed bilateral symmetric 
signal changes in putamen, substantia nigra, cerebellar peduncles and brain stem. MR 
spectroscopy showed elevated lactate concentration of 10 mM. Soon after admission 
he died. In muscle, related to CS, the activity was 0.04 (reference range 0.20 - 0.54), 
and related to complex II: 0.15 (reference range 0.43 – 1.33). Complex I activity was 
not measured in fibroblasts.
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The second patient, with a homozygous p.Val122Met NDUFS7 mutation, was a son 
of healthy, non-consanguineous Dutch parents. He had normal development until 11 
months, when he regressed and his growth stagnated. The patient started vomiting 
and severe gastro-oesophageal reflux was found. On physical examination, nystagmus, 
ophthalmoplegia and hypotonia were noted. Cranial MRI showed bilateral hyperintensi-
ties in the medulla oblongata, medial thalamus and cerebral penduncles. He died at the 
age of 20 months, after a viral infection with rapid neurological deterioration preceding 
hypoventilation and coma. Complex I activity in this patient was 353 mU/U CII (refe-
rence range 783 – 1,497 mU/U CII).
The third case is a boy with a homozygous p.Val122Met NDUFS7 mutation, born from 
healthy, non-consanguineous Dutch parents. He developed normally until 9 months, 
when parents noticed he was clumsy but able to learn to walk. At one year of age, 
nystagmoid eye movements were observed. At the age of 2 years and 3 months, he 
was admitted to a local hospital with progressive gait disturbances, lethargy and arti-
culation problems. No laboratory abnormalities were observed. At physical examination 
two months later, he had a bilateral ptosis, hypertonia of all limbs, severe axial ataxia, 
intention tremor and hypertension. A slightly elevated lactate was found in serum and 
CSF fluid. MRI showed hyperintensities in the medial thalamus, brainstem and cere-
bellum, indicative of Leigh syndrome. One month later, he developed respiratory insuf-
ficiency, for which he was admitted to the intensive care, but continued to deteriorate. 
He is now 10 years old and severely disabled due to contractures and dystonia, but 
able to make good contact with his environment. An NADH : ubiquinone oxidoreduc-
tase activity of 24 mU/U CS (reference range 70 – 250 mU/U CS) was found in skeletal 
muscle. 
The forth patient, with a heterozygous NDUFV1 p.Ser56Pro and p.Thr423Met mutation, 
was born from healthy, non-consanguineous parents. His development was normal 
until the age of 8 months, when he deteriorated after an ear infection. His development 
regressed until the age of 11 months, followed by a partial recovery of motor skills. 
MRI showed white signal abnormalities, without involvement of the basal ganglia and 
brainstem. At present, he shows motor delay, including pyramidal signs, hypotonia and 
a mild ataxia, but is able to walk with support. He is 2.5 years old with minor cognitive 
impairment with borderline-normal language production. The NADH:ubiquin oxidoreduc-
tase activity was 50 mU/U CS in skeletal muscle (reference range 100 – 401 mU/U CS).
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Results
Search results
Forty-eight articles describing patients with nuclear encoded Complex I deficiency 
were found by searching the Pubmed database,8,17,20-22,26,28-68 identifying a total of 126 
patients. We additionally describe four new Complex I deficient cases of nuclearDNA 
origin. Ten out of twelve colleagues responded to our request for more information 
on patients who were still alive when the article was written or on patients who had a 
incomplete clinical case description.
Genetic background
Including the new cases, the assembly factor group consists of 44 patients: two patients 
with a mutation in NDUFAF1, eight patients with a mutation in NDUFAF2, four patients 
with a mutation in NDUFAF3, nine patients with mutations in NDUFAF4, seven patients 
with mutations in ACAD9, two patients with mutations in FOXRED1, one patient with 
a mutation in NUBPL, eight patients with a mutation in C20orf7, and two patients with 
mutations in C8orf38. 
The structural gene group consists of: five patients with a mutation in NDUFA1, one 
patient with a mutation in NDUFA2, one patient with a mutation in NDUFA10, five 
patients with a mutation in NDUFA11, one patient with a mutation in NDUFA12, ten 
patients with mutations in NDUFS1, fifteen patients with a mutation in NDUFS2, one 
patient with a mutation in NDUFS3, fourteen patients with a mutation in NDUFS4, six 
patients with a mutation in NDUFS6, six patients with a mutation in NDUFS7, three 
patients with a mutation in NDUFS8, seventeen patients with a mutation in NDUFV1 
and one patient with a mutation in NDUFV2. No patients with mutations in NDUFV3, 
NDUFS5, NDUFA3-9, en NDUFA12-13, NDUFC1-2, NDUFB1-11 or NDUFAB1 were 
found in literature. We additionally described four patients with mutations in NDUFAF2, 
NDUFS7, and NDUFV1. Sixty children (71%) were born from consanguineous parents. 
Fifty-six patients belonged to 23 families, the other patients were the only patient within 
the family. 
Biochemical results
Median complex I activity in muscle was 29% of the lowest normal reference value, 
with a range of 3 - 100% (n = 68). The three patients with normal Complex I activity 
in muscle had a low Complex I activity in fibroblasts. Complex I activity in fibroblasts 
had a median value of 35% of the lowest normal reference value, with a range of 5 
- 82% (n = 59). Of the 14 patients reported to have abnormal findings on histology, 
three patients had ragged red fibres, seven had increased lipid content of the muscle, 
two had atrophic type 2 fibres, one had a atrophic of type 1 fibres, four had abnormal 
mitochondria, and two had a reduced number of type 1 fibres. In five patients, excretion 
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of TCA cycle intermediates was reported (n = 12). Of the 96 patients in which lactate 
levels were reported, 86 had an increased lactate, of which 37 had an mildly increased 
lactate, 20 had a moderately increased lactate, and 29 had a severely increased lactate 
concentration. Lactate in CSF was elevated in 31 out of 34 patients of which 14 had a 
mild increase and 15 had a moderate increase. Serum alanine was only reported in 9 
patients, all but one being increased. 
Clinical details
See Figure 1, Table 1 and the Supplementary Document 5 for a detailed description of 
the age of presentation and age of death of patients, categorised by gene mutation, 
including the new cases described. Sixty-seven boys (58%) and 49 girls were reported; 
of 15 patients no gender was mentioned in the case report. The median age at presen-
tation was four months (range 0 months to nine years; n = 130). Median age of death 
was 10 months (range 0 months to 13.5 years; n = 90). Thirty-four patients died before 
the age of six months (25%), 47 died before the age of one year (36%), 74 patients 
died before the age of two years (58%), 81 patients died before the age of four years 
(66%) and 85 patients died before the age of ten years (75%). The patients who are still 
alive are now six months to 38 years old (median age 9 years; n = 33). Nine patients 
were reported to have died from a cardiorespiratory failure, fifteen patients died from 
respiratory failure, six patients died from central hypoventilation, three patients died 
from multiple organ failure, twenty-one patients died from lactic acidosis, two patients 
suffered from aspiration pneumonia, three patients from cardiomyopathy, and four 
patients died from infection.
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Table 1.
Age of death. Age of death (range, in years) per mutation; > means beyond the age of. 
Gene mutated Range age of death (years) Number of observations
NDUFAF1 0.6 - >24 2
NDUFAF2 0.8 - 13.5 9
NDUFAF3 0.2 - 0.3 4
NDUFAF4 0 - 1.5 9
ACAD9 0.1 - >12 7
FOXRED1 >10 - >22 2
NUBPL >8 1
C20orf7 0 - >29 8
C8orf38 > 1.8 - 2.9 2
NDUFA1 1.2 - >38 5
NDUFA2 0.9 1
NDUFA10 1.9 1
NDUFA11 0 - 4 5
NDUFA12 > 10 1
NDUFS1 0.4 - >4 10
NDUFS2 0.3 - >17 15
NDUFS3 13 1
NDUFS4 0.3 - 2.3 14
NDUFS6 0 6
NDUFS7 0.5 - 5 6
NDUFS8 0.2 - >9 3
NDUFV1 0.3 - >13 17
NDUFV2 0.2 1
In seven patients, a microcephaly was described, one patient had macrocephaly with 
wide anterior fontanel, in one patient a hydroureter with hydronephrosis and in one child 
upslanting palpebral fissures and hypospadias were reported. The latter patient was a 
child of consanguineous parents. For a more detailed summary of the prevalence and 
age of presentation of the individual symptoms (Table 2).
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Clinical symptom Prevalence (%) Median age of onset 
(months)
Range (years)
Hypotonia 60 5 0 - 6
Failure to thrive 34 6 0 - 2.8
Nystagmus 34 7 0 - 10
Dys- or hypertonia 32 12 0 - 9
Psychomotor retardation 30 6 0 - 6
Feeding problems 29 5 0 - 5.2
Pyramidal symptoms 28 13 0 - 13
Respiratory abnormalities 27 11 0 - 12
Developmental regression 25 11 0 - 7,5
Vomiting 22 7 0 - 4
Epilepsy 21 8 0 - 10
Cardiomyopathy 20 4 0 - 3
Optic atrophy 20 10 0 - 11
Deterioration after infections 18 6 0.3 - 3.2
Ataxia 18 24 0.5 - 8
Lethargy 18 6 0 - 20
Encephalopathy 16 6 0 - 2.5
Vision problems 16 6 0 - 10
Muscle weakness 15 8 0 - 11.6
Irritability 15 7 0 - 16
Extrapyramidal symptoms 15 14 0.3 - 10
Strabismus 14 7 0.1 - 6
Dysphagia 13 6 0 - 9
Pure motor retardation 11 9 0 - 2
Dystrophy 9 6 0.3 - 8
Myoclonic epilepsy 8 10 0.2 - 10
Hearing loss 8 16 0.1 - 10
Ptosis 7 16 0.3 - 2.5
Exercise intolerance 7 48 0 - 20
Temperature regulation 
problems 
5 6 0.4 - 20
Gastrooesophageal reflux 5 6 0 - 1,1
Hepatopathy 4 4 0 - 1,3
Ophthalmoplegia 4 9 0.6 - 2.2
Constipation 4 6 0.2 - 7
Osteoporosis 3 78 5-16
Table 2. 
Reported clinical symptoms in patients with nuclear encoded Complex I deficiency. Reported symptoms 
including the prevalence and mean age of presentation in our cohort (n = 130). 
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Neuropathy 3 8 0.5 - 30
Tension abnormalities 2 51 0.5 - 8
Renal involvement 2 17 0.5 - 2
Retinitis pigmentosa 1 13
Sixty-five patients with Leigh syndrome were described, of which 47 had hyperinten-
sities in the basal ganglia and thalamus, 14 had lesions in the midbrain, and 23 had 
lesions in the brainstem. Spinal cord hyperintensities were described in one patient and 
lesions in the cerebellum were reported in four patients. Fourteen patients had cerebral 
atrophy and six patients had cerebellar atrophy. Leukoencephalopathy was present in 
26 patients. Hypoplasia of the corpus callosum was present in three patients. In two 
patients, no abnormalities on brain MRI were described. For a detailed description of 
the MRI abnormalities in our patients (Table 3). Of the 50 patients who had lesions in the 
basal ganglia or midbrain, 27 had pyramidal or extrapyramidal features (54%). Of the 23 
patients with hyperintensities in the brainstem, 20 had features of brainstem dysfunc-
tion (87%) and 13 had pyramidal or extrapyramidal signs (56%). Of the 24 patients with 
leukoencephalopathy, 17 had pyramidal or extrapyramidal signs (70%). 
Table 3.
The prevalence of MRI abnormalities in patients with nuclear encoded Complex I deficiency. 
MRI abnormality Prevalence (%)
Leigh syndrome 84
basal ganglia 53
midbrain 17
brainstem 27
spinal cord 1
cerebellum 4
Cerebral atrophy 12
Cerebellar atropy 9
Leukencephalopathy 28
Hypoplasia of the corpus callosum 3
Normal MRI 2
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Statistical analysis
No correlation between the Complex I activity and age of onset (p = 0.38; n = 82) or age 
of death (p = 0.15; n = 53) was found. A moderate correlation was found between age 
of presentation and age of death (r = 0.58; p = <0.001; n = 91). No significant differences 
in age of death or age of onset were found between the functional subunits, order within 
the assembly of the holo-complex, or the subcomplex in which the protein is present. 
Survival of patients with mutations in assembly genes was lower compared to patients 
with mutations in structural genes (b = 5.2; HR = 186; p = <0.001; n = 123). Survival of 
patients with mutations in core subunits was lower than of patients with mutations in 
non-core genes (b = -0.6; HR = 0.55; p = 0.022 n = 81). Survival of patients with muta-
tions in genes encoding proteins built late in the assembly was worse compared to 
survival of patients with mutations in genes encoding subunits which were built in early 
in the assembly (b = 0.95; HR 0.39; p = 0.029; n = 30). No difference could be observed 
between patients having mutations in different functional subunits (p = 0.775; Figure 2). 
Discussion
In this review, we describe the disease course of 130 patients with mutations in either 
structural or assembly proteins leading to Complex I deficiency. The disease course 
of nuclear encoded Complex I deficiency is quite homogeneous, with ultimately most 
children having a severe multi-system disease with prominent neurological involvement. 
Most children with an age of younger than six months presented with hypotonia, feeding 
problems and failure to thrive, vomiting, encephalopathy, epilepsy, and eye movement 
disturbances. Children beyond the age of six months more frequently presented with 
psychomotor retardation or developmental regression, pyramidal signs and symp-
toms, dystonia, ataxia, epilepsy, failure to thrive, vomiting, and optic atrophy. The most 
specific signs pointing to a nuclear encoded Complex I deficiency are brainstem invol-
vement, optic atrophy and Leigh syndrome characteristics on MRI. Cardiac, renal, or 
hepatic involvement was seen in 24% of the children. Deterioration with infections was 
described in only 18% of the patients, which is less frequent than generally found in 
children with mitochondrial disorders and may therefore be an underreporting. No 
dysmorphic features were present, except for two children of consanguineous parents. 
Most children appear normal at birth, five percent of the patients were born mildly 
premature and seven percent had a low birth weight, similar to what was previously 
described.9 Increased lactic acid concentration was present in 90% of the patients.
Importantly, not all patients with a nuclear encoded Complex I deficiency have a poor 
prognosis and quality of life. For example the girl with a compound heterozygous 
NDUFV1 mutation described by Zafeiriou et al.21 has developed normally after the initial 
regression around the age of one year. She has learning problems and mild spasticity, 
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but is able to ride a bicycle and walk without support. The patient with a compound 
heterozygous mutation in NDUFAF1, described by Dunning et al.,30 is still alive at the 
age of 24 years. He works part time, he has Asperger syndrome and kyphosis, but has 
a sense of humour is generally cheerful.
Only two patients without abnormalities on MRI were reported.31 Possibly, these siblings 
would have developed brain abnormalities if they had lived longer than three months. 
Of the patients dying before the age of six months, two patients were reported without 
any brain abnormalities (15%), whereas only four patients older than six months (6%) 
were described with brain atrophy without Leigh syndrome or leukoencephalopathy. No 
clear correlation between the anatomic location of the hyperintensities and the clinical 
symptoms was observed. 
Historically, no obvious mutation-related phenotype apparent in Complex I deficiency 
was reported.9 For example, cardiomyopathy has first been reported as characteristic 
for the NDUFS2 gene39 but was later reported in other nuclear Complex I genes as well.9 
Moreover, after the first three patients with NDUFS2 mutations with cardiomyopathy, no 
patients with this combination have been described (Supplementary Document 5).65 
Besides, mutations in the same gene can express a high variety of clinical and bioche-
mical phenotypes, even within the same family.42 If more than four patients with muta-
tions in a certain gene have been described we analysed the genotype-phenotype 
relation. We found that cardiomyopathy was more prevalent in patients with ACAD9 
and NDFUA11 mutations. In patients with NDUFAF2 mutations, brainstem symptoms 
and Leigh syndrome on MRI were observed in all patients, as well as a high prevalence 
of pale optic discs or optic atrophy. Patients with NDUFAF4 and NDUFS6 patients 
seem to have a very poor prognosis, but since all NDUFAF4 patients are from the same 
family, no solid conclusions can be drawn. In patients with NDUFA1 mutations, hearing 
loss seems more common and prognosis is often quite good. Leukoencephalopathy 
seems more prevalent in patients with NDUFS1 and NDUFV1 mutations, but mutations 
in both genes may also lead to Leigh syndrome. Patients with NDUFS4 and NDUFS7 
mutations almost invariably have Leigh syndrome, in patients with NDUFS7 mutations, 
the brainstem is often affected. 
The prognosis of nuclear Complex I deficiency is generally very poor (Figure 1 and 2), 
however quite a few exceptions exist. More than half of the patients died before the 
age of two years and 79% died before the age of ten years. In comparison, children 
with a mitochondrial DNA encoded Complex I deficiency present at the median age of 
12 months and have a tendency towards a longer survival than patients with nuclear 
encoded Complex I deficiency.69 Although lactic acidosis was described as the cause 
of death in 41% of the patients dying before the age of six months, a high lactate is 
not necessarily associated with a poor prognosis. The same applies to a high lactate in 
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the CSF. No correlation between the age of death and the location of the protein within 
the assembly, function or structure of Complex I could be elucidated. Strikingly, within 
one family harbouring the same mutation, one child may die before the age of one year 
whereas a sibling lives into the first decade.17 In the patients living into their first decade, 
no lower prevalence of cardiomyopathy, brainstem dysfunction, Leigh syndrome, or a 
higher Complex I activity could be observed. Although patients with mutations in core 
subunits have a significantly poorer prognosis than patients with mutations in non-core 
subunits, the variability in prognosis is extremely high. The value of predicting outcome 
based on this kind of molecular characteristics warrants further research, e.g. in silico. 
In previous studies in a heterogeneous group of children with mitochondrial disorders, 
cardiomyopathy was found to be a significant predictor of a fatal outcome.70 However, 
since the neurological phenotype of patients with nuclear encoded Complex I defi-
ciency is so overwhelming, this observation is difficult to confirm in our cohort. For 
example, all patients with mutations in Complex I assembly genes and cardiomyopathy 
survived beyond the age of five years, although all children with mutations in structural 
genes and cardiomyopathy died before the age of two years. Cardiomyopathy may be 
present in both patients with structural and assembly factor mutations, and in combi-
nation with various clinical phenotypes ranging from lactic acidemia and progressive 
encephalomyopathy,39 to mild and stable neurological syndromes.30,62 
Although cardiomyopathy always presented before the age of three years in this cohort, 
cardiac function should be checked regularly in all patients with nuclear encoded 
Complex I deficiency. We also advice to regularly check the ocular manifestations of the 
disease, for it is important to adapt the environment to visual disturbances in children 
with optic neuropathy, severe ptosis or ophthalmoplegia.71 General advices, such as 
tube-feeding in case of malnutrition or aspiration, and aggressively treating fever and 
infectious diseases also apply to these patients to prevent secondary malfunction 
or challenging of the energy metabolism.72 For patients with dystonia or spasticity, a 
combination of physiotherapy and pharmacotherapy may relieve symptoms.71 
This is the first retrospective study of the clinical disease course of patients with a 
nuclear encoded Complex I deficiency. Although the number of patients analysed is 
high considering the prevalence of this condition, the number of patients with particular 
gene mutations is still too low to see clear genotype-phenotype patterns. Besides, an 
obvious report bias exists and the quality of our data is inherently limited by the quality 
and completeness of the data reported by other research groups. Some case reports 
were very brief and only reported the main symptoms. Furthermore, it is more likely 
that the symptoms present in previously reported patients with the same mutation will 
be diagnosed and reported, e.g. optic atrophy or retinitis pigmentosa. The median 
and mean age we calculated was based on the observation and description of others, 
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sometimes in only a few papers. Therefore, the numbers in our paper should be care-
fully interpreted and interpreted in a clinical context. 
For future research, we would suggest to perform prospective follow-up of these 
patients, for example with the Newcastle Paediatric Mitochondrial Disease Scale.73 Only 
a prospective follow-up will provide valid data to be used in the preparation clinical trials 
in predicting the natural disease course or selecting relevant outcome measures.
We also suggest to continue publishing clinical details of these rare diseases. Only more 
case descriptions will enable us to predict the natural disease course of patients with 
these rare diseases, which is not only useful for future clinical trials, but is also indispen-
sible for the patients and their families. 
Conclusion
In conclusion, nuclear encoded Complex I deficiency generally has a devastating clinical 
disease course, characterised by a severe neurological phenotype including brainstem 
involvement and optic atrophy, in combination with lactic acidosis and Leigh syndrome 
on MRI. Most patients die before the age of one year, but patients in their third decade 
have been described. We advise to regularly check cardiac and ocular manifestations 
of the disease, to optimise nutrition, to treat intercurrent illnesses promptly, and to 
provide adequate symptomatic relieve and family support. 
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The m.3243A>G mutation has become known as the MELAS mutation. However, many 
other clinical phenotypes associated with this mutation have been described, the most 
frequently being Maternally Inherited Diabetes and Deafness. The m.3243A>G mutation 
can be detected in virtually all tissues, however heteroplasmy differs between samples. 
Recent reports indicate, a preference to perform mutation analysis in Urinary Epithelial 
Cells (UEC). To test this and to study the correlation between the mutational load in 
different tissues with two mitochondrial scoring systems (NMDAS and NPMDS), we 
investigated 34 families carrying the m.3243A>G mutation. Heteroplasmy was deter-
mined in three non-invasively collected samples, namely leucocytes, UEC and buccal 
mucosa. We included 127 subjects, of which 82 carried the m.3243A>G mutation. 
None of the children (n = 11) had specific complaints. In adults (n = 71), a median 
NMDAS score of 15 (IQR 10 - 24) was found. The most prevalent symptoms were 
hearing loss (68%), gastro-intestinal problems (59%), exercise intolerance (54%), and 
glucose intolerance (52%). Ten patients had neurologic involvement. Buccal mucosa 
had the best correlation with the NMDAS in all adults (r = 0.44; p <0.001), whereas UEC 
had the strongest correlation with the NMDAS in severely affected patients (r = 0.59; p 
= 0.002). Heteroplasmy declined significantly with increasing age in all three samples 
(r(leucocytes) = -0.71; p <0.001); r(UEC) = -0.37; p = 0.001); r(buccal mucosa) = -0.46; 
p <0.001). In our cohort of 82 carriers, the m.3243A>G mutation causes a wide variety 
of signs and symptoms, MIDD being far more prevalent than MELAS. Looking at the 
characteristics of the three non-invasively available tissues for testing heteroplasmy we 
confirm that UEC are the preferred sample to test.
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Introduction
Mitochondria are responsible for production of adenosine triphosphate (ATP), through 
oxidative phosphorylation (OXPHOS). Mitochondrial dysfunction can result from muta-
tions in either nuclear DNA or mitochondrial DNA (mtDNA). The incidence of congenital 
mitochondrial disorders based on an OXPHOS defect is at least 1:8,500 of all live 
births.1 Mitochondrial DNA encodes 37 genes, 22 code for tRNAs, two for rRNAs and 
thirteen code for subunits of the OXPHOS complexes I, III, IV and V. Two important 
features of mitochondrial mutations are i) maternal inheritance, it can be assumed that 
all relatives from the maternal line are (dormant) carriers of the mutation. This applies 
only if there is not a de novo mutation. And ii) heteroplasmy, human cells contain over 
100 – 1,000 mitochondria each, every mitochondrion contains one to ten copies of 
mtDNA. When all mtDNA copies are mutated, there is a homoplasmic mutation. When 
however not all mtDNA copies are mutated, there is a variation in mutation load and 
the mutation is called heteroplasmic.2 Heteroplasmy can vary between different tissues 
of one patient and between one tissue in one patient in time.3 This variation in hetero-
plasmy between tissues complicates the demonstration of a relationship between the 
severity of the disease in a non-accessible organ (e.g. the heart or the brain) and the 
degree of heteroplasmy in blood, urine or buccal mucosa. 
The acronym MELAS was first used in 1984 by Pavlakis et al. to describe a group of 
patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes.4 In 1990 the Adenine to Guanine transition at position 3243 of mitochondrial 
DNA (m.3243A>G) in the MT-TL1 gene encoding tRNALEU(UUR) was found as molecular 
basis for this disease.5,6 A mutation in tRNA commonly causes a combined defect of 
the mtDNA encoded OXPHOS complexes. tRNALEU(UUR) is partially (~12%) responsible 
for the incorporation of leucine into mitochondrial DNA encoded proteins, tRNALEU(CUN) is 
responsible for the other part (~88%).7 It is proposed that because of the minimal role 
of tRNALEU(UUR) in incorporation of leucine, a mutation the tRNALEU(UUR) is less lethal and 
therefore more frequently detected.7 
The m.3243A>G mutation in the MT-TL1 gene is the most common cause of MELAS 
syndrome, therefore the mutation is also known as the MELAS mutation. Later, more 
and more phenotypic expressions of the m.3243A>G mutation were found, including 
maternally inherited diabetes deafness (MIDD),8 hypertrophic cardiomyopathy,9 macular 
dystrophy,10 focal segmental glomeruloslerosis (FSGS),11 myoclonic epilepsy with 
ragged-red fibers (MERRF syndrome),12 and oligosymptomatic variants of the acronym 
MELAS.13
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Epidemiologic studies show a m.3243A>G mutation prevalence of 7.59/100,000 in 
the population of North-East England,14 16.3/100,000 in the population of Northern 
Finland15 and up to 236/100,000 in the population of Australia.16 These studies did not 
give a complete insight in the phenotypic expression of the m.3243A>G mutation in the 
subjects examined. The high mutation prevalence in the most recent study indicates a 
high number of undiagnosed carriers of the m.3243A>G mutation. 
Since mitochondria and mtDNA are present in almost all tissues, heteroplasmy can 
theoretically be assessed in virtually every tissue. Two issues arise when testing hetero-
plasmy: the convenience of obtaining the sample and the differences in heteroplasmy 
levels between samples. For example, invasively obtained muscle tissue heteroplasmy 
usually gives a higher and more consistent level than conveniently attained blood, in 
de last case possibly leading to false-negative results. Recent studies showed a supe-
riority of urine over blood as preferred non-invasive tissue for mutation analysis.3,17,18 
The relationship between mutation load and clinical phenotypes has been a subject of 
research for many years.19 Whittaker et al. and Ma et al. recently showed a relationship 
between heteroplasmy levels in urinary epithelial cells and clinical symptoms in a small 
number of patients.17,20
Some of the many questions regarding the m.3243A>G mutation that we have include: 
Are all mutation carriers symptomatic? Should these carriers undergo screening for 
frequent and preventable symptoms such as cardiomyopathy, glucose intolerance, 
nephropathy or macular dystrophy? How should female carriers be counseled regarding 
fertility questions? 
In this study, we clinically evaluated 34 Dutch families, probands and maternal relatives, 
carrying the m.3243A>G mutation. We provide data about the whole phenotypic spec-
trum of m.3243A>G mutation as well as information regarding the correlation between 
the level of heteroplasmy in different samples and the clinical severity of the disease. 
Patients and methods
Patients
All probands are patients of the Nijmegen Centre for Mitochondrial Disorders at the 
Radboudumc, Nijmegen, The Netherlands, diagnosed with the m.3243A>G mutation in 
muscle or blood. All patients and maternal relatives were recruited by a letter, in which 
they were invited to participate in this study. This study was approved by the ethics 
committee of the Nijmegen-Arnhem region, The Netherlands. Written informed consent 
according to the Helsinki agreement was obtained from all parents and patients ≥12 
years.
170
Chapter 5  |  Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation
Newcastle Mitochondrial Disease Scales
All patients were invited for a single visit to our outpatient clinic. Adult patients (>18yr) 
were scored using the Newcastle Mitochondrial Disease Adult Scale (NMDAS),21 
paediatric patients (≥18yr) were scored using the Newcastle Paediatric Mitochondrial 
Disease Scale (NPMDS).21 The NMDAS and NPMDS constitute a validated method to 
monitor the clinical expression of mitochondrial disease and to follow-up the course of 
disease in time. The NMDAS and NPMDS consist of the following four sections. Section 
1: Current function, gives insight into the general functioning of patients in past four 
weeks. Section 2: System-specific involvement, uses a clinical history supplemented 
by specific information to gain insight in the functioning of individual organ-systems. 
Section 3: Current clinical assessment, a general and neurological clinical examination, 
gives insight in the current functional status of the patient. This section includes three 
cognition tests. We were able to use the English symbol test, since it does not use 
language. For the reading test we used a Dutch equivalent test. In absence of a Dutch 
equivalent test for the Speed of Comprehension we could not use this test. We scored 
the cognition based on the symbol test and reading test only. 
Section 1 to 3 of the NMDAS consists respectively of ten, nine and ten questions, which 
can be scored from 0 (no involvement) to 5 (severe involvement). For section 4, Quality 
of life (QoL), we used a Dutch translation of the SF-12v2 quality of life test. A score from 
0 to 70 for mental and physical health, where 50 is the population mean, is obtained 
from this QoL score. The NPMDS exist respectively of seven, ten and nine questions, 
which can be scored from 0 (no involvement) to 3 (severe involvement). Section 4: 
Quality of life, uses a specially designed QoL questionnaire for children. These do not 
have a reference score, so we can only use them to show a difference in time, there-
fore they are not mentioned in this report. Intra-observer and inter-observer variability 
was shown to be low in both the NMDAS and the NPMDS.21 All patients were scored 
independently by the same two investigators (PdL, SK), after which consensus was 
reached. The consensus score is used in the results of the study.
m.3243A>G mutation analysis
At the same visit during which the NMDAS or NPMDS was scored, blood, saliva and 
urine was collected for heteroplasmy analysis. DNA was isolated from peripheral blood 
leukocytes using a salting-out method. The urine sediments and buccal swab samples 
were centrifuged for 10 minutes at 3000 rounds per minute, the pellet was washed 
with phosphate-buffered saline. DNA was extracted using a commercially available 
DNA isolation kit (PuregeneTM DNA isolation kit; Gentra Systems, MN). DNA samples 
were analysed quantitatively using PyrosequencingTM technology (Pyrosequencing, 
Upsala, Sweden). Pyrosequencing was performed according to the protocol of the 
manufacturer. PCR of a mtDNA fragment containing the 3243 position was performed 
using the following primers: universal primer (biotinylated), 50-GGGACACCGCTGATC-
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GTTTA-30; forward primer, 50-GACGGGACACCGCTGATCGTTTACAACTTAGTA 
TTATACCCACAC-30; and reverse primer, 50-ATTAGAATGGGTACAATGAGGA-30. 
PCR was carried out in a 50 ml volume containing 0.02 mM forward primer, 0.2 mM 
reverse primer and 0.2 mM of the biotinylated universal primer. PCR conditions were 
92°C for 30 s, 55°C for 30 seconds, 72°C for 30 seconds, for a total of 40 cycles. 
Single-stranded template DNA, which in the present assay is the forward strand of the 
fragment, was purified using streptavidin-coated Sepharose beads. The actual pyrose-
quencing was performed on the PSQ96 platform using sequence primer 50-TATGC-
GATTACCGGGC-30. In a pyrosequence reaction, the four different deoxynucleotide 
triphosphates (dNTPs) are added separately one after the other. The incorporation of 
dNTP is accompanied by release of pyrophosphate (PPi). This PPi is involved in a 
light-producing reaction of which the amount of light produced is proportional to the 
number of nucleotides incorporated. The light is detected by a charge coupled device 
camera and seen as a peak in a pyrogram. Apyrase, a nucleotide-degrading enzyme, 
continuously degrades ATP involved in the light-producing reaction, and unincorpo-
rates dNTPs. This switches off light production and regenerates the reaction solution. 
Because the forward strand is used as template in the sequencing reaction, the change 
detected in the present assay concerns a T to C exchange. In fact, the amount of dTTP 
and dCTP incorporated at position 3243 during the sequencing reaction was deter-
mined in this way and from this the percentage of heteroplasmy was calculated. The 
pyrosequence reaction of the m.3234A>G mutation has a precision of 1.5%. The muta-
tion is detected from a heteroplasmy level of 5%. The detection limit for the MELAS 
mutation (m.3243A>G) was determined by serial dilution of a sample containing this 
mutation with wild type mtDNA.
Statistics
We used descriptive statistics to present patient characteristics and the results of the 
NMDAS and NPMDS. All data are presented as a median with interquartile ranges 
(IQRs). Non-parametric tests were used if the data did not reflect a Gaussian distri-
bution. Spearman’s rho correlation coefficient was used to evaluate the relationship 
between the clinical scores with the heteroplasmy in the different tissues. Pearson’s 
correlation was used to correlate heteroplasmy in different levels to each other and 
to age. A t-test was used to compare the quality of life of the m.3243A>G mutation 
carriers to reference values.
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Results
Patient characteristics 
Hunderd-twenty-seven individuals from 34 families were included in the study. The 
cohort consists of 24 probands. Forty-eight family members were related in the first 
degree to a proband, 28 in the second degree, 18 in the third degree and nine in the 
fourth degree. The age of the patients ranged from two months to 80 years, median 39 
years (IQR 25 – 54 years). Forty-two patients were male and 85 female (ratio 1:2.02). In 
82 individuals the m.3243A>G mutation was detected in at least one of the samples. In 
45 family members the mutation was not detected. 
Children
Eleven children (4 male, 7 female) carrying the m.3243A>G mutation were scored using 
the NPMDS. Two boys were probands, the other nine patients were maternal family 
members. The median age was 6 years (IQR 5.5 – 8.5 years). Five children scored zero 
points on the NPMDS, two children scored one point, three children scored two points 
and one child scored four points. The main complaints were a delay in development (in 
five children) in early childhood, which had been caught up by the time of investigation. 
One girl attended special school for learning difficulties. One boy had communicational 
problems both in his native language (Turkish) as in Dutch. Heteroplasmy in UEC in 
these children ranged from 8 - 93% and had a median level of 59% (IQR 32 – 77%). 
Adults
Seventy-one adult carriers (25 male, 46 female) of the m.3243A>G mutation were 
scored using the NMDAS. The median age was 45 years (IQR 34 – 55 years). They had 
a median clinical score of 4 (IQR 1 - 7) on Section 1; 4 (IQR 1 - 8) on section 2; and 3 
(IQR 0 - 6) on Section 3. The total median score of Section 1-3 was 15 (IQR 10 - 24). 
Table 1 presents the symptoms sorted by prevalence. A complete overview of all results 
can be found in Figures 1A-C. 
Table 1. 
Signs and Symptoms of the m.3243A>G mutation scored by the NMDAS. Signs and symptoms scored by 
the NMDAS, sorted by prevalence (n = 71).
Signs & Symptoms Prevalence (%)
Hearing loss 68
Gastro-intestinal Symptoms 59
Decreased Vision 59
Exercise Intolerance 54
Glucose Intolerance 52
Gait Instability 51
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Summary of the most important findings: 
Hearing: 48 carriers (67.6%) had hearing difficulties; 24 carriers experienced mild deaf-
ness; whereas another 19 carriers had moderate deafness (not fully corrected with 
hearing aid); three carriers had severe deafness (poor even with hearing aid) and two 
carriers had end stage deafness requiring a cochlear implant. 
Exercise Tolerance: 38 carriers (53.5%) had a compromised exercise tolerance; 25 
were only limited on inclines or stairs; whereas the other carriers were also limited on 
flat services.
Cerebellar Ataxia 49
Myopathy 48
Cognition < 33th percentile 45
Ptosis 45
Cardiovascular Involvement 44
Vision Complaints 37
Respiratory Muscle Weakness 37
Problems Dressing 34
Problems Hygiene 34
Speech Difficulties 31
Psychiatric Problems 28
Migraine Headaches 25
Neuropathy 20
Swallowing Difficulties 18
Dysphonia / Dysarthria 17
Apraxia 13
Handwriting Difficulties 13
Seizures 13
CPEO 7
Encephalopatic Episodes 6
Stroke-like Episodes 6
Pyramidal Involvement 6
Extrapiramidal Involvement 3
CPEO = Chronic progressive ophthalmoplegia
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Figure 1 A-C
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Gait stability and cerebellar ataxia: 36 carriers (50.7%) reported difficulties maintaining 
their stability; 35 carriers (49.3%) had difficulties with the heel-toe test at the clinical 
assessment; eight carriers reported difficulties on uneven grounds; and 21 carriers 
reported occasional balance problems when walking. Six carriers reported occasional 
fal assessment 23 carriers had a hesitant heel-toe test; nine were unable to maintain 
heel-toe walking and three carriers were unable to walk heel-toe. 
Gastro-intestinal Symptoms: 42 carriers (59.2%) reported gastro-intestinal symp-
toms. 14 had mild constipation; six had occasional symptoms of irritable bowel; 17 
carriers had severe constipation (requiring daily medication) or severe irritable bowel 
complaints; in five carriers gastro-intestinal symptoms were that severe they needed 
hospital admission; three of them underwent surgical procedures for gastro-intestinal 
dysmotility.
Diabetes Mellitus: 37 carriers (52.1%) had a compromised glucose tolerance, for which 
ten were treated with tablets (non insulin depending diabetes mellitus) and 20 required 
insulin treatment (insulin depending diabetes mellitus); four patient were on a diet and 
two carriers received no treatment for impaired glucose tolerance, one patient reported 
diabetes gravidarum.
Ptosis: 32 carriers (45.1%) had a ptosis, mild ptosis (not obscuring either pupil) occurred 
in 23 carriers; moderate ptosis occurred in eight carriers; whereas one patient had a 
severe ptosis (obscuring bilateral >1/3 of pupils). 
Myopathy: 34 carriers (47.9%) had reduced muscle strength; 21 carriers had minimal 
muscle weakness in hip flexion or shoulder abduction only (MRC 4+/5); eight carriers 
had mild proximal muscle weakness (MRC 4/5) and four carriers had moderate muscle 
weakness (MRC 4) with difficulty to rise from 90 degree squat; one patient was unable 
to rise from 90 degree squat.
Cardiomyopathy: 25 carriers (38.5%) had cardiac involvement; 16 had asymptomatic 
changes on electrocardiogram, mainly repolarisation disturbances; one had asymptom-
atic left ventricular hypertrophy; seven had cardiomyopathy of which four had a ejection 
fraction of less than 30%; one patient had a pacemaker for a complete AV-block. 
Epilepsy: A history of seizures was present in nine carriers, of which three had had 
seizures in thalls because of balance problems; one patient was unable to walk unsup-
ported onclinice past year. 
Stroke-like episodes: A history of stroke-like episodes was present in four carriers, of 
which three had stroke-like episodes in the past year. 
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Further neurologic examination: Twelve carriers had subtle sensory symptoms or 
areflexia (in knee and elbow reflexes); four carriers showed symptoms of pyramidal 
involvement and two carriers showed symptoms of extrapyramidal involvement. 
Section 4 of the NMDAS scores QoL. It distinguishes Quality of Physical Health (QoLP) 
and Quality of Mental Health (QoLM). QoLP had a range of 17 to 61, with a median of 41 
(IQR 32 - 50). QoLM had a range of 25 to 66, with a median of 48 (IQR 42 – 48; Figure 2).
Using a t-test a significantly (p <0.001) lower QoLP was found in patients carrying the 
m.3243A>G mutation against the test average of 50. No difference in QoLM in carriers 
against the test average could be found (p = 0.055). Comparing QoL in carriers to non-car-
riers, there was a significant lower QoLP in carriers (p <0.001) and no difference in QoLM 
(p = 0.40). The QoLP was significantly negatively correlated to the NMDAS (r =  -0.57; 
p >0.001). There was no correlation between QoL and the heteroplasmy in any of the 
samples.
Figure 2 .
Quality of Life. Section 4 of the NMDAS is a QoL test, divided in QoLP and QoLM. All adult carriers of the 
m.3243A>G mutation are shown (n = 71). The line at 50 shows the US average of the test. QoLP is significantly 
lower than the US average.
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Heteroplasmy Levels
Heteroplasmy levels in leucocytes were determined in 126 individuals (one child refused 
the blood draw), in UEC in 121 individuals (insufficient material was received at the 
laboratory in six individuals) and in buccal mucosa in all 127 individuals. Eighty-two indi-
viduals had a heteroplasmy level of ≥5% in at least one of the samples. In the carriers, 
the mean heteroplasmy in leucocytes was 22% (range 2 - 65%); in UEC 48% (range 4 
- 96%) and 35% (range 2 - 74%) in buccal mucosa. Despite these differences between 
the samples there were strong pair wise correlations between the samples (r = 0.66 
- 0.85; p <0.001; Figures 3A-C). A negative correlation between the level of hetero-
plasmy and age was present in all samples , for leucocytes (r = -0.68; p <0.001), for 
UEC (r = -0.34; p = 0.003), and for buccal mucosa (r = -0.43; p <0.001), Figures 4A-C.
Figure 3A-C. 
Heteroplasmy levels in all patients carrying the m.3243A>G mutation. Heteroplasmy levels in all patients 
carrying the m.3243A>G mutation (n = 82) in three different samples (leucocytes, UEC and buccal mucosa) are 
correlated .
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Figure 4A-C.
Heteroplasmy versus age. Heteroplasmy levels in all patients carrying the m.3243A>G mutation (n = 82) 
show a negative correlation to age in leucocytes, UEC and buccal saliva.
The heteroplasmy level in UEC was below the detection limit in one (1%) carrier that 
did have a detectable mutation load in buccal mucosa and leucocytes. Heteroplasmy 
levels in buccal mucosa were below the detection limit in seven (9%) carriers that did 
have a detectable mutation load in UEC. Heteroplasmy levels in leucocytes were below 
the detection limit in 12 (15%) carriers that did have a detectable mutation load in UEC.
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A correlation between clinical condition of the patient and the level of heteroplasmy 
could not be made using the NPMDS in children, because of the limited number of 
paediatric carriers included in the study. In adults, there was a correlation between the 
score on the NMDAS and the heteroplasmy, in leucocytes (r = 0.25; p = 0.032), in UEC 
(r = 0.29; p = 0.016), and in buccal mucosa (r = 0.43; p <0.001; Figures 5A-C). Patients 
with a NMDAS of more than 20 (n = 25), have a better correlation between the clinical 
scores and the heteroplasmy levels in leucocytes (r = 0.37; p = 0.072), and UEC (r = 0.53; 
p = 0.008).
Figure 5A-C.
Heteroplasmy vs NMDAS score. Heteroplasmy levels in leucocytes, UEC and buccal saliva in all adult 
patients carrying the m.3243A>G mutation (n = 71) show a correlation to the score on the NMDAS.
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Discussion
Following the results of this study, we propose to introduce a new term in the mitochon-
drial genetic nomenclature: dormant carrier. The term ‘dormant carrier’ is used to indi-
cate that a patient that has a mitochondrial mutation, but has no obvious clinical symp-
toms of the mutation (yet). We have chosen this new term because we experienced 
that the nomenclature in mitochondrial inheritance has an overlap with nomenclature 
in Mendelian inheritance, which causes confusion in providing patient information. In 
the Mendelian nomenclature, a carrier is a patient that has a recessive mutation on one 
allele , and is never going to be a patient. On the contrary, a dormant carrier of a mito-
chondrial mutation may at some point become symptomatic (awake), depending on 
heteroplasmy levels and unknown other factors. In patient counseling and preventive 
medicine this makes a big difference. 
Since the Newcastle scores consists of subjective questions regarding the personal 
opinion of the patient on daily functioning (Section 1) and the interpretation of the find-
ings at physical examination (Section 3), all patients were scored separately by two 
investigators. Only ten patients aged under eighteen were included in the study. All ten 
children had no or only minor complaints. However, we did include four families in which 
a child had died earlier because of symptoms of the m.3243A>G mutation, so no defi-
nite assumption can be made concerning the phenotype of the m.3243A>G mutation 
in children based on this study. The study does however show that children can be 
free of symptoms even with a high level of heteroplasmy (up to 93% in UEC). The adult 
patients with high levels of heteroplasmy developed complaints in late infancy to early 
adolescence. The younger children with high levels of heteroplasmy should therefore be 
closely monitored to indentify early symptoms of the clinical expression of the mutation 
at an early stage.
The m.3243A>G mutation is most known for its relation with MELAS syndrome. In this 
study only one patient had stroke-like episodes in the past year and three other patients 
had stroke-like episodes in the past. Other neurologic symptoms as seizures (n = 9) 
and encephalopathy (n = 4) occurred also infrequent. Giving an indication that MELAS 
syndrome is not the primary expression of the m.3243A>G mutation in this cohort. 
This finding is in line with recent reports16 that the m.3243A>G mutation is much 
more prevalent than previously thought. Patients presenting with symptoms of MELAS 
syndrome are often referred to a specialised centre in which exploratory research for 
mitochondrial mutation in performed. A patient with the m.3243A>G mutation with a 
MELAS syndrome phenotype is therefore unlikely to be missed. 
Forty-eight patients (67.6%) of this study had self reported hearing loss. Thirty-seven 
patients (52.1%) have diabetes mellitus. Only six of the 37 patients with diabetes 
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mellitus do not have hearing loss. Making a total of 31 patients in this study that have 
diabetes deafness, giving an indication that MIDD is a more frequent expression of the 
m.3243A>G mutation than MELAS syndrome. The combination of diabetes mellitus 
and hearing loss is however less a trigger to refer a patient to a specialised centre. So 
a mutation analysis is less frequently performed. 
Besides the typical symptoms of MELAS syndrome or MIDD we observed high frequen-
cies of other symptoms. Cardiac involvement, gastro-intestinal symptoms and visual 
disturbances are most frequent. Cardiac involvement has previously been described.9,22,23 
In our cohort we found a large group of patients with asymptomatic ECG changes on 
one hand, but some severely affected patients as well. In the four patients with an 
ejection fraction of less than 30% the cardiac problems dominate the clinical picture. 
A large number of patients in our cohort exhibits gastro-intestinal problems. In most 
cases patients suffer from mild to moderate constipation or symptoms of irritable bowel 
syndrome. In five patients symptoms required admission or even surgical intervention. 
Cases of chronic intestinal pseudo obstruction have previously been described in patients 
with the m.3243A>G mutation.24,25 Twenty-six percent of the patients reported visual 
disturbances and 42% of the patients did not have a vision of 1.0 on a brief visual acuity 
test. Previous reports indicate the presence of macular dystrophy in patients with the 
m.3243A>G mutation.10,26 Because of this multi-organ involvement of the m.3243A>G 
mutation we recommend that all carriers of the mutation are checked for early stages of 
these symptoms by specialised physicians, including a consultation by a cardiologist and 
a ophthalmologist, also when there is no diabetes present.
 
We assessed quality of life in our cohort using the SF-12v2 questionnaire. A lower QoLP 
is negatively correlated to the NMDAS. Indicating, as suspected, that when a patient 
has more symptoms of the m.3243A>G mutation, a lower QoLP is reported. QoLM was 
not different from healthy controls nor from their relatives that do not carry the muta-
tion. Twenty patient did report a history of depression or anxiety. This was however not 
significantly different from their relatives that did not carry the mutation.
As indicated in Figure 5A-C we found a correlation between NMDAS and heteroplasmy 
in all three samples, of which buccal mucosa had the best correlation (r = 0.43; p <0.001 
versus r = 0.25; p = 0.032 in leucocytes and r = 0.29; p = 0.016 in UEC). When we 
selected for the most severely affected patients (NMDAS >20) we found stronger correla-
tion for leucocytes (r = 0.37; p = 0.072) and UEC (r = 0.53; p = 0.008). Whittaker et al. 
20 was the first to describe a correlation between heteroplasmy and symptoms. We 
confirm the good ability of UEC heteroplasmy predict clinical outcome but add that this 
accounts most for the more severely affected patients. In the general group of carriers 
of the m.3243A>G mutation heteroplasmy in buccal saliva has a better ability to predict 
clinical outcome. 
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Different studies have described a decrease in heteroplasmy with increasing age.3,13,27 
As demonstrated in Figure 4A-C, we also find a decreasing heteroplasmy in all samples. 
The decrease in heteroplasmy with increasing age is much more prominent in leuco-
cytes (r = -0.71; p <0.001) than in the other samples (r(UEC) = -0.37; p = 0.001; 
r(buccal mucosa) = -0.46; p <0.001). However the decrease in heteroplasmy level with 
age can only be confirmed after a prospective follow-up study. We also found that 
heteroplasmy in UEC has a 26 percent point higher value than heteroplasmy in leuco-
cytes and a 11 percent point higher value than heteroplasmy in buccal mucosa. The 
m.3243A>G mutation was undetectable in leucocytes in 12 patients in which the muta-
tion was detected in UEC. Of these 12 patients the mutation was also undetectable 
in buccal mucosa in seven patients. There was one patient in which the m.3243A>G 
mutation could not be detected in UEC, where it was detected in leucocytes and buccal 
mucosa. However we should take in account that we can never predict the values of 
untested tissues as muscle, heart, kidney, liver or brain. This makes that UEC are the 
best non-invasively available tissue to test if a patient is suspected of the m.3243A>G 
mutation. 
Conclusion
We conclude that the m.3243A>G mutation causes a wide variety of signs and symp-
toms, MIDD being the most prevalent phenotypic expression. Of the three non-invasively 
available tissues for testing heteroplasmy, we advice to use UEC to detect the mutation. 
Dormant carriers should be checked regularly by a specialised physician to see whether 
the disease has awaken and to be early in preventing and treating symptoms. 
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Lack of energy and tiredness are among the most burdensome complaints experi-
enced by children with mitochondrial disease and therefore, outcome measures for 
these symptoms are urgently needed. Many laboratory tests and questionnaires to 
assess fatigability are not feasible in children with mitochondrial disease. Moreover, 
measuring the activity at home may better reflect the lack of energy and tiredness 
experienced by these children than a laboratory test. The aim of this study was to test 
the feasibility, validity, and test-retest reliability of measuring daily physical activity with 
3D accelerometers placed on chest, upper arm, lower arm, leg and if available wheel-
chair in children with mitochondrial disease and compare them to healthy age- and 
gender-matched controls. 
In 17 children with confirmed mitochondrial disease and 16 peers, we found that 
measuring daily physical activity during the whole weekend was practically feasible in all 
participants. Four percent of the measurements failed because of hardware problems, 
leading to the exclusion of one healthy child. We found good face validity by visually 
correlating the validation videos and activity diaries to the accelerometer data-graphs. 
Moreover, accelerometry confirmed lower dynamic activity (i.e. walking) in non-ambu-
latory patients compared to ambulatory patients. Patients with mitochondrial disorders 
had significantly lower peak-intensity and were resting more compared to their age- 
and gender-matched peers. Testing eight children in another season with significantly 
different temperature and hours of sun showed good test-retest reliability.
We conclude that accelerometry is a promising measurement tool for future studies in 
children with mitochondrial disease. Before using the accelerometer as an outcome 
measure in clinical trials, technical failures will have to be solved and family activities 
should be standardised. 
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Introduction
Many potential therapies have been attempted in patients with mitochondrial disorders, 
however to date, none of them has proven beneficial.1 This is partly due to a lack of 
sensitive and responsive outcome measures. In a recent review of all published studies 
in mitochondrial disease, an international expert panel recommended (amongst others) 
to use validated and clinically meaningful end points.1 Only very few studies investiga-
ting outcome measures in paediatric mitochondrial disease have been published and 
most of the outcome measures studied are not generally applicable among children 
with mitochondrial disease. 
Since lack of energy and fatigue are among the most burdensome complaints experi-
enced by children with mitochondrial disease and their parents,2 this symptom should 
be covered in future clinical trials. However, testing fatigue or fatigability in this paedi-
atric population is challenging, since many children are not able to rate their fatigue 
using one of the widely used self-report fatigue questionnaires3,4 because of intellec-
tual disabilities and most endurance tests (e.g. cycle ergometry5) are not feasible or 
too burdensome for children with mitochondrial disorders. Besides, measuring perfor-
mance in a laboratory situation may not always reflect the disabilities experienced in 
daily life since the performance in daily life may differ from the abilities of the child.6-8
We hypothesised that measuring daily physical activity at home is a clinically relevant 
outcome measure and a good reflection of the fatigue experienced by children with 
mitochondrial disease in daily life. Physical activity is defined as ‘any bodily move-
ment produced by skeletal muscle contraction that results in caloric expenditure’ and 
includes sports, hobbies, playing, walking, cycling and activities of daily living.9 Of the 
many dimensions of physical activity (type, intensity, frequency, and duration), we were 
most interested in the intensity, frequency and the duration of movement. We hypo-
thesised that the physical activity of children with mitochondrial disease would be less 
intense and consisting of shorter active periods with longer periods of resting. 
Daily physical activity in a home situation can be measured by using 3D accelero-
metry.10-16 For this study, we selected the MOX-accelerometer, a device with opportu-
nities to design a tailored analysis and to measure for long periods of time (14 days). 
Here, we aim to test the feasibility, validity and test-retest reliability of using 3D acceler-
ometry as a predictor for daily activity of children with mitochondrial disease.
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Methods
This is an observational study, testing the feasibility, validity and test-retest reliability 
of various parameters that were calculated based on accelerations measured by 3D 
accelerometers in indicating physical activity of children with mitochondrial disorders. 
MOX-accelerometer
For this study, we used a MOX accelerometer (MOX sensor, model MMOXX1.01, Maas-
tricht Instruments BV, The Netherlands), that measures accelerations (range ± 6G) in 
three degrees of freedom with a sample frequency of 25Hz. The acceleration data was 
fi ltered with a Butterworth 0.025-7.5Hz 4th-order high-pass fi lter to remove noise and 
movement artefacts. 
A set of four or fi ve sensors was used. The accelerometers were attached to the chest, 
dominant lower arm and upper arm and to the leg using an attachment band (limbs) or 
a top (chest; Figure 1). If the patient used a wheelchair, a fi fth accelerometer was atta-
ched to the wheelchair. The wheelchair sensor was used to indicate passive moments 
of the child.
To estimate the amount of daily activity, various parameters were calculated from the 
acceleration data of each sensor, by using Matlab procedures that were developed 
before.17 The fi rst parameter are the activity counts, which was calculated by integrating 
the acceleration over 1-minute episodes and summing this outcome over all three axes. 
A constant acceleration of 1G (gravitational constant) over 1 minute corresponds with 
1,000 counts.
A
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We used the following outcome measures: i) average amount of counts per hour 
the sensors were worn (average counts (total amount of counts measured with the 
sensor/worn hours; counts/hour), also referred to activity level); ii) the maximal inten-
sity (maximal amount of counts per min (counts/min)); and iii) the largest area under 
the curve (AUC) during 30 minutes (largest AUC during ½ hour (counts)). The second 
outcome measure is an activity classifi cation which categorises the performed activi-
ties per second into lying, standing or being dynamically active. Lying and standing 
are classifi ed depending on the gravitational angle acting on the posterior-anterior and 
cranial-caudal axes. Being dynamically active is classifi ed when the integration of the 
acceleration over 1-second episodes is above a pre-defi ned threshold.
Study protocol
Study protocol for patients
Patients were recruited at the Nijmegen Centre for Mitochondrial Disorders. Patients 
aged 4 - 18 years old with a confi rmed mitochondrial disease, either based on patho-
logical mutations in mtDNA or nuclear DNA or on mitochondrial dysfunction in fresh 
muscle as measured by routine biochemistry as applied in our centre, were eligible for 
inclusion. Exclusion criteria: i) expected by the treating physician that travelling to the 
hospital would be too burdensome to the patient; ii) fever; iii) epilepsia continua; or iv) 
altered state of consciousness compared to normal at the time of inclusion. 
Patients were assessed at the outpatient clinic of the Nijmegen Centre for Mitochondrial 
Disorders (NCMD) on Fridays. An experienced paediatric physiotherapist performed the 
Gross Motor Function Measure-88 (GMFM) and the Modifi ed Tardieu test for spasticity 
to assess the motor abilities and the presence of spasticity in each individual child. 
Figure 1. 
The accelerometer localisations. A) The MOX-accelerometer is approximately 4.5 x 4.0 x 1.4 cm in size 
and weighs 27 grams; B) Attachment of the accelerometer to the (dominant) upper leg; C) to the chest; D) the 
upper- and E) the lower arm.
D E
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The GMFM is an instrument measuring gross motor abilities in children. Though it was 
originally designed for and validated in patients with cerebral palsy,18-20 the GMFM is 
able to measure reliably in neuromuscular disorders as well.21 The GMFM is expressed 
as a percentage of the highest score. The modified Tardieu test measures spasticity 
by passively moving the joint at specified velocities and scoring the angle at which the 
muscle reaction to stretch is felt.22, 23 We performed the Modified Tardieu of the ankles 
(mm. gastrocnemicus), the elbows (mm. biceps brachii) and the knees (hamstrings) 
bilaterally in patients with increased muscle tone. 
After the two tests, parents were instructed how to attach the accelerometers. Wearing 
the sensors, patients were – if possible - instructed to follow a validation protocol 
(standardized activities, including waving, throwing a ball, lying down, sitting, standing, 
walking and running). In case of limited physical abilities, the position (orientation) of the 
arm, leg and chest was changed passively, if possible at low, middle and high velocity 
(intensity). The patient was videotaped with a synchronized camera during all tests, 
to be able to correlate specific movements (e.g. raising an arm, walking, movement 
disorders or epilepsy) to the data obtained by the accelerometer. By correlating these 
video images with the accelerometer data-graphs (correspondence of orientation and 
intensity for each sensor) we determined the face validity of the measurements in a 
laboratory situation.
After completion of the validation protocol, patients were asked to wear the sensors 
over the weekend, while the parents completed a diary, rating the happiness and the 
activity of the child. The accelerometry measurements were located at the patients’ 
home environments. Parents were asked to complete the diary with the exact timing 
and a description of the activity (e.g. 12:36 – 13:18: Lunch, independently eating bread 
with knife and fork). During the weekend, patients were asked to wear the accelerome-
ters at all waking hours, with the exception of bathing, showering and swimming. The 
reported activities were also correlated to the accelerometer data-graphs to determine 
face validity of the measurements at home.
On Monday, the feasibility and comfort of the accelerometers was evaluated and the 
Pediatric Evaluation of Disability Inventory (PEDI) measuring the performance and capa-
bility (self-care, mobility and transfers and functioning) in the activities of daily life of 
children up to 7.5 years of age, was performed by phone.19, 24 Since most children with 
mitochondrial disease are severely limited in their daily activities, we used the PEDI for 
all age groups. 
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Study protocol for healthy controls
The healthy controls were recruited at two regular schools in the surroundings of 
Nijmegen. Healthy controls were eligible for inclusion when they were healthy and aged 
between 4 and 18 years. Exclusion criteria: i) confirmed diagnosis of Attention Deficit 
and Hyperactivity Disorder (ADHD); ii) symptoms of exercise intolerance, fatigue or 
muscle problems; or iii) the child was under regular surveillance of a paediatrician. 
Controls were gender- and age matched to a single patient.
Healthy controls were instructed in their home-environment in the same weekend as 
the age- and gender-matched patient. The attachment and localisation of the acceler-
ometers was the same as the patient protocol. Validation, using the validation protocol 
and videotaping, was also similar to the patient protocol. Healthy controls were also 
instructed to wear the accelerometer during waking hours and to keep an activity diary. 
On Monday, the feasibility and comfort of the accelerometers was evaluated.
Analyses
Feasibility
Feasibility was tested using the parent reported complications of wearing the acce-
lerometers and the quantity of the data obtained (% of subjects; the time the device 
collected data as a percentage of the intended measurement period (Saturday 0:00 – 
Sunday 23:59) and the time the device collected data as a percentage of the time the 
sensor was worn). Only patients in whom more than one sensor failed were excluded 
from the analyses. For the patients in which one sensor failed, only the available data 
are presented. 
Validity
Validity was assessed by visually correlating the videos with the obtained accelero-
meter data-graphs (correspondence of orientation and intensity for each sensor) during 
the validation protocol in each subject. Subsequently, the data from the diaries was 
correlated to the accelerometer data-graphs (correspondence of the intensity of the 
movements during the described activities). Only when the video images and described 
activities clearly did not correlate to the data-graphs, the data were excluded from the 
analyses. We assessed whether the percentage of dynamic activity and the total leg 
activity was lower in non-ambulatory children compared to ambulatory children. Finally, 
the functional abilities, assessed by the GMFM and the PEDI were correlated to the 
measurements. 
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Patients versus controls
We compared patients and their age- and gender matched controls on each of the 
above mentioned variables. On an individual level, only the percentage of rest was 
compared between patients and their age and gender matched controls.
Test-retest reliability
Test-retest reliability was assessed by asking five patients and five age- and gender 
matched controls to wear the sensors in another season (summer versus spring). 
Covariates
The presence of covariates was assessed by interviewing parents (hours of sports and 
screen time per week, level of education of parents, hours or sports and body mass 
index (BMI) of the parents) or by the weather report (Buienradar, Weerplaza). For the 
analyses assessing the influence of weather conditions, both the results of the test and 
the retest were used. The following cut-off values were used to indicate ‘good weather 
conditions (e.g. to play outside)’: less than 5 mm of rain over the whole weekend; 
average maximum temperature between 15 and 25 degrees Celsius; and average more 
than 6 hours of sun per day. Good weather was defined as matching 2 out of 3 criteria; 
perfect weather was defined as matching all criteria. The influence of these covariates 
was on the following parameters for activity was assessed: percentage of rest, percen-
tage of dynamic activity, average activity of the upper leg and maximal activity of the 
upperleg in 30 minutes. 
Statistical analyses
Because of the relatively small number of subjects included in our study, we used 
non-parametric tests to assess differences and correlations. Correlation coefficients 
were interpreted in accordance with the guidelines provided at the BMJ website 
(http://www.bmj.com/about-bmj/resources-readers/publications/statistics-squa-
re-one/11-correlation-and-regression). We used a p-value of 0.05 for statistical signifi-
cance. Because of the small numbers and the exploratory character of this study, we 
did not use Bonferroni adjustment. All analyses were performed using IBM’s SPSS 
statistics software packages, version 20.0.0.1. 
Ethics
This study was approved by the regional Medical Research Ethics Committee (MREC 
NL50560.091.14). In accordance with the Helsinki agreement, written informed consent 
was obtained from participant’s legal guardian and, where indicated, the participant.
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Results
Study population
Seventeen patients and 16 healthy age- and gender-matched controls were included 
in this study from February to May 2015. One healthy control withdrew his consent 
one day before the measurement would start and no other age- and gender matched 
control was available for that weekend. The groups were comparable with respect to 
age, gender, BMI and sports- and highest education of parents, but – as expected – 
differed significantly with respect to height, weight, time spent at sports and the level 
of education of the child (Table 1), as well as for the BMI of father. There was a wide 
variability in the genetic, biochemical, clinical and functional abilities in the children with 
mitochondrial disease (Supplementary Document 6). 
Table 1: Characteristics of patients and their age- and gender-matched controls. 
Patients (n = 17) Healthy controls (n = 15)
Median (range) Median (range) Difference 
between groups 
(p-value)
Gender (male) 8  6  0.69
Age, years 13 (7 - 16) 13 (8 - 17) 0.58
Height, cm 141 (123 - 182) 163 (133 - 188) 0.01
Weight, kg 35 (22 - 75) 52 (30 - 74) 0.01
BMI (kg/m2) 17.4 (11.7 – 25.0) 19 (14.2 - 24.4) 0.26
Sports, min/week 0 (0 - 240) 300 (60 - 720) <0.001
Level of education
Primary education 2  3  <0.001
Lower general secondary 
education
1  1  
Higher to a-level general 
secondary education
1  11  
Special education 13  0  
Screen time, min/day 90 (0 - 300) 150 (60 - 210) 0.91
BMI father (kg/m2) 27.0 (22.0 - 39.2) 23.4 (20.8 - 31.2) 0.004
BMI mother (kg/m2) 26 (20.5 - 41.8) 24.0 (19.6 - 28.0) 0.15
Completed education father
Intermediate vocational 10  3  0.05
Higher vocational 6  6  
University 1  5  
Completed education 
mother
Intermediate vocational 10  7  0.13
201
Feasibility
All participants, including patients with severe mental retardation, tolerated wearing the 
accelerometers for the duration of the measurement. One patient experienced squee-
zing of the attachment-top for the chest sensor. The full study protocol was completed 
by 29 children (88% of total study population): three participants temporarily removed 
the sensors: two removed the top to ventilate after exercise and because of a party, 
one did not attach the chest sensor on Sunday because of discomfort of the top and 
one boy lost his upper leg sensor during outdoor playing. Five sensors failed to record 
any data and the batteries of one sensors failed during the measurements (18% of all 
participants; 4% of all measurements). Due to these technical issues, 6% of the total 
measured time and 8% of the time the sensors were worn was missing in 6 partici-
pants (4 patients and 2 healthy controls). One healthy control had to be excluded from 
the analyses because he lost his upper leg sensor and his upper arm sensor failed 
to record any data. Most subjects wore their sensors from the moment they awoke 
to the moment they undressed for bed; three participants removed all sensors after 
dinner (averagely sensors were worn 94% of the woken time). The time the sensors 
were taken off because of swimming, showering or bathing was 1.9%. The time the 
sensors were not worn because of lack of understanding or lack of motivation was 
8.7%. The GMFM and the PEDI were successfully executed in all patients. The Tardieu 
was feasible in all but one patient, who was not able to relax and lie still.
Validity
For all patients and healthy controls, the movements (orientation, intensity) at the videos 
corresponded to the acceleration data that was visualized in graphs. In ambulatory 
versus non-ambulatory patients, dynamic activity (i.e. walking) was higher, but the total 
activity of arms and legs did not reach significance in our small cohort (Table 2; p = 
0.03 (p-level of 0.0042 accepted after Bonferroni correction)). For these analyses, we 
excluded a boy who was not able to walk but had excellent abilities to move (on his 
buttock), but not to walk, from these analyses since we could not define in which group 
he belonged. We found a (very) strong and significant correlation between the motor 
abilities as measured with the GMFM and the resting percentage (ρ = -0.82), the largest 
amount of activity of the leg during half an hour (ρ = 0.65) and the peak-activity of the 
lower arm (ρ = 0.67; all p <0.0001). The score on the mobility domain of the PEDI 
Higher vocational 7  4  
University 0  3  
Sports father, min/week 0 (0 - 240) 150 (0 - 360) 0.06
Sports mother, min/week 60 (0 - 180) 120  0.13
Significant p-values are 
indicated in bold; BMI = 
Body Mass Index
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Figure 2.
Raw data for a matched couple. The couple (couple 3) with the most striking difference was selected, the 
healthy control is in Figure 2A and Figure 2B represents the patient.
(functional abilities) also correlated very strongly with the resting percentage (ρ = -0.87) 
and strongly with the largest amount of activity of the leg during half an hour (ρ = 0.70) 
and the peak-activity of the leg (ρ = 0.60; all p <0.0001; Supplementary Document 7).
Patients versus controls
The patients with mitochondrial disorders in our cohort had lower maximal intensity 
and were resting more compared to their age- and gender-matched controls (Table 2; 
Figure 2). 
A
B
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We saw no difference in arm activity between patients and controls. When compa-
ring individual results, all but one patient had higher percentages of rest during the 
weekend, except for one girl matched to a healthy girl who had to study for her final 
exams during the whole weekend (couple 2 in Figure 3). 
Test-retest reliability
Five patients and five healthy controls were included in the retest from June to July 
2015. Two patients were matched to another age- and gender matched control 
because of the healthy control was not available in the same weekend as the patient. 
One patient refused to participate because of the weather conditions (exceptionally 
warm for the Netherlands: 35°C with high humidity); her healthy control was therefore 
also excluded from the analyses. We experienced no technical failures during the retest. 
The retest was averagely executed 2.4 months later (spread 1.7 – 3.5 months), always 
in a different season (spring versus summer). The children selected for the retest were 
comparable with respect to age, BMI, screen time, time spent at sports activities, as 
well as PEDI and GMFM score (p = 0.05 – 0.8). The weather was not comparable 
with respect to temperature and hours of sun (p = 0.012 and p = 0.036, respectively; 
higher in summer), though the amount of rain was comparable (p = 0.13). The time the 
sensorswere worn at the retest were not significantly different from the first test (p = 
0.48). We found that the activity (activity level, maximal intensity and largest AUC during 
30 minutes) in summer were not significantly different from the activity in spring (p = 
0.21 – 1.0; Table 3). 
Figure 3.
Percentage of rest during the weekend for patients versus matched controls. The healthy girl of couple 
2 had to study the for her final exams during the weekend. The patient in couple 3 is a boy with behavioural 
problems and hyperactivity who removed the sensors during his afternoon nap (percentage of rest is 
expressed as a percentage of the hours the accelerometers were worn). The dark bar represent the patients 
and the light bars represent their matched controls. 
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Table 2.
Average activity over the w
eekend for children w
ith m
itochondrial disease com
pared to age- and gender-m
atched controls. W
e excluded a boy w
ho w
as not able to 
w
alk but had excellent abilities to m
ove (on his buttock), but not to w
alk, from
 the am
bulatory/non-am
bulatory analyses since w
e could not define in w
hich group he belonged.
Patients (n = 17)
H
ealthy controls 
(n = 15)
Am
bulatory 
patients (n = 9)
N
on am
bulatory 
patients (n = 7)
M
yopathy (n = 7)
Enchephalo-
m
yopathy (n = 10)
M
edian
Range
M
edian
Range
p-value 
for 
difference 
betw
een 
patients 
and 
healthy 
controls
M
edian
Ranger
M
edian
Ranger
p-value for 
difference 
betw
een 
am
bula-
tory and 
non-
am
bu-
latory 
patients
M
edian
Ranger
M
edian
Ranger
p-value for 
difference 
betw
een 
patients w
ith 
m
yopathy 
and patients 
w
ith 
encephalo-
m
yopathy
W
ear tim
e (hours 
per day)
10
(8 - 13)
12
(6 - 15)
0.004
12
(9 - 14)
11
(9 - 12)
0.54
11
(8 - 13)
10
(8 - 12)
0.28
Average %
 rest
86
(44 - 99)
60
(2 - 89)
<0.001
73
(44 - 90)
98
(86 - 99)
0.006
77
(63 - 99)
89
(44 - 98)
0.6
Average %
 
standing
4
(0 - 23)
18
(7 - 48)
0.004
16
(4 - 23)
1
(0 - 3)
<0.001
10
(0 - 23)
3
(0 - 22)
0.8
Average %
 
dynam
ic activity
13
(1 - 50)
18
(5 - 33)
0.02
14
(3 - 34)
5
(1 - 50)
0.09
13
(1 - 50)
9
(5 - 35)
0.4
Average counts 
upper leg (1.000 
counts/hour)
9.4
(3.1 - 29.6)
18.0
(7.0 - 27.2
0.008
12.7
(8.2 - 29.6)
5.5
(3.1 - 17.4)
0.03
9.1
(3.1 - 16.9)
10.0
(5.1 - 29.6)
0.7
Average counts 
upper arm
 (1.000 
counts/hour)
15.7
(11.3 - 36.2)
19.0
(10.5 - 30.2)
0.3
18.9
(14.2 - 32.2)
14.3
(11.3 - 36.2)
0.10
16.5
(11.3 - 25.2)
15.5
(13.2 - 36.2)
0.6
Average counts 
low
er arm
 (1.000 
counts/hour)
21.5
(16.1 - 41.8)
27.1
(15.3 - 37.1)
0.3
23.3
(18.9 - 40.3)
20.0
(16.1 - 41.8)
0.10
21.5
(16.1 - 31.8)
21.2
(17.8 - 41.8)
0.9
Average counts 
w
heelchair (1.000 
counts/hour)
1.3
(0.7 - 1.4)
NA
NA
NA
0.8
1.3
(0.7 - 1.5)
0.60
NA
1.4
1.2
(0.7 - 1.5)
0.9
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M
axim
al intensity 
upper leg (1.000 
counts/m
in)
0.97
(0.5 - 2.6)
1.9
(0.9 - 2.6
<0.001
1.3
(0.7 - 2.6)
0.9
(0.5 - 1.0)
0.03
0.9
(0.5 - 1.7)
1.0
(0.9 - 2.6)
0.6
M
axim
al intensity 
upper arm
 (1.000 
counts/m
in)
0.97
(0.8 - 1.9)
1.6
(0.9 - 2.1)
<0.001
1.1
(0.8 - 1.9)
0.9
(0.8 - 1.2)
0.06
1.0
(0.9 - 1.4)
1.0
(0.8 - 1.9)
0.8
M
axim
al intensity 
low
er arm
 (1.000 
counts/m
in)
1.2
(0.9 - 2.2)
1.9
(1.0 - 2.5)
<0.001
1.4
(1.0 - 2.2)
1.1
(0.9 - 1.4)
0.09
1.2
(1.0 - 1.8)
1.2
(0.9 - 2.2)
0.9
Largest AUC 
during ½
 hour 
upper leg (1.000 
counts)
10.4
(6.4 - 37.3)
26.8
(11.4 - 66.2)
<0.001
20.2
(8.9 - 37.2)
9.9
(6.4 - 17.3)
0.03
9.5
(6.4 - 37.3)
13.9
(7.4 - 30.7)
0.4
Largest AUC 
during ½
 hour 
upper arm
 (1.000 
counts)
15.8
(1.1 - 27.3)
25.3
(11.7 - 368)
0.003
17.9
(14.0 - 27.3)
14.6
(11.1 - 25.1)
0.09
15.5
(11.1 - 27.3)
17.0
(11.9 - 25.1)
0.5
Largest AUC 
during ½
 hour 
low
er arm
 (1.000 
counts)
21.2
(16.0 - 34.8)
30.8
(16.7 - 43.4)
0.004
25.6
(18.5 - 34.8)
18.2
(16.0 - 29.3)
0.04
20.4
(16.0 - 34.8)
22.9
(16.7 - 29.9)
0.5
S
ignificant p-values are indicated in bold; A
U
C
 = A
rea under the curve; m
in = m
inutes
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Except for the temperature (p = 0.02), the weather between the Saturdays and the 
Sundays was comparable (Table 4). Comparing Saturday to Sunday, we only found 
signficantly lower arm activity in patientsin on Sunday compared to Saturday (21.1 vs 
21.9; Table 4). Sensors were worn for more hours on Saturdays compared to Sundays 
(p = 0.002 for both groups).
Covariates
Good or perfect weather was not associated with increased activity (p = 0.25 – 0.74 
and p = 0.37 – 0.71, respectively). Activity was also not different between weekends 
with more than 5 mm of rain, compared to those with less than 5 mm of rain (p = 0.36 
– 0.81).
Table 3. 
Test-retest in four patients and four controls. One patient refused to wear the accelerometers because of 
warm weather (35 °C). 
First weekend Second weekend P-value for difference 
between first and 
second weekend
Median (range) Median (range)
Wear time (hours per day) 11 (9 - 14) 10 (6 - 15) 0.48
Sun (hours) 8 (2 - 10) 13 (7 - 18) 0.002
Temperature (°C) 34 (13 - 25) 33 (30 - 37) 0.001
Amount of rain (mm) 2 (0 - 9) 0 (0 - 4) 0.9
Average % rest 75 (32 - 98) 70 (55 - 98) 0.5
Average % standing 5 (0 - 48) 14 (0 - 32) 0.8
Average % dynamic activity 14 (2 - 33) 13 (2 - 21) 0.6
Average counts upper leg 
(1.000 counts/hour)
12.4 (5.1 - 27.2) 12.6 (4.8 - 21.6) 0.6
Average counts upper arm 
(1.000 counts/hour)
16.6 (13.8 - 25.0) 16.3 (11.5 - 22.3) 0.3
Average counts lower arm 
(1.000 counts/hour)
21.9 (17.8 - 34.5) 22.5 (11.9 - 30.8) 0.7
Maximal intensity upper leg 
(1.000 counts/min)
1.3 (0.9 - 2.5) 1.3 (0.7 - 3.3) 0.7
Maximal intensity upper arm 
(1.000 counts/min)
1.3 (0.8 - 1.9) 1.3 (0.7 - 2.1) 0.3
Maximal intensity lower arm 
(1.000 counts/min)
1.6 ( 0.9 - 2.5) 1.3 (1.0 - 2.5) 0.7
Largest AUC during ½ hour 
upper leg (1.000 counts)
17.1 (9.9 - 45.8) 18.0 (7.4 - 23.2) 0.2
Largest AUC during ½ hour 
upper arm (1.000 counts)
17.5 (11.9 - 30.7) 19.5 (11.1 - 24.2) 1.0
Largest AUC during ½ hour 
lower arm (1.000 counts)
21.8 (16.7 - 36.2) 21.6 (16.0 - 33.4) 0.8
Significant p-values are indicated in bold; AUC = Area under the curve; min = minutes
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M
axim
al intensity upper arm
 
(1.000 counts/m
in)
1.0
(0.7 - 1.9)
1.0
(0.8 - 1.5)
0.7
1.4
(0.8 - 2.1)
1.2
(0.8 - 1.9)
0.6
M
axim
al intensity low
er arm
 
(1.000 counts/m
in)
1.1
(0.9 - 2.2)
1.2
(0.9 - 1.8)
0.6
1.8
(1.0 - 2.8)
1.5
(1.0 - 2.5)
0.3
Largest AUC during ½
 hour 
upper leg (1.000 counts)
10.4
(6.4 - 37.3)
9.9
(1.3 - 18.7)
0.5
24.0
(11.4 - 66.2)
19.0
(6.0 - 63.2)
0.7
Largest AUC during ½
 hour 
upper arm
 (1.000 counts)
15.3
(10.5 - 27.3)
15.2
(11.1 - 26.4)
0.5
23.4
(11.7 - 25.8)
18.3
(8.0 - 36.8)
0.6
Largest AUC during ½
 hour 
low
er arm
 (1.000 counts)
20.4
(12.7 - 34.8)
19.4
(15.8 - 32.8)
0.7
37.1
(16.5 - 40.6)
24.8
(11.7 - 43.4)
0.2
A
 level of p = 0.0042 w
as used for significance; significant p-values are indicated in bold; A
U
C
 = A
rea under the curve; m
in = m
inutes 
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Table 4. 
Activity on Saturday versus Sunday for patients and healthy controls. 
Patients (n = 17)
Saturday
Sunday
Healthy controls (n = 17)
Saturday
Sunday
M
edian (range)
M
edian (range)
p-value for 
difference betw
een 
Saturday and 
Sunday in patients
M
edian (range)
M
edian (range)
p-value for difference 
betw
een Saturday 
and Sunday in 
healthy controls
W
orn hours
11
(8 - 16)
10
(4 - 13)
0.002
13
(10 - 18)
11
(7 - 15)
0.002
Sun (hours)
2.5
(0.8 - 10.0)
5.6
(0.0 - 13.7)
0.1
2.8
(0.0 - 7.6)
7.6
(0.0 - 13.4)
0.1
Tem
perature (°C)
15.5
(7.4 - 17.0)
16.5
(6.4 - 19.1)
0.02
15.4
(5.5 - 17.7)
17.1
(5.5 - 17.7)
0.02
Am
ount of rain (m
m
)
0.8
(0 - 5.1)
0
(0.0 - 20.6)
0.6
1.6
(0.0 - 6.3)
0
(0.0 - 15.3)
0.4
Average %
 rest
83
(51.7 - 99.2)
89
(35.4 - 99.3)
0.5
65
(35 - 84)
54
(28 - 94)
0.7
Average %
 standing
1
( 0.0 - 22.3)
5
(0.0 - 25.5)
0.7
17
(7 - 46)
18
(3 - 49)
0.4
Average %
 dynam
ic activity
6
(0.8 - 30.6)
6
(0.7 - 39.0)
0.7
17
(6 - 27)
22
(3 - 51)
0.2
Average counts upper leg 
(1.000 counts/hour)
9.7
(2.9 - 29.3)
9.2
(3.4 - 30.0)
0.2
15.2
(7.8 - 23.6)
18.2
(5.6 - 40.2)
0.4
Average counts upper arm
 
(1.000 counts/hour)
16.6
(10.3 - 36.5)
16.2
(12.0 - 36.0)
0.4
17.8
(11.2 - 25.4)
20.3
(9.3 - 35.0)
0.2
Average counts low
er arm
 
(1.000 counts/hour)
21.9
(14.9 - 41.3)
21.1
(14.0 - 42.3)
0.03
26.0
(14.1 - 32.6)
28.0
(13.6 - 41.5)
0.2
Average counts w
heelchair 
(1.000 counts/hour)
2.6
(0.5 - 3.2)
2.2
(1.2 - 3.2)
0.9
NA
 
NA
NA
M
axim
al intensity upper leg 
(1.000 counts/m
in)
1.0
(0.5 - 2.6)
0.9
(4.3 - 29.4)
0.4
1.0
(0.8 - 2.5)
1.4
(0.8 - 2.4)
0.9
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Discussion
In this study, we showed that measuring physical activity in a home-situation with 3D 
accelerometers was feasible in all seventeen children with mitochondrial disorders, 
although we experienced technical difficulties with the hardware in 18% of the subjects 
(4% of the measurements). We found good face validity by visually correlating the vali-
dation videos and the diaries to the data-graphs. Moreover, non-ambulatory patients 
had lower dynamic activity (i.e. walking) compared to ambulatory patients, although the 
leg activity level only showed a trend towards lower activity levels in non-ambulatory 
children. Generally, patients with mitochondrial disorders had lower maximal intensity 
and were resting more, compared to their age- and gender-matched peers. A retest 
was performed in eight patients in a weekend with significantly different weather and 
showed good test-retest reliability. 
A previous study in six children with mitochondrial disease showed a lower activity level 
compared to healthy controls and less time spent in moderate to vigorous activities.25 
Our cohort included both schoolchildren and adolescents, of which the latter are known 
to be much less active compared to schoolchildren.26 Unexpectedly, arm activity levels 
were comparable between patients and healthy controls. Our data could not confirm 
that this was due to compensatory use of arms in non-ambulatory children or high 
levels of unpurposeful arm activity in children with movement disorders. It could also be 
suggested that arm activity is normal in children with mitochondrial disorders, or that 
our method was not sensitive enough to detect any differences. The resting percentage 
in the study by Martens et al. was lower compared to what we found, even in ambula-
tory patients only. This could be due to selection bias: Martens et al. studied ambula-
tory children without severe cognitive impairment and none of them had a genetically 
confirmed mitochondrial disease. 
Objectively measuring daily physical activity in a patient’s home environment was feasible 
using a 3D accelerometer in five young boys (4 - 6 years) with Duchenne Muscular 
Dystrophy (DMD).13 In this study, the accelerometer was able to reliably measure body 
posture, walking parameters and the distribution of these activities over the day. These 
ambulatory boys, although significantly younger than our study subjects, had compa-
rable levels of dynamic activity, but much less time spent resting, compared to our 
ambulatory patients.13 In patients with cerebral palsy (CP) with different levels of disabi-
lity, no adverse effects or discomfort were reported when wearing one accelerometer.27 
The average time spent resting for ambulatory children in our cohort was comparable 
to the resting time of children with CP GMFCS level I and II. Non-ambulatory patients 
were comparable to GMFCS level IV patients. The percentage of resting in ambula-
tory normally-weighted children with Downs, Williams and Prader-Willi syndrome was 
comparable to our ambulatory patients.28 
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During a retest in eight during weekends with significantly different temperature and 
hours of sun, none of the parameters (activity level, maximal intensity and largest AUC 
during 30 minutes) was significantly different. In healthy adults, test-retest reliability of 
accelerometry was reported to be very good to excellent and there were no differences 
in activity measured for 7-day periods, 1 to 4 weeks apart.29 The activity pattern of 
healthy children is more stable over the day during weekends.26, 30 Activity is known to 
be significantly lower in winter,26 mainly during rainfall and cold and windy weather.31 In 
our small and heterogeneous sample, we could not detect these differences. During 
maturation, day-to-day variability in activity and the seasonal influence on activity 
decrease.32 We found no correlation between age and activity nor higher activity in 
children under 12 years (both in the patient group and the healthy control group). 
Whereas most accelerometers are attached to the hip and only report the level of acti-
vity, we used a set of accelerometers at the chest, the lower arm and upper arm, 
upper leg and if present the wheelchair, to assess both the orientation and the intensity 
of movements of the these body parts. In the future, this measurement protocol will 
allow us to customize our analyses to increase the sensitivity of the measurements. 
These analyses might for example include characterization of gait pattern, but also the 
parallel measurement of physiological parameters could be used to indicate the effort of 
movements, which might increase the sensitivity of the measurement, but also requires 
more sophisticated methods for data-analysis. Alternatives include the use of a simple 
commercially available activity monitor, that provides insight in the overall activity of a 
person. Although such a monitor may be more user-friendly in use, it most probably 
doesn’t allow specific tailor-made analyses. Another alternative would be to make the 
current method more user-friendly by reducing the number of sensors and/or improving 
the convenience of using the script. 
Strengths of this study include the large and clinically heterogeneous group of patients 
with genetically confirmed mitochondrial disease in this study, which allows for conclu-
sions about the feasibility of the accelerometers in both patients with high and with 
limited abilities. Secondly, a healthy age- and gender-matched population was included 
at the same weekend as the patient was measured to minimize the influence of weather 
conditions. Finally, the influence of season and weather to the activity of both patients 
and their peers was assessed in a formal but small test-retest reliability study.
In contrast to most previous studies, we also included non-ambulatory patients in 
our study. Measuring daily activity in these patients is challenging, because accele-
rations elicited by the wheelchair are also measured by the other sensors. We found 
that the wheelchair accounted for about one fourth of the leg activity level in non-am-
bulatory children. Other methodological issues include the lack of measurement of 
stable, sustained body positions since accelerometers measure acceleratio,n and that 
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the current data analysis is not able to differentiate between meaningful movements 
and aberrant movements, such as myoclonus or ataxia. In our patient cohort, none of 
the arm-parameters was significantly higher in patients with ataxia. Other weaknesses 
include the technical challenges that still remain, including the failure of the batteries. 
Finally, we only measured physical activity during two days, whereas measuring for 
longer periods decreased variability substantially in patients with CP.33
In the near future, we will optimize the technical issues (i.e. the MOX-accelerometer 
battery) and analysis methods. The latter will include the validation of an analysis to correct 
for wheelchair movements and more detailed methods to quantify activity. Finally, we will 
define a more detailed and clinically relevant end point in close dialogue with patients and 
their families. For example, since patients frequently report gait disturbances and balance 
problems2 especially when they are tired, we might focus on analysing gait disturbances. 
In conclusion, measuring daily activity with 3D accelerometers was practically feasible 
in all seventeen patients with mitochondrial disease, although we were confronted with 
hardware failures in 18% of the cases. Sensors were worn approximately 94% of the 
woken time. Validity was good and test-retest reliability looks promising. When using 
the accelerometer in a future clinical trial, we suggest including a longer measurement 
period and standardization of family activities during the measurements, to provide 
representative activity patterns and reduce random variability. Although compliance 
was good for this study, some adaptations can be made to make wearing an accelero-
meter more acceptable.34 In the near future, we will optimize our measurement protocol 
by defining more sensitive and clinically relevant outcome parameters in close dialogue 
with patient and parents.
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There is an urgent need for reliable and universally applicable outcome measures for 
children with mitochondrial diseases. In this study, we aimed to adapt the currently 
available Newcastle Paediatric Mitochondrial Disease Scale to the International Paedi-
atric Mitochondrial Disease Scale (IPMDS) during a Delphi-based process with input 
from international collaborators, patients and caretakers as well as a pilot reliability 
study in eight patients. Subsequently, we aimed to test the feasibility, construct validity 
and reliability of the IPMDS in a multi-centre study.
A clinically, biochemically and genetically heterogeneous group of seventeen patients 
(age 1.6 -16 years) from five different expert centres from four different continents were 
included in this study. The feasibility of the IPMDS was good, as indicated by a low 
number of missing items (4%) and the positive evaluation of patients, parents and 
users. Principal component analysis of our small sample identified three factors, which 
explained 57.9% of the variance. Good construct validity was found using hypothesis 
testing. The overall inter-rater reliability was good (median ICCagreement 0.85; range 0.23 
– 0.99). 
In conclusion, we suggest using the IPMDS for the assessment of natural history in 
children with mitochondrial diseases. These data should be used to further explore the 
construct validity of the IPMDS and to set age limits. In parallel, responsiveness and 
the minimal clinically important difference should be studied to facilitate sample size 
calculations in future clinical trials.
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Introduction
Mitochondrial diseases are the most prevalent inherited metabolic diseases, with an 
incidence of approximately 1 in 5,000 live births.1 Since mitochondria are present in 
almost all cells, symptoms can arise theoretically from every organ. The most commonly 
affected organs and tissues include the brain, eye, heart and skeletal muscle.2 There is 
enormous variability in the pattern of affected organs and the degree of disability expe-
rienced. Whereas some children with mitochondrial disease thrive in mainstream school 
and live well into adult life, others follow a more rapidly progressive course and die in 
the neonatal period or function at a low level, barely interacting with their environment.
Currently, there is no cure for mitochondrial diseases, but there are some promising 
results of pharmacological interventions in cells and animals and the prospects for 
randomised clinical trials of novel and re-purposed pharmaceuticals are increasing.2-8 
Outcome measures that are valid, reliable, sensitive and clinically relevant are critical 
to the success of such trials, but the heterogeneity and multi-systemic nature of 
mitochondrial diseases pose significant challenges in choosing an appropriate, univer-
sially applicable outcome measure.9 To be able to measure disease severity and disease 
progression within the full range of the phenotypic spectrum, a combination of objec-
tive, subjective, functional and biochemical end points will probably be indicated. 
A mitochondrial disease specific follow up tool for children already exists, namely the 
Newcastle Paediatric Mitochondrial Disease Scale (NPMDS).10 This scale was originally 
designed to be a concise and pragmatic clinical tool to monitor the biophysical markers 
of disease progression. Although the NPMDS fits this purpose from a natural disease 
course perspective, it was not designed as an end point instrument and probably lacks 
a sufficient level of detail required for this purpose in clinical trials. Moreover, the scale 
was not developed to measure the clinically relevant concept of functional disability.10
In this study, we aim to adapt the NPMDS to a more clinically relevant and more detailed 
scoring system for future clinical trials in paediatric mitochondrial disease. This Interna-
tional Paediatric Mitochondrial Disease Scale (IPMDS) should cover more of the symp-
toms indicated by patients and parents as ‘burdensome’, such as tiredness and lack 
of energy, behavioural problems and depression.11 Besides, we aimed to include a 
functional domain to quantify changes in the motor abilities of the child, since clini-
cally relevant changes in motor function are not always equally reflected by changes in 
muscle power or tone, and vice versa.12-14 After a Delphi-based development process, 
we aimed to test the construct validity and reliability (inter-rater, intra-rater and test-re-
test) by field testing in several international expert centres. 
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Methods
The IPMDS was developed during a Delphi-based process, consulting patients, parents 
and mitochondrial disease experts. After a first pilot reliability test, the scale was further 
optimised for subsequent testing in five expert centres. At each centre, two to four 
randomly selected patients were assessed by three to four physicians to evaluate inter-
rater reliability. The construct validity was tested using factor analysis and by hypothesis 
testing. In a subset of patients within these studies, test-retest reliability and intra-rater 
reliability was tested. 
This study was conducted in all countries after approval from the regional Medical 
Research Ethics Committee (MREC NL.44833.091.13). In accordance with the Helsinki 
agreement, written informed consent was obtained from each participant or his/her 
legal guardian(s). 
Development of the scale
The first version of the scoring list was composed and reviewed by a team of six physi-
cians from Nijmegen, which included three paediatricians, one paediatric resident, 
one paediatric rehabilitation specialist and one internal medicine physician, all seeing 
patients with mitochondrial diseases on a regular basis. To get a general impression 
of the functioning of the patient, both subjective and objective items were included. 
For the subjective part, we chose to interview parents and ask for their opinion on 
the child’s health in the past 4 weeks, similar to the NPMDS. Items in the subjective 
domain were based on a previous study on which sign and symptoms parents would 
most like to change.11 Besides, some items were partly adopted from existing scales, 
such as the NPMDS,10 the Newcastle Mitochondrial Disease Adult Scale (NMDAS)15 
and the Paediatric Evaluation of Disability Inventory (PEDI).16 Items within the objective 
physical examination were dictated by the relevant general paediatric and neurological 
examination, including items scored with previously validated scores.17 Functional tests 
were inspired both by the prevalence and severity of disabilities within the International 
Classification of Functioning in Children and Youth (ICF-CY)11 and the domains of the 
Motor Function Measure (MFM).18 Since children under 6 years are not expected to be 
able to hop, this item (3.10), as well as the running item (3.9) and the rotation of a pen 
with a single hand (3.13), were left out of the questionnaire for children under 6 years. A 
manual was constructed to facilitate similar conduction of the items by all researchers. 
All items were reviewed critically for completeness, relevance, uniformity, acceptability 
for patients and practicability by the six physicians from Nijmegen. Missing items were 
included. The adapted, second version of the scoring list was applied to two children 
with a mitochondrial disease, one child with a mild phenotype and one child with a 
severe condition to test for acceptability and practical difficulties. Practical adaptations 
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were made afterwards and evaluated again by all physicians. To facilitate exclusion of 
items that were difficult to assess (e.g. headache in a severely intellectually disabled 
child), it was made possible to adapt the maximum score if an item was impossible to 
indicate. 
The pilot scoring list was sent to all centres participating in this study for revision and 
adaptations were made on the consensus. 
Pilot study
For the reliability and validity study of the pilot scoring list, eight patients were invited 
to the Nijmegen Centre for Mitochondrial Disorders outpatient clinic. A heterogeneous 
group of patients was selected, with the focus on patients in which  previously  difficul-
ties in performing the NPMDS were experienced. Over the course of one day, patients 
were scored by four physicians, with a break of 15 minutes between all consultations 
and a one-hour lunch break between the second and third consultation, with the aim 
of in keeping the programme balanced, feasible and fun for the children. The results of 
this scoring were used to calculate the inter-rater reliability. After the first consultation, 
parents were asked to fill in an evaluation form on the acceptability and the burden of 
the scale. 
Composition of the final scale
Since all patients and parents evaluated the completeness and acceptability as ‘good’, 
no adaptations were made based on patient suggestions. Except for one boy with 
autism who was not able to complete only three out of four examinations during the 
pilot study because he was bored, all other children were able to complete the pilot 
study. Based on the experiences of the physicians involved and the inter-rater reliability, 
the pilot scoring list was adapted (see Supplementary Document 11). In addition, the 
instructions within the manual were clarified, especially for the physical examination 
domain. Subsequently, the list was again applied to two children with a mitochondrial 
disease with a mild and a severe phenotype who were not involved in the pilot study. In 
addition, the list was tested in patients in three other centres, who checked for accep-
tability and practical issues. After that, the scoring list was adapted again and sent to 
all participating centres. Again, adaptations were made in a Delphi-based process to 
compose the final scoring list, named the IPMDS (Supplementary Document 8 and 9). 
A 5-minute instructional video was prepared to illustrate the execution of some of the 
items (Supplementary Document 10).
Testing the final scale
Feasibility, validity and reliability studies were performed in two to four children each 
using the IPMDS in the Departments of Paediatrics from the Universities of Pretoria, 
Hong Kong, München, Rotterdam, and the Children’s Hospital of Philidelphia.. Children 
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with a mitochondrial disease, either based on pathological mutations in mtDNA or 
nuclear DNA or on mitochondrial dysfunction in muscle as measured by biochemistry, 
were eligible for inclusion. Exclusion criterion included treating physician expectation 
that travelling to the hospital would be too burdensome to the patient. Each individual 
centre selected children randomly. The number of patients and physicians was based 
on the local feasibility of executing the study.
Feasibility
Feasibility was tested by asking (patients and) parents about their experiences after the 
first consultation and by counting the number of children in which the whole scoring 
list could be completed safely. The response was used as a measure for the raters’ 
feasibility. 
Factor analysis
We used exploratory factor analysis to identify the underlying dimensions in the ques-
tionnaire.
Construct validity
To test the construct validity of the factors, the hypothesis was proposed that patients 
rated as having severe disease by the physicians had higher sum scores for the factors 
compared to patients rated as having mild disease. Since there is no gold standard for 
mitochondrial disease severity, we used anchors to test construct validity. The NPMDS, 
a measure for global mitochondrial disease severity, was performed at the second 
consultation in every patient. The total score of the NPMDS was correlated to the total 
IPMDS score. In addition, all physicians were asked to rate: i) the general severity of 
the mitochondrial disease; ii) the subjective severity of the mitochondrial disease as 
experienced by parents; iii) the abnormalities at the physical examination; iv) the func-
tional capabilities of the child, from 0 (not severe at all) to 10 (extremely severe) after 
every consultation. The PEDI was used to assess functional performance and abilities 
of the child. We hypothesised good correlation coefficients between: the total score 
of the NPMDS and the total IPMDS score; the general severity of the mitochondrial 
disease rated by physicians and the total IPMDS score; the subjective severity of the 
mitochondrial disease as experienced by parents and the IPMDS score; the abnorma-
lities at the physical examination rated by physicians and Domain 2; and the functional 
capabilities of the child rated by physicians and Domain 3; the PEDI and Domain 3.
Reliability
Inter-rater reliability was calculated using the scores of the same patient between physi-
cians. Intra-rater reliability was tested by re-scoring the video recording of their own 
interview and examinations, approximately 6 months later (2 physicians from Eras-
musMC, Rotterdam). Test-retest reliability was tested by asking parents to rate the 
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items within the first domain by telephone, both by the same rater also participating in 
the study (the University of Hong Kong) and between the mean score at the initial evalu-
ation and evaluation by a nurse specialist (ErasmusMC, Rotterdam) one week later. 
Statistics
Because of the relatively small number of subjects included in our study, we used 
non-parametric tests for our analyses and reported median and range. The experiences 
of the parents and patients were assessed for each patient individually. From a rater 
perspective, the number of blank items was counted to test feasibility. 
Factor analysis was used to explain the variance-covariance matrix for data in terms of 
relationships between a much smaller number of unobserved variables, called factors. 
We used the rater’s data with the least missing data, missing items were replaced by 
the mean of the other three raters. We removed the items of which less than 80% was 
completed, including the items which could only be assessed in children older than 6 
years old (hopping, running and rotating) and in case the child was not able to report 
complaints such as headache, gastroesophageal reflux or muscle pain or vibration or 
subtle touch at physical examination. Items with little variance (less than two items score 
1 or more) were also removed for the factor analysis. Principal component analysis (PCA) 
was used as the extraction method for factors. The orthogonal rotation (varimax) with 
Kaiser’s normalisation was used to simplify the interpretation of factors. The number of 
factors extracted was based on Eigen values >1. The adequacy of the sampling was 
determined using the Kaiser-Meyer-Olkin (KMO) measure. In addition, Bartlett’s test 
of sphericity was applied to test if correlations between items were sufficiently large 
for PCA. The percentage of variance explained by each factor is also presented. Sum 
scores for the factors were calculated using clinically suitable items. Cronbach’s alpha 
was calculated as a measure of internal consistency of each constructed factor. The 
difference between the patients with mild and with severe disease (the median value 
rated by physicians) for these sum scores was tested using a Mann-Whitney U test. 
We used hypothesis testing to assess construct validity. Since mentioned hypotheses 
in this study involve two measurements of the same construct, we aimed at moderate 
to good correlations (ρ = 0.4 to 0.79). We used Spearman’s correlation coefficients to 
correlate between continuous or interval variables (IPMDS and its sub domains and 
functional parameters). The mean raters’ score in each patient was used to calculate 
the correlation. 
Inter-rater reliability between the physicians within one centre seeing one patient was 
calculated using intraclass correlation coefficient for agreement between raters (ICCagree-
ment). Intra-rater reliability within two physicians was calculated using intraclass correla-
tion coefficient for agreement between the rater’s scores (ICCagreement). Test-retest relia-
225
bility was calculated using intraclass correlation coefficient for agreement between the 
scores (ICCagreement). An ICCagreement ≥ 0.7 was used as ‘acceptable’.19 
A p-value of 0.05 was set for statistical significance. Correlation coefficients were inter-
preted in accordance with the guidelines provided at the BMJ website (http://www.bmj.
com/about-bmj/resources-readers/publications/statistics-square-one/11-correlati-
on-and-regression). All analyses were performed using IBM’s SPSS Statistics 22.0.0.1. 
Results
Cohort description
A clinically and genetically heterogeneous cohort of seventeen children, aged 1.6 to 
16 years, from five expert centres participated in this study (Supplementary Table 12). 
Rater details are presented in Supplementary Document 13. 
Scale description
After our Delphi-based process, the IPMDS consists of 61 items in three Domains: 23 in 
Domain 1 (Subjective complaints and symptoms; obtained by interviewing parents); 25 
in Domain 2 (Physical examination; obtained by physical examination) and 13 in Domain 
3 (Functional assessment; obtained by physical/motor function evaluation). 
Feasibility
The average time to complete the IPMDS was 35 minutes. Ninety-six percent of all 
items, relevant to the patient based on age and/or mental capacities, was completed 
(range 85 - 100%). 
Sixteen (patients and their) parents filled out the feasibility questionnaire. All patients 
and parents indicated that the number of questions, the burden of the physical exami-
nation to the child, the duration of the interview, physical examination and the total 
time-burden were just right or could be (much) longer. The parents of a two-year-old 
patient experienced difficulties in translating the questions to the situation of a toddler. 
This was not reflected in the number of missing items for the toddlers (94%; range 91 – 
97%) and in the inter-rater reliability for the first and the third domain (ICCagreement 0.86 
versus 0.74 and 0.96 versus 0.97, respectively for toddlers versus all children). The 
inter-rater reliability of the second domain was low in toddlers compared to the whole 
cohort (ICCagreement 0.39 versus 0.81).
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Factor analysis
A total of 44 out of 61 items were included in the factor analysis. Based on factor loadings 
and communalities, we were able to include 32 out of the 49 items in one of the factors 
(Table 1A). Items with little variance were removed (items: 1.17. Diarrhoea, 2.03 Alertness, 
2.04 Breathing, and 2.09 Nystagmus). Sample adequacy of the factor analysis was suffi-
cient for all items within the IPMDS (KMO 0.51). Bartlett’s tests of sphericity indicated that 
correlation between items were sufficiently large for PCA (p <0.001).
Table 1.
Factor analysis. A) The factor loadings for the individual items. Based on clinical communalities between 
items we composed three factors (in grey) including 32 out of the 49 included items; B) the factors and 
their characteristics resulting from factor analysis on the items within the IPMDS; C) Spearman’s correlation 
coefficients between the sum scores of factors; D) median and IQR of the factor sum scores for patient groups 
within different disease stages and of the difference between these groups.
Basic functioning Eating and 
digesting
Abnormalities 
at neurological 
examination
3.05 Sitting 0.926
3.11 Reaching 0.916
3.12 Grasping 0.901
1.13 Communicating 0.871
3.07 Standing 0.875
3.04 Sitting up 0.867
2.18 Hypertonia 0.848
3.08 Walking 0.847
3.06 Standing up 0.843
3.02 Head control 0.831
3.03 Rolling over 0.821
2.20 Rigidity 0.808
3.01 Communication 0.772 0.513
1.22a Continence day 0.592
1.18 Cognitive 0.547 0.486
2.11 Prox muscle 0.408 0.614
1.11 Swallowing 0.894
1.10 Chewing 0.536 0.764
1.14 Vomiting 0.74 0.476
2.01 Growth 0.507 -0.405
1.16 Constipation -0.49
2.02 Weight -0.404 0.448
2.08 Eye movements -0.698
A
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2.16 Tremor -0.628
2.13 Hypokinesia 0.745 0.568
1.01 Response 0.543
2.19 Hypotonia 0.525
2.15 Ataxia -0.511
1.23a Strabismus -0.498
2.14 Abnormal movement 0.69 -0.496
1.12 Hearing 0.403 0.494
2.17 Reflexes 0.419
1.22b Continence night 0.75
2.07 Strabismus 0.741
2.10 Vision 0.717
1.02 Exercise 0.616
1.09 Infections
1.04 Tired
1.23b Ptosis
1.06 Epilepsy
1.21 Breathing
2.06 Ptosis    
Only factor loadings > 0.4 are presented
Factor n Eigenvalues % of 
explained 
variance
% of 
explained 
variance 
(total)
Cronbach's 
alpha
Basic functioning 16 14.3 31.1 31.1 0.97
Eating and digesting 6 5.2 14.1 45.2 0.76
Abnormalities at neurological 
examination
10 4.8 12.7 57.9 0.16
n = number of items in the factor
Basic functioning Eating and 
digesting
Abnormalities 
at neurological 
examination
Basic functioning 1.00
Eating and digesting 0.47** 1.00
Abnormalities at neurological 
examination
0.42** 0.13 1.00
* significant at the 0.05 level; ** significant at a 0.01 level.
B
C
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We identified three factors (Table 1A and 1B). Based on the items included in these 
factors, they were named: 1: basic functioning (31.1% of explained variance), 2: eating 
and digesting (14.1% of the explained variance) and 3: abnormalities at neurological 
examination (12.7% of explained variance). The internal consistency of these factors 
was good for factor 1 (Cronbach’s alpha = 0.97), acceptable for factor 2 (Cronbach’s 
alpha = 0.76) and poor for factor 3 (Cronbach’s alpha = 0.16). The total percentage of 
explained variance by the three factors was 57.9%. The Spearman’s correlation coef-
ficient’s between the factors (Table 1C), indicate that all factors represent a unique 
identity. 
Construct validity
We hypothesised that patients with a severe general mitochondrial disease severity 
would show higher median scores on the extracted factors compared to patients with 
mild disease (Table 1D). This hypothesis was confirmed for factor 1(basic functioning; 
p = 0.01; n = 13), but not for factor 2 (eating and digesting) and 3 (abnormalities at 
neurological examination (p = 0.07 and 0.28, respectively). In Table 2 the correlation 
coefficients between the factors, the IPMDStotal, the IPMDS sub domains, the severity 
scores, the PEDI and the NPMDS are presented. The correlation between the basic 
functioning factor and the PEDI, rating the functional performance and abilities of the 
child, was excellent (ρ = 0.90; p < 0.001); the correlation between the abnormalities at 
neurological examination factor and the rater-rated severity of abnormalities at general 
physical examination was weak (ρ = 0.23; p < 0.05). All pre-defined hypotheses used 
for construct validity testing indeed had good to excellent correlations (ρ = 0.64 - 0.90; 
Table 2). 
Mild disease 
(n = 3) 
Severe disease 
(n = 10)
Difference between 
mild and severe 
patients
Factor median IQR median IQR p = 
Basic functioning 0 (0 - 0) 43 (14 – 56) 0.01
Eating and digesting 2 (0 – 2) 10 (5 – 16) 0.08
Abnormalities at neurological 
examination
3 (1 – 3) 10 (2 – 12) 0.29
IQR: interquartile range 
D
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Table 2. 
C
onstruct validity of the IPM
D
S.
C
orrelation coeffi
ients of the total score and sub-scores of the IP
M
D
S
 w
ith subjective disease severity as rated by parents, subjective disease severity by the physicians (m
ean), 
w
ith the NPM
DS total and sub dom
ain scores and w
ith the PEDI total and sub dom
ains scores. 
IPM
D
S - total
IPM
DS – 
Dom
ain 1
IPM
DS – 
Dom
ain 2
IPM
DS – 
Dom
ain 3
Sum
 of basic 
functioning
Sum
 score 
of eating and 
digesting
Sum
 score of 
abnorm
a-
lities at 
neurological 
exam
ination
G
eneral disease severity (P)
0.806**
0.480**
0.558**
0.725**
0.658**
0.426*
0.038
G
eneral disease severity (R)
0.642**
0.529**
0.744**
0.810**
0.786**
0.476**
0.237*
Severity of the abnorm
alities at physical exam
ination (R)
0.853**
0.536**
0.750**
0.839**
0.803**
0.519**
0.226*
Functional lim
itations (P)
0.665**
0.500**
0.563**
0.779**
0.740**
00.328
0.135
Functional lim
itations (R)
0.817**
0.573**
0.719**
0.809**
0.760**
0.381**
0.293**
PEDI - total
0.912**
-0.784**
-0.773**
-0.890**
-0.904**
-0.668**
-0.283
PEDI – self-care
-0.916**
-0.767**
-0.767**
-0.881**
-0.882**
-0.684**
-0.263
PEDI - m
obility
-0.918**
-0.749**
-0.797**
-0.917**
-0.901**
-0.588**
-0.243
PEDI – social function
-0.673**
-0.750**
-0.569**
-0.662**
-0.713**
-0.552**
-0.297
N
PM
DS - total
0.840**
0.475**
0.771**
0.836**
0.816**
0.572**
0.183
N
PM
DS – Section 1
0.887**
0.512**
0.777**
0.865**
0.882**
0.606**
0.27
N
PM
DS – Section 2
-00.144
-0.172
-0.117
0.100
00.029
-00.133
-0.146
N
PM
DS – Section 3
0.854**
0.597**
0.855**
0.773**
0.657**
0.676**
0.196
IPM
DS - total
1.000
0.836**
0.929**
0.907**
0.884**
0.557**
0.553**
IPM
DS - Dom
ain 1
0.836**
1.000
0.551**
0.551**
0.750**
0.632**
0.439**
IPM
DS - Dom
ain 2
0.929**
0.551**
1.000
0.883**
0.835**
0.615**
0.529**
IPM
DS - Dom
ain 3
0.907**
0.551**
0.883**
1.000
0.931**
0.528**
0.426**
* significant at the 0.05 level; ** significant at a 0.01 level; in bold the correlations used for the construct validity hypothesis testing.
CM<>?
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ICC-agreement n = 
1.01 Response to environment 0.670 17
1.02 Exercise capacity 0.701 13 x
1.03 Walking distance 0.847 16
1.04 Tiredness 0.780 16
1.05 Depressed 0.847 12 x
1.06 Epilepsy 0.855 17
1.07 Headache 0.931 12 x
1.08 Muscle pain 0.575 12 x
1.09 Infections 0.581 17
1.10 Chewing 0.942 17
1.11 Swallowing 0.886 17
1.12 Hearing 0.762 17
1.13 Communicating 0.953 16
1.14 Vomiting 0.972 17
1.15 Gastroesophageal reflux 0.962 15
1.16 Constipation 0.833 17
1.17 Diarrhoea 0.976 16
1.18 Cognitive functioning 0.635 15
1.19 Behavioural problems 0.443 16
1.20 Autistic features 0.661 11 x
1.21 Breathing subjective 0.934 15
1.22a Continence day 0.725 14
1.22b Continence night 0.725 14
Reliability
Table 3 and Supplementary Table 14 and 15 show the inter-rater, intra-rater and test-re-
test reliability of the IPMDS. The inter-rater reliability of the sum scores of the three 
factors was good (ICCagreement = 0.98, 0.94, and 0.78 for basic functioning, eating and 
digesting, and abnormalities at neurological examination, respectively). The median 
ICCagreement of all individual items within the IPMDS was 0.85 (range 0.23 – 0.99). The 
median ICCagreement was 0.81 (range 0.44 – 0.98) of the first domain, 0.74 (range 0.23 – 
0.93) of the second domain and 0.97 (range 0.93 - 0.99) in the third domain (Table 3). 
Video rated intra-rater reliability was good (median ICCagreement = 0.87; Supplementary 
Table 14). Test-retest reliability by telephone interviewing of the first Domain after one 
week was excellent when performed by the same rater (median ICCagreement = 1.0 in 
15 out of 16 items with variance) but inconsistent when performed by a different rater 
(median ICCagreement 0.73; Supplementary Document 16). 
Table 3. 
Inter-rater reliability. 
Inter-rater reliability (ICCagreement) per item of the IPMDS. Items with an ICCagreement ≥ 0.7 (good agreement) are 
marked in green; ≤0.3 (poor agreement) marked in blue. 
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1.23a Strabismus when tired 0.736 15
1.23b Ptosis when tired 0.573 15
1.23c Dysarthria when tired 0.838 13 x
x: feasible in less than 80% of study participants
ICC-agreement n = 
2.01 Growth 0.944 15
2.02 Weight 0.751 15
2.03 Alertness NV 17
2.04 Breathing 0.740 17
2.05 Dysarthria 0.901 12 x
2.06 Ptosis 0.553 17
2.07 Strabismus 0.82 16
2.08 Eye movements 0.691 16
2.09 Nystagmus 0.925 16
2.10 Vision 0.343 11 x
2.11 Proximal muscle power 0.913 15
2.12 Distal muscle power 0.738 14
2.13 Hypokinesia 0.306 14
2.14 Abnormal movements 0.884 16
2.15 Ataxia 0.858 14
2.16 Tremor 0.864 15
2.17 Reflexes 0.312 16
2.18 Hypertonia 0.649 17
2.19 Hypotonia 0.470 17
2.20 Rigitidy 0.597 17
2.21a Vibration 0.231 11 x
2.21b Subtle touch NV 11 x
x: feasible in less than 80% of study participants NV = no variance
ICC-agreement n = 
3.01 Communicating 0.957 17
3.02 Head control 0.983 17
3.03 Rolling over 0.985 16
3.04 Sitting up 0.963 17
3.05 Sitting up 0.984 17
3.06 Standing up 0.979 17
3.07 Standing 0.974 17
3.08 Walking 0.989 17
3.09 Running 0.968 13 only >6 years
3.10 Hopping 0.954 13 only >6 years
3.11 Reaching 0.964 16
3.12 Grasping 0.949 16
3.13 Rotating 0.985 14 only >6 years
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Discussion
The International Paediatric Mitochondrial Disease Scale (IPMDS), a multi-dimensional 
scale rating clinically relevant aspects of mitochondrial disease in children, was deve-
loped during a Delphi-based process by an international expert team in close dialogue 
with patients and their parents. Designing a scale for general mitochondrial disease 
severity is challenging because of the wide variability in symptoms and (dis)abilities seen 
in children with mitochondrial disease. This complexity is reflected in the high number 
of items included in the IPMDS and the breath of the items reflecting the multi-systemic 
nature of the disease. Critically evaluating the psychometric properties in seventeen 
children in five international expert centres, we found good feasibility and an acceptable 
construct validity and reliability. 
We found a suboptimal inter-rater reliability for some of the items of the IPMDS, mainly 
within the physical examination domain of the IPMDS. This is in agreement with litera-
ture, where low inter-rater agreement in gait analysis, neurological reflexes and classifi-
cation of movement disorders has been reported.20-23  Lower agreement was observed 
in patients with developmental delay24 and in general neurologists compared to resi-
dents and experts.20 Our teams of raters indeed reported difficulties in agreeing on the 
hypertonia and rigidity. This might be explained by the mixed picture of pyramidal and 
extrapyramidal syndromes in patients with mitochondrial disease (and more specifi-
cally in patients with Leigh syndrome; about half of the cases included in this study). 
Moreover, tone is highly dependent on the child’s level of alertness, emotional state, 
fatigue and posture25 and changes in tone during the day were frequently reported by 
our raters. One option is to remove Domain 2 from our scale. This option will be studied 
in more detail when we have obtained more experience and patient data on the IPMDS. 
Although the IPMDS was adopted from the NPMDS, there are important differences. 
First of all, the NPMDS consists of 26 items with mostly a 0-3 scale, whereas the 
IPMDS consists of 61 items, mostly on a 0-5 scale. For example, the ‘feeding’ item in 
the NPMDS was replaced by items on chewing (including the ability to chew e.g. bread 
crusts and meat), swallowing (including difficulties/choking with dry food or fluids) and 
vomiting. The IPMDS therefore takes longer to execute (on average: 35 minutes), but is 
considerably more detailed. Although the burden to the patient doesn’t seem to be too 
high, as indicated by the positive evaluation of the IPMDS by patients and parents, the 
feasibility of performing the IPMDS as part of daily care at the outpatient clinic, a central 
tenet of developing the NPMDS, is questionable. Secondly, since behavioural problems 
and speech and language problems were among the most burdensome complaints 
experienced by patients and their parents,11 we included these items in the complaints 
and symptoms and in the functional (communication) domain of the IPMDS. Thirdly, the 
IPMDS has a functional domain that is expected to be the most objective, responsive 
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and relevant item for natural history and intervention studies. Lastly, we use the same 
scoring system for all ages (with the exception of some functional items). Although 
this complicates the analysis in very young children – which was also difficult in the 
NPMDS 0-24 months since newborns differ from toddlers – longitudinal analysis is 
more meaningful when using the same scoring system. These differences are illustrated 
by the lack of a statistically significant correlation between the IPMDS and the NPMDS. 
Strengths of our study include: following of the applicable guidelines provided by the 
US Food and Drug administration26 for the design of the IPMDS, the international 
expert team giving input to the content of the IPMDS and the validation in five interna-
tional expert centres in a heterogeneous group of children with mitochondrial disease. 
However, since we aimed at a scale covering the complete phenotypic spectrum of 
mitochondrial diseases, the IPMDS may contain many irrelevant items for individual 
patients. Other weaknesses include the undetermined influence of normal development 
on the score and relatively small study population per centre. The small population also 
affects the validity of the factor analysis and exploratory factor analysis should be repe-
ated when more data is obtained. 
Based on our data, we suggest using the IPMDS for the assessment of natural history 
in children with mitochondrial diseases. Since the IPMDS also includes subjective and 
functional parameters, this natural history data will ultimately not only provide clinicians 
with relevant information for clinicians about which patients will be at risk to develop 
e.g. a cardiomyopathy or renal failure, but will also provide relevant prognostic infor-
mation to patients and their parents. The data collected in these natural history studies 
should be used for another exploratory factor analysis to obtain further evidence for 
the construct validity of the IPMDS (we kindly invite you to upload your IPMDS scoring 
sheets on our website http://www.ncmd.nl/ipmds). Besides, this data will facilitate 
setting age-limits for the IPMDS, since both the number of missing items and the inter-
rater reliability indicate that adaptations necessary for babies and toddlers. In parallel, 
the minimal clinically important difference should be assessed, for example by asses-
sing which changes patients and parents feel to be relevant compared to the previous 
assessment in a prospective natural history study or by statistically-based approached, 
although the latter does not take into account the patients’ perspective.27
In conclusion, the IPMDS seems a robust tool for the follow-up of children with 
mitochondrial diseases. The data obtained in natural history studies in combination 
with a close dialogue with parents regarding the minimal clinically important difference 
will further substantiate the instrument in the near future. 
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The 6-minute walking test is frequently used as an outcome measure for clinical trials 
in neuromuscular disease. Since this submaximal endurance test is not feasible for 
non-ambulatory patients, the motor-assisted 6-minute cycling test was developed. 
Nineteen children with neuromuscular disorders and children with OXPHOS dysfunc-
tion performed the cycling test and the 6-minute walking test to explore feasibility and 
construct validity. Test-retest reproducibility was tested within three weeks.
The assisted 6-minute cycling test was feasible in 90% and 78% of the patients with 
a neuromuscular disorder and OXPHOS-dysfunction, respectively. Heart rate indcated 
the submaximal character of the test in the majority of patients. The assisted 6-minute 
cycling test for legs correlated with the 6-minute walking test in patients with OXPHOS 
dysfunction, but did not reach significance in patients with neuromuscular disease. 
Acceptable reproducibility was shown for both legs and arms. 
This exploratory study indicates that the assisted 6-minute cycling test seems a promi-
sing outcome measure for specific subgroups of patients with a neuromuscular disorder 
and patients with OXPHOS-dysfunction. Before we can recommend the 6-minute 
cycling test over the 6-minute walking test more studies, especially in weaker and/or 
non-ambulatory children, are indicated. 
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Introduction
More and more therapeutic studies are being performed in children with neuromus-
cular disorders and patients with mitochondrial oxidative phosphorylation dysfunc-
tion in fresh muscle specimen (OXPHOS dysfunction). To measure the effect of these 
promising interventions, it is important to have reliable, valid and responsive outcome 
measures that measure clinically relevant aspects of the child’s abilities and limitations. 
Since endurance and fatigability are important determinants of the patients’ abilities to 
perform the activities of daily life,1 it seems reasonable to use instruments measuring 
these disease aspects in clinical trials. 
Endurance can be measured using maximal and submaximal endurance tests. The 
submaximal test only gives an indication of the maximal endurance.2 Children with a 
neuromuscular disorder are mainly limited in performing physical activities requiring 
endurance of muscle function rather than they are limited in their maximal aerobic 
power.3 Therefore, submaximal exercise tests are more relevant to and more feasible 
for these children than maximal exercise tests. Testing submaximal endurance provides 
data on the endurance required to perform the activities of daily life1 and previous 
studies showed promising results in patients with Duchenne muscular dystrophy 
(DMD).4 Currently, there is no gold standard to measure submaximal endurance in 
children. The most commonly used test to measure submaximal endurance in neuro-
muscular disorders is the 6-minute walk test (6MWT).1 However, this test could only be 
used in patients who are able to walk and are not expected to lose the ability to walk 
during the trial. 
The assisted 6-minute cycling test (A6MCT) for legs and arms was developed as a 
non-invasive and quantitative method to measure submaximal endurance in ambula-
tory and non-ambulatory children with a neuromuscular disorder. A previous study by 
our group showed that the A6MCT was feasible in >90% of the boys with DMD and that 
the distance cycled correlated with the distance walked at the 6MWT.5 It is likely that 
this test is not specific for DMD only, but also applicable to other neuromuscular disor-
ders, including OXPHOS dysfunction. However, other factors could play a role such 
as behaviour problems, present in both some types of neuromuscular disorders and 
OXPHOS dysfunction, or the difference between the presence of paresis at start (neuro-
muscular) or developing/increasing paresis during the test (OXPHOS dysfunction). 
The aim of this exploratory study was to evaluate the psychometric properties (feasi-
bility, validity and test-retest reproducibility) of the A6MCT in a group of children with 
neuromuscular disorders other than DMD and in children with OXHPOS dysfunction.
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Methods
Study population
Children with neuromuscular disorders and children with OXPHOS dysfunction in 
muscle, regularly seen at the Radboudumc, Nijmegen, The Netherlands (Department 
of Rehabilitation and the Nijmegen Centre for Mitochondrial Disorders, respectively) 
were selected for this study. Children aged 6 - 18 years with a confirmed neuromus-
cular diagnosis of myotonic dystrophy (MD), spinal muscular atrophy type 3 (SMA), 
limb-girdle muscular dystrophy (LGMD), or congenital myopathy (CM) were included. 
Children with OXHPOS dysfunction were included when mitochondrial dysfunction was 
detected in fresh muscle according to one or more of the following criteria: i) decrease 
in ATP production (≤90% of lowest reference value); and/or ii) deficiency of one or more 
enzyme complexes of the oxidative phosphorylation system (below the lowest refe-
rence value) and/or iii) a pathogenetic mutation in mitochondrial or nuclear DNA. Both 
children with a neuromuscular and OXHPOS dysfunction needed to be able to walk 
for at least 75 meters. Exclusion criteria in both groups included severe behavioural 
problems, severe cognitive impairment, severe respiratory insufficiency, high likelihood 
of falls and/or symptomatic cardiomyopathy. Patients (and their parents) who met the 
inclusion criteria were informed about the study by their physician. Interested patients 
and parents were further informed about the study by an information letter in which 
they were invited to participate in the study. All parents, and participants who were 
over 12 years old and mentally competent, gave their written informed consent. This 
study has been conducted after approval from the Medical Research Ethics Committee 
Arnhem-Nijmegen (MREC NL.37246.091.11). 
Study protocol
All tests were performed at the outpatient clinic at the Department of Rehabilitation 
at the Radboudumc. All patients followed the same time-schedule, including a lunch 
break of 60 minutes and a pause of 10 - 15 minutes after each test in which patients 
could have a drink (see Figure 1). Patients were asked to wear comfortable clothes and 
to use a wheelchair to come to the outpatient clinic where possible. Height and weight 
were measured before the tests were performed. 
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Figure 1. 
Flowdiagram from recruitment to experiments in both children with a neuromuscular disorder and 
OXPHOS dysfunction. A6MCT = assisted 6-minute cycling test; 6MWT = 6-minute walk test; MFM = motor 
function measure.
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First the Brooke and Vignos scale were determined. The Brooke scale grades upper 
limb function on an ordinal scale from 1 - 6; 1 means that the patient is able to abduct 
the arms in a full circle until they touch above the head, and 6 means that patients are 
unable to raise their hands to their mouth and have no useful function of the hands. The 
Vignos scale grades lower limb function on an ordinal scale ranging from 1 - 10, with 
1 meaning that the patient can walk and climb stairs without assistance and 10 means 
that the patient is bed-bound.6 
Subsequently, patients with a neuromuscular disorder performed the A6MCTlegs 
followed by the A6MCTarms (see Figure 2 for starting position of both tests). To exclude 
the infl uence of the commonly reported general fatigue after one A6MCT infl uencing 
the result of the second A6MCT, patients with OXPHOS dysfunction were randomly 
assigned to the ‘legs fi rst’ or ‘arms fi rst’ group. Both tests were performed according 
to the previously described protocol by Jansen et al.5 The participants were asked to 
cycle as fast as possible and keep this up for 6 minutes. Every 15 seconds the children 
were encouraged with standardised phrases to maintain attention and to complete the 
test as well as possible. Positioning and motor assistance were standardised (passive 
mode 1, no-load speed 7 RPM). During both A6MCTs, the number of revolutions (rev.) 
was noted every minute, with the primary outcome being the total number of rev. in 6 
minutes. 
Figure 2.
Initial position of the A6MCTlegs and A6MCTarms. This fi gure has been previously published in Jansen et al. 
(2010)7. Permission was obtained from the original publisher, BioMedCentral, to reproduce the fi gure. 
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After lunch, the 6MWT was performed, following the protocol of McDonald et al.,8 
except for that the parents were allowed to be present, but not to encourage the child. 
Patients were asked to walk (not run or hop) as fast as possible for 6 minutes on a 25 
meter course. They were allowed to rest, but not to sit or lay down (timing continued 
during resting). During the 6MWT, one of the researchers walked behind the patient 
for safety reasons and to encourage the patient every 15 seconds with standardised 
phrases. The distance walked was recorded every minute, with the primary outcome 
being the distance walked in 6 minutes. During both A6MCTs and the 6MWT, fatigue 
was monitored every minute by measuring heart rate using a standard heart rate 
monitor (Onyx Classic; Sigma, Germany) and the OMNI scale for perceived exertion 
that grades the perception of fatigue on a scale from 0 (not tired at all) to 10 (very very 
tired) and contains both verbal and pictorial descriptions.9,10 
After the 6MWT and a short break, the timed tests were performed to measure the 
functional abilities of the patients.6,11 They were asked to rise from the floor from sitting 
position, walk or run for 10 meters, climb 4 stairs and rise from a chair. The time and 
the performance (the presence of compensatory movements, the use of help of hands 
on thighs, arm-rest, handrail or chair) was noted.12 Since these tests are performed 
differently in various studies, these results are not reliable and therefore we cannot 
compare our results with other studies. Finally, the Motor Function Measure (MFM) was 
performed to assess motor performance.13,14 This test is composed of 32 items in three 
dimensions: standing position and transfers, axial and proximal motor function, and 
distal motor function. The maximum score on this test is 100%, a higher score reflects 
better motor function. 
After finishing the last test, parents received an evaluation form (designed by the 
authors for the purpose of this study) to report possible complications, such as an 
increase in fatigue, muscle pain, muscle weakness, epilepsy, coordination problems, 
behaviour problems, concentration problems or other problems in the day after the 
test. Items were scored on a 4 point scale: a lot more than normally (3), slightly more 
than normally (2), barely more than normally (1) and not different from normal (0). 
Feasibility 
The A6MCT is rated as successful if the test has been completed (cycling the full 6 
minutes, if necessary with pauses but restart within 15 seconds) without severe compli-
cations like muscle pain or stiffness the day after the test. 
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Test results
The results of the A6MCT for boys were compared to the results of Jansen et al.5 Girls 
were compared to the z-scores for healthy girls obtained in a pilot study in 50 healthy 
girls. Results of the 6MWT were compared with gender-, height- and age-matched 
controls.19
Validity
First, we assessed whether the A6MCT measured submaximal exercise capacity by 
interpreting heart rate, subjective fatigue and the slope of the distance per minute 
curve. Submaximal exercise capacity was defined as 70% of maximal heart rate and the 
targeted OMNI score was defined as ≤6.5 Secondly, since there is no gold standard to 
measure endurance in patients with MD, SMA, LGMD, CM, and patients with OXPHOS 
dysfunction we used construct validity for the validation of the A6MCT. We used hypo-
thesis testing to assess construct validity. The results of the A6MCTs were correlated to 
the results of the test rating walking capacity (6MWT), gross motor function (MFM) and 
functional abilities (timed tests) to determine construct validity. We hypothesised a good 
correlation between the A6MCTlegs and the 6MWT and moderate correlations between 
the other motor function parameters and the A6MCTs. 
Reliability 
Children were asked to participate in a restest after 4 weeks. All children who agreed to 
participate were eligible for inclusion.
Statistical analysis
In this explorative study, data were analysed separately for the neuromuscular disorders 
and children with OXHPOS dysfunction in muscle. Since this study included a small 
number of patients per group continuous data were expressed as median and inter 
quartile range (IQR) and ordinal data were expressed as median with range. Construct 
validity was calculated by correlating the results of the different tests by Spearman’s 
correlation coefficients. Correlation coefficients were interpreted in accordance with the 
guidelines provided at the BMJ website.15 The Wilcoxon signed-rank test was used to 
compare median scores in case of paired measurements. To evaluate test-retest repro-
ducibility, intraclass coefficient ((ICC) absolute agreement) was calculated to compare 
the number of rev. on the A6MCTleg/arms and the distanced walked at the 6MWT at the 
test and at the retest. An α of 0.05 was used for statistical significance. Because of 
the small numbers and the exploratory character of this study, we did not use Bonfer-
roni adjustment. Statistical analyses were performed using SPSS (version 20.0) for 
Windows (SPSS, Inc. Chicago, Illinois).
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Results
Patient characteristics 
Nineteen children participated in this study. Ten of them (five boys, five girls) had a 
neuromuscular disorder, whereas nine children (eight boys, one girl) had mitochondrial 
OXHPOS dysfunction in muscle. Characteristics of the children are described in Table 
1A and 1B. 
Feasibility of the tests
Both A6MCTs were feasible in nine out of ten patients with a neuromuscular disorder 
(90%) and in seven out of nine (78%) patients with a OXPHOS dysfunction. In one 
neuromuscular patient (ID 8, with MD) the A6MCTs were not feasible during the retest 
because of behavioural problems. The A6MCTs were not feasible in the two children 
with OXPHOS who had a mental retardation and failed to complete the tests because 
of behavioural problems (previously not rated as severe) and/or decreased attention 
span and lack of cooperation and understanding of the tasks. In OXPHOS dysfunction 
patient 1 and 8, both pubertal boys with near-normal muscle strength and coordina-
tion problems, the bicycle was unstable during the exercise. Therefore, both patients 
seemed to be limited in reaching their maximally possible number of rev.
The 6MWT was not feasible for three children (feasibility 70%, ID, 6, 8 and 9) with a 
neuromuscular disorder when following the McDonald protocol. One child with SMA 
(ID 6) had to take pauses after three minutes of walking and during the last minute she 
was not able to walk anymore. In a patient with MD (ID 8) the retest was not feasible 
because of behavioural problems. One child with a CM (ID 9) had to sit down after 
three minutes of walking. The 6MWT was not feasible in three children with OXHPOS 
dysfunction in muscle (feasibility 66%, ID 2, 3 and 5). Two patients with developmental 
delay (ID 2 and 5) were not able to complete the test because of decreased attention 
span and lack of cooperation and understanding of the tasks. In patient 3, the first 
6MWT was not valid because he was joking around and not doing the best he could. 
No serious adverse events were reported during or directly after performing the A6MCT 
and 6MWT. To report possible complications the day after the tests, parents were 
asked to fill in a complication form. Eleven complication forms from seven patients with 
a neuromuscular disorder (four patients completed the form for both the test and the 
retest) were returned to the researchers. The median scores were 0 (not more than 
normally) for tiredness (IQR 0 - 2; range 0 - 3) muscle weakness (IQR 0 - 1.25; range 
0 - 2), balance (IQR 0 - 0; range 0 - 1), coordination problems (IQR 0 - 0; range 0 - 0), 
behavioural (IQR 0 - 0; range 0 - 2), and concentration problems (IQR 0 - 0; range 0 - 0) 
the day after the test was. The median score for muscle pain was 1 (barely more than 
normally; IQR 0 - 2; range 0 - 3). 
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Seventeen complication forms from eight patients with a OXHPOS dysfunction in 
muscle were returned to hospital. Only patient 1 and 2 reported no complaints after the 
test, though patient 1 reported mild tiredness after one out of three tests. The median 
scores for tiredness (IQR 1 - 2.5; range 0 - 3), muscle pain (IQR 0.5 - 3; range 0 - 3) 
and concentration problems (IQR 0 - 2.8; range 0 - 3) the day after the test was 2 (a 
bit more than normally). The median scores for muscle weakness (IQR 0 - 2; range 
0 - 3), balance (IQR 0 - 1; range 0 - 2), coordination problems (IQR 0 - 1; range 0 - 2) 
and behavioural problems (IQR 0 - 2.5; range 0 - 3) were 1 (barely more than normally). 
Only three patients reported a 3 (a lot more than normally) tiredness, muscle weakness, 
muscle pain or behavioural problems, though only one patient reported a 3 consistently. 
Test results 
Neuromuscular disorders 
Table 1A shows the test results for the patients with neuromuscular disorders. The 
median number of rev. cycled during the first test was 534 (IQR 449 - 607 rev.; range 
366 - 655 rev.) with the arms and 509 (IQR 437 - 552 rev.; range 323 - 688 rev.) with 
the legs. The median walking distance with the 6MWT was 434 m (IQR 246 - 492 m; 
range 99 - 509 m). 
OXPHOS dysfunction
Table 1B shows the test results for the patients with OXPHOS dysfunction. The median 
number of rev. achieved during the A6MCT at the first visit was 600 rev. (IQR 542 – 748 
rev.; range 499 – 823 rev.) with the arms, and 665 rev. (IQR 599 - 795 rev.; range 511 
– 795 rev.) with the legs. The median walking distance in 6 minutes was 434 m (IQR 
3 - 586 m; range 312 – 625 m). The median time for standing up from a chair and for 
climbing the stairs were not reliable because the timing mainly reflected the reaction 
time of the researcher. 
Validity
Although the limited number of patients included in this exploratory study will not allow 
us to draw firm conclusions, we aimed to get an impression of validity by testing the 
concept of submaximal exercise capacity and by correlating with motor capacities 
Neuromuscular disorders
The median percentage of the maximal heart rate (aim 70%) during the A6MCTarms, 
A6MCTlegs and the 6MWT were 62%, 62% and 71% respectively. The median OMNIs-
cores during the 6th minute (aim 6) were 10 (IQR 3 – 10) for the arms and 3 (IQR 1 – 9) 
for the body during the A6MCTarms and 6 (IQR 2 – 10) for the legs and 3 (IQR 1 – 9) for 
the body during the A6MCTlegs. The validity of this OMNI scale is, however, uncertain 
because many patients had difficulty indicating their tiredness and some OMNI scores 
fluctuated at the end of the test. The A6MCTlegs did not correlate significantly to the 
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6MWT (p = 0.96) or any of the sub domains of the MFM or timed tests (p = 0.13 – 0.70; 
n = 8). The A6MCTarms did not correlate statistically significantly with the 6MWT (p = 
0.04), any of the sub domains of the MFM or timed function tests (p = 0.42 – 0.88). The 
slopes of the A6MCTs showed a stable number of rev. per minute (Figure 3A and 3B). 
In two patients with SMA type 3 we found near to normal results for the A6MCTarms, but 
not for the A6MCTlegs which fits the disease course and gives an indication that both 
A6MCT are able to measure disease severity in upper and lower limb. 
OXPHOS dysfunction 
We found a median % of maximal heart rate (aim 70%) of 62% in both A6MCTs and 
77% during the 6MWT. The OMNI score showed poor face validity (e.g. rating a 10 after 
1 minute despite not looking tired) in most patients and is therefore not reported. The 
slopes of the A6MCTs showed a stable number of rev. per minute (Figure 3D and 3E). 
The A6MCTlegs correlated strongly with the 6MWT (r = 0.83; p = 0.042), but not with 
the total and the individuals domain scores of the MFM (p = 0.05 – 0.63) or the timed 
function tests (p = 0.20 – 0.51). No significant correlations were found between the 
A6MCTarms and the 6MWT (p = 0.71), any of the domains of the MFM (p = 0.18 – 0.40), 
or timed function tests (p = 0.60 – 0.80). 
Test-retest reliability
Neuromuscular disorders 
Seven patients with neuromuscular disorders agreed to participate in the retest. The 
median time between test and retest was 14 days (IQR 13 - 20; range 12 - 21 days). 
The results of the retest of patient 8, in which the test was not feasible, were excluded 
from the analyses. The mean absolute differences between the scores of the test and 
the retest of the A6MCTarms and the A6MCTlegs were 53 (min-max: -50 - +107) and 73 
(min-max: -25 -+ 165) rev., respectively. Five out of six children had a higher number 
of rev. during the retest for the legs, compared to two out of six for the arms.The ICC 
of the A6MCT was 0.77 (95% CI 0.05-0.97) for arms and 0.72 (95% CI -0.07 - 0.96) 
for the legs. 
OXPHOS dysfunction 
Five patients with OXPHOS dysfunction agreed to perform a retest. The median time 
between the test and the retest was 22 days (IQR 11 - 29 days; range 7 – 30 days). 
The mean absolute differences between the test and retest for the A6MCTarms and 
A6MCTlegs were 57 (range 18 - 135) and 61 (range 6 - 105), respectively. The ICC for the 
A6MCTarms was 0.73 (95% CI -0.21 - 0.97). The ICC for the A6MCTlegs was 0.91 (95% 
CI 0.37 – 0.99). The distance at the retest was higher compared to the initial test in the 
A6MCTarms, the A6MCTlegs and the 6MWT for all children (average 34 and 110 rev. and 
45 m, respectively). 
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Figure 3. 
Results of the 6-minute walking and assisted 6-minute cycling tests with arms and legs in patients with 
neuromuscular disorders and patients with OXPHOS dysfunction. Number of revolutions for the arms (A) 
and legs (B) assessed using the A6MCT, and distance (meters) assessed using the 6MWT (C) per minute per 
patient for neuromuscular disorders. Number of revolutions for the arms (D) and legs (E) assessed using the 
A6MCT, and distance (meters) assessed using the 6MWT (F) per minute per patient with OXPHOS dysfunction. 
A6MCT = assisted 6-minute cycling test; 6MWT = 6-minute walk test.
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Discussion
In this study, we aimed to explore the feasibility, construct validity and test-retest repro-
ducibility of the A6MCT for arms and legs in children with a neuromuscular disorder 
other than DMD, or OXPHOS dysfunction. The A6MCT seems to be a feasible test to 
measure submaximal exercise capacity in the majority of children in both ambulatory 
patient groups without moderate to severe cognitive impairment, behavioural problems 
or attention deficit. 
In contrast to the 6MWT, which was feasible in only 70% of the children with a neuro-
muscular disorder and in 67% of the children with OXPHOS dysfunction, the A6MCT 
was feasible in 90% of the children with a neuromuscular disorder and in 78% of the 
patients with OXPHOS dysfunction. As expected, the A6MCT was not feasible in 
children with behavioural problems or severe developmental delay. Face validity was 
limited in two patients with OXPHOS dysfunction, with coordination problems and near-
normal muscle strength, where the bicycle could not be stabilised during cycling with 
the legs, and it patients were not able to reach their submaximal exercise capacity 
(heart rate 56 and 61% of maximal heart rate). Good construct validity of the A6MCT 
was indicated by the moderate correlation between the A6MCTlegs and the 6MWT in 
patients with OXPHOS dysfunctio, but not in patients with neuromuscular disease. We 
could not confirm the correlation between the MFM and A6MCTlegs found in patients 
with DMD.5 Test-retest reliability of both A6MCTs was acceptable in both groups, which 
is in concordance with the data found by Jansen et al.,5 and comparable with reliability 
results of the 6MWT in children.16,17 
The submaximal character of the A6MCT was confirmed by a median percentage of 
maximal heart rate of 62% in both patients groups. The median heart rate was slightly 
but significantly lower during both A6MCTs compared to the 6MWT (71% for Neuro-
muscular Disorders and 77% for patients with OXHPOS dysfunction). However, since 
the maximum heart rate of children with neuromuscular disorder or with OXPHOS 
dysfunction during submaximal exercise has never been studied, these numbers 
should be interpreted cautiously. The constant slope of the number of rev. per minute 
curves of both A6MCT in all patients compared to the 6MWT curve, which showed 
deflecting curves in some patients, also suggests the ability of the A6MCTs to measure 
submaximal exercise capacity. 
Although the A6MCT was developed for patients who are expected to lose their walking 
ability and for children who already have become wheelchair-dependent, we included 
less severely affected children to allow validation based on the results of the 6MWT. 
Especially the patients with OXHPOS dysfunction had near normal motor abilities, illus-
trated by the (near) normal MFM scores in all patients. The combination of the near 
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normal MFM and A6MCT results and the low heart rate during the A6MCTs suggests 
that the A6MCT was not strenuous enough for some of these ambulatory children. One 
should however keep in mind that the inclusion of ambulatory children with near normal 
motor abilities limits the external validity to non-ambulatory children or to children who 
are about to lose their ability to walk. 
Since endurance and fatigability are important determinants of the patients’ abilities to 
perform activities of daily life4 and children with OXPHOS dysfunction and their parents 
rate fatigue and lack of energy as one of the most burdensome symptoms,18 it seems 
reasonable to use outcome measure for endurance in future clinical trials for children 
with neuromuscular disorder and OXPHOS dysfunction. Since the most commonly 
used submaximal endurance test in children, the 6MWT, is not feasible in non-ambula-
tory children or children who are about to lose their ability to walk, the A6MCT seems a 
good alternative for these patients and should be studied in more detail. 
The major weakness of this exploratory study includes the small number of children 
with heterogeneity clinical background not belonging to the target population for which 
the A6MCTs were developed. Future studies should therefore focus on validating the 
A6MCT tests in a larger group of patients within the targeted population (i.e. children 
who are about to lose their ability to walk or are already non-ambulatory). Since the 
6MWT is not feasible in non-ambulatory patients, we suggest to use other functional 
tests to confirm construct validity. Since responsiveness was not tested in this study, 
we also suggest longitudinal studies in patients with progressive neuromuscular or 
OXPHOS dysfunction. For future studies in patients with OXPHOS dysfunction, we 
suggest to include patients with mitochondrial myopathies and below-normal exercise 
capacity on the 6MWT; alternatively the A6MCT can be used when the device is better 
fixed or more resistance is used. For the latter population, the possibility of a learning 
effect in the A6MCTs should also be evaluated. 
In conclusion, the A6MCTs seem a promising test to measure submaximal endurance 
and fatigability in children with a neuromuscular disorders and children with OXPHOS 
dysfunction. In children who are able to walk and are not expected to lose their ability 
to walk during the study, we still recommend the 6MWT. 
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Cardiomyopathy is a common complication of mitochondrial disorders, associated with 
increased mortality. Two dimensional speckle tracking echocardiography (2DSTE) can 
be used to quantify myocardial deformation. Here, we aimed to determine the useful-
ness of 2DSTE in detecting and monitoring subtle changes in myocardial dysfunction in 
carriers of the 3243A>G mutation in mitochondrial DNA.
In this retrospective pilot study, thirty symptomatic and asymptomatic carriers of the 
mitochondrial 3243A>G mutation of whom two subsequent echocardiograms were 
available were included. We measured longitudinal, circumferential and radial strain 
using 2DSTE. Results were compared to published reference values.
Speckle tracking was feasible in 90% of the patients for longitudinal strain. Circumfe-
rential and radial strain showed low face validity (low number of images with sufficient 
quality; suboptimal tracking) and were therefore rejected for further analysis. Global 
longitudinal strain showed good face validity and was abnormal in 56 – 70% (depen-
ding on reference values used; n = 27) of the carriers. Reproducibility was good (mean 
difference of 0.83 for inter- and 0.40 for intra-rater reproducibility; ICC 0.78 and 0.89, 
respectively). The difference between the first and the second measurement exceeded 
the measurement variance in 39% of the cases (n = 23; feasibility of follow-up 77%). 
In conclusion, two-dimensional strain echocardiography seems a feasible method to 
detect and monitor subtle changes in longitudinal myocardial deformation in adult 
carriers of the mitochondrial 3243A>G mutation. Based on our data and the reported 
accuracy of global longitudinal strain in other studies, we suggest the use of global 
longitudinal strain in a prospective intervention study.
264
Chapter 9  |  Is 2D speckle tracking echocardiography useful for detecting and monitoring myocardial dysfunction in adult m.3243A>G carriers? – a retrospective pilot study
Introduction
Cardiomyopathy is a common complication of mitochondrial disorders, with a preva-
lence up to 14% in adults1 and 58% in children.2,3 The presence of cardiomyopathy has 
been associated with increased mortality in both children and adults.2-5 In carriers of the 
m.3243A>G mutation, the most common genetic cause of mitochondrial disease,6 the 
prevalence of either symptomatic or asymptomatic cardiomyopathy ranges from 18 to 
56%, depending on the population studied and the method used.5,7,8 Cardiomyopathy 
associated with this mutation was characterised as a concentric left ventricle hyper-
trophy8,9 with progressive dilation and decreased systolic function, developing over 
several years.10 Some, but not all of these small studies, identified more severe disease 
and high heteroplasmy percentage as factors contributing to cardiac involvement.7,8,11
The m.3243A>G mutation is a mutation in mitochondrial DNA and therefore follows 
maternal inheritance.12 Of importance for understanding this study are the following 
aspects: the mutation is present in a variable percentage of all mtDNA (heteroplasmy), 
virtually all organs may be affected in various different patterns, and this is not only 
dependent on the heteroplasmy percentage of the mutation. 
The severity of the myocardial dysfunction is usually assessed by conventional echocar-
diography and tagged cardiac magnetic resonance imaging (cMRI). Previously, tagged 
cMRI showed abnormal myocardial deformation in 22 asymptomatic m.3243A>G 
carriers.13 cMRI is used as a reference standard for myocardial deformation, but it is a 
time-consuming and expensive procedure which requires dedicated expertise. There-
fore, this method is less feasible as a bed side modality in multi-centre trials. Conventi-
onal echocardiography, in contrast, is widely available, but has low sensitivity in detec-
ting subtle and regional changes in myocardial function.14 The off-line processing of 
conventional echocardiograms using 2 dimensional speckle tracking echocardiography 
(2DSTE) software enables more sensitive quantification of the global and regional 
myocardial deformation15. This software tracks myocardial ‘speckle’ patterns throug-
hout the myocardial cycle, facilitating calculation of myocardial deformation or strain 
in three directions (longitudinal, radial, and circumferential). The technique is reliable16 
and accurate17,18 and is able to detect subtle changes in myocardial function at an 
early stage, even before decrease in conventional echocardiographic parameters (e.g. 
ejection fraction and shortening fraction) are observed.19 Recently, global longitudinal 
strain, known as the most reliable component of strain analysis,20 was incorporated into 
the recommendations for multi-modality imaging evaluation and monitoring of cardiac 
(dys)function of adult patients during and after cancer therapy.21 A 10% decrease in 
longitudinal strain is a significant outcome mesure for chemotherapy induced cardio-
myopathy.21
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In this retrospective pilot study we aim to evaluate the usefulness and feasibility of 
2DSTE in detecting and monitoring subtle changes in myocardial deformation in adults 
carriers of the m.3243A>G mutation with a wide spectrum of clinical disease severity, 
since 2DSTE might be a potential outcome measure to evaluate responsiveness to 
future therapy for this group of carriers. 
Methods
Study population
All subjects were identified from our ‘National inventory of patients with the m.3243A>G 
mutation’ study, including both symptomatic and asymptomatic carriers.22 Subjects 
with a detectable heteroplasmy percentage (detection limit ≥5%) in either buccal 
mucosa cells, leukocytes, or urinary epithelial cells (UEC) are considered to be carriers 
of the mutation. As part of usual clinical care, both symptomatic and asymptomatic 
carriers undergo cardiac ultrasound (approximately two-yearly in asymptomatic indi-
viduals; more frequently if clinically indicated). Carriers of the m.3243A>G mutation of 
whom two subsequent echocardiograms were available were included in this study. 
Only part of these patients were included in our previously published study on biomar-
kers.23
Clinical assessment protocol
The carriers’ clinical assessment at the time of the echocardiogram included the carri-
er’s medical history, current cardiac complaints and the use of medication, physical 
examination including blood pressure, height and weight and an electrocardiogram 
(ECG). 
In the context of the ‘National inventory of patients with the m.3243A>G mutation’, 
patients and their maternal relatives undergo several investigations including the assess-
ment of general mitochondrial disease severity using the Newcastle Mitochondrial 
Disease Adult Scale (NMDAS).24 The NMDAS score closest in time to the echocardio-
graphy was reported. The NMDAS contains the following four domains: i) current func-
tion; ii) system specific involvement; iii) current clinical assessment; and iv) quality of life. 
In our analysis, we used domains i-iii to calculate disease severity. Severe mitochondrial 
disease was defined previously as an NMDAS score above 20.22 We defined asympto-
matic disease as an NMDAS = 0; mild mitochondrial disease as an NMDAS score of 1 
through 5; and moderate mitochondrial disease as an NMDAS score of 6 through 20.25 
The presence and severity of diabetes mellitus (DM) and cardiovascular involvement 
was also obtained from the NMDAS.26 Quality of life, with sub scores for mental and 
physical quality of life, was determined using a Dutch translation of the SF-12v2 and 
American reference values.27 The quality of life can vary from 0 to 70 for both mental 
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and physical health, where 50 is the population’s mean (standard deviation 10). Subjec-
tive change during follow-up was part of the general history taking of the cardiologist. 
Laboratory investigations (+/- 6 months) were reported. Carriers were classified as 
having decreased creatinine clearance only, microalbuminuria only, both or neither. 
Microalbuminuria was defined as an albumin-to-creatine-ratio of >2.0 g/mol for men 
and >2.5 g/mol for women. Decreased creatinine clearance was defined as a glome-
rular filtration rate <60 ml/min/1.73m2. 
Echocardiography 
All carriers underwent a transthoracic 2D echocardiogram in supine and lateral position 
at rest. The echocardiogram was performed as part of our regular patient care (using 
a standardised echocardiographic protocol published previously28), by an experienced 
echocardiography technicians and supervised by experienced cardiologist. Images 
were obtained with a, M3S transducer using the Vivid 7 and M5S transducer using 
Vivid E9 echographic scanners (GE, Vingmed Ultrasound, Horten, Norway). Quantifica-
tion of cardiac chamber size, left ventricular mass and systolic and diastolic left ventri-
cular function were performed in accordance with the recommendations for chamber 
quantification by the American Society of Echocardiography’s Guidelines and Standard 
Committee and the Chamber Quantification Writing Group29-31 and were obtained from 
the 2D echocardiogram, as previously described.28 In case the ejection fraction (EF) 
was not available, fractional shortening (FS) was used. 
Strain analysis was done according to our previously published protocol,16 by an expe-
rienced investigator (LK), using two-dimensional gray scale images taken in the paras-
ternal apical 4-chamber view (4-CV) and at mid-cavity short-axis view (at the level of the 
papillary muscle; SAX-PM). The investigator was not aware of the clinical condition and 
medical treatment of the patients. A sector scan angle of 30-60 degrees was chosen 
and frame rates of 70 Hz or more were used.32 Cine loops of preferably three cardiac 
cycles triggered by the R wave of the QRS complex were digitally saved. Offline analysis 
was performed using software for echocardiographic quantification (EchoPAC 6.1.0, 
GE Medical Systems, Horten, Norway). Timing of aortic valve closure and mitral valve 
opening was used to indicate end-systole and start of diastole respectively. Manual trac-
king of the endomyocardial borders was performed at the end-systolic frame. An auto-
matic generation of the second epicardial tracing was created by the software, which 
also automatically divided the LV myocardium into six equal segments, which were 
named and localised according to the statement of the Cardiac Imaging Committee of 
the Council on Clinical Cardiology of the American Heart Association.33 Quality of the 
speckle tracking was verified for each segment and adjusted when needed. Tracking 
was only accepted if visual inspection indicated adequate tracking over the full cardiac 
cycle. Preferably, three cardiac cycles were analysed for each segment and exported 
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as text files for further post-processing. As a next step the exported strain curves were 
post-processed, in a custom made software package using Matlab (r2013b), in order 
to estimate the average strain curve and to obtain the final strain parameters out of 
this data.34 Figure 1 shows a composite figure with the region of interest (left side) and 
graphic depiction of longitudinal strain in 4-chamber long axis view and for radial strain 
in the mid-cavity short-axis view. The inter and intra-rater variability of our group was 
previously published.34
Figure 1. 
Two-dimensional strain measurement. Two-dimensional strain measurement in longitudinal plane. At the left 
top, the region of interest is shown, at the right the graphic depicture of the transmural strain in a young female 
m.3243A>G carrier who was found to have severe cardiomyopathy in 2010. After diagnosis, she was started 
on medication (diuretics, ACE inhibitor and β blocker) and underwent an intensive heart failure rehabilitation 
programme. At the echocardiogram in 2013, she reported a highly significant increased in exercise tolerance. 
The coloured lines represent the measurements of regional deformation of the individual regions, the dotted 
line represents their average (global strain), analysed by GE EchoPac. GLS increased from -12.7 to -19.6.
To evaluate the conventional echocardiographic values obtained in our patient group, we 
used the reference values described by the American Society of Echocardiography.29,30 
Strain values are dimensionless and are expressed in percentage. The average values 
per segment of longitudinal, radial and circumferential end-systolic strain was deter-
mined.35 End-systolic strain, the recommended measure for reporting myocardial 
deformation in a recent consensus paper,36 is strain measured at end-systole, by time 
of aortic valve closure. Global longitudinal myocardial strain (GLS) was calculated by 
averaging the six segments using the apical 4-chamber view (4-CV). Global radial 
and circumferential myocardial strain (GRS and GCS, respectively) were calculated by 
averaging the six segments of the mid-cavity short-axis view (SAX-PM). When less 
than four segments were available for averaging, global strain was not calculated. In 
a recent consensus paper by Voigt et al. end-systolic strain (at the time of the aortic 
valve closure) was strongly recommended as “the measure” for reporting myocardial 
deformation.36 Since the end-systolic strain value may differ from peak systolic strain, 
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which is a measurement of peak deformation at any point during systole, we only used 
published reference values for end-systolic strain. Age-matched reference values for 
end-systolic strain were obtained from Kocabay et al.20 and from Kuznetsova et al.37 
Values were considered abnormal when deviating >2 standard deviations (SD) from 
mean (Kocabay) or < p5 or > p95 (Kuznetsova, SDs were not reported). Each carrier 
was compared individually to his/her age-matched reference values. Changes were 
reported as absolute numbers and changes of ≥ 10% were accepted as real changes, 
as this number exceeds the coefficient of variation reported in literature38 recommended 
by Plana et al.
Reproducibility studies
Ten images in which strain analysis was possible were randomly selected by a physi-
cian not involved in the strain measurements for reproducibility studies. To determine 
inter-observer reproducibility, longitudinal strain was analysed by another experienced 
rater (GW), blinded to previous results. Intra-rater reproducibility was determined by 
rating the same images, more than six months later. For both inter- and intra-observer 
reproducibility, absolute differences and the intraclass correlation coefficients were 
calculated. 
Follow-up study
Only carriers of whom two echocardiograms in which GLS analysis was feasible were 
available were included in this study. Subjective and objective changes in clinical 
status, changes in the use of medication and changes in conventional parameters 
were assessed during follow-up. Since all echocardiograms were performed as part of 
clinical care, the time between two examinations varies. 
Medical ethical approval
This study is part of the “National Inventory of Patients with the m.3243A>G mutation”, 
which was approved by the regional Medical Research Ethics Committee. In accor-
dance with the Helsinki agreement, written informed consent was obtained from each 
participant.
Statistical analysis
The absolute difference was calculated by subtracting the first measurement from 
the second measurement. All variables were assessed for (log)normality. To prevent 
non-real values for zero values of the NMDAS including its sub domains and symptom 
specific items, these values were increased by 1 prior to elog transformation. Variables 
with a (log)normal distribution, were compared using parametric tests, and the mean 
and 95%-confidence intervals (95%CIs) are reported. Variables that deviated strongly 
from a (log)normal distribution were analysed by performing a non-parametric test and 
the median and interquartile ranges (IQRs) are reported. Inter- and intra-rater reliability 
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were calculated using intraclass correlation coefficients for absolute agreement (ICC). 
Correlation coefficients were interpreted in accordance with the guidelines provided 
at the BMJ website (http://www.bmj.com/about-bmj/resources-readers/publications /
statistics-square-one/11-correlation-and-regression). 
All analyses were performed using IBM’s SPSS statistics software packages, version 
20.0.0.1. 
Results
Carrier description 
The study algorithm is presented in Figure 2. Thirty carriers of the m.3243A>G mutation 
of whom two subsequent echocardiograms were available for 2D strain analysis were 
included in this study (Table 1). Nineteen of these carriers were female; five of them 
were current smokers. Eighteen carriers had diabetes mellitus, six microalbuminuria, 
one decreased creatinine clearance and ten carriers had cardiovascular involvement 
according to the NMDAS.
In the ‘National Inventory of Patients with the m.3243A>G mutation’, eighty adult 
carriers had been included before 2012 (since the regular follow-up time is 2 years, we 
do not account for carriers included before 2012). For a variety of reasons (e.g., only 
one echocardiogram available, or echocardiogram made using a wrong echocardio-
graph device), only data of 30 carriers (38%) from 20 families could be analysed (1-3 
family members per family). These 30 carriers were not different compared to the total 
cohort with respect to their total NMDAS score (p = 0.35), nor in their sub scores for 
diabetes mellitus or cardiovascular disease (p = 0.37 and 0.81 respectively). BMI was 
significantly higher in the included carriers compared to the other carriers (p = 0.0062).
Table 1.
Carrier characteristics. Clinical features of the included carriers compared to all adult carriers in the ‘National 
inventory of carriers with the m.3243A>G mutation’. The presence of Diabetes Mellitus was obtained from the 
NMDAS scale (score on Diabetes Mellitus item ≥3); the presence of cardiovascular involvement was obtained 
from the NMDAS scale (score on Cardiomyopathy ≥ 1). p-values for the difference at baseline between this 
cohort and all adult carriers included before 2012 were calculated. 
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 n = mean (range)
total 
number 
of patients
Difference from 
total cohort 
of carriers 
(n = 80) p =
Gender Female 19   30  
Age 45.2 (16.7 - 64.5) 30 0.90
BMI (kg/m2) 23.8 (17.3 - 34.0) 30 0.006
Alcohol Use 6   27  
Abuse 1   27  
Smoking Current 5   27  
Stopped 5   27  
Renal abnormalities Micro-albuminuria 6   30  
Decreased creatinine 
clearance
1   30  
Diabetes Mellitus 
(NMDAS)
Yes 18   30 0.37
HbA1c  (mmol/mol) 6.7 (5 - 9.7) 28  
Cardiovascular 
involvement 
(NMDAS)
Yes 10   30 0.84
Systolic blood 
pressure
127 (95 - 167) 23  
 <120 mmgHg 5     
 120 - 140 mmHg 13     
 > 140 mmHg 5     
Diastolic blood 
pressure
(mmHg) 79 (58 - 98) 23  
Total cholesterol (mmol/l) 4.8° (3.5 - 9.2) 23  
HDL cholesterol (mmol/l) 1.1  (0.6 - 1.9) 21  
LDL cholesterol (mmol/l) 2.9 (0.9 - 4.8) 21  
Heteroplasmy 
in leucocytes
(%) 28 (3 - 73) 30  
Heteroplasmy 
in UEC
(%) 52 (7 - 96) 30  
NMDAS  18.6 (0 - 49) 30 0.35
Domain 1 7.5 (0 - 21) 30 0.11
Domain 2 7.3 (0 - 18) 30 0.20
Domain 3 2.6* (0 - 13) 30 0.96
QoL Mental 46 (25 - 59) 28 0.34
QoL Physical 40 (21 - 58) 28 0.09
Medication¤ β blocker 6   30
Calcium channel blocker 1   30  
ACE inhibitor 6   30  
Angiotensin II blocker 2   30  
Insulin 5   30  
BMI = body mass index; Domain 1 = current function; Domain 2 = system specific involvement; Domain 3 = current clinical 
assessment; IQR = interquartile range; n = number of carriers of which data were available at that specific time point; NMDAS 
= Newcastle Mitochondrial Disease Adult Scale; QoL = Quality of Life; UEC = urinary epithelial cells. *lognormal distribution; ° 
median is given instead of mean; ¤ not mutually exclusive
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Conventional echocardiography at baseline
Table 2 presents the echocardiographic parameters of our patients. Using conventi-
onal echocardiography, seven carriers (23%) did not present with (sub-clinical) cardiac 
abnormalities. Hypertrophy was reported in 40% of the carriers, mild mitral insufficiency 
in 13% and mild aortic insufficiency in 27% of the carriers. 
Table 2.
Cardiac characteristics at baseline. Conventional echocardiographic and myocardial deformation in 
m.3243A>G carriers compared to the reference population. Reference values were obtained from Nagueh et 
al. en Lang et al. for the conventional echocardiographic parameters and to Kocabay et al. and Kuznetsova et 
al. for strain data. High (>+2SD) and low (-2SD) are based on age-matched reference values.
 median (spread)
High values 
(n (%))
Low values 
(n (%)) n = 
FS (%) 36 (11 - 56) 2 (7%) 10 (33%) 30
EF (%) 64 (25 - 68)  - 3 (30%) 10
Interventricular septum 
thickness in diatsole (cm)
0.9 (0.6 - 3.0) 12 (41%)  - 29
LV posterior wall thickness (cm) 0.9 (0.7 - 1.4) 13 (45%)  - 29
LV internal diameter in diastole (cm) 4.4 (1.9 - 6.0) 1 (3%) 6 (21%) 29
Mitral valve E/A Ratio 1.1 (0.7 - 4.0) 2 (7%) 1 (3%) 29
LV performance (Tei) index 0.4 (0.3 - 0.8) 11 (41%)  - 27
Isovolumic relaxation time (ms) 84 (50 - 120) 9 (32%) 2 (7%) 28
Pulmonary Vein S/D Ratio 1.4 (0.54 - 2.2) 5 (21%)  - 24
Left ventricular mass index (g/m2) 76 (23 - 140) 4 (17%) 2 (8%) 24
Global longitudinal strain 
compared to Kocabay et al.
-16.3 (-7.9 - -20.7)  - 15 (56%) 27
compared to Kuzenetsova et al.    - 19 (70%) 27
E/A ratio = ratio between early (E) and late (A) filling velocity, measured at the mitral valve; LV = left ventricular, 
S/D ratio = ratio between the velocity of the flow in systole and diastole, ¤ not mutually exclusive, ° median and 
IQR are given instead of mean and 95%CI
The previously observed correlation between the left ventricular mass index and the 
NMDAS and heteroplasmy percentage9 could not be confirmed in our cohort (r(he-
teroplasmy UEC) = -0.01; p = 0.97; r(heteroplasmy leucocytes) = -0.04, p = 0.87; 
r(NMDAS) = 0.01, p = 0.97; n = 24). 
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Figure 2.
Study algorithm.
4-CV = 4 chamber view; ΔGLS = change in global longitudinal end-systolic strain; GLS = global longitudinal 
end-systolic strain; ICC = intraclass correlation coefficient; SAX-PM = short axis view at level of papillary 
muscle
Cohort of m.3243A>G carriers 
present in this study 
( n = 30)
4-CH view (longitudinal strain (GLS))
Feasible in 151/161 segments
3 echocardiograms excluded
( n = 27)
SAX-PM (radial and circumferential strain)
Feasible in 58/102 segments
18 echocardiograms excluded
Total cohort of m.3243A>G 
carriers in 2012
( n = 80)
Exclusion criteria:
- <2 echocardigrams available
- wrong echocardiography device use
GLS <-2 SD
n = 12 (44%) No further data processing
GLS -2 – 0 SD
n = 15 (56%)
ΔGLS ≥10%
n = 9 ( 39%; n = 23)
Inter-observer ICC = 0.78
Intra -observer ICC = 0.89
Strain feasibility
For the analysis of GLS on the 4-CV images, three patients (10%) had to be excluded 
because no GLS analysis could be performed. Two instead of three cycles were suitable 
for analyses in 33% (e.g., bad quality of the images, only two cardiac cycles recorded). 
The assessment of GLS was feasible in 151 (94%) of the 161 segments available for 
analysis. During follow-up; two subsequent images could be analysed in 23 patients 
(feasibility 77%). 
For the SAX-PM view, only 57% of the segments had sufficient image quality to perform 
radial and circumferential strain analyses and 18 patients (30%) had to be excluded 
because of low image quality. Because of the low number of high-quality images, the 
suboptimal tracking performance of some specific segments (mainly posterior and lateral) 
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even in the high-quality images, and the current debate on the reproducibility of radial 
strain,“ we chose not to further process these results and concentrate only on the longi-
tudinal 2D strain.
Longitudinal 2D strain at baseline
When comparing our results to the age-matched reference values of Kocabay et al., 15 
carriers (56%) had abnormal GLS (Table 3). When comparing to the age-matched refe-
rence values of Kuznetsova, 19 carriers (70%) had abnormal GLS. Of the seven carriers 
with normal cardiac function and diameters assessed by conventional echocardiography, 
two or four (depending on the reference values used) had abnormal GLS. In the ten 
carriers with low fractional shortening, 5 had low GLS (one GLS not available). In the nine 
carriers with a high diastolic left ventricular posterior wall thickness, seven had decreased 
GLS. 
Sex Age
Heter-
oplasmy 
Leuco-
cytes (%)
Heter-
oplasmy 
UEC (%) NMDAS FS
 (%
)
EF
 (%
)
LV
ID
d 
(c
m
) 
LV
PW
d 
(c
m
)
IV
Sd
 (c
m
) 
M
V 
E/
A 
R
at
io
G
LS
#
G
LS
*
M 29 51 98 49  25 1.08 -7.9 -7.9
F 30 42 ND 16 18 6 1 0.7 4 -12.7 -12.7
F 31 49 57 13 11 1.9 0.9 1.3 0.99 -12.8 -12.8
M 43 19 ND 7 20 3.9 1 1 0.8 -13.1 -13.1
F 47 31 61 43 17 4.4 0.9 0.8 1.26 -13.2 -13.2
F 58 17 41 21 37 63 3.8 1.3 1.8 1.49 -13.9 -13.9
F 38 23 30 21 44 4.4 1.2 1.4 -13.9 -13.9
M 51 16 78 16  51 4.4 1.3 1.4 0.91 -14.1 -14.1
F 57 25 85 15 49 3.5 1.1 1 0.75 -14.2 -14.2
F 49 17 45 38 33 67 3.8 1.4 1.3 0.86 -14.3 -14.3
M 39 30 54 11 43 5.6 0.9 1 1.44 -16.1 -16.1
F 28 27 67 8 27 66 4.8 0.9 0.9 0.71 -16.1 -16.1
F 60 6 30 26 40 4.6 1 1 1.01 -16.9 -16.9
M 54 6 77 15 30 4.5 0.9 1 1.16 -17.1 -17.1
F 26 34 86 0 30 66 4.4 0.9 0.8 2.22 -17.1 -17.1
F 56 10 27 26 24 4.5 0.9 0.9 0.73 -17.6 -17.6
F 46 19 44 21 15 48 4 0.9 0.6 0.89 -17.7 -17.7
M 17 19 58 0 37 5.3 0.8 0.8 1.97 -17.7 -17.7
Table 3. 
Global strain in carriers individually compared to age-matched controls. Global longitudinal end-systolic 
strain in m.3243A>G compared to the age-matched reference population (n = 27). Marked in blue the low 
values (under -2 SD for age-matched reference values), marked in gray the values below the mean (between 0 
and -2 SD). In green the high values (above +2 SD).
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M 40 17 84 7 4.5 0.9 0.8 1.62 -18.3 -18.3
M 61 16 79 20 37 4.7 1.3 1.2 1.09 -18.6 -18.6
M 25 28 64 0 36 63 5.2 0.8 3 3.04 -18.9 -18.9
F 53 8 38 24 39 67 4.7 0.8 0.6 1.1 -19.4 -19.4
F 65 7 52 39 43 4.8 0.7 0.9 0.9 -19.4 -19.4
F 39 27 79 17 21 4 0.9 0.7 0.93 -19.6 -19.6
F 57 12 86 25 37 68 4.7 0.9 0.8 1.4 -19.9 -19.9
F 33 14 32 10 56 4.5 0.8 0.8 1.26 -20 -20
F 48 17 52 25 39  3.8 1 0.9 0.95 -20.7 -20.7
E/A ratio = ratio between early (E) and late (A) filling velocity, measured at the mitral valve; F = female; FS = fractional shorte-
ning; GLS = global longitudinal end-systolic strain; GRS = global radial end-systolic strain; LVPWd = diastolic left ventricular 
posterior wall thickness; M = male; NMDAS = Newcastle Mitochondrial Disease Adult Scale; UEC = urinary epithelial cells; * = 
Kocabay reference values (95%CI); # Kuznetsova reference values (90%CI)
No significant correlation between age and GLS was found (r = -0.21; p = 0.30). GLS 
was not significantly lower in carriers with DM (p = 0.68). GLS was not significantly lower 
in carriers with a score 0 versus ≥1 on the cardiovascular involvement item in the NMDAS 
(p = 0.10). There was no correlation between IVSd and GLS (ρ = 0.35; p = 0.08). Carriers 
with renal abnormalities (including microalbuminuria) did not have significantly lower GLS 
compared to carriers without renal abnormalities (p = 0.65).
GLS correlated significantly to the heteroplasmy percentage in UEC , but not to heterop-
lasmy percentage in leucocytes (r = 0.45; p = 0.05 and r = -0.17; p = 0.36, respectively). 
No significant correlation between the NMDAS score and GLS was found (r = 0.29, p = 
0.17). The score in the first, subjective domain of the NMDAS did not correlate signifi-
cantly to GLS (r = 0.18, p = 0.41). There was no significant difference in the GLS between 
carriers with asymptomatic, mild, moderate and severe general mitochondrial disease 
severity (p = 0.65). Physical quality of life did not correlate significantly to GLS (r = 0.18, 
p = 0.38). No significant correlation between mental quality of life and GLS was found (r 
= 0.15, p = 0.49). 
Inter- and intrarater reliability
The ICC of inter-rater reliability was 0.78, with a mean difference of 0.83 (95%CI 0.38 – 
1.85). The ICC of intra-rater reliability was 0.89, with a mean difference of 0.40 (95%CI 
0.11 – 1.42). 
Follow-up
Twenty-three patients were suitable for the analysis of changes in myocardial deforma-
tion during follow-up (feasibility 77%). Table 4 shows the changes in GLS, the subjective 
changes in exercise tolerance and changes in medication. The median time between the 
first and the second echocardiogram was 2.0 years (IQR 1.1 – 2.7 years; range 0.5 – 4.6 
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years). The disease severity (including the Cardiovascular and Diabetes Mellitus score and 
sub domains) as well as the quality of life didn’t change significantly during follow-up (p 
= 0.11 - 0.92). 
Nine carriers (39%) had a change in GLS ≥10%. The change in GLS ranged from -7.1 
to +6.9 (mean 0.33; 95%CI -5.5 - +2.3), where a higher (thus positive) value represents 
an improvement in longitudinal strain. Nine carriers (39%) had a change in GLS ≥10%. 
Examples of the difference in responsiveness of myocardial strain include two cases of 
young carriers with m.3243A>G related cardiomyopathy which were documented in 
more detail: One young woman with a generally mild phenotype and newly discovered 
severe heart failure at the first echocardiogram recovered very well under pharmacothe-
rapy and rehabilitation (GLS -12.7 to -19.6), while a male carrier with MELAS syndrome 
had a stable, severe heart failure (GLS -7.9 to -5.4). See Figure 1 for the first case. 
Table 4. 
Clinical and strain parameters during follow-up in m.3243A>G carriers. Description of the change 
during follow-up and the change in global end-systolic strain in longitudinal and radial direction at 
baseline and during follow-up in m.3243A>G carriers (n = 23). Time between echocardiograms, subjective 
change in exercise tolerance and changes in medication are also depicted. Blue marking indicates a ≥10% 
increase in myocardial strain; green marks a ≥10% decrease in myocardial strain during follow-up. 
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Discussion
The aim of this retrospective pilot study was to evaluate the usefulness and feasibility 
of 2DSTE in detecting and monitoring myocardial dysfunction in both symptomatic and 
asymptomatic carriers of the m.3243A>G mutation. 2DSTE seems a feasible method 
to quantify longitudinal myocardial deformation (strain) in m.3243A>G carriers with a 
wide spectrum of clinical disease severity and for this reason it should be considered 
as an outcome measure in future clinical trials. Although the images were obtained as 
part of clinical care, strain analysis was feasible in 90% of the images for global longitu-
dinal strain (GLS). Radial and circumferential strain were not further processed because 
of a low number of high-quality images and suboptimal tracking even in high-quality 
images, which is in line with the current debate on the reproducibility of radial strain.39 
Decreased GLS was found in more than half of the m.3243A>G carriers; none of the 
carriers had a higher GLS than the average of the age-matched reference group. Inter- 
and intra-rater reliability was good, with a mean difference of 0.83 for inter and 0.40 for 
intra-rater reproducibility. Since our centre has no experience in tagged cMRI, we could 
not confirm the very strong correlation between cMRI and 2DSTE17 for this specific 
indication. 
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A previous study showed that myocardial deformation, measured by cMRI, in m.3243A>G 
mutation carriers without known clinical cardiac involvement showed abnormal longitu-
dinal shortening, whereas radial and circumferential strain were comparable to matched 
healthy controls.9 This is in line with studies in other populations where GLS by echocar-
diography is reported to be most sensitive strain parameter to assess systolic dysfunc-
tion.19,40 Global longitudinal strain is therefore accepted as a major outcome parameter 
of e.g. chemotherapy related cardiac dysfunction.21 In general, GLS is reported to be 
relatively easy to measure and more consistent and reproducible compared to GCS.20 
The hypothesis is that GLS is affected at first because the longitudinally orientated 
subendocardial fibres are most susceptible to injury.19 In our present study, we found 
no correlation between the longitudinal myocardial deformation and the clinical para-
meters or clinical scoring such as the NMDAS. Nevertheless, one should keep in mind 
that mild general mitochondrial disease may be associated with severe cardiomyopathy 
and therefore all carriers of the m.3243A>G mutation should be screened for any sign 
of (subclinical) cardiomyopathy. 
In another follow-up study of m.3243A>G carriers, cMRI was used to monitor cardiac 
adaptations and safety of endurance training. No difference was found in GCS during 
follow-up; however, GLS was not assessed.41 Other studies report good responsive-
ness of radial (and in lesser extent of longitudinal) strain,42 and improvement of longitu-
dinal strain under treatment43 while others report no changes in myocardial strain during 
the follow-up of patients with progressive (non-mitochondrial) diseases.44 In the present 
pilot study, we found changes in GLS exceeding the inter- and intra-observer variability 
in 39% of our cohort. Since we were not able to measure the disease progression with 
other methods rather than 2DSTE itself, one can not rule out that these changes in GLS 
could still partly represent the influence of other factors, e.g. changes in medication, 
or treatment of the most common cause of cardiac hypertrophy: hypertension. The 
influence of covariates of diminished myocardial deformation, including the decreased 
myocardial deformation associated with physiological aging45 and with the presence 
of diabetes mellitus,46 was not significant in our cohort. This is probably caused by the 
high number of young subjects with severe m.3243A>G associated cardiomyopathy 
included in our cohort and the lack of correlation between the presence of m.3243A>G 
associated cardiomyopathy and m.3243A>G associated symptoms in general and 
m.3243A>G associated diabetes mellitus, specifically. Although we found a moderate 
correlation between GLS and the heteroplasmy percentage measured in urinary epit-
helial cells, the heteroplasmy percentages in these tissues do not always represent the 
heteroplasmy percentage measured in cardiac muscle.4
Tagged cMRI is considered the reference standard for measuring myocardial deforma-
tion,47 yet the lack of availability and expertise in many centres hampers its use in future 
clinical trials. Although 2DSTE is dependent on operator experience, machine settings 
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and the acoustic window for transducer placement of the patient,47 the technique is 
recently often used in multi-centre clinical trials. Pitfalls of the 2DSTE method itself 
include its dependence on high quality images, frame rate and pre- and afterload, the 
high labour-intensity, and the limited standardisation between vendors. Weaknesses of 
this study include the data gathering as part of clinical care, the relatively small number 
of carriers of whom two echocardiograms were available for further 2DSTE, and the 
lack of standardised follow-up protocol to allow firm conclusions about the responsi-
veness of 2DSTE. Despite the fact that the 2D images were obtained as part of clinical 
care, the proportion of high quality images on which analysis was feasible was compa-
rable to the literature.48 
More and more trials are performed in patients with mitochondrial disease. There is 
an urgent need for robust outcome measures.49 The wide availability, the non-invasive 
nature and independence of voluntary effort of 2DSTE makes it promising as an objec-
tive and quantitative end point for clinical trials. The data for this retrospective pilot 
study were collected as part of routine care (using a standardised imaging protocol) and 
only 77% of the patients were suitable for the assessment of longitudinal myocardial 
strain using 2DSTE. Since these numbers are probably higher in highly standardised 
prospective studies, we recommend testing the feasibility and responsiveness of GLS 
in more detail in a prospective (intervention) study. Myocardial deformation reflects not 
only the myocardial contractility, but probably also global forces such as pre- and after-
load. For proper use in future clinical trials, we suggest standardisation of e.g. medica-
tions and fluid intake at the time of the echocardiography.
Given the high prevalence of cardiac abnormalities and the lack of clear clinical predic-
tors for the presence of not-yet-symptomatic cardiomyopathy, screening for this condi-
tion might be of major importance. Whether early detection of myocardial dysfunction in 
these patients will be beneficial for the long term prognosis in this population, remains 
to be further clarified. Although myocardial deformation seems to be predictive of heart 
failure50 and all-cause mortality,51 the value of treating subtle sub clinical changes in 
myocardial deformation, detected using 2DSTE, should be studied prospectively in a 
larger cohort of adult m.3243A>G carriers. 
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The objective of this study was to determine the value of fibroblast growth factor 21 
(FGF21), a recently discovered biomarker for mitochondrial disease, in predicting clinical 
disease severity and disease progression in adult carriers of the m.3243A>G mutation. 
We compared the prognostic value of FGF21 with mtDNA heteroplasmy percentages. 
In the context of a national inventory, the heteroplasmy levels of the m.3243A>G muta-
tion were measured in leukocytes and urinary epithelial cells. The Newcastle Mitochon-
drial Disease Adult Scale was determined and blood was drawn for measuring FGF21 
concentration. This prognostic study included 99 adult carriers of the m.3243A>G 
mutation. Our analysis revealed a moderate, significant correlation between FGF21 
concentration and disease severity (r = 0.49; p = <0.001). No significant correlations 
were found between disease severity and the heteroplasmy percentage determined 
in urinary epithelial cells or the heteroplasmy percentage determined in leukocytes. 
Weak yet significant correlations were also found between FGF21 concentration and 
the severity of the myopathy (r = 0.38; p = <0.001) and between the concentration 
of FGF21 and the severity of the encephalopathy (r = 0.30; p = <0.001). Repeated 
measurements following 25 subjects for two years revealed no significant correlation 
between FGF21 concentration and disease progression. We conclude that measuring 
FGF21 concentration had little added value in monitoring and predicting the disease 
course in this specific patient group.
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Introduction
Within an individual, the mutation load (i.e. heteroplasmy) of mitochondrial DNA (mtDNA) 
mutations can vary widely among tissues. Despite some exceptions,1 high levels of 
heteroplasmy are often associated with a measurable deficiency in oxidative phosphor-
ylation and with more severe signs and symptoms.2 With respect to the m.3243A>G 
mutation, the most common mutation in mtDNA, high heteroplasmy levels are often 
associated with a severely debilitating syndrome called mitochondrial encephalomyop-
athy, lactic acidosis and stroke-like episodes (MELAS) syndrome, whereas moderate 
heteroplasmy levels are associated with milder phenotypes including e.g. maternally 
inherited diabetes and deafness (MIDD) or myopathic symptoms.3,4 However, because 
the percentages of heteroplasmy measured in urine epithelial cells and leukocytes are 
only weakly to moderately correlate with disease severity in m.3243A>G patients,4,5 
using the percentage of heteroplasmy measured in accessible tissues such as blood 
and urine has limited prognostic value in individual patients. Therefore, a more reliable 
method is needed in order to predict disease severity of these patient’s families. 
A recent study reported that serum FGF21 is a novel diagnostic biomarker for differ-
entiating between patients with muscle-manifesting mitochondrial disease and other 
neuromuscular disorders.6 In a large cohort of patients with confirmed mitochondrial 
disease, the sensitivity and specificity of FGF21 was 92.3% and 91.7%, respectively. 
More recent studies have confirmed that patients with mitochondrial disease have 
increased FGF21 concentrations,7,8 although the results obtained from patients and 
healthy volunteers overlapped.6,8,9,10 In the present study, we examined the prognostic 
value of FGF21 in indicating disease severity and monitoring disease progression in 
adult carriers of the m.3243A>G mutation.
 
Methods
Hypothesis
Our pre-specified hypothesis was that the concentration of fibroblast growth factor 
21 (FGF21) in serum correlated with the clinical disease severity, as measured by the 
Newcastle Mitochondrial Disease Adult Score in adults with carrying the m.3243A>G 
mutation. We assumed that this correlation would be higher compared to the correla-
tion with heteroplasmy percentages in urinary epithelial cells (UEC) and leukocytes. 
Furthermore, we hypothesised that an increase in FGF21 would correlate positively 
with disease progression in 25 randomly selected carriers during a two year follow-up.
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We collected blood from patients with a confirmed m.3243A>G mutation and from their 
maternal relatives; these patients and relatives provided blood samples in the context 
of the ‘National Inventory of Patients with the m.3243A>G mutation in the Nether-
lands’, which was initiated in May 2010.5 This study investigates the clinical and genetic 
features of patients with the m.3243A>G mutation and their maternal relatives. To date, 
117 adult subjects from 48 families have been enrolled. 
The concentration of FGF21 was measured using a commercially available Human 
FGF21 enzyme-linked immuno sorbent assay (ELISA) kit for detecting human FGF21 
(Biovendor, Brno, Czech Republic), following the instruction of the manufacturer. Each 
sample was measured in duplicate. The inter-assay and intra-assay variability for high 
and low values was determined based on high and low controls samples, respectively. 
The functional sensitivity determined at 20% covariance (CV) was 7.35 pg/ml. At a level 
of 106 pg/ml the within-assay CV was 9.1% and the between assay CV was 9.2%. At 
a level of 618 pg/ml the within-assay CV was 2.5% and the between-assay CV was 
6.4%. Samples with an initial intra-assay CV >15% (in samples with an FGF21 concen-
tration > 100 pg/ml) or >25% (in samples with a first FGF21 concentration <100 pg/ml,) 
were repeated; if a high intra-assay CV was detected a second time, these samples 
were excluded from further analysis. According to the kit’s manufacturer, the assay has 
no cross reactivity with human FGF19 and FGF23. The two values obtained from the 
duplicated measurements were averaged, and the mean of these two measurements 
was used for further analysis. Samples with a concentration higher than the highest 
standard value were diluted, and the ELISA was repeated. Reference values (< 200 pg/
ml) were obtained from the first study of FGF21 in mitochondrial disease.6
Phlebotomy was performed at the outpatient clinic during appointments that were 
made by the subjects (i.e. the appointments occurred at random times of the day 
during regular office hours). The subjects were not instructed to fast prior to the proce-
dure. Because the phlebotomy was performed immediately following a standardised 
clinical assessment, the timing of the initial and follow-up appointments was used to 
calculate the difference in time of the day the samples were taken for the patients 
included in this follow-up study. No other biomarkers, such as lactate, pyruvate or 
creatine kinase were evaluated. 
Within 24 hours of obtaining the blood samples, the serum was stored in cryotubes at 
-20°C. In accordance with the kit’s manufacturer’s instructions, the samples were stored 
-20°C for a maximum of 10 months and multiple freeze-thaw cycles were avoided. After 
thawing at 4°C, the samples were analysed within 16 hours. According to the kit’s 
manufacturer, handling the samples in this manner does not result in a decline in the 
concentration of FGF21 in serum.
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Clinical and genetic assessment
In the ‘National Inventory of Patients with the m.3243A>G mutation’, all patients and 
~50-60% of all maternal relatives (including both symptomatic or asymptomatic rela-
tives) with the m.3243A>G mutation are seen approximately once every two years 
at our outpatient clinic. All carriers were assessed by the same clinical investigator. 
Patients were searched for in our genetic database; maternal relatives were recruited 
for participation by a (maternally related) patient with a proven m.3243A>G mutation. 
In this study, a total of 135 carriers - 118 of whom were adults - from 48 families have 
been seen to date. In 78 percent of the carriers included in 2010-2011 (82 adults and 
12 children), the study was repeated after two years (76% of the adults; 83% of the chil-
dren), 3 of the participants (3%; one child) died and 18 subjects (19%; one child) were 
(temporarily) lost to follow-up (mostly because of insurance or coping issues). Forty-one 
carriers (5 children) were seen for the first time at the time of the follow-up visit of the 
first subjects (2012). Twenty-five patients were selected at random from the follow-up 
group by colleagues who were not involved in the analyses of these results.
The Newcastle Mitochondrial Disease Adult Scale (NMDAS)11 was used to assess the 
presence and severity of mitochondrial disease-related clinical symptoms. The NMDAS 
contains the following four sections: i) current function; ii) system specific involvement; 
iii) current clinical assessment; and iv) quality of life (QoL). In our analysis, we used 
sections i-iii to calculate disease severity. Severe mitochondrial disease was defined 
previously as an NMDAS score above 20.5 For this study, we defined asymptom-
atic disease as an NMDAS = 0; mild mitochondrial disease as an NMDAS score of 
1 through 5 and moderate mitochondrial disease as an NMDAS score of 6 through 
20. We quantified ‘myopathy’ using the total score for the following items: exercise 
intolerance, respiratory muscle weakness, ptosis, external ophthalmoplegia and myop-
athy. ‘Encephalopathy’ was quantified using the total score obtained from the following 
items: psychiatric symptoms, migraine, seizure, stroke-like episodes, encephalopathy 
and cognition. The presence and severity of diabetes mellitus (DM) was obtained from 
the NMDAS. Renal function was assessed by measuring glomerular filtration rate (using 
the MDRD equation) and using albumin levels. Microalbuminuria was defined as an 
albumin-to-creatine-ratio of >2.0 g/mol for men and >2.5 g/mol for women. Renal 
failure was defined as a glomerular filtration rate <60 ml/min/1.73m2. Patients were 
classified as having renal failure only, microalbuminuria only, both or neither. 
In each subject, the heteroplasmy percentage in the UEC and leukocytes was deter-
mined using pyrosequencing,12 a heteroplasmy percentage ≥5% can be detected using 
this technique. Subjects with a detectable heteroplasmy percentage in either leukocytes, 
UEC and/or buccal mucosa cells (the results of buccal mucosa cells are not shown) were 
considered to be carriers of the mutation. Subjects with heteroplasmy percentages ≤4% 
(the assay’s detection limit) in all tissues were included in the family-matched control group; 
291
note that although the mutation was not detected in three different tissues (leukocytes, 
UEC and buccal mucosa cells) we cannot be 100% certain that these family members 
do not carry the mutation. In 7 of these family-matched controls, heteroplasmy percent-
ages were also determined using a more sensitive assay (detection limit 1%); in none of 
these 7 family-matched controls the mutation was found. The FGF21 concentration in 
randomly selected non-related healthy controls can be found in published literature.13
We also analysed nine paediatric carriers; because the Newcastle Mitochondrial Disease 
Scale is different for children than for adults, we analysed the correlation between 
serum FGF21 concentration and disease severity score separately, using the Paediatric 
version of the Newcastle Mitochondrial Disease Scale in carriers under 18 years of age. 
Standard Protocol Approvals, Registrations, and Patient Consents 
This study was approved by the regional Medical Research Ethics Committee. In accor-
dance with the Helsinki agreement, written informed consent was obtained from each 
participant (or the participant’s legal guardian in the case of paediatric subjects) in the 
context of the ‘National Inventory of Patients with the m.3243A>G mutation’.
Statistics
All parameters were assessed for (log)normality. To prevent non-real values for zero 
values of the NMDAS and its symptom specific items and heteroplasmy, all values 
were increased by 1 prior to log-transformation. Variables with a (log)normal distri-
bution, were compared using parametric tests, and the mean and 95%-confidence 
intervals are reported. Variables that deviated strongly from a (log)normal distribution 
were analysed by performing a non-parametric test and the median and interquartile 
ranges are reported. Outliers were not excluded from any analyses. Missing data were 
not replaced. In case a high number tests were performed (5 or more), critical p-values 
adjusted using the Bonferroni method (i.e. 0.05/n, n = number of tests) leading to a 
critical p = 0.0019 for 26 comparisons and a critical p = 0.0013 for 38 correlations in 
our manuscript. Correlation coefficients were interpreted in accordance with the guide-
lines provided at the BMJ website (http://www.bmj.com/about-bmj/resources-readers/
publication s/statistics-square-one/11-correlation-and-regression; consulted 09-Dec-
2013). Thus, a correlation (r) of 0.8 to 1.0 is considered a very strong relationship; r = 
0.6 to 0.79 is considered a strong relationship; r = 0.4 to 0.59 is considered a moderate 
relationship; r = 0.2 to 0.39 is considered a weak relationship; and r = 0.0 to 0.19 is 
considered a weak or no relationship.
The relative difference between the first and the second measurements was calculated 
by dividing the second measurement by the first measurement, and expressing as the 
difference as a percentage change. The absolute difference was also calculated by 
subtracting the first measurement from the second measurement. 
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Because 40% percent of the variance in concentration of FGF21 is determined genet-
ically,14 we performed two additional analyses to correct for the effect of kinship in 
our analyses. First, we performed a separate analysis that included only the most 
severely affected patient in each family. Second, we used generalised estimating equa-
tion models (working correlation structure: independence, with robust standard error 
for correction) to predict the contribution of covariates and candidate predictors with 
correction for kinship. Gender, age, body mass index (BMI), heteroplasmy percentage 
in UEC and leukocytes, myopathy, encephalopathy, DM, renal function classification 
and the disease severity (NMDAS) were included as possible covariates and candi-
date predictors for FGF21. Gender, age, BMI, heteroplasmy percentage in UEC and 
leukocytes and the concentration of FGF21 were included as possible covariates and 
candidates for disease severity (NMDAS score). 
Because genetic factors between family members are not likely to influence intra-indi-
vidual changes in FGF21 levels over time, the influence of covariates in the changes 
during follow-up was calculated using linear regression models. The changes in BMI, 
the change in sampling time and the changes in myopathy, encephalopathy, diabetes 
mellitus and disease severity were included as covariates and candidate predictors for 
the change in FGF21 concentration. The changes in BMI, heteroplasmy percentage in 
UEC and leukocytes, and FGF21 concentration were included as covariates and candi-
date predictors for the change in disease severity (NMDAS severity). 
All analyses were performed using IBM’s SPSS statistics software packages, version 
20.0.0.
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Table 1.
Patient characteristics of the cohort of all adult m
.3243A>G
 carriers and the follow
-up cohort. Patient characteristics for all adult carriers (n = 99) and for the follow
-up 
patients (n = 25). The change in the 25 patients in the follow
-up group w
as calculated as the ratio of the second m
easurem
ent and the first m
easurem
ent and is expressed as 
the percentage that the variable changed relative to the first m
easurem
ent. 
All carriers (n = 99)
Follow
-up patients (n = 25)
All carriers 
com
pared to 
follow
-up patients
C
hange (%
 higher)
Param
eter
M
edian (IQ
R
)
R
ange
n =
M
ean (95%
C
I)
R
ange
n =
p =
M
edian change (IQ
R
)
R
ange
G
ender (%
 fem
ale)
72
99
64
25
0.56
Age (years)
46
(34 - 56)
18 - 81
99
44
(20 - 68 )
19 - 64
25
0.31
B
M
I (kg/m
2)
23.8
(20.8 - 26.6)
16.8 - 40.9
64
22.4
(16 - 31.4)
17.6 - 35.8
12
0.64
1b
(-5 - + 7d)
+0 - + 10
Heteroplasm
y percen-
tage 
leucocytes (%
)
17
(8 - 26)
2 - 56
98
22
(0 - 48)
2 - 51
25
0.02
0
(-15 - + 8)
-50 - + 133
Heteroplasm
y percen-
tage U
EC
 (%
)
46
(28 - 70)
4 - 96
96
55
(4.8 - 105)
8 - 98
23
0.007
0
(-8 - + 10)
-37 - + 350
NM
DAS score
14
(6 - 22)
0 - 82
99
16a
(7 - 26c)
0 - 74
25
0.07
9
(-13 - + 30)
-50 - + 400
Dom
ain 1
5
(1 - 9)
0 - 38
99
8a
(3.5 - 12)
0 - 35
25
0.05
0
(-40 - + 33)
-99 - + 200
Dom
ain 2
5
(2 - 9)
0 - 24
99
6a
(2 - 9.5)
0 - 19
25
0.03
0
(-24 - + 25)
-100 + 100
Dom
ain 3
5
(2 - 9)
0 - 20
99
3
(0 - 7)
0 - 20
25
0.39
0
(-75 - + 20)
-100 + 100
M
yopathy score
2
(1 - 4)
0 - 14
99
2
(1 - 4)
0 - 11
25
0.19
0
(-50 - + 38)
-100 + 100
Encephalopathy score
2
(0 - 3)
0 - 20
99
1
(1 - 3)
0 - 22
25
0.73
-26
(-100 + 100)
-100 + 100
DM
 severity
0
(0 - 5)
0 - 5
99
1.8
(0 - 6.4)
0 - 5
25
0.60
-34
(-99 - + 0)
-100 + 125
FG
F21 (pg/m
l)
263
(140 - 523)
3 - 3,742
99
434
(41 - 1,870)
56 - 1,776
25
0.28
+36
-(26 - + 63)
-73 - + 7,025
B
M
I = body m
ass index; C
I = 95%
 confidence interval; D
M
 = diabetes m
ellitus; Encephalopathy score = sum
 of the encephalopathic sym
ptom
s of the N
M
D
A
S
 (psychiatric sym
ptom
s, m
igraine, 
seizure, stroke-like episodes, encephalopathy and cognition); FG
F21 = Fibroblast G
row
th Factor 21; IQ
R
 = interquartile range; M
yopathy score = sum
 of the m
yopathic sym
ptom
s of the N
M
D
A
S
 
(exercise intolerance, respiratory m
uscle w
eakness, ptosis, external ophthalm
oplegia and m
yopathy); n = num
ber of carriers of w
hich data w
ere available at that specific tim
e point; N
M
D
A
S
 = 
N
ew
castle M
itochondrial D
isease A
dult S
cale; S
ection 1 = current function; S
ection 2 = system
 specific involvem
ent; S
ection 3 = current clinical assessm
ent; U
EC
 = urinary epithelial cells. *signifi-
cantly different (p < 0.0019), a = m
edian is given instead of m
ean; b = m
ean is given instead of m
edian; c = IQ
R
 is given instead of C
I; d = C
I is given instead of IQ
R
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Results 
Patient characteristics
We initially included 118 adult subjects in our study. For a variety of reasons (e.g., the 
samples were not available or were insufficient for measuring FGF21), we were unable 
to determine the FGF21 levels in 15 of these subjects. Three additional subjects were 
excluded because of high intra-assay covariance. Thus, our final cohort included 99 
adult carriers of the m.3243A>G mutation. These carriers were from 39 distinct families 
(median: 3 subjects per family; range: 1-10 subjects per family; Table 1). This cohort 
contained two asymptomatic patients (2%), 20 patients with mild mitochondrial disease 
(20%), 47 patients with moderate mitochondrial disease (48%), and 30 patients with 
severe mitochondrial disease (30%). Since not always sufficient material was available, 
heteroplasmy percentage in UEC was available for 96 subjects; heteroplasmy percentage 
in leukocytes was available for 98 patients. 
At the time of our analysis, renal function had been studied in 88% of the subjects. Four 
patients had renal problems (with FGF21 levels of 403, 236, 21 and 16 pg/ml). Three 
other patients had received a kidney transplant; two of these patients had a normal trans-
plant function (with FGF21 levels of 407 and 1,082 pg/ml) and the third patients had a 
moderate transplant function (with an FGF21 level of 663 pg/ml). Finally, one severely 
affected patient had focal segmental glomerulosclerosis, but normal renal function (with 
an FGF21 level of 3,742 pg/ml).
The value of FGF21 as an indicator of clinical disease severity
In the total cohort containing 99 subjects, the correlation between the concentration of 
FGF21 and total NMDAS score was r = 0.49 (p = <0.001; Figure 1A and Table 2). The 
three outliers in Figure 1A represent a 47-year-old female with diabetes mellitus, hearing 
loss, focal segmental glomerulosclerosis, cardiomyopathy, exercise intolerance and mild 
cognitive disturbances (FGF21 = 3,742 pg/ml), an 18-year-old asymptomatic male with 
a heteroplasmy percentage of 93% in the urine (FGF21 = 523 pg/ml) and a 31-year-old 
female with exercise intolerance and clinical obesity (FGF21 = 1,463 pg/ml). No significant 
correlation was found between the heteroplasmy percentage in UEC and the NMDAS 
score, nor between the heteroplasmy percentage in leukocytes and the NMDAS score 
(Table 2). Among the 47 patients with mild or moderate disease, no significant correlation 
was found between the total NMDAS score and FGF21 concentration or heteroplasmy 
percentages (either measured in UEC or leukocytes). Among the 30 patients with severe 
disease, no significant correlation was found between the total NMDAS score and the 
heteroplasmy percentage in either UEC or leukocytes.
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Figure 1.
Correlation between the concentration of FGF21 and disease severity/ and myopathy score in adult 
carriers of the m.3243A>G mutation. A. The correlation between the concentration of FGF21 and general 
disease severity (total NMDAS) is r = 0.49 (p <0.001). The interquartile range is 140 - 523 pg/ml. The two 
vertical lines represent the NMDAS score reference values for mild (<5) , moderate (5-19) and severe (≥20) 
mitochondrial disease. The horizontal line represents the FGF21 reference value (≤200 pg/ml). B. The 
correlation between the concentration of FGF21 and the myopathy score is r = 0.38 (p <0.001). The y-axis is 
loglinear. FGF21 = Fibroblast Growth Factor 21; Myopathy score = sum of the myopathic symptoms of the 
NMDAS (exercise intolerance, respiratory muscle weakness, ptosis, external ophthalmoplegia and my opathy ); 
MD = Mitohcondrial Disease; NMDAS = Newcastle Mitochondrial Disease Adult Scale 
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Table 2. 
Correlations between NMDAS score and myopathy score and FGF21 and the heteroplasmy percent-
ages in leukocytes and UEC at baseline and at follow-up. Correlations between the total NMDAS score 
and the myopathy score and the concentration of FGF21 and the heteroplasmy percentages for all adult 
carriers (n = 99) and between the ratios (second measurement/first measurement) of these parameters for the 
follow-up patients (n = 25). *Significant correlations (p <0.0013).
Because FGF21 was described previously as a marker for muscle-manifesting mitochon-
drial disease,6 we also examined the correlation between FGF21 concentration and the 
muscle symptoms rated by the NMDAS (i.e. the myopathy score). We found a weak but 
significant correlation between the myopathy score and FGF21 concentration (r = 0.38; 
p = <0.001). No significant correlation was found between myopathy score and hetero-
plasmy percentage in leukocytes or UEC (Table 2).
Consistent with previous reports,15 we also found a negative correlation between age and 
the heteroplasmy percentage in leukocytes (r = -0.56; p <0.001; n = 98). A weak negative 
correlation was also found between age and the heteroplasmy percentage in UEC (r = 
-0.23; p <0.001; n = 96). Finally, a moderate positive correlation was found between age 
and FGF21 concentration (r = 0.49; p <0.001).
Correcting for kinship, generalised estimating equations revealed a significant contribu-
tion of the age at assessment to the disease severity (NMDAS) (r = 0.05; n = 62 (63%)), 
but gender, BMI, FGF21 concentration and heteroplasmy percentage in leukocytes or 
UEC did not contribute significantly to disease severity. We found a moderate positive 
correlation between age and the NMDAS score (r = 0.40; p = <0.001). Correcting for 
kinship, generalised estimating equations, revealed no significant contribution of age at 
assessment, gender, BMI, FGF21 concentration, to heteroplasmy percentage in leuko-
cytes or UEC.
Baseline (n = 99) Follow-up (n = 25)
Correlation with 
NMDAS (r)
Correlation with 
myopathy score (r)
Correlation 
between ratio’s 
and the ratio of the 
NMDAS (r)
Correlation 
between ratio’s 
and the ratio of the 
myopathy score (r)
FGF21 in serum (pg/ml) 0.49 (p = <0.001) 0.38 (p = <0.001) 0.35 ( p = 0.09) 0.47 (p = 0.02)
Heteroplasmy in leukocytes (%) 0.15 ( p = 0.13) 0.21 (p = 0.43) -0.15 (p = 0.48) 0.39 (p = 0.06)
Heteroplasmy in UEC (%) 0.29 (p = 0.03) 0.19 (p = 0.68) -0.32 ( p = 0.14) 0.31 (p = 0.14)
*Significant correlations (p <0.0013); FGF21 = Fibroblast Growth Factor 21; Myopathy score = sum of the myopathic symp-
toms of the NMDAS (exercise intolerance, respiratory muscle weakness, ptosis, external ophthalmoplegia and myopathy ); 
NMDAS = Newcastle Mitochondrial Disease Adult Scale; UEC = urinary epithelial cells
297
Among the 37 mutation carriers with normal levels of FGF21 (≤200 pg/ml), two subjects 
were asymptomatic (5.4%) and 16 subjects had mild mitochondrial disease (44%). 
Carriers with elevated FGF21 levels (>200 pg/ml) had higher scores on the first section 
of the NMDAS, however, their heteroplasmy percentages in leukocytes and UEC, total 
NMDAS scores, myopathy and encephalopathy scores, DM score and BMI values were 
similar to the carriers with normal FGF21 levels. The FGF21 levels these two cohorts are 
summarised in Table 3.
Table 3.
Patient characteristics of m.3243A>G carriers with normal concentrations of FGF21 versus carriers 
with increased levels of FGF21. The characteristics of carriers with a normal concentration of FGF21 (≤ 200 
pg/ml; n = 37) and those with increased levels of FGF21 (>200 pg/ml; n = 62) are shown. Medians are given. 
For the categorical disease severity, the percentages of the total group are given as well. 
[FGF21] normal (n = 37) [FGF21] increased  (n = 62)
BMI (kg/m2) 23.4 24.4
Heteroplasmy leucocytes (%) 12 19*
Heteroplasmy UEC (%) 36 52*
Asymptomatic 2 (5%) 0
Mild disease 16 (43%) 4 (6%)
Moderate disease 11 (30%) 34 (55%)
Severe disease 3 (22%) 24 (39%)
Total NMDAS score 7 15*
Domain 1 1 6*
Domain 2 4 6*
Domain 3 2 4*
DM score 0 0
Encephalopathy score 1 2*
Myopathy score 1 2*
*significantly higher (p <0.0019); BMI = body mass index; DM = diabetes mellitus; Section 1 = current function; Section 2 = 
system specific involvement; Section 3 = current clinical assessment; Encephalopathy score = sum of the encephalopathic 
symptoms of the NMDAS (psychiatric symptoms, migraine, seizure, stroke-like episodes, encephalopathy and cognition); 
FGF21 = Fibroblast Growth Factor 21; Myopathy score = sum of the myopathic symptoms of the NMDAS (exercise intole-
rance, respiratory muscle weakness, ptosis, external ophthalmoplegia and myopathy); NMDAS = Newcastle Mitochondrial 
Disease Adult Scale; UEC = urinary epithelial cells
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Correcting for kinship, generalised estimating equations revealed no significant contri-
bution of gender, age, BMI, heteroplasmy percentage in UEC or leukocytes, myopathy, 
encephalopathy, DM, renal function and the disease severity (NMDAS score) to FGF21 
concentration.
 
One patient died at the age 58 years during the year of follow-up period due to heart 
failure secondary to m.3243A>G-related hypertrophic cardiomyopathy. The concentra-
tion of FGF21 in this patient at the time of assessment was 1,231 pg/ml. The 3-year old 
child who died during follow-up due to intractable epilepsy, had an FGF21 concentration 
of 21 pg/ml one year prior to his death.
We next analysed only the most severely affected patient in each of the 39 families. The 
results of this subset analysis were similar to those found in the entire cohort. Specif-
ically, the correlation between the total NMDAS score and FGF21 concentration was 
0.56 (p = <0.001). No significant correlation was found between myopathy score and 
FGF21 concentration (r = 0.48; p = 0.002). Moreover, no significant correlation was found 
between the heteroplasmy percentage in UEC and the NMDAS score and/or the myop-
athy score. 
Follow-up data
In a subset of 25 carriers who were selected at random from the initial cohort of 99 
subjects, FGF21 concentration and NMDAS scores were measured approximately two 
years after the initial assessment. The median interval between the two assessments was 
20 months (range 15 - 24 months). These 25 carriers in the follow-up study were similar 
to the full cohort with respect to gender, age, BMI, FGF21 concentration, heteroplasmy 
percentages and NMDAS total and subsections scores. With respect to time of the day, 
the follow-up sample was obtained 1.5 hours later in the day (median value; range 0.5 
hours earlier up to 3 hours later) than the first sample. The characteristics of the entire 
cohort and the follow-up subgroup of subjects are summarised in Table 1. 
The value of FGF21 in predicting clinical disease progression
We found no significant correlation between the difference in NMDAS score (i.e. the 
change in NMDAS score from the follow-up visit to the second follow-up visit) and the 
difference in FGF21 concentration (i.e. the change in FGF21 concentration from the 
first follow-up to the second follow-up visit; Figure 2B and Table 2). Similar results were 
obtained with respect to the change in the heteroplasmy percentages in leukocytes and 
UEC between the first and second follow-up visits. 
We found no correlation between the change in the myopathy score and the change in 
the concentration of FGF21 (r = 0.47; p = 0.017; n = 25). There was no significant correla-
tion between myopathy progression and the change in the heteroplasmy percentage in 
leukocytes or UEC (Table 2). 
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Figure 2.
Predictive and monitoring value of FGF21 in estimating disease severity in adult carriers of the 
m.3243A>G mutation A) There is no significant correlation (r = -0.11; p = 0.601) between the concentration 
of FGF21 at the first assessment and the progression of the disease (here displayed as the difference between 
the second measurement and the first measurement). B) There is no significant correlation (r = 0.35; p = 0.086) 
between the ratio of the first and the second FGF21 concentration measurements and the ratio of the first and 
the second NMDAS measurements. The outliers are discussed in the text. FGF21 = Fibroblast Growth Factor 
21; NMDAS = Newcastle Mitochondrial Disease Adult Scale
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No significant correlation was found between FGF21 concentration at the first follow-up 
visit and disease progression during follow-up (r = -0.11; p = 0.60). Moreover, no signif-
icant correlation was found between the disease progression during follow-up and the 
initial heteroplasmy percentage measured in leucocytes (r = -0.19; p = 0.36) or UEC (r = 
0.035; p = 0.87), respectively. The three outliers in Figure 2B are a 32-year-old female with 
MELAS syndrome and a severely progressive disease with severe depression requiring 
hospitalisation (the first and second FGF21 levels were 716 and 1,585 pg/ml respectively) 
a 47-year-old female with MELAS syndrome and a relatively stable disease course (the 
first and second FGF21 levels were 1,494 and 707 pg/ml respectively) and a 20-year-old 
man with MELAS syndrome and cardiomyopathy with improving functional abilities in 
daily life but then developed diabetes mellitus that required insulin treatment (the first and 
second FGF21 levels were 1,346 and 437 pg/ml respectively).
A linear regression model revealed that neither the change in BMI, the change in hetero-
plasmy percentages in UEC and leukocytes, nor the change in FGF21 concentration 
contributed significantly to the change in disease severity (i.e. NMDAS score).
 
A linear regression model also revealed that neither the change in BMI, the change in 
sampling time nor the change in myopathy, encephalopathy, DM, or disease severity 
contributed significantly to the change in FGF21 concentration. 
Family matched controls
The family-matched controls were similar to their mutation-carrying maternal relatives with 
respect to age (p = 0.069), gender (p = 0.81) and BMI (p = 0.14), and encephalopathy 
scores p = 0.002). As expected, compared to the mutation-carrying relatives, the controls 
scored significantly lower with respect to their total NMDAS scores (p <0.001) and myop-
athy scores (p <0.001). The median FGF21 concentration in the family-matched control 
group was 31 pg/ml (IQR 7 - 173 pg/ml; range 7 - 1,072 pg/ml), which was significantly 
lower than their mutation-carrying maternal relatives (p <0.001).
Results in children carrying the m.3243A>G mutation
We also studied nine children, who were carriers of the m.3243A>G mutation, and found 
no significant correlation between the disease severity and FGF21 concentration. 
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Discussion
There is currently an urgent need for biomarkers that can reliably, objectively and quan-
titatively monitor the effect of new treatments and interventions on the disease course in 
patients with mitochondrial disease. Measuring the concentration of FGF21, a relatively 
new diagnostic biomarker, was recently reported to be indicative of clinical severity and 
disease progression in a heterogeneous cohort of patients with mitochondrial disease.6 
To investigate further the potential prognostic value of this new mitochondrial biomarker 
with respect to monitoring disease severity and predicting disease progression, we 
measured serum FGF21 levels in a genetically homogeneous but clinically heteroge-
neous disease cohort comprised of m.3243A>G carriers, with various levels of hetero-
plasmy. 
In this prognostic study, we first evaluated whether FGF21 concentration can be 
used to indicate disease severity at a single time point. In clinical practice, hetero-
plasmy levels are routinely used to cautiously predict the course of the disease, even 
though these parameters correlate only weakly, or at best moderately, with disease 
severity in patients carrying the m.3243A>G mutation.5 In a cohort of 99 carriers of 
the m.3243A>G mutation, we found that serum FGF21 concentration correlated only 
moderately with disease severity (measured using the multi-dimensional and detailed 
NMDAS). Although the correlation between disease severity and FGF21 concentration 
was stronger compared to the heteroplasmy percentages in leukocytes and urinary 
epithelial cells, our results suggest that FGF21 level is not suitable as an indicator of 
disease severity in adult m.3234A>G carriers. 
Given the urgent need for a reliable prognostic biomarker for following treatment 
effects, one might be tempted to take a biomarker that seems suitable for diagnostic 
purposes and use it for longitudinal follow-up purposes. Based on this reasoning, we 
systematically studied whether FGF21 could be used to monitor disease progression 
in 25 of the patients in our study. We found no significant correlation between disease 
progression and FGF21 concentration (i.e. the concentration prior to disease progres-
sion and the change in concentration between the two follow-up measurements) during 
2-year follow-up. These results suggest that FGF21 may not be a suitable prognostic 
biomarker for follow-up studies in this particular patient group. Nevertheless, FGF21 
could still be studied as a potential biomarker of other mitochondrial diseases. 
Because FGF21 has been reported previously as a diagnostic biomarker for muscle-man-
ifesting disease,6 we also examined the correlation between myopathic clinical features 
and FGF21 concentration (Table 2). We found a weak correlation between FGF21 
concentration and myopathy (i.e. myopathy score). In contrast, we found no signifi-
cant correlation between FGF21 concentration and muscle disease progression nor a 
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significant correlation between heteroplasmy percentage and myopathy severity. It is 
important to note that because we did not analyse muscle biopsies (for example, using 
cytochrome c oxidase staining), and we could only examine the correlation between 
FGF21 and clinical data.
We also examined the contribution of several previously identified covariates to FGF21 
concentration. Because 40% of the variation in FGF21 concentration is genetically 
determined,14 we corrected our data for inherited factors other than the m.3243A>G 
mutation using two methods: first, we analysed only the most severely affected patient 
in each family, and second, we corrected for kinship when assessing the effect of covari-
ates. The correlation between FGF21 concentration and disease severity strength-
ened slightly (to r = 0.56 compared to r = 0.49) when only one patient per family was 
included. The following covariate analyses were all corrected for kinship. Firstly, we 
did not observe the covariance by BMI and by diabetes mellitus, parameters known 
to correlate with FGF21 levels in large studies.14-22 However, the pathophysiology of 
mitochondrial diabetes mellitus seems to involve impaired insulin secretion rather than 
hyperinsulinism.23 Secondly, the increased levels of FGF21 that have been described 
in patients with chronic kidney disease24 were not observed in seven patients with 
renal failure and microalbuminuria. Although our study failed to replicate the correlations 
reported in studies with larger sample sizes, our results suggest that none of these 
parameters is likely to have caused any major bias with respect to our correlations. 
In healthy volunteers, circulating FGF21 levels do not follow a clear diurnal rhythm, and 
ketosis induced by either a 2-day fast or a ketogenic diet does not significantly increase 
serum FGF21 levels.25,26 The median FGF21 level in healthy individuals was 156 pg/
ml (90%CI 29 – 1,844 pg/ml) and previous reports showed that this level varies phys-
iologically by 64 - 250 fold between-subjects16,18 and by approximately 20% within a 
given subject during the day.18 Although we observed higher concentrations of FGF21 
in the cohort carrying the m.3243A>G mutation compared to family matched controls 
with undetectable heteroplasmy percentages in three different tissues, the variability in 
FGF21 levels within the healthy population may complicate the interpretation of FGF21 
values in diagnostic and prognostic studies.
A strength of our study is the high number of carriers with different levels of the same 
mutation in their mtDNA, resulting in a heterogeneous multi-system disease that we 
quantified systematically. Because we included both patients and dormant (i.e. asymp-
tomatic) carriers, we were able to study the role of FGF21 in reflecting the clinical 
expression of the disease in a representative, heterogeneous population. Studying 
a genetically homogeneous population reduces potential confounding by individual 
biochemical abnormalities. Although no clear differences in FGF21 concentration were 
reported between patients with nuclear mutations and mtDNA mutations (or between 
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various mtDNA mutations),6 the ability to generalise these results into other popula-
tions with mitochondrial disease warrants further study. Our quantitative follow-up of 25 
patients, including both clinical and biochemical parameters enabled us to draw tenta-
tive conclusions regarding the value of FGF21 as a prognostic biomarker for monitoring 
disease progression. 
There is currently no gold standard for measuring disease severity in patients with 
mitochondrial disease. In this study, we used the NMDAS, a multi-dimensional, stan-
dardised questionnaire to measure disease severity in patients with mitochondrial 
disease. It is important to note that the first and the second sections of the NMDAS are 
obtained from the patient history, thus measuring the most important factor of disease 
severity (namely the complaints experienced by the patient); however this approach 
potentially limits the reliability of this parameter. Moreover, the specificity of some of 
the NMDAS items is relatively low, including frequently commonly reported complaints 
such as gastrointestinal - and mood problems, as well as complaints common to the 
ageing process, including hearing loss and exercise intolerance. These aging-related 
complaints might explain the significant positive contribution of age to the disease 
severity. 
In conclusion, we report that FGF21 concentration correlates moderately with disease 
severity but not to disease progression in carriers of the m.3243A>G mutation. There-
fore, we conclude that FGF21 has little added value in monitoring and predicting the 
disease course in this specific patient group. In the quest to identify an objective, quan-
titative, sensitive and responsive prognostic biomarker that correlates with clinically 
relevant parameters, the validation of functional tests will take the highest priority in the 
preparation of future clinical trials.
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Serum GDF15 levels correlate to mitochondrial disease severity 
and myocardial strain, but not to disease progression in adult 
m.3243A>G carriers
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In this observational cohort study, we examined the prognostic value of growth and 
differentiation factor 15 (GDF15) in indicating and monitoring general mitochondrial 
disease severity and progression in adult carriers of the m.3243A>G mutation. 
Ninety-seven adult carriers of the m.3243A>G mutation were included in this study. 
The Newcastle Mitochondrial Disease Adult Scale was used for rating mitochondrial 
disease severity. In parallel, blood was drawn for GDF15 analysis by ELISA. Forty-nine 
carriers were included in a follow-up study. In a small subset of subjects of whom an 
echocardiogram was available from general patient care, myocardial deformation was 
assessed using two-dimensional speckle-tracking strain analysis.
A moderate positive correlation was found between the concentration of GDF15 and 
disease severity (r = 0.59; p <0.001). The concentration of serum GDF15 was higher 
in m.3243A>G carriers with diabetes mellitus, cardiomyopathy and renal abnormalities. 
After a two-year follow-up, no significant correlation was found between the change 
in disease severity and the change in the concentration of GDF15 or between the 
GDF15 level at the first assessment and the change in disease severity. In the subco-
hort of patients of whom an echocardiogram was available, the concentration of GDF15 
correlated moderately to longitudinal global strain (r = 0.55; p = 0.006; n = 23) but 
not to circumferential or radial strain. Our results indicate that serum GDF15 is not a 
strong surrogate marker for general mitochondrial disease severity. Its value in indi-
cating myocardial deformation should be confirmed in a prospective longitudinal study. 
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Introduction
One of the key aspects of improving the quality of clinical trials is the identification of 
biomarkers that are indicative of clinically relevant outcome.1 The perfect biomarker, 
correlating closely to clinical disease severity, would make the follow-up of patients 
easier, cheaper and less invasive, both in clinical trials and in regular patient care.2 
Moreover, since functional measures are subject to bias (including patient factors influ-
encing performance, report bias, and inter- and intra-rater variability), measuring more 
objective disturbances of physiology may seem more reliable. Several tests have been 
used to indirectly measure the disturbed mitochondrial energy metabolism in patients 
with mitochondrial disease, including the determination of lactic acid concentration in 
the brain by magnetic resonance spectroscopy or serum and serum Fibroblast Growth 
Factor 21 (FGF21).3 Although both lactic acid and FGF21 seemed to correlate to disease 
severity, the concentration during follow-up did not correlate to disease progression.4,5
A recent study reported growth and differentiation factor 15 (GDF15) as a potential 
new diagnostic biomarker for mitochondrial disease.6 GDF15 was already known as 
a quite non-specific biomarker for cancer, as well as cardiac, pulmonary, renal and 
gynaecological disease.7-10,11,12 However, the concentrations reported in these disorders 
are within the 1,000 – 7,000 pg/mL range,8,9,11,13,14 whereas concentrations as high as 
85,252 pg/mL were reported in patients with mitochondrial disease.6 A child with the 
m.3243A>G mutation, the most commonly observed mutation leading to mitochondrial 
disease, was reported to have a concentration of 6,999 pg/mL (reference value 380 pg/
mL (95% CI 59 - 701 pg/mL)). 
To evaluate the value of GDF15 as a surrogate marker for disease severity and disease 
progression, we examined GDF15 in a large cohort of adult carriers of the m.3243A>G 
mutation. Since GDF15 was previously reported as a biomarker for symptoms asso-
ciated with the m.3243A>G mutation, such as cardiomyopathy,15,16 diabetes mellitus13 
and renal failure14,17,18 we assessed these symptoms and organ functions in more detail.
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Methods
Patients
We determined the serum GDF15 concentration in adult carriers of the m.3243A>G 
mutation included in our ‘National inventory of patients with the m.3243A>G mutation’ 
study. In each subject, the heteroplasmy percentage in buccal mucosa cells, urinary 
epithelial cells (UEC) and leukocytes was determined using pyrosequencing.19 A hetero-
plasmy percentage ≥5% can be detected using this technique. Subjects with a detect-
able heteroplasmy percentage in either buccal mucosa cells, leukocytes, or UEC were 
considered to be carriers of the mutation. In this national inventory, clinical disease 
severity is monitored approximately two-yearly in both symptomatic and asymptomatic 
subjects carrying the m.3243A>G mutation.19 Clinical disease severity is rated using 
the Newcastle Mitochondrial Disease Adult Scale (NMDAS), a multi-dimensional clinical 
scale encompassing current function (patient’s opinion), system specific involvement 
(assessment of multi-system disease), and current clinical assessment (physical exam-
ination).20 Carriers were rated as having asymptomatic (NMDAS = 0); mild (NMDAS 1-5), 
moderate (NMDAS 6-20) or severe (NMDAS >20) mitochondrial disease (cut-off values 
based on expert opinion). Seventy-six carriers were included in the follow-up study, 
serum of 50 of these carriers was available for analysis (Figure 1). For a more detailed 
description of the methods, we refer to our previous study on FGF21 concentrations 
in this population.4 Patients with cancer and pregnant women were excluded since 
GDF15 is a known biomarker for these conditions. Since cardiomyopathy, diabetes 
mellitus and renal failure – for which GDF15 is also a biomarker - are highly prevalent 
in carriers of the m.3243A>G mutation,19 we also evaluated the influence of these 
conditions on the GDF15 concentration. Microalbuminuria was defined as an albumin-
to-creatine-ratio of >2.0 g/mol for men and >2.5 g/mol for women, measured in a spot 
sample of urine. Decreased creatinine clearance was defined as a glomerular filtration 
rate <60 ml/min/1.73m2. Carriers were classified as having decreased creatinine clear-
ance only, microalbuminuria only, both or neither. The presence and severity of diabetes 
mellitus (DM) follows from the NMDAS (the presence of DM was rated as DM requiring 
diet or medication). The measurement of myocardial strain is explained in more detail 
later in this section. 
Thirty non-carrier family members were included as a nuclear genetic and environ-
mental matched reference population. The maternal relatives who showed no signs of 
diabetes mellitus, renal disease or cardiac disease were included in the study. In these 
subjects, heteroplasmy percentages ≤4% (the assay’s detection limit) in UEC, leuco-
cytes and/or buccal mucosa cells were established. 
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GDF15
All samples were measured in duplicate, following the instructions of the manufacturer 
(R&D Biosystems, Minneapolis, US). The inter-assay and intra-assay variability for high 
and low values was determined based on high and low controls samples, respectively. 
The functional sensitivity determined at 20% covariance (CV) was 9.8 pg/ml. At a level 
of 1,695 pg/ml the within-assay CV was 3.5% and the between assay CV was 5.7%. 
At a level of 729 pg/ml the within-assay CV was 3.6% and the between-assay CV was 
2.2%. Samples with an initial intra-assay covariance (CV) >15% were repeated. The 
two values obtained from the duplicated measurements were averaged, and the mean 
of these two measurements was used for further analysis. Samples with a concentra-
tion higher than the highest standard value were diluted and analysis was repeated. 
According to the kit’s manufacturer, the assay has no cross reactivity with human GDF9 
and GDF11. Age- and gender based reference values for serum GDF15 were adopted 
from the Framingham Offspring Study21 (elevated GDF15 concentration is above the 
97.5th percentile matched for age and gender). 
Medical ethical approval
This study (‘National Inventory of Patients with the m.3243A>G mutation’) was 
approved by the regional Medical Research Ethics Committee. All procedures followed 
were in accordance with the ethical standards of the responsible committee on human 
experimentation (institutional and national) and with the Helsinki Declaration of 1975, 
as revised in 2013.22 Informed consent was obtained from all patients before being 
included in the study.
Myocardial strain measurement
As part of general patient care, carriers of the m.3243A>G mutation regularly undergo 
diagnostic echocardiography. Myocardial deformation was only assessed only if an 
echocardiogram was performed less than one year from an available GDF15 sampling. 
The myocardial strain, a measure for the deformation of the myocardium throughout 
the cardiac cycle, was determined using two-dimensional speckle-tracking strain anal-
ysis in accordance with a previously published protocol.23 Since echocardiography 
was done as part of general patient care and 2D strain measurement can only be 
performed when the images are obtained following a specific protocol, only a subset 
of carriers was included in this part of the study. Strain values are dimensionless and 
are expressed in percentages. Global longitudinal left ventricular myocardial strain was 
calculated by averaging the six segments of the 4-chamber long-axis view. Global radial 
and circumferential myocardial strain were calculated by averaging the six segments 
of the mid-cavity short-axis view (at the level of the papillary muscles). If less than four 
out of six segments showed valid tracking of the myocardium (e.g. because of regional 
inferior image quality or poor tracking by the software), the strain measurement was 
excluded from our analyses.
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Statistics
The absolute difference between two parameters was calculated by subtracting the 
first measurement from the second measurement. All parameters were assessed for 
(log)normality. To prevent non-real values for zero values of the NMDAS including 
its subsections and symptom specific items, all values were increased by 1 prior to 
log transformation. The changes in GDF15 concentration and NMDAS score were 
increased by 3,000 and 10, respectively. Variables with a (log)normal distribution, 
were compared using parametric tests, the mean and 95%-confidence intervals are 
reported. Variables that deviated strongly from a (log)normal distribution were analysed 
by performing a non-parametric test, the median and interquartile ranges are reported. 
Correlation coefficients were interpreted in accordance with the guidelines provided 
at the BMJ website (http://www.bmj.com/about-bmj/resources-readers/publications/
statistics-square-one/11-correlation-and-regression; consulted 31-Jul-2014). Thus, a 
correlation coefficient (r) of 0.80 to 1.0 is considered a very strong relationship; r = 0.60 
to 0.79 is considered a strong relationship; r = 0.40 to 0.59 is considered a moderate 
relationship; r = 0.20 to 0.39 is considered a weak relationship; and r = 0.00 to 0.19 is 
considered a very weak or no relationship.
Several covariates for GDF15 are known from literature,21 including age, the presence 
of DM, smoking (covariates with higher estimated coefficient than 0.1) and renal failure. 
These, together with other possible clinical including covariates (gender, body mass 
index (BMI), heteroplasmy percentage in UEC and leukocytes and disease severity 
(NMDAS)) were included as candidate predictors for GDF15. Gender, age, BMI, hetero-
plasmy percentage in UEC and leukocytes and the concentration of GDF15 and FGF21 
were considered candidate predictors for disease severity (NMDAS score). The influence 
of nominal and ordinal candidate predictors was determined by comparing between 
groups; the influence of continuous data was evaluated in a by linear regression analysis. 
The influence of cardiomyopathy was studied in more detail in a subgroup of carriers. 
For the correlation between the concentration of GDF15 and strain measurements, 
only echocardiography examinations performed no more than 1 year from sampling, 
were analysed. Forward and backward iterative multi-variate linear regression models 
were used to determine the influence of covariates and to determine the contribution of 
GDF15 in predicting or monitoring the disease course. Possible candidate predictors 
were only included for iterative multi-variate modelling if they correlated to the depen-
dent variable during univariate correlation analysis (p <0.1). Standardised regression 
coefficients (β) are presented for each variable.
Because 38 percent of the variance in the concentration of GDF15 is genetically deter-
mined,21 we performed two additional analyses to correct for the effect of kinship in 
our analyses. First, we performed a separate analysis that included only the most 
severely affected patient in each family (in case two family members had the same 
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NMDAS score, we included the youngest person with that score, assuming a relatively 
more severe disease in this person as age related complaints are also included in the 
NMDAS). Secondly, we used generalised estimating equation models (working correla-
tion structure: independence, with robust standard error for correction) to confirm the 
contribution of covariates and candidate predictors found by linear regression models, 
corrected for kinship. 
Because genetic factors between family members are not likely to influence (intra-in-
dividual) changes in GDF15 levels during follow-up, we only used linear regression 
models to determine the influence of covariates on the change in disease severity 
and the concentration of GDF15 (longitudinal study). The (absolute) change in disease 
severity (i.e. NMDAS score) was used as a possible candidate predictor for the change 
in GDF15 concentration. Both the change in the concentration of GDF15 and the 
change in the concentration of FGF21 were included as candidate predictors for the 
change in disease severity (i.e. NMDAS score). 
In case a high number of tests were performed (5 or more), critical p-values were 
adjusted using the Bonferroni method (i.e. critical p = 0.05/n where n = number of 
tests). All analyses were performed using IBM’s SPSS statistics software packages, 
version 20.0.0.1. 
Results 
Patient characteristics
We initially included 118 adult subjects in our national inventory study. For a variety 
of reasons (e.g., the samples were not available or had too small remaining volume 
for measuring GDF15), we were unable to determine the GDF15 levels in 21 of these 
subjects. No data were excluded because of high intra-assay covariance of GDF15 
assessment. Thus, our final cohort included 97 adult carriers of the m.3243A>G muta-
tion (Figure 1). The m.3243A>G mutation is not associated with a higher prevalence 
of cancer, and none of our subjects was known to suffer from any form of cancer at 
the time of the study. One patient did have a history of acute myeloid leukaemia (in 
remission for 8 years before samples were taken; [GDF15] 731 (baseline) and 1,926 
(follow-up) pg/ml). One pregnant woman was excluded ([GDF15] 43,304 pg/ml) from 
the follow-up cohort.24 For patient characteristics, we refer to Table 1. Renal function 
at the time of the sampling (spread: 6 months) was known in 86 patients (89% of 
total). Seventy-one percent of the total cohort had normal renal function, 17% had 
micro-albuminuria only, 2% had decreased creatinine clearance only and 9% suffered 
from both. Three patients had had a renal transplant, two of which had moderate trans-
plant function (GFR 24 and 50 ml/min/1.73m2) and one had normal transplant function 
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(GFR >75 ml/min/1.73m2). The m.3243A>G carriers came from 41 distinct families 
(median: 2 subjects per family; range: 1-10 subjects per family). This cohort of adult 
carriers contained two asymptomatic patients (2%), 18 patients with mild mitochondrial 
disease (19%), 46 patients with moderate mitochondrial disease (47%), and 31 patients 
with severe mitochondrial disease (32%). Because sufficient material was not always 
available, heteroplasmy percentage in UEC is absent in two subjects; heteroplasmy 
percentage in leukocytes is absent for another two patients. In these four subjects, 
heteroplasmy levels ≥5% were established in the other available tissue (buccal mucosa 
cells, leucocytes or UEC).
Figure 1.
Flowchart of the study cohort
Cohort of 118 m.3243A>G carriers
97 samples included in analysis of 
diseases severity 
76 carriers included in follow-up study
50 samples included in follow-up study
samples unavailable or insufficient
samples unavailable or insufficient
24 carriers underwent diagnostic 
echocardiography using the 2D strain 
protocol
24 carriers included in 2D strain analysis
21 valid 
circumferential 
strain
22 valid radial 
strain
23 valid 
longitudinal strain
exclusion based on poor tracking or suboptimal image quality
49 carrier included in follow-up study
1 pregnant carrier excluded
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Table 1.
C
haracteristics of the cohort of all adult m
.3243A>G
 carriers at baseline, the follow
-up cohort and the fam
ily m
atched controls. Characteristics for all adult carriers 
(n = 97) at baseline, for the patients w
ithin the follow
-up cohort (n = 49; A
) at follow
-up and for the fam
ily m
atched controls (n = 30; B
). p-values for the difference at baseline 
betw
een the follow
-up cohort and all carriers w
ere calculated (difference at baseline; C
hi square test (2-sided); Fisher’s exact test (2-sided); M
ann W
hitney U
 test; indepen-
dent sam
ple t-test). A
lso, p-values for the difference betw
een the first and the second m
easurem
ent w
ithin the follow
-up cohort are show
n (difference from
 baseline; W
ilcoxon 
signed rank test, paired t-test) . The presence of D
iabetes M
ellitus w
as obtained from
 the N
M
D
A
S
 scale (score on D
iabetes M
ellitus item
 ≥3). 
All carriers
Follow-up (49 carriers)
D
ifference 
at baseline
D
ifference 
from
 
baseline
central value
spread
range
n = 
central value
spread
range
n = 
p = 
p = 
Gender
%
 fem
ale
71
97
65
0.20
Age (years)
m
ean, 95%
C
I
45
17 - 72
18 - 81
97
45#
18 - 64
22 - 64
49
0.65
BM
I (kg/m
2)
m
edian, IQR
22.8
20.7 - 26.0
16.7 - 40.9
97
23.6#
17.6 - 33.2
17.6 - 33.1
49
0.96
Sm
oking (current)
%
 yes
22
84
25
48
1.00
D
iabetes M
ellitus (prevalence)
%
 yes
39
97
37#
49
0.62
H
eteroplasm
y percentage leucocytes (%
)
m
edian, IQR
17
8 - 26
2 - 49
95
19#§
4 - 41
2 - 49
47
0.56
H
eterplasm
y percentage U
EC
 (%
)
m
edian, IQR
45
27 - 69
4 - 96
95
52#§
7 - 91
5 - 96
47
0.1
NM
DAS score
m
ean, 95%
C
I
12*
1 - 67
0 - 56
97
14*
2 - 47
1 - 92
49
0.81
0.15
Dom
ain 1
m
edian, IQR
4
1 - 9
0 - 23
97
6*§
1 - 21
0 - 38
49
0.85
0.001
Dom
ain 2
m
edian, IQR
5
3 - 9
0 - 22
97
5*§
0 - 16
0 - 31
49
0.81
0.48
Dom
ain 3
m
edian, IQR
3
1 - 6
0 - 20
97
3*§
0 - 14
0 - 23
49
0.87
0.96
M
yopathy score
m
edian, IQR
2
1 - 4
0 - 11
97
2*§
0 - 12
0 - 14
49
0.96
0.11
Encephalopathy score
m
edian, IQR
2
0 - 3
0 - 12
97
1*§
0 - 5
0 - 17
49
0.98
0.38
D
iabetes M
ellitus (severity)
m
edian, IQR
0
0 - 5
0 - 5
97
1*§
0 - 3
0 - 5
49
0.37
0.002
C
ardiom
yopathy (severity)
m
edian, IQR
0
0 - 1
0 - 5
97
0
0 - 5
0 - 5
49
0.59
0.001
Stroke-like episodes (severity)
m
edian, IQR
0
0 - 0
0 - 5
97
0
0 - 0
0 - 5
49
0.98
0.58
QoL m
ental
m
edian, IQR
48
41 - 55
25 - 66
97
45
39 - 55
14 - 62
47
0.11
0.63
QoL physical
m
edian, IQR
41
33 - 51
17 - 61
97
41
35 - 49
21 - 64
47
0.29
0.36
[G
D
F15] (pg/m
l)
m
ean, 95%
C
I
1525*
411 - 5691
333-7421
97
1484¤ 
1072 - 2577
370 - 7359
49
0.66
0.22
[FG
F21] (pg/m
l)
m
edian, IQR
263
142 - 534
3 - 1491
93
278
117 - 473
56 - 1776
24
0.96
0.27
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Family matched controls (n = 30) Difference 
from all 
carriers
central value spread range n = p = 
Gender % female 73 30 1.00
Age (years) mean, 95%CI 41 20 - 68 18 - 68 30 0.518
BMI (kg/m2) median, IQR 24.0* 19.7 - 33.0 19 - 37 30 0.004
Smoking (current) % yes 8 13 0.286
Diabetes Mellitus (prevalence) % yes 7 30 0.001
Heteroplasmy percentage leucocytes (%) median, IQR 1§ 0 - 3 0 - 3 30 <0.001
Heterplasmy percentage UEC (%) median, IQR 1§ 0 - 2 0 - 2 29 <0.001
NMDAS score mean, 95%CI 3* 0 - 17 0 - 22 30 <0.001
Domain 1 median, IQR
Domain 2 median, IQR
Domain 3 mean, 95%CI
Myopathy score median, IQR
Encephalopathy score
Diabetes Mellitus (severity)
Cardiomyopathy (severity)
Stroke-like episodes (severity)
QoL mental 49§ 33 - 64 31 - 65 30 0.314
QoL physical 51 43 - 56 33 - 64 l <0.001
[GDF15] (pg/ml) 490* 272 - 1616 236 - 1687 30 <0.001
[FGF21] (pg/ml) 13§ 0 - 444 3 - 1072 25 <0.001
BMI = body mass index; 95%CI = 95% confidence interval; Section 1 = current function; Section 2 = system specific invol-
vement; Section 3 = current clinical assessment; Encephalopathy score = sum of the encephalopathic symptoms of the 
NMDAS (psychiatric symptoms, migraine, seizure, stroke-like episodes, encephalopathy and cognition); GDF15 = Growth and 
Differentiation Factor 15; IQR = interquartile range; Myopathy score = sum of the myopathic symptoms of the NMDAS (exercise 
intolerance, respiratory muscle weakness, ptosis, external ophthalmoplegia and myopathy); n = number of carriers of which 
data were available at that specific time point; NMDAS = Newcastle Mitochondrial Disease Adult Scale; UEC = urinary epit-
helial cells; *lognormal distribution; # at baseline; ¤ median and IQR instead of mean and 95%CI are give;, § mean and 95%CI 
instead of median and IQR are giv.
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The value of GDF15 as an indicator of clinical disease severity
Fifty-one carriers (53%) had an elevated concentration of GDF15 (i.e. higher than 
the 97.5th percentile of healthy age and sex matched controls) compared to the age- 
and gender matched reference population from literature.21 Carriers with an elevated 
concentration of GDF15 had higher NMDAS scores compared to carriers with normal 
concentrations of GDF15 (2,440 pg/ml (95%CI 1,097 – 5,431 pg/ml) versus 902 pg/ml 
(95%CI 381 – 2,131 pg/ml); p < 0.001). The correlation between the concentration of 
GDF15 and total NMDAS score in the cohort of m.3243A>G carriers at baseline was r 
= 0.59 (p <0.001; n = 97; Figure 2). This correlation coefficient is not significantly higher 
(p = 0.20) than the correlation between NMDAS score and FGF21 (r = 0.45; p <0.001; 
n = 93) in this cohort) 95 out of 99 patients (96%) of the current cohort are the same as 
in the study of FGF21.4 No significant correlation was found between the heteroplasmy 
percentage in UEC and the NMDAS score, nor between the heteroplasmy percentage 
in leukocytes and the NMDAS score. Among the 66 patients with asymptomatic, mild 
or moderate disease, the correlation coefficient between the total NMDAS score and 
GDF15 was 0.54 (p <0.001); among the 31 patients with severe disease, we found 
no significant correlation between the total NMDAS score and the concentration of 
GDF15. The correlation between the heteroplasmy level in UEC and GDF15 was 0.30 
(p = 0.003; n = 95). The correlation between the heteroplasmy level in leucocytes and 
GDF15 was 0.22 (p = 0.031; n = 95). 
Since the 97 adult carriers came from 41 families, we minimised the role of kinship 
in these associations by analysing only the most severely affected patient in each 
of the 41 families. The correlation coefficient between the total NMDAS score and 
GDF15 concentration in this cohort was r = 0.46 (p = 0.003) and was similar (p = 0.58) 
compared to the full cohort. During iterative multi-variate linear modelling, the following 
parameters were found to be independent predictors for disease severity: concentra-
tion of GDF15, age, concentration of FGF21, and the heteroplasmy percentage in UEC 
(β(GDF15) = 0.38 (p <0.001); β(age) = 0.32 (p <0.001); β(heteroplasmy UEC) = 0.24 
(p = 0.005); β(FGF21) = 0.21; p = 0.033). When GDF15 and FGF21 were included as 
the only independent predictors for disease severity in a linear regression model , only 
GDF15 was included (β(GDF15) = 0.59; p <0.001).
We found a moderate correlation between the concentration of GDF15 and the concen-
tration of FGF21 (r = 0.54; p > 0.001; n = 93).
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Figure 2.
Correlation between the concentration of GDF15 and disease severity in adult m.3243A>G carriers. The 
correlation between the concentration of GDF15 and the total NMDAS score (disease severity) is r = 0.59 (p 
<0.001). Scales are loglinear. [GDF15] = the concentration of Growth and Differentiation Factor 15; NMDAS = 
Newcastle Mitochondrial Disease Scale
Covariates for the concentration of GDF15 
The concentration of GDF15 was not higher in females compared to males (p = 0.38). 
The concentration of GDF15 was not higher among smokers compared to non-smokers 
(p = 0.70; n = 84). Patients without micro-albuminuria or decreased creatinine clear-
ance had lower concentrations of GDF15 compared to patients with micro-albuminuria 
only or both micro-albuminuria or decreased creatinine clearance (p = 0.031 and 0.002 
respectively), but not compared to patients with decreased creatinine clearance only 
(p = 0.24). The subgroups with renal abnormalities were comparable with respect to 
GDF15 concentrations (Figure 3).The concentration of GDF15 was significantly higher 
in patients with any kind of renal abnormalities compared to those without renal abnor-
malities (2,515 pg/ml (95%CI 699 - 9,045 pg/ml) versus 1,261 pg/ml (95%CI 373 - 
4,264 pg/ml; n = 61); p <0.001). Carriers with micro-albuminuria had higher concen-
trations of GDF15 compared to those without micro-albuminuria (2,574 pg/ml (IQR 
1,937 – 4,069 pg/ml; n = 25) versus 1,406 pg/ml (IQR 781 – 1,973 pg/ml); p <0.001). 
Carriers with decreased creatinine clearance had higher concentrations of GDF15 
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compared to carriers with normal creatinine clearance including those with micro-albu-
minuria only (3,418 pg/ml (IQR 2,463 – 4,388 pg/ml; n = 12) versus 1,471 pg/ml (IQR 
867 – 2,105 pg/ml); p <0.001). 
Figure 3.
GDF15 concentrations in patients with and without renal abnormalities, including decreased creatinine 
clearance and micro-albuminuria.
Carriers with DM had higher concentrations of GDF15 compared to carriers without DM 
(1,958 pg/ml (95%CI 579 - 6,620 pg/ml) versus 1,299 pg/ml (95%CI 345 - 4,902 pg/
ml); p = 0.003; Figure 4). We found significantly higher serum GDF15 concentrations in 
patients with cardiomyopathy according to the NMDAS (including patients with asymp-
tomatic ECG changes; NMDAS-Cardiomyopathy ≥ 1) compared to carriers without 
cardiomyopathy (2,574 pg/ml (998-6,638) versus 1,371 pg/ml (381-4,937); p < 0.001). 
Univariate regression analysis showed that the total NMDAS score was the only signif-
icant contributor to the concentration of GDF15 (β(NMDAS) = 0.59; p < 0.001). In our 
cohort, we found no significant contribution of age and BMI to the concentration of 
GDF15. Generalised estimating equations confirmed the predictive value of disease 
severity as a significant contributor to the concentration of GDF15, after correcting for 
kinship clustering (p < 0.001). 
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Figure 4.
GDF15 concentrations in patients with and without diabetes mellitus.
The value of GDF15 in predicting clinical disease progression
Approximately two years after the initial assessment, the GDF15 concentration and 
disease severity (NMDAS score) were measured again in 76 carriers from the initial 
cohort of 97 carriers. Of these 76 carriers, 50 samples were available (Figure 1). One 
carrier included in the follow-up group was excluded because of pregnancy. The 
remaining 49 carriers in the follow-up study were similar compared to the total cohort 
with respect to (distribution of) gender, age, BMI, GDF15 concentration, the presence 
and severity of DM, cardiomyopathy, stroke-like episodes, myopathy and encepha-
lopathy, heteroplasmy percentage in UEC, heteroplasmy percentage in leucocytes 
and NMDAS total and subsections scores. The characteristics of the entire cohort of 
m.3243A>G carriers at baseline and the follow-up cohort are summarised in Table 1. 
In this follow-up cohort, we found no significant correlation between the change in the 
NMDAS score (i.e. the change in NMDAS score between the first and second follow-up 
visit) and the change in the concentration of GDF15 (i.e. the change in GDF15 concen-
tration between the first and the second follow-up visit) (r = 0.006; p = 0.97; n = 49). 
Moreover, no significant correlation was found between GDF15 concentration at the 
first visit and change in the NMDAS (disease progression) during follow-up (r = -0.19; 
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p = 0.18; n = 49). Linear regression also revealed that the change in total disease 
severity did not contribute significantly to the change in the GDF15 concentration (p 
= 0.72). A linear regression model revealed that the change in FGF21 concentration, 
but not the change in GDF15 concentration contributed significantly to the change in 
disease severity (i.e. NMDAS score; β(FGF21) = 0.45 (p = 0.03; n = 24)). There was no 
correlation between the change in the concentration of GDF15 and the change in the 
concentration of FGF21 (r = -0.047; p = 0.85; n = 18). 
Myocardial strain
Twenty-four subjects underwent echocardiographies as part of clinical care within one 
year of GDF15 sampling. These subjects were similar compared to the whole group 
with respect to gender, age, BMI and total NMDAS score and cardiac and DM sub 
scores (Table 2). Qualitative descriptions of gross echocardiography findings include 
(not mutually exclusive): left ventricle (LV) hypertrophy (n = 8), LV systolic dysfunction 
(n = 3); LV diastolic dysfunction (n = 8); mild aortic regurgitation (n = 2) and mild mitral 
regurgitation (n = 1). Ten carriers had normal gross echocardiography findings. 
The correlation coefficient between global longitudinal strain and the concentration of 
GDF15 was 0.55 (p = 0.006; n = 23). There was no correlation between global circum-
ferential or radial strain and the concentration of GDF15 (r = 0.17; p = 0.47; n = 21 and 
r = 0.20; p = 0.37; n = 22, respectively). 
Family matched controls
The family-matched controls (n = 30) were similar to their maternal relatives carrying 
the m.3243A>G mutation with respect to age (p = 0.52), gender (p = 1.0) and smoking 
(p = 0.29), but not with respect to BMI (p = 0.004) and the presence and severity of 
DM (p = 0.001; Table 1). The mean GDF15 concentration in the family-matched control 
group was 490 pg/ml (95%CI 272 – 1,616 pg/ml; range 236 – 1,687 pg/ml), which 
was significantly lower than their relatives carrying the m.3243A>G mutation (1,525 pg/
ml (95%CI 411 - 5,691 pg/ml) range 333 - 7,421 pg/ml; p <0.001). Only one maternal 
family member had an elevated concentration of GDF15 (1,560 pg/ml in a 18-year-old 
female) compared to age- and gender matched controls. None of the maternal relatives 
was pregnant or known to have cancer, renal dysfunction or cardiac problems. 
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Tabel 2.
Patient characteristics of the cohort of all adult m.3243A>G carriers of which myocardial strain was 
reported. Patient characteristics for those adult carriers (n = 24) for whom myocardial strain was measured. 
The difference at baseline between this cohort and all carriers was calculated. The presence of Diabetes 
Mellitus was obtained from the NMDAS scale (score on Diabetes Mellitus item ≥3). 
Cardiac 2D strain cohort (24 carriers) Difference
central value (spread) range n = p =
Gender % female 75 24 0.80
Age (years) mean, 95%CI 44 (25 - 63) 24 - 64 24 0.80
BMI (kg/m2) median, IQR 22.3 (21 - 26) 18.3 - 35.8 24 0.91
Smoking (current) % yes 22 23 0.78
Diabetes Mellitus (prevalence) % yes 45 24 0.48
Heteroplasmy percentage 
leucocytes (%)
mean, 95%CI 18* (7 - 50) 7 - 49 23 0.22
Heterplasmy percentage 
UEC (%)
mean, 95%CI 56 (24 - 93) 23 - 96 24 0.08
NMDAS score mean, 95%CI 20 (1 - 54) 0 - 56 24 0.11
Section 1 mean, 95%CI 5* (0 - 23) 0 - 23 24 0.11
Section 2 mean, 95%CI 8 (0 - 23) 0 - 23 24 0.015
Section 3 mean, 95%CI 3* (0 - 16) 0 - 18 24 0.97
Myopathy score mean, 95%CI 3 (0 - 7) 0 - 7 24 0.57
Encephalopathy score median, IQR 2 (1 - 5) 0 - 11 24 0.25
Diabetes Mellitus (severity) mean, 95%CI 2 (0 - 5) 0 - 5 24 0.31
Cardiomyopathy (severity) median, IQR 0 (0 - 2) 0 - 5 24 0.06
Stroke-like episodes (severity) median, IQR 0 (0 - 0) 0 - 5 24 0.055
QoL mental mean, 95%CI 44 (27 - 61) 25 - 61 24 0.055
QoL physical mean, 95%CI 38 (18 - 59) 17 - 60 24 0.081
[GDF15] (pg/ml) mean, 95%CI 1,687* (483 - 5,791) 420 - 5,981 24 0.41
[FGF21] (pg/ml) median, IQR 321 (252 - 768) 4 - 14,91 24 0.084
BMI = body mass index; 95%CI = 95% confidence interval; Section 1 = current function; Section 2 = system specific 
involvement; Section 3 = current clinical assessment; Encephalopathy score = sum of the encephalopathic symptoms 
of the NMDAS (psychiatric symptoms, migraine, seizure, stroke-like episodes, encephalopathy and cognition). GDF15 = 
Growth and Differentiation Factor 15; IQR = interquartile range; Myopathy score = sum of the myopathic symptoms of the 
NMDAS (exercise intolerance, respiratory muscle weakness, ptosis, external ophthalmoplegia and myopathy); NMDAS = 
Newcastle Mitochondrial Disease Adult Scale; UEC = urinary epithelial cells. *lognormal distribution.
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Discussion
This study explored the value of serum GDF15 in indicating and monitoring mitochon-
drial disease severity and disease progression in adult m.3243A>G carriers. We found 
that the concentration of serum GDF15 correlates moderately to disease severity but 
does not correlate to disease progression in m.3243A>G carriers. Analysis of data 
obtained in general patient care indicated that GDF15 might be a surrogate biomarker 
of left ventricular myocardial strain. 
So far, a few studies have found promising results regarding the diagnostic properties 
of GDF15 in patients with mitochondrial disease.6,25 None of these studies focused on 
the value of GDF15 as a surrogate marker for predicting or monitoring disease progres-
sion. We found normal (age- and gender matched21) concentrations of GDF15 in 47% 
of our carriers, including both symptomatic and asymptomatic individuals and in 97% 
of our family-matched controls. The family-matched controls (bearing the same nuclear 
genetic and environmental background as the carriers, but without the m.3243A>G 
detectable in UEC, leucocytes or buccal mucosa cells) had significantly lower GDF15 
concentrations compared to their maternal relatives carrying the m.3243A>G mutation. 
GDF15 has also been reported as a non-specific biomarker for many diseases, including 
cancer, cardiac, pulmonary, renal and gynaecological disease.7-10 Since several of these 
conditions are highly prevalent in m.3243A>G carriers,19,26 including kidney failure,12 
diabetes mellitus13 and cardiomyopathy,11 the contribution of these conditions to the 
concentration of GDF15 was studied in more detail. We observed higher concen-
trations of GDF15 in carriers with renal abnormalities (mainly micro-albuminuria) and 
diabetes mellitus.27 
The myocardial strain measured in echocardiograms29 collected as part of general 
patient care with a maximum of one year apart from GDF15 sampling, indicate that 
GDF15 may be a promising surrogate marker for myocardial deformity in patients 
with the m.3243A>G mutation. The correlation between the concentration of GDF15 
and longitudinal myocardial strain, but not between the concentration of GDF15 and 
circumferential or radial strain28,30,31 might be explained by the observation that changes 
in longitudinal myocardial strain precede changes in ejection fraction and global longitu-
dinal strain is now part of the recommendations in the assessment of cardiac function, 
e.g. in monitoring chemotherapy.15,32-35 In summary, GDF15 is a non-specific marker 
that seems to be highly influenced by several other symptoms frequently seen in this 
patient group. 
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The previously proposed biomarker FGF21 had no additional value to GDF15 in 
predicting and monitoring disease severity in m. 3243A>G carriers.6,36 It seems, neither 
of the two parameters are useful as a surrogate marker for disease severity and disease 
progression.43
Strengths of our study include the high number of carriers with different levels of the 
same mutation in their mitochondrial genome, resulting in a heterogeneous multi-
system disease that we quantified systematically using a standardised and quantitative 
follow-up, enabling us to draw tentative conclusions regarding the value of GDF15 as 
a prognostic biomarker for monitoring disease progression. Several limitations to our 
study are worth mentioning. The period of follow-up is relatively short for this slowly 
progressive and often oscillating disease. The NMDAS used in the follow-up of disease 
severity is not very accurate and lacks sensitivity, making it unfit to establish subtle 
changes, in this aspect the study is underpowered. The quality of the serum may have 
been influenced by the storage and previous use (freeze-thawing) of the samples used 
in our study. Since the echocardiograms for 2D strain analysis were collected as part 
of clinical care, the level of standardisation was suboptimal and samples for GDF15 
analysis were not taken at the same moment as the echocardiography. Therefore, 
the results of this pilot study, including the responsiveness of GDF15 as a biomarker 
for myocardial strain, need to be confirmed in a prospective study. Finally, since only 
carriers of the m.3243A>G were included in this study, one may not extrapolate these 
findings to other causes of mitochondrial failure 
The mitochondrial disease field is diligently looking for easy-to-measure biomarkers, 
both for diagnostic and prognostic purposes. In this study, we have demonstrated that 
the concentration of serum GDF15 is moderately related to disease severity, but not 
to disease progression. Although the current study does not focus on the diagnostic 
applicability of GDF15, the lack of correlation between the concentration of GDF15 and 
disease progression in this two-year follow-up study makes this biomarker unsuitable 
as a prognostic biomarker. The moderate correlation between myocardial strain and the 
concentration of GDF15 is a promising starting point for finding a prognostic biomarker 
for myocardial deformity but warrants further confirmation, preferably in a longitudinal 
study including an in depth evaluation of renal function, glucose tolerance and the 
effects of pharmacological interventions.
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Supplementary Document 1
Jadad score for included studies.
Study Intervention Disease n
Total 
Jadad 
score
Klopstock et al. (2011)1 Idebenone LHON 85 5
Kaufmann et al. (2006)2 Dichloroacetate MELAS (m.3243A>G) 30 5
Kornblum et al. (2005)3 Creatine PEO and KSS (single deletion) 15 5
Liet et al. (2003)4 Dimethylglycine SLSJ-COX deficiency 5 5
Stacpoole et al. (2006)5 Dichloroacetate Congenital lactic acidosis 43 4
Mancuso et al. (2010)6 Glutamylcysteine PEO 13 4
Glover et al. (2010)7 Coenzyme Q10 Various MM 30 3
Klopstock et al. (2000)8 Creatine PEO and MM 16 3
De Stefano et al. (1995)9 Dichloroacetate Various syndromes 11 3
Tarnopolsky et al. (1997)10 Creatine MELAS or MM 7 3
Rodriguez et al. (2007)11 Creatine, coenzyme Q10, 
lipoic acid
Various syndromes 16 2
Bresolin et al. (1990)12 Coenzyme Q10 Various MM 16 2
Duncan et al. (2004)13 Dichloroacetate Various syndromes 9 2
Chen et al. (1997)14 Coenzyme Q10 Various MM 8 2
Barshop et al. (2004)15 Dichloroacetate Various syndromes 37 1
Cejudo et al. (2005)16 Exercise PEO and MM 20 1
Martinelli et al. (2012)17 EPI-743 Leigh syndrome 10 1
Taivassalo et al. (2006)18 Exercise PEO (single deletion) 8 1
Remes et al. (2002)19 Coenzyme Q10 and nicoti-
namide
MELAS (m.3243A>G) 7 1
Sadun et al. (2012)20 EPI-743 LHON 5 1
Komura et al. (2003)21 Creatine Various MM 5 1
Suzuki et al. (1998)22 Coenzyme Q10 MIDD (m.3243A>G) 44 0
Stacpoole et al. (2008)23 Dichloroacetate Congenital lactic acidosis 36 0
Mashima et al. (2000)24 Idebenone, vitamins B2 and C LHON 28 0
Koga et al. (2005)25 L-arginine MELAS (m.3243A>G) 24 0
Blankenberg et al. (2012)26 EPI-743 Various syndromes 22 0
Campos et al. (1993)27 Carnitine Various MM 21 0
Mathews et al. (1993)28 Coenzyme Q10 Various MM 16 0
Panetta et al. (2004)29
Coenzyme Q10, thiamine, 
riboflavin, vitamin C, high 
fat diet
Various syndromes 15 0
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Enns et al. (2012)30 EPI-743 Various syndromes 14 0
Gold et al. (1996)31 Coenzyme Q10 Various MM 8 0
Ogasahara et al. (1986)32 Coenzyme Q10 KSS 5 0
Bernsen et al. (1993)33 Riboflavin Complex I deficiency 5 0
Mori et al. (2004)34 Dichloroacetate MELAS (m.3243A>G) 4 0
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Supplementary Document 2
Summary of p values for clinically relevant end point.
Study Jadad score Outcome p value Comment
Klopstock et al. (2011)1 5 Best visual acuity 0.29 –
Kaufmann et al. (2006)2 5 GATE score (various time 
points)
0.16–0.78 –
Kornblum et al. (2005)3 5 Modified Boston score NS No p value was 
reported
Liet et al. (2003)4 5 Oxygen consumption 0.08 "Trend" favouring 
placebo
Stacpoole et al. (2006)5 4 GATE score 0.91 –
Mancuso et al. (2010)6 4 MRC score NS No p value was 
reported
Mancuso et al. (2010)6 4 SF36 score NS No p value was 
reported
Glover et al. (2010)7 3 ADL score 0.26 –
Glover et al. (2010)7 3 QoL score 0.09 –
Klopstock et al. (2000)8 3 MRC scale 0.14 –
Klopstock et al. (2000)8 3 NSS score 0.42 –
Klopstock et al. (2000)8 3 Hammersmith scale 0.92 –
Rodriguez et al. (2007)9 3 N/A – No relevant clinical 
end point or any 
single primary end 
point
De Stefano et al. (1995)10 3 Neurological strength/
gait examination score
>0.1 –
Tarnopolsky et al. (1997)11 3 ADL score NS No p value was 
reported
Tarnopolsky et al. (1997)11 3 2-minute walk NS No p value was 
reported
Cejudo et al. (2005)12 2 Functional exercise 
capacity
<0.01 –
Cejudo et al. (2005)12 2 Nottingham Health 
Profile
NS No p value was 
reported
Bresolin et al. (1990)13 
(double-blind part only)
2 Global MRC scale NS No p value was 
reported
Bresolin et al. (1990)13 
(open-label part only)
0 Global MRC scale 0.01 –
Duncan et al. (2004)14 2 N/A – No relevant clinical 
end point or any 
single primary end 
point
Chen et al. (1997)15 2 Global MRC scale 0.05 –
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Chen et al. (1997)15 2 ADL score ‘Trend’ towards 
improvement
We assumed a p 
value of 0.1
Barshop et al. (2004)16 1 Structured neurological-
examination score
0.066 –
Barshop et al. (2004)16 1 Structured neurological 
symptom score
0.003 –
Martinelli et al. (2012)17 1 NPMDS score 0.02 –
Martinelli et al. (2012)17 1 PedsQL score 0.006 –
Martinelli et al. (2012)17 1 GMFM score (various 
time points)
0.005–0.007 –
Taivassalo et al. (2006)18 1 SF36 score 0.05 –
Remes et al. (2002)19 1 CIBIC score NS No p value was 
reported
Sadun et al. (2012)20 1 N/A – Multiple visual 
parameters 
reported in 
individual patients; 
no p value was 
reported
Komura et al. (2003)21 1 N/A – Clinically relevant 
end points were 
reported (time to 
climb 13 steps or 
run 9 m) but raw 
data not given, 
and no p values 
reported
Suzuki et al. (1998)22 0 Prevention of hearing 
loss
0.02 –
Stacpoole et al. (2008)23 0 QoL score NS No p value was 
reported
Mashima et al. (2000)24 0 Visual recovery >0.3 NS No p value was 
reported
Mashima et al. (2000)24 0 Time to visual recovery 
>0.3
0.01 –
Koga et al. (2005)25 0 Clinical disability score 0.05 –
Blankenburg et al. (2012)26 0 NPMDS score 0.13 p value was calcu-
lated ourselves 
using raw data 
given in the paper: 
two-sided grouped 
student t-test
Campos et al. (1993)27 0 N/A – Subjective 
assessments only; 
no p value was 
reported
Mathews et al. (1993)28 0 N/A – No relevant clinical 
end point or any 
single primary end 
point
Panetta et al. (2004)29 0 N/A – Subjective 
assessments only; 
no p value was 
reported
340
Supplementary Documents 
Enns et al. (2012)30 0 NPMDS score 0.004 –
Gold et al. (1996)31 0 N/A – No relevant clinical 
end point or any 
single primary end 
point
Ogasahara et al. (1986)32 0 N/A – No relevant clinical 
end point or any 
single primary end 
point
Bernsen et al. (1993)33 0 N/A – No relevant clinical 
end point or any 
single primary end 
point
Mori et al. (2004)34 0 N/A – No relevant clinical 
end point or any 
single primary end 
point
Koga et al. (2002)35 0 Clinical disability score 0.05 –
ADL, activities of daily living; CIBIC, Clinician Interview-Based Impression of Change; GATE, Global Assessment of 
Treatment Efficacy; GMFM, Gross Motor Function Measure; MRC, Medical Research Council; N/A, not applicable; 
NPMDS, Newcastle Paediatric Mitochondrial Disease Scale; NS, not significant; SF36 ; NSS, Neuromuscular 
Symptom Scale; PedsQL, Paediatric Quality of Life Inventory; QoL, quality of life.’Short Form 36 Health Survey 
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Questionnaires (English translation) assessing i) complaints and most burden-
some complaints, ii) limitations in body functions and iii) limitations in activity 
and participation in Dutch.
i) Complaints and symptoms present in children with mitochondrial disease. 
Parents and their children were asked to answer the following questions (three separate 
questionnaires):
The complaints my child experiences include:
The three complaints (I expect my child) to find most burdensome and most wanted 
to change include:
The three complaints I find most burdensome and most wanted to change include:
• Tiredness
• Lack of energy
• Frequent infections
• Delayed development
• Diminished intelligence
• Growth failure
• Diminished interaction
• Muscle weakness
• Low muscle power
• Stiff arms and legs
• Coordination problems
• Involuntary movements
• Restlessness
• Balance problems
• Epilepsy
• Vision problems
• Hearing problems
• Speech problems
• Swallowing problems
• Breathing problems
• Muscle pain
• Headache
• Pain in stomach/belly
• Vomiting
• Diarrhoea
• Constipation
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• Behavioural problems
• Concentration problems
• Depressed mood
• Other, namely.....
• Other, namely.....
• Other, namely.....
ii ) and iii) Checklist International Classification of Functioning (under 3 years)
This is a questionnaire designed by the World Health Organization (WHO) to identify 
complaints and limitations in children. 
This questionnaire consists of two parts. The first part is about body functions. The 
second part is about the limitations experienced by your son/daughter. Please fill out 
for every question whether this is a problem to your child or not. If you reply positively, 
please indicate the burden caused by this complaint/disability. 1 indicates a very little 
burden, whereas 10 indicates a very high burden. 
 
Does your son/daughter have problems…  Burden due to this problem
…being alert and awake?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with tasks requiring thinking?   Yes/no  1 2 3 4 5 6 7 8 9 10
…falling asleep or staying asleep?   Yes/no  1 2 3 4 5 6 7 8 9 10
…paying attention to someone?   Yes/no  1 2 3 4 5 6 7 8 9 10
…remembering or recalling something?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with clumsiness or coordinating parts of Yes/no  1 2 3 4 5 6 7 8 9 10
   the body?
…distinguishing sounds, shapes or smells? Yes/no  1 2 3 4 5 6 7 8 9 10
…seeing things?     Yes/no  1 2 3 4 5 6 7 8 9 10
…hearing sounds?    Yes/no  1 2 3 4 5 6 7 8 9 10
…experience pain more than other children Yes/no  1 2 3 4 5 6 7 8 9 10
   of the same age?
…the heart?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with allergies or hypersensitivities to any Yes/no  1 2 3 4 5 6 7 8 9 10
   food, plant or animal?
…breathing?     Yes/no  1 2 3 4 5 6 7 8 9 10
…eating?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with bowel movements?   Yes/no  1 2 3 4 5 6 7 8 9 10
…getting the right amount of nutrients?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with urination ?    Yes/no  1 2 3 4 5 6 7 8 9 10
…with the onset menstruation?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with movement of wrists, elbows,  Yes/no  1 2 3 4 5 6 7 8 9 10
   shoulders or knees?
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…with muscles of the body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with stiffness of body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with automatic muscle reflexes?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with balance or body control?   Yes/no  1 2 3 4 5 6 7 8 9 10
…controlling arm and leg movements?  Yes/no  1 2 3 4 5 6 7 8 9 10
…tics, tremors or other unusual movements? Yes/no  1 2 3 4 5 6 7 8 9 10
…the skin?     Yes/no  1 2 3 4 5 6 7 8 9 10
 
Does your son/daughter have problems…        Burden of this limitation
…mouthing, touching, or tasting things?  Yes/no  1 2 3 4 5 6 7 8 9 10
…playing with things?   Yes/no  1 2 3 4 5 6 7 8 9 10
…using words, phrases or sentences?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with concepts such as amount, length,  Yes/no  1 2 3 4 5 6 7 8 9 10
   the same or different? 
…performing a single task or responding to  Yes/no  1 2 3 4 5 6 7 8 9 10
   a single command?
…understanding what others say?  Yes/no  1 2 3 4 5 6 7 8 9 10
…understanding the meaning of gestures  Yes/no  1 2 3 4 5 6 7 8 9 10
   or pictures?
…speaking?    Yes/no  1 2 3 4 5 6 7 8 9 10
…making different vocal sounds?  Yes/no  1 2 3 4 5 6 7 8 9 10
…gestures, pictures or drawings to   Yes/no  1 2 3 4 5 6 7 8 9 10
   communicate?
…sitting up or getting to stand?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with uncontrolled movements of arms  Yes/no  1 2 3 4 5 6 7 8 9 10
   or legs?
…using hands, fingers and thumb?   Yes/no  1 2 3 4 5 6 7 8 9 10
…walking     Yes/no  1 2 3 4 5 6 7 8 9 10
…relating to others?   Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in pre-school education?  Yes/no  1 2 3 4 5 6 7 8 9 10
…playing alone or with others?   Yes/no  1 2 3 4 5 6 7 8 9 10
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Checklist International Classification of Functioning (3–6 years)
This is a questionnaire designed by the World Health Organization (WHO) to identify 
complaints and limitations in children. 
This questionnaire consists of two parts. The first part is about body functions. The 
second part is about the limitations experienced by your son/daughter. Please fill out 
for every question whether this is a problem to your child or not. If you reply positively, 
please indicate the burden caused by this complaint/disability. 1 indicates a very little 
burden, whereas 10 indicates a very high burden. 
Does your son/daughter have problems…  Burden due to this problem
…being alert and awake?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with tasks requiring thinking?   Yes/no  1 2 3 4 5 6 7 8 9 10
…falling asleep or staying asleep?   Yes/no  1 2 3 4 5 6 7 8 9 10
…paying attention to someone?   Yes/no  1 2 3 4 5 6 7 8 9 10
…remembering or recalling something?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with clumsiness or coordinating parts of Yes/no  1 2 3 4 5 6 7 8 9 10
   the body?
…distinguishing sounds, shapes or smells? Yes/no  1 2 3 4 5 6 7 8 9 10
…seeing things?     Yes/no  1 2 3 4 5 6 7 8 9 10
…hearing sounds?    Yes/no  1 2 3 4 5 6 7 8 9 10
…experience pain more than other children Yes/no  1 2 3 4 5 6 7 8 9 10
   of the same age?
…the heart?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with allergies or hypersensitivities to any Yes/no  1 2 3 4 5 6 7 8 9 10
   food, plant or animal?
…breathing?     Yes/no  1 2 3 4 5 6 7 8 9 10
…eating?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with bowel movements?   Yes/no  1 2 3 4 5 6 7 8 9 10
…getting the right amount of nutrients?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with urination ?    Yes/no  1 2 3 4 5 6 7 8 9 10
…with the onset menstruation?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with movement of wrists, elbows,  Yes/no  1 2 3 4 5 6 7 8 9 10
   shoulders or knees?
…with muscles of the body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with stiffness of body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with automatic muscle reflexes?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with balance or body control?   Yes/no  1 2 3 4 5 6 7 8 9 10
…controlling arm and leg movements?  Yes/no  1 2 3 4 5 6 7 8 9 10
…tics, tremors or other unusual movements? Yes/no  1 2 3 4 5 6 7 8 9 10
…the skin?     Yes/no  1 2 3 4 5 6 7 8 9 10
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Does your son/daughter have problems…        Burden of this limitation
…mouthing, touching, or tasting things?  Yes/no  1 2 3 4 5 6 7 8 9 10
…playing with things?   Yes/no  1 2 3 4 5 6 7 8 9 10
…using words, phrases or sentences?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with concepts such as amount, length,  Yes/no  1 2 3 4 5 6 7 8 9 10
   the same or different? 
…performing a single task or responding to  Yes/no  1 2 3 4 5 6 7 8 9 10
   a single command?
…understanding what others say?  Yes/no  1 2 3 4 5 6 7 8 9 10
…understanding the meaning of gestures or  Yes/no  1 2 3 4 5 6 7 8 9 10
   pictures?
…speaking?    Yes/no  1 2 3 4 5 6 7 8 9 10
…making different vocal sounds?  Yes/no  1 2 3 4 5 6 7 8 9 10
…gestures, pictures or drawings to   Yes/no  1 2 3 4 5 6 7 8 9 10
   communicate?
…sitting up or getting to stand?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with uncontrolled movements of arms  Yes/no  1 2 3 4 5 6 7 8 9 10
   or legs?
…using hands, fingers and thumb?   Yes/no  1 2 3 4 5 6 7 8 9 10
…walking     Yes/no  1 2 3 4 5 6 7 8 9 10
…relating to others?   Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in pre-school education?  Yes/no  1 2 3 4 5 6 7 8 9 10
…playing alone or with others?   Yes/no  1 2 3 4 5 6 7 8 9 10
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Checklist International Classification of Functioning (7-12 years)
This is a questionnaire designed by the World Health Organization (WHO) to identify 
complaints and limitations in children. 
This questionnaire consists of two parts. The first part is about body functions. The 
second part is about the limitations experienced by your son/daughter. Please fill out 
for every question whether this is a problem to your child or not. If you reply positively, 
please indicate the burden caused by this complaint/disability. 1 indicates a very little 
burden, whereas 10 indicates a very high burden. 
Does your son/daughter have problems…  Burden due to this problem
…being alert and awake?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with tasks requiring thinking?   Yes/no  1 2 3 4 5 6 7 8 9 10
…falling asleep or staying asleep?   Yes/no  1 2 3 4 5 6 7 8 9 10
…paying attention to someone?   Yes/no  1 2 3 4 5 6 7 8 9 10
…remembering or recalling something?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with clumsiness or coordinating parts of Yes/no  1 2 3 4 5 6 7 8 9 10
   the body? 
…distinguishing sounds, shapes or smells?  Yes/no  1 2 3 4 5 6 7 8 9 10
…seeing things?     Yes/no  1 2 3 4 5 6 7 8 9 10
…hearing sounds?    Yes/no  1 2 3 4 5 6 7 8 9 10
…experience pain more than other children Yes/no  1 2 3 4 5 6 7 8 9 10
   of the same age?
…the heart?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with allergies or hypersensitivities to any Yes/no  1 2 3 4 5 6 7 8 9 10
   food, plant or animal?
…breathing?     Yes/no  1 2 3 4 5 6 7 8 9 10
…eating?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with bowel movements?   Yes/no  1 2 3 4 5 6 7 8 9 10
…getting the right amount of nutrients?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with urination ?    Yes/no  1 2 3 4 5 6 7 8 9 10
…with movement of wrists, elbows,  Yes/no  1 2 3 4 5 6 7 8 9 10
   shoulders or knees?
…with muscles of the body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with stiffness of body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with automatic muscle reflexes?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with balance or body control?   Yes/no  1 2 3 4 5 6 7 8 9 10
…controlling arm and leg movements?  Yes/no  1 2 3 4 5 6 7 8 9 10
…tics, tremors or other unusual movements? Yes/no  1 2 3 4 5 6 7 8 9 10
…the skin?     Yes/no  1 2 3 4 5 6 7 8 9 10
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Does your son/daughter have problems…        Burden of this limitation
…mouthing, touching, or tasting things?  Yes/no  1 2 3 4 5 6 7 8 9 10
…playing with things?   Yes/no  1 2 3 4 5 6 7 8 9 10
…using words, phrases or sentences?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with concepts such as amount, length,  Yes/no  1 2 3 4 5 6 7 8 9 10
   the same or different? 
…learning to read?   Yes/no  1 2 3 4 5 6 7 8 9 10
…learning to write?   Yes/no  1 2 3 4 5 6 7 8 9 10
…learning to calculate?   Yes/no  1 2 3 4 5 6 7 8 9 10
…performing a single task or responding to  Yes/no  1 2 3 4 5 6 7 8 9 10
   a single command?
…performing multiple tasks or responding  Yes/no  1 2 3 4 5 6 7 8 9 10
   to a command with multiple components?  
…following the requirements of a daily  Yes/no  1 2 3 4 5 6 7 8 9 10
   routine?
…being consistent in behaviour from  Yes/no  1 2 3 4 5 6 7 8 9 10
   day to day? 
…understanding what others say?  Yes/no  1 2 3 4 5 6 7 8 9 10
…understanding the meaning of gestures or 
   pictures?    Yes/no  1 2 3 4 5 6 7 8 9 10
…speaking?    Yes/no  1 2 3 4 5 6 7 8 9 10
…making different vocal sounds?  Yes/no  1 2 3 4 5 6 7 8 9 10
…gestures, pictures or drawings to   Yes/no  1 2 3 4 5 6 7 8 9 10
   communicate?
…sitting up or getting to stand?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with uncontrolled movements of   Yes/no  1 2 3 4 5 6 7 8 9 10
   arms or legs? 
…using hands, fingers and thumb?   Yes/no  1 2 3 4 5 6 7 8 9 10
...using hands?     Yes/no  1 2 3 4 5 6 7 8 9 10
…walking     Yes/no  1 2 3 4 5 6 7 8 9 10
…washing self?    Yes/no  1 2 3 4 5 6 7 8 9 10
…using the toilet?    Yes/no  1 2 3 4 5 6 7 8 9 10
…dressing self?     Yes/no  1 2 3 4 5 6 7 8 9 10
…eating?     Yes/no  1 2 3 4 5 6 7 8 9 10
…avoiding harm to self?    Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in the activities of  Yes/no  1 2 3 4 5 6 7 8 9 10
   the household? 
…playing alone or with others?   Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in school education?  Yes/no  1 2 3 4 5 6 7 8 9 10
…engaging in activities in school,   Yes/no  1 2 3 4 5 6 7 8 9 10
   neighbourhood or community?
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Checklist International Classification of Functioning (over 13 years)
This is a questionnaire designed by the World Health Organization (WHO) to identify 
complaints and limitations in children. 
This questionnaire consists of two parts. The first part is about body functions. The 
second part is about the limitations experienced by your son/daughter. Please fill out 
for every question whether this is a problem to your child or not. If you reply positively, 
please indicate the burden caused by this complaint/disability. 1 indicates a very little 
burden, whereas 10 indicates a very high burden. 
Does your son/daughter have problems…  Burden due to this problem
…being alert and awake?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with tasks requiring thinking?   Yes/no  1 2 3 4 5 6 7 8 9 10
…falling asleep or staying asleep?   Yes/no  1 2 3 4 5 6 7 8 9 10
…paying attention to someone?   Yes/no  1 2 3 4 5 6 7 8 9 10
…remembering or recalling something?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with clumsiness or coordinating parts of Yes/no  1 2 3 4 5 6 7 8 9 10
   the body?
…distinguishing sounds, shapes or smells?  Yes/no  1 2 3 4 5 6 7 8 9 10
…seeing things?     Yes/no  1 2 3 4 5 6 7 8 9 10
…hearing sounds?    Yes/no  1 2 3 4 5 6 7 8 9 10
…experience pain more than other children Yes/no  1 2 3 4 5 6 7 8 9 10
   of the same age?
…the heart?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with allergies or hypersensitivities to any Yes/no  1 2 3 4 5 6 7 8 9 10
   food, plant or animal?
…breathing?     Yes/no  1 2 3 4 5 6 7 8 9 10
…eating?     Yes/no  1 2 3 4 5 6 7 8 9 10
…with bowel movements?   Yes/no  1 2 3 4 5 6 7 8 9 10
…getting the right amount of nutrients?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with urination ?    Yes/no  1 2 3 4 5 6 7 8 9 10
…with movement of wrists, elbows,  Yes/no  1 2 3 4 5 6 7 8 9 10
   shoulders or knees?
…with muscles of the body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with stiffness of body, arms or legs?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with automatic muscle reflexes?   Yes/no  1 2 3 4 5 6 7 8 9 10
…with balance or body control?   Yes/no  1 2 3 4 5 6 7 8 9 10
…controlling arm and leg movements?  Yes/no  1 2 3 4 5 6 7 8 9 10
…tics, tremors or other unusual movements? Yes/no  1 2 3 4 5 6 7 8 9 10
…the skin?     Yes/no  1 2 3 4 5 6 7 8 9 10
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Does your son/daughter have problems…       Burden of this limitation
…reading?    Yes/no  1 2 3 4 5 6 7 8 9 10
…writing?    Yes/no  1 2 3 4 5 6 7 8 9 10
…calculating?    Yes/no  1 2 3 4 5 6 7 8 9 10
…solving problems?    Yes/no  1 2 3 4 5 6 7 8 9 10
…performing a single task or responding to  Yes/no  1 2 3 4 5 6 7 8 9 10
   a single command?
…performing multiple tasks or responding  Yes/no  1 2 3 4 5 6 7 8 9 10 
   to a command with multiple components?  
…following the requirements of a   Yes/no  1 2 3 4 5 6 7 8 9 10  
   daily routine?
…being consistent in behaviour from Yes/no  1 2 3 4 5 6 7 8 9 10
   day to day?
…understanding what others say?  Yes/no  1 2 3 4 5 6 7 8 9 10
…understanding the meaning of gestures or  Yes/no  1 2 3 4 5 6 7 8 9 10
   pictures?
…speaking?    Yes/no  1 2 3 4 5 6 7 8 9 10
…making different vocal sounds?  Yes/no  1 2 3 4 5 6 7 8 9 10
…gestures, pictures or drawings to   Yes/no  1 2 3 4 5 6 7 8 9 10 
   communicate?
…sitting up or getting to stand?  Yes/no  1 2 3 4 5 6 7 8 9 10
…with uncontrolled movements   Yes/no  1 2 3 4 5 6 7 8 9 10
   of arms or legs? 
…using hands, fingers and thumb?   Yes/no  1 2 3 4 5 6 7 8 9 10
...using hands?     Yes/no  1 2 3 4 5 6 7 8 9 10
…walking     Yes/no  1 2 3 4 5 6 7 8 9 10
…washing self?    Yes/no  1 2 3 4 5 6 7 8 9 10
…using the toilet?    Yes/no  1 2 3 4 5 6 7 8 9 10
…dressing self?     Yes/no  1 2 3 4 5 6 7 8 9 10
…eating?     Yes/no  1 2 3 4 5 6 7 8 9 10
…avoiding harm to self?    Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in the activities of the  Yes/no  1 2 3 4 5 6 7 8 9 10
   household?
…in forming and keeping social relationships?Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in school education?  Yes/no  1 2 3 4 5 6 7 8 9 10
…participating in programs to prepare for  Yes/no  1 2 3 4 5 6 7 8 9 10
   employment?
…engaging in activities in school,   Yes/no  1 2 3 4 5 6 7 8 9 10
   neighbourhood or community?
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Supplementary Document 4
Systematic overview of the outcome measures with good face validity for  
mitochondrial diseases.
Online at  http://onlinelibrary.wiley.com/store/10.1111/dmcn.12119/asset/supinfo/
dmcn12119-sup-0005-FileS5.pdf?v=1&s=deed31905ca20b2566e6eb0bd-
3c05d00134bef71
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Supplementary Document 5
Genetic, biochemical and clinical features of patients with nuclear encoded 
Complex I deficiency
Online at http://static-content.springer.com/esm/art%3A10.1007%2Fs10545-012-
9492-z/MediaObjects/10545_2012_9492_MOESM1_ESM.xls
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Supplementary Document 6
Patient characteristics. Genetic, biochemical and clinical details for each patient. 
Psychomotor retardation is defined: IQ<50 = severe; IQ 50-70 = mild and IQ >70 = 
normal.
Clinical characteristics Genetics Biochemistry muscle GMFM GMFM PEDI Tardieu
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1 F 10 MTTL1 65 (L) / 93 (UEC) ND ND Exercise intolerance x No Yes 98.0 95 97 95 95 100 100
2 F 16 MTTL1 87 (Mu) 67 Normal Small stature, exercise intolerance x x Mild Yes 99.3 92 100 94 80 100 100
3 F 16 FRDA ND ND Friedreich ataxia x No No 32.4 81 31 100 65 17 100
4 M 16 Pending 50 C III (61%) Ataxia x Mild With help 67.7 70 55 86 58 60 84 A
5 M 11 SDHA 86 C II (26 %) and C II + III (31%) Dystonia, ataxia, chorea x Severe No 49.0 58 45 50 60 51 40
6 F 9 Pending 50 C I, II and III slightly ↓ Exercise intolerance x No Yes 100 73 98 97 55 94 100
7 F 13 AGK 5 CI (26%), CIII (26%), CIV (20%) en CII + CIII (52%) Sengers-like syndrome x No Yes 95.5 95 95 100 95 100 100
8 M 12 MTTL1 75 (Mu) 100 C I (89%) Failure to thrive, muscle weak-ness, exercise intolerance x No Yes 100 95 100 100 95 100 100
9# M 17 RARS2 60 CI (71%) en CIII (83%) Ataxia x x Mild No 36.5 41 48 83 30 46 48 A
10# F 12 Pending ND ND Mild ataxia x x Mild Yes 96.3 86 94 95 73 91 76 A
11 F 15 Pending 43 CI (83%) and CIII (82%) Severe PMR, opticushypop-lasia, epilepsy x x Severe With help 24.7 12 6 17 0 2,9 4
12 M 17 Pending 88 CI (86%) Epilepsy x x Mild Yes 99.6 80 89 86 60 88 64
13 M 6 MTTS1 97 (L)/96 (UEC) CI and CIV slightly
Deafness, hyperactivity, beha-
vioural problems x x Mild Yes 96.7 78 98 83 58 100 52
14 F 11 NGLY1 50 CI (80%) and CII (80%) Epilepsy, spasticity x x Severe No 8.0 18 6 18 3 0 0
15 M 8 CDH13 + ND1 100 6.2 CI (4%) and CIV (67%) Hyperactivity, ataxia, spasticity x x Mild No 44.1 45 54 42 18 60 12 A
16 F 15 FRDA ND ND Friedreich ataxia x x No No 27.0 70 37 100 33 37 96
17 M 12 TAZ 38 CI (36%), CIII (55%), II en IV slightly ↓ Barth syndrome x No Yes 99.7 100 97 88 100 100 80
# siblings; A = Ankle; CI = Complex I; F = female; GMFM = Gross Motor Function Measure; L = leukocytes; M = male; Mu = muscle; ND = not 
done; PEDI = Pediatric Evaluation of Disability Inventory; PMR = psychomotor retardation; UEC = Urinary epithelial cells
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GMFM GMFM PEDI Tardieu
C
lin
ic
al
 p
he
no
pt
yp
e 
M
yo
pa
th
y
En
ce
pa
hl
op
at
hy
PM
R 
Ab
le
 to
 w
al
k
G
M
FM
 s
co
re
 (%
) Functional skills (%) Caregiver assistance (%)
Po
st
ive
 Ta
rd
ieu
Se
lf 
ca
re
M
ob
ilit
y 
So
cia
l 
fu
nc
tio
n 
Se
lf 
ca
re
 
M
ob
ilit
y
So
ci
al 
fu
nc
tio
n
Exercise intolerance x No Yes 98.0 95 97 95 95 100 100
Small stature, exercise 
intolerance x x Mild Yes 99.3 92 100 94 80 100 100
Friedreich ataxia x No No 32.4 81 31 100 65 17 100
Ataxia x Mild With help 67.7 70 55 86 58 60 84 A
Dystonia, ataxia, chorea x Severe No 49.0 58 45 50 60 51 40
Exercise intolerance x No Yes 100 73 98 97 55 94 100
Sengers-like syndrome x No Yes 95.5 95 95 100 95 100 100
Failure to thrive, muscle weak-
ness, exercise intolerance x No Yes 100 95 100 100 95 100 100
Ataxia x x Mild No 36.5 41 48 83 30 46 48 A
Mild ataxia x x Mild Yes 96.3 86 94 95 73 91 76 A
Severe PMR, opticushypop-
lasia, epilepsy x x Severe With help 24.7 12 6 17 0 2,9 4
Epilepsy x x Mild Yes 99.6 80 89 86 60 88 64
Deafness, hyperactivity, beha-
vioural problems x x Mild Yes 96.7 78 98 83 58 100 52
Epilepsy, spasticity x x Severe No 8.0 18 6 18 3 0 0
Hyperactivity, ataxia, spasticity x x Mild No 44.1 45 54 42 18 60 12 A
Friedreich ataxia x x No No 27.0 70 37 100 33 37 96
Barth syndrome x No Yes 99.7 100 97 88 100 100 80
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Correlations between the GMFM and the PEDI and activity parameters measured 
with the accelerometer. 
A level of p = 0.0001 was used for significance; significant p-values are indicated in bold.
GMFM PEDI 
self-care
PEDI 
mobility
PEDI - social 
function
Rest (%) -0.82 -0.54 -0.87 -0.17
Dynamic activity (%) 0.40 0.25 0.50 0.30
Average counts upper leg (counts/hour) 0.61 0.28 0.70 -0.10
Average counts upper arm (counts/hour) 0.50 0.16 0.49 -0.18
Average counts lower arm (counts/hour) 0.51 0.24 0.60 0.05
Average counts wheelchair (counts/hour) 0.11 0.16 0.09 0.65
Maximal intensity upper leg (counts/min) 0.57 0.18 0.60 -0.07
Maximal intensity upper arm (counts/min) 0.54 0.30 0.48 0.15
Maximal intensity lower arm (counts/min) 0.67 0.26 0.52 0.57
Largest AUC during ½ hour upper leg (counts) 0.65 0.29 0.70 -0.07
Largest AUC during ½ hour upper arm (counts) 0.51 0.96 0.43 -0.22
Largest AUC during ½ hour lower arm (counts) 0.59 0.19 0.56 -0.12
AUC = Area under the curve; GMFM = Gross Motor Function Measure; min = minutes; PEDI = Pediatric Evaluation of Disability 
Inventory
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Supplementary Document 8
The final version of the International Paediatric Mitochondrial Disease Scale 
(IPMDS).
Name:        
Date of birth:       
Date of assessment:        
Time since previous IPMDS:       
Name physician:         
Domain 1:  (raw score)  /(103 -  ) =  %
Domain 2:  (raw score)  /(76 -    ) =  %
Domain 3:  (raw score)  /(64 -    ) =  %
Total score:  (raw score)  /(243 -  ) =  % 
 
We kindly ask you to upload your PDF at http://www.ncmd.nl to facilitate data collection
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Disease course since previous IPMDS  
Parents:   Stable  Improving Deteriorating
Physician:   Stable  Improving Deteriorating
Over the past 2 days:
1. How is your child’s physical condition?
A Stable
B Deteriorating
C Improving
2. How is your child’s mental health?
A Stable
B Deteriorating
C Improving
3. In general, how happy is your child feeling?
A Unhappy
B Not happy nor unhappy
C Happy
D Very happy, more happy than others
4. In general, how comfortable is your child?
A Uncomfortable
B Not comfortable nor uncomfortable
C Comfortable
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1. Complaints and symptoms
Please answer the following questions with regard to how your child was complainin
over the past 4 weeks: 
1. Which of the following best describes your child’s alertness and response to
 his/her environment?
0 Appropriately alert during daytime hours; good response to the environment
1 Alternates between periods of sleepiness and full alertness and/or requires stimulation 
to remain alert
2 Sleepy, only reacting to touch, noise or visual stimulation
3 Alternating between periods with no response to environment and periods of sleeping
2. How well has your child been able to perform exercise?
0 Normal compared to peers
1 Limited in playing sports, participating in (adapted) physical education
2 Symptomatic on inclines or stairs
3 Adaptations to save energy required for playing outside
4 Adaptations to save energy required for playing inside
5 Restricted on playing inside and frequent resting required despite adaptation of playing 
inside
* Not playing due to severe cognitive impairment 
3. For how long is your child able to walk? 
0 Normal compared to peers
1 Rest required or impaired coordination after 1 hour of walking
2 Rest required or impaired coordination after 30 minutes of walking 
3 Rest required or impaired coordination after 15 minutes of walking 
4 Rest required or impaired coordination after 5 minutes of walking 
5 Not at all
4. How tired has your child been?
0 Normal
1 Tired the day after going on an exciting day out e.g. an amusement park or zoo (with 
or without use of wheelchair)
2 Not able to go on an exciting day out e.g. a amusement park or zoo (with or without 
use of wheelchair) because of tiredness
3 Not able to go on half day family trips e.g. to park or playground (with or without use 
of wheelchair) because of tiredness
4 Not able to go to school for a full week because of tiredness
5 Not able to go to school at all because of tiredness
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5. Has your child been depressed, sad, withdrawn, anxious or quiet?
0 Not more than peers
1 Only in specific circumstances (tired, exciting events, setbacks, life events)
2 Symptoms present every week 
3 Symptoms present every day but not limiting school performance or the ability to make 
friends
4 Symptoms limiting school performance or the ability to make friends
5 Severe depressive symptoms requiring hospitalization
* Impossible to indicate due to severe cognitive impairment
6. Has your child experienced epileptic seizures? At the moment these are
 treated / untreated * (*please circle)
0 No
1 Once with self recovery this month (seizure lasted      sec/min)
2 Two or three times with self recovery this month, or absence epilepsy
3 One convulsion in which emergency medication was necessary or where there was no 
recovery within 5 minutes, or more than 3 with self recovery last month
4 Multiple or prolonged convulsions in which emergency medication was given or where 
there was no recovery within 5 minutes
5 Hospitalization or more than 3 generalized convulsions (not absences) a week
 
7. Has your child suffered from headache?
0 No
1 Mild headaches not limiting daily activities
2 Daily activities limited by headaches less than once a week
3 Daily activities limited at least once a week or true migraine attacks at least once a month
4 True migraine attacks despite chronic treatment or true migraine attacks at least once 
a week 
5 Chronic migraine: true migraine headaches 15 days/month for longer than 3 months
* impossible to indicate
8. Has your child suffered from muscle pain?
0 No
1 Occasional muscle pain after exercise not limiting daily activities
2 Recurrent mild muscle pain after exercise not limiting daily activities
3 Muscle pain after exercise limiting daily activities
4 Spontaneous muscle pain (not only after exercise) limiting daily activities
5 Severe, spontaneous muscle pain 
* impossible to indicate
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9. Has your child suffered any infections?
0 No or only mild infection
1 Infection with subsequent tiredness limiting daily activities for more than one day
2 Infection with subsequent tiredness limiting daily activities for more than one week
3 Infection taking more than one week, with subsequent school absence for more than 
one day
4 Infection taking more than one week, with subsequent school absence for more than 
one week 
10. Has your child experienced problems with chewing?
0 No
1 Bread-crusts and meat are tiring
2 Bread-crusts and meat are avoided because of the chewing problems
3 Food is pureed because of the chewing problems
4 Pureed food is supplemented with tube feeding because of chewing difficulties
5 Only tube feeding because of chewing problems
11. Has your child experienced problems with swallowing?
0 No
1 Difficulties (choking) with fluids or dry food
2 Difficulties (choking) with all foods; adaptation of the diet
3 Choking despite adaptation of the diet (e.g requiring supplementary tube feeding)
4 Solely tube feeding because of choking
5 Spontaneous choking on saliva, or recurrent aspiration pneumonia
12. Has your child experienced hearing problems?
0 No
1 Proven hearing loss, without the need for a hearing aid or fully corrected with hearing aid
2 Not fully corrected with hearing aid, but no impaired communication
3 Not fully corrected with hearing aid, impaired communication
4 Reaction to loud sounds (e.g. clapping) only, despite use of a hearing aid
5 No reaction to loud sound 
13. Has your child found problems in communicating?
0 Normal, age appropriate communication
1 Stammer, dysarthria or language delay impairing communication with strangers
2 Stammer, dysarthria or language delay impairing communication with parents 
3 Effective communication only using alternative methods (speech computer, sign 
language)
4 No effective communication with strangers despite using appropriate alternative methods
5 No effective communication with parents despite alternative methods
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14. Has your child been vomiting?
0 No frequent vomiting
1 Vomiting at least once a week 
2 Vomiting once a day despite adaptation of feeding
3 Vomiting more than once a day despite adaptation of feeding
4 Continuous tube feeding 
5 Malnourished as a consequence of vomiting despite adaptations in feeding
15. Has your child been having symptoms of (or medication for) gastroesophagal  
  reflux?
0 No symptoms of gastroesophageal reflux (heartburn, regurgitation, uncomfortable 
 when lying down after consumption of food)
1 No symptoms with one medication
2 No symptoms with multiple medications
3 Symptoms despite multiple medications
4 Esophageal erosions despite treatment 
5 Fundoplication or malnourished despite adaption of feeding
* impossible to indicate
16. Has your child had symptoms of constipation?
0 No constipation 
1 Variable defecation pattern with defecation between 2x/week and 3x/day
2 Constipation fully resolved with oral medication 
3 Constipation not fully resolved with oral medication (frequency 1-2x per week)
4 Constipation with frequency <1x/week despite oral medication 
5 Constipation requiring clysters or colonic lavage
17. Has your child had symptoms of diarrhoea?
0 No diarrhoea
1 Loose stool ≥ 3x/day 
2 Shapeless or watery stool < 3x/day
3 Shapeless or watery stool ≥ 3x/day
4 Episodes of diarrhoea that require a change of clothes, occurring at least once per week 
5 Severe diarrhoea necessitating increased fluid supply
18. Cognitive development
0 Normal cognitive development, mainstream school or attending special school only 
because of physical disability
1 Attending special school because of mental disability but learning new skills
2 Attending special school because of mental disability but not learning new skills
3 Losing skills in one area (cognitive, language, motor, social/emotional)
4 Losing skills in more than one area or severe cognitive impairment due to prior loss of skills
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19. Does your child have behavioural problems?
0 Normal compared to peers
1 More severe behavioural problems compared to peers
2 Behavioural problems limiting the ability of the family to go out
3 Behavioural problems limiting the ability to make friends
4 Behavioural problems limiting the ability to go to school
5 Not attending school because of behavioural problems
20. Does your child have autistic features?
0 Normal compared to peers
1 No official diagnosis of an autism spectrum disorder. Parents do recognize autistic 
features which cannot be explained by mental retardation, in their child
2 Official diagnosis of an autism spectrum disorder. Limited social interaction, limited 
flexibility of behavior or difficulty switching between activities requiring support, but not 
limiting daily functioning
3 Official diagnosis of an autism spectrum disorder. Clear problems in social interaction, 
difficulty with change and limited flexibility in behavior, limiting daily functioning
4 Official diagnosis of an autism spectrum disorder. Severe deficit in social communica-
tion, great difficulty with change and very limited flexibility in behavior despite the use 
of medication
* impossible to indicate due to severe cognitive impairment
21. Breathing pattern 
0 Normal breathing pattern
1 Frequent sighing or irregular breathing
2 Nocturnal ventilator support required
3 Periods of apnoea (> 20 sec) or continuous ventilation
22. Has your child been continent of urine (able to indicate when toilet visit is  
   needed > 90% of time)?
During the day     Yes (0) /No (1)
During the night     Yes (0) /No (1)
23. Does your child experience any of the following items when tired?
Strabismus (squint)    Yes (1) /No (0)
Ptosis (drooping eyelids)    Yes (1) /No (0)
Dysarthria (impaired speech)   Yes (1) /No (0)
 
379
2. Physical examination 
In the case of asymmetrical abnormalities, score the most severely affected side
1. Growth 
0 Normal (-2 to +2 SD) for target height/catch up growth
1 Growing parallel to growth curve, but below -2SD for target height
2 Deviating from his/her own growth curve appropriate for target height
3 Deviating from his/her own growth curve, and below -2SD for target height
2. Weight for height 
0 Normal or catch up growth when under -2 SD
1 Growing parallel to -2 SD or deviating (≥ 1 SD) in positive direction in children above 
+2 SD
2 Deflecting (≥ 1 SD) from growth curve in negative direction
3 Unintentionally losing ≥3% weight compared to the last measurement
3. Alertness 
0 Eyes opened spontaneously
1 Opens eyes when talking (verbal child) or to parent’s voice
3 Opens eyes when touched
3 Opens eyes on pain stimulus
4 Not opening eyes
4. Breathing pattern 
0 Normal breathing pattern
1 Sighing or irregular breathing observed during physical examination
2 Periods of apnoea (> 20 sec) during examination
5. Dysarthria 
0 No dysarthria
1 Nasal, hoarse, low pitch voice, or irregular speech, but easily understood
2 Obvious dysarthria, understood more than 50% of the time
3 Obvious dysarthria, understood less than 50% of the time
4 Not able to communicate verbally or use of alternative methods primarily due to 
dysarthria
* Not able to communicate due to other causes
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6. Ptosis 
0 Normal
1 Mild ptosis not obscuring either pupil
2 Unilateral ptosis obscuring > 1/3 of pupil
3 Bilateral ptosis obscuring > 1/3 of pupils
4 Bilateral ptosis obscuring > 2/3 of pupils, or previous ptosis surgery
7. Strabismus 
0 Normal
1 Permanent strabismus of one eye
2 Permanent strabismus of both eyes
8. Eye movements 
0 Normal
1 Some restriction in any of the eye movements with normal abduction 
2 Partial abduction possible 
3 Abduction minimal 
9. Nystagmus 
0 No or physiological (endpoint) nystagmus
1 Gaze evoked nystagmus
2 Spontaneous nystagmus
10. Vision – using glasses and both eyes
0 ≥1.0 (Snellen or crowded LogMAR chart) or attention to small objects at a distance
1 ≥0.5 – <1.0 (Snellen or crowded LogMAR chart) 
2 ≥0.1- <0.5 (Snellen or crowded LogMAR chart) 3 < 0.1 (Snellen or crowded LogMAR 
chart) 
4 Only reaction to big, colored objects within reach
5 No reaction to big, coloured objects within visual field
* Impossible to indicate due to severe cognitive impairment
11. Proximal muscle strength 
0 Normal power in arms and legs
1 Moves legs and arms against resistance, but not against full resistance 
2 Moves arms and legs against gravity, but not against resistance
3 Active joint movement when gravity is eliminated (e.g. in horizontal plane)
4 Contraction of muscle is visible, but no movement of the joint
5 No contraction visible
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12. Distal muscle strength 
0 Normal power in feet and hands
1 Moves hands and feet against resistance, but not against full resistance 
2 Moves hands and feet against gravity, but not against resistance
3 Active joint movement when gravity is eliminated (e.g. on a underground) 
4 Contraction of muscle is visible, but no movement of the joint
5 No contraction visible
13. Hypokinesia 
0 Absent or reduced facial expression due to other causes (e.g. facies myopathica)
1 Reduced facial expression only, no slowing of body movements
2 Reduced facial expression, mild slowing of body movements
3 Significant slowing of body movements
14. Abnormal, involuntary movements and abnormal posturing 
0 Absent
1 Intermittent involuntary movements of one extremity, not interfering with daily activities
2 Intermittent involuntary movements of multiple extremities, mildly interfering with daily 
activities
3 Continuous involuntary movements of whole body, markedly interfering with daily acti-
vities
15. Ataxia 
0 Absent
1 Impaired coordination (dysmetria) compared to peers on examination only (hesitant 
heel-toe, disturbed alternate movements)
2 Gait reasonably steady, but unable to maintain heel-toe, mild dysmetria, truncal ataxia, 
not limiting the ability to sit
3 Ataxic gait, not able to walk 2 passes heel-toe, past pointing with intention tremor, 
truncal ataxia, limiting the ability to sit
4 Walking unsafe or sitting impossible without support, primarily due to ataxia
16. Tremor 
0 Absent or physiological tremor
1 Tremor present at rest, but not affecting coordination
2 Tremor affecting coordination
3 Unable to grab things primarily due to tremor
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17. Reflexes 
0 Normal, brisk, indifferent or hypoactive reflexes 
1 Abnormally brisk reflexes 
2 Expansion of the reflex zone or crossed adductor response
3 Non sustained clonus 
4 Sustained clonus 
18. Hypertonia 
0 Normal tone or hypotonic
1 Increased tone, catch followed by relaxation or minimal resistance at the end of the 
range of motion
2 Increased tone, catch followed by minimal resistance during less than the half of the 
range of motion
3 Resistance during most of the whole range of motion
4 Resistance, passive movements are difficult
5 Rigid flexion or extension
19. Hypotonia 
0 Normal tone or hypertonic
1 Mild slipping through/head lag or hypotonia or hypermobility on physical examination
2 Obvious slipping through/head lag, sits with curved back
3 Obvious slipping through/head lag, difficulty maintaining the head in midline position 
while sitting with lower backsupport
4 Obvious slipping through/head lag, unable to sit with or without backsupport only 
primarily due to hypotonia
20. Rigidity
0 No rigidity or hypertonia only
1 Paratonia 
2 Mild and inconsistent resistance throughout the range of motion
3 Resistance is detected consistently during the range of motion, but full range of 
motion is obtained easily
4 Resistance to obtain passive movement requires maximal effort by the rater or full 
range of motion is not obtained primarily due to rigidity
21. Sensory examination 
Vibration  Normal (0) / Abnormal (1) / Absent (2)/Impossible to indicate (*)
Subtle touch  Normal (0) / Abnormal (1) / Absent (2) /Impossible to indicate (*)
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3. Functional tests 
Some, indicated items are only for children ≥ 6years
1. Communication 
0 Actively interacting with researcher, easily understood, follows complex instructions
1 Actively interacting with researcher; difficulty expressing self; uses alternative methods 
to communicate; follows simple instructions 
2 Actively interacting with researcher; difficult to understand despite use of alternative 
communication methods; child has difficulty understanding simple instructions
3 Reactive to researcher but no understanding of simple single-level instruction and not 
understood by researcher
4 Reacts only to tactile, auditory or visual stimulation
5 No reaction to tactile, auditory or visual stimulation
2. Head control – maintains head in midline while sitting with back support
0 Normal
1 Control, but only with back support
2 Control longer than 1 min
3 Control between 30 seconds and 1 min
4 Control shorter than 30 seconds
5 Absent
3. Rolling over – from supine to prone and back
0 Able to roll over from supine to prone and back over both sides
1 Able to roll over from supine to prone and back, but only to left or right
2 Able to roll over from supine to prone and back, but only to supine or prone
3 Initiates movement and lifts shoulder and hip from underground
4 Initiates movement and moves arm over the midline
5 No attempt to roll over
4. Sitting up – from lying supine to sitting
0 Able to sit up without help of elbows or hands
1 Able to sit up with help of elbows or hands
2 Able to sit up using a trick manoeuvre (e.g. turns to prone side)
3 Lifts head from ground, but unable to sit up
4 Not able to lift head from the ground
5 No attempt to sit up
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5. Sitting position – sits without back support
0 Normal
1 Able to sit without support for at least 5 seconds, but not able to hold arms upright 
for 5 seconds
2 Able to sit without support, but for less than 5 seconds 
3 Able to sit only with support of the hands
4 Not able to sit
6. Standing up from a chair [chair at a height that allows both feet to be resting flat 
on the ground] if possible without support of hands
0 Normal
1 Compensatory movements, but within normal time and no help of hands
2 Slips off, needs own hands for support or abnormal method, but within normal time
3 Takes longer than expected for age, due to cognitive or motor inabilities
4 Only possible with help of caretaker, or unsafe procedure
5 Not able to stand up
7. Standing – stands without support
0 Normal
1 Compensatory movements or abnormal posture
2 Stands for less than one minute without support
3 Stands for less than 30 seconds without support
4 Stands (>10 seconds) only with support 
5 No attempt
8. Walking – walking without support
0 Normal
1 Compensatory movements or abnormal posture
2 Walks for more than 10 m, but not for 20 m
3 Walks for less than 10 m
4 Walks only a few (1-3 steps) or only walks with support
5 No attempt to walk or not able to walk with support 
9. Only ≥ 6years: Running
0 Normal
1 Normal, but slower
2 Compensatory movements or abnormal posture
3 Decreased time of lifting both feet from the floor (levitation)
4 Increases speed but no levitation (moment that both feet are lifted from the floor)
5 Absent
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10. Only ≥ 6years: Hopping on one foot – 10 times
0 Normal
1 Normal but decreasing hopping height during exercise; OR able to hop normally more 
than 5 times
2 Hops 10 times, starts with toes from the floor, finishes not lifting toes from the floor; OR 
able to hop normally more than 3 times
3 Hops 10 times but not lifting toes from the floor
4 Stands on one foot
5 No attempt
11. Reaching – grasp pen/small toy held in the air by the examiner within arm 
   length of the patient
0 Normal
1 Abnormal movements
2 Abnormal movements, much slower to reach object
3 Possible to approach the item, but not grab it
4 Only inefficient/uncoordinated efforts not approaching the item
5 No attempt
12. Grasping – grasps pen within arm length from the table and transfers pen/
    small toy to other hand
0 Normal
1 Abnormal movements, but able to achieve both grasping and transferring
2 Able to grasp but not transfer
3 Able to approach the item, but not grasp it
4 Only inefficient/uncoordinated efforts not approaching the item
5 No attempt
13. Only ≥ 6 years: rotates pen within the hand with fingers
0 Normal
1 Rotates the pen, but with compensatory movements or tricks
2 Initiates rotating movement, but unable to turn pen around
3 Opens hand with pen in it, but unable to initiate rotating movement
4 Attempts, but fails to open hand
5 No attempt 
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Supplementary Document 9
The final version of the manual for the International Paediatric Mitochondrial 
Disease Scale (IPMDS).
Introduction
The IPMDS was designed to monitor general disease progression of symptoms asso-
ciated with mitochondrial disease in children (aged 0 – 18 years) with a mitochondrial 
disorder. The scale provides detailed insight into the complaints and symptoms (domain 
1), physical examination (domain 2) and functioning of the patient (domain 3). 
PREREQUISITS
TRAINING
In order to familiarize examiners with the utilization of the IPMDS and its scoring princi-
ples, a training session, in which the items are practiced in a in a role-play at least twice, 
is recommended. 
Please also watch our instructional video.
MATERIAL
• A complete growth chart of the child
• A Snellen or crowded LogMAR chart at least 3 m from a wall
• A physiotherapy mat or a wide examination table
• A chair (with adjustable height if possible). The height of the seat should be such 
that the person’s feet touch the floor or footstool when seated (with or without 
footstool)
• A footstool if indicated
• A pillow for back support if indicated
• Space within a corridor, wide at least 2m, to enable free movement of 20 m, with 
marks at 10 and 20 m
• A marked line traced on the floor, approximately 3 m long and 2 cm wide.
• A penlight
• A reflex hammer
• A tuning fork
• A pen
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PATIENT
The patient should be wearing comfortable clothes, which will not interfere with move-
ments. Corsets should be removed, if possible. Patients should be barefooted without 
orthoses and socks.  
SPECIFIC INSTRUCTION
The order of the items should be respected.
DOMAIN 1
The questions in domain 1 should be assessed with a caregiver/patient interview and not 
by chart review nor the physician’s own judgment. 
All questions enquire about the severity of the complaints and symptoms over the past 
4 weeks.
The answer “normal” should always be verified by asking for the symptoms rated 1 or 2 
points (e.g in question 1 “So he doesn’t need stimulation to remain alert? And there are 
no periods of sleepiness during the day?”). 
DOMAIN 2
The items in domain 2 are assessed by physical examination. In the case of asymme-
trical abnormalities, the worse side is scored. If the item is difficult to interpret, please 
note this on the scoring sheet. 
Item specific instructions
Item 1: Growth
The height curve of the past 6 months is used to determine this item. 
The individual target height of the child is calculated as following
 o Girls: (height father + height mother – 13) / 2 + 4.5 ( in cm)
 o Boys: (height father + height mother + 13) / 2 + 4.5 ( in cm)
Item 2: Weight for height
The weight for height curve of the past 6 months is used to determine this item. 
Item 3: Alertness
No specific instructions, may be observed during the completion of domain 1
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Item 4: Breathing pattern
No specific instructions, sighing and breathing pattern may be observed during the 
completion of domain 1
Item 5: Dysarthria 
May be observed during the completion of domain 1. The type of dysarthria (spastic, 
myopathic, extrapyramidal, ataxic) is not relevant, the consequences for communication 
are. If the child is not able to communicate for other reasons, score a *. 
Item 6: Ptosis 
Ptosis is observed when the child is looking forward with his/her head in a neutral posi-
tion. Ask for previous ptosis surgery.
Item 7: Strabismus
The light reflex in both eyes is observed when looking forward. In case of strabismus, the 
light reflex will be assymetrical (not on the pupil). 
Item 8: Eye movement
The child is asked or stimulated to follow a penlight or an interesting object from left to 
right; up and down; and up and down when the eyes are deviated left and right. Espe-
cially the abduction (pull out) of both eyes is observed. 
Item 9: Nystagmus
Nystagmus is observed by looking at the blood vessels on the sclera or the iris during 
the eye movement examination. Physiological nystagmus (small-amplitude (<2°) conju-
gate jerk nystagmus on far eccentric gaze (>40°)) is rated as a 0. When nystagmus is 
observed when the child’s looking forward, this is noted as spontaneous nystagmus. 
Item 10: Vision
The child sits or stands at a known distance (e.g. 3m) from the Snellen chart with both 
eyes opened and using usual glasses. Visual acuity is calculated as (distance to chart 
(e.g. 3m) / number behind last row adequately seen). If the child is not able to read, the 
circle (O) can be searched for (“Is this a circle?”) or the response to visual stimuli is noted. 
In case of cognitive impairment, note the reaction to “interesting objects” at a distance. 
Item 11: Proximal muscle strength 
The m. biceps brachii and the m. quadriceps femoris are tested bilaterally. The strength 
of the child is compared to peers when differentiating between a score of 0 and 1. 
Gravity is eliminated by asking to move the joint in a horizontal plane on a surface.
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Item 12: Distal muscle strength 
The grip strength and the m. tibialis anterior are tested bilaterally. The strength of the 
child is compared to peers when differentiating between a score of 0 and 1. Gravity is 
eliminated by asking to move the joint in a horizontal plane on a surface.
Item 13: Hypokinesia
The facial expressions are observed during interaction. Decreased facial expression due 
to other causes (e.g. facies myopathica) is not rated in this item. Slowing of body move-
ments (hypokinesia) is observed during the other items of the physical examination, 
walking or playing. 
Item 14: Abnormal, involuntary movements and abnormal posturing
The presence of dystonia (abnormal positioning of e.g. hands), chorea (quick, jerky 
movements), athetosis (slow, writhing movements) or hemiballismus (unilateral, flinging 
movements) is assessed. The effect of these movement disorders on coordination is 
observed during (un)dressing, walking or playing. 
Tics and tremor are not scored at this item.
Item 15: Ataxia
Ataxia is tested by heel-toe, alternate movements, the tap nose test and – if abnormal 
- the ability to sit. The performance on the heel-toe and alternate movements should be 
compared to peers. Abnormal coordination without ataxia is not rated in this item.
Item 16: Tremor
The presence of a tremor is tested by asking the child to put both hands (palm down) 
forward with straight arms. A physiological tremor is defined as a tremor of 10 Hz. 
Item 17: Reflexes
Deep tendon reflexes (patellar reflexes, ankle jerk reflexes and biceps brachii reflexes) 
including reflex spread are tested bilaterally. Physiologically brisk but normal reflexes are 
rates as a 0. Expansion of the reflex zone is reflex contraction after tapping on the tibia 
instead of the knee tendon. The crossed conductor response is reflex contraction of the 
right muscle when tapping on the left knee tendon (and vice versa). The worse side is 
scored.
Item 18: Hypertonia
The presence of hypertonia is assessed by flexion and full extension of the ankles, knees 
and elbows bilaterally, at slow and at fast speed when the child is relaxed or distracted. 
The presence of spastic resistance or a catch is observed. Contractures are looked for 
by fully extending and flexing the ankles, knees and elbows. 
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Item 19: Hypotonia
Muscle tone is assessed by holding the child under the axillae and by placing the child in 
sitting position. In older children, the tone is assessed during passive movement of the 
elbow and observing the sitting position. 
Item 20: Rigidity
The presence of hypertonia is assessed by flexion and full extension of the ankles, 
knees and elbows bilaterally, at slow speed when the child is relaxed or distracted. The 
presence of (cogwheel) rigidity is rated. Paratonia, the active resistance of the patient 
to any movement despite distraction, often augmented by increasing the speed of the 
movement and often interpreted as “poor cooperation”, is rated as a 1. When the full 
range of motion cannot be obtained due to contractures or spasticity, the rigidity over 
the remaining free trajectory is rated.
Item 21: Sensory examination
Vibration and subtle touch are tested on the big toe of both feet. The child is asked 
to close his eyes and say if he can feel that he’s being touched, in children not able to 
respond appropriately, the reaction to the stimulus is noted. 
 
DOMAIN 3
In domain 3, the functional abilities of the child are assessed. For this domain, the reason 
why the child is not able to sit (PMR, ataxia, hypotonia, contractures) is not relevant. 
Three attempts are allowed if the investigator expects the child to be able to perform 
better. Using tricks during three attempts is rated as “compensatory movements”. If 
the child refuses to attempt the item, if the item was forgotten, if the item is not safe to 
execute or if the child is not able to maintain the starting position, the score for the item 
is 5. “Refusal” or “forgotten” should be noted on the scoring sheet.
Some items are dependent on the normal development of the child and are therefore 
only applicable to patients aged 6 years and older. This is indicated at the item (item 10 
an 13). 
Investigators are allowed to give an example of the intended movement at every attempt. 
The instructor is allowed to show the movement by moving the child’s limb in the intended 
direction (e.g. by letting the pen rotate in his/her hand and asking the child to continue). 
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Item specific instructions
Item 1. Communication 
As observed during the assessment of domain 1 and 2. Complex instructions are double 
instructions (do this followed by that) such as the verbal instructions for the dysdia-
dochokinesis and ataxia exercises. Simple instructions include single instructions (get on 
the examination table). The cause of the difficulty expressing him/herself (PMR, autism, 
dysarthria) is not relevant. 
Item 2. Head control 
Adequate back support is a straight back of a (wheel)chair, supporting at least ¾ of 
the back, but not more than shoulder height. The researcher is allowed to position the 
head above the pelvis, if necessary; the ability to remain the head in this position is 
scored.  
Item 3. Rolling over 
Child is lying flat on his/her back with the head in the midline on a broad examination 
table or on a hard mat on the ground. The child is asked or tempted (with an interesting 
object) to roll over to both sides and back.
Item 4. Sitting up 
Child is lying flat on his/her back on a hard mat on the ground. The child is asked or 
encouraged (with an interesting object) to sit up, if possible without hands (e.g. by asking 
the child to stab the arms forward).
Item 5. Sitting position 
The child sits without backsupport on a hard mat on the ground. The child is asked to sit 
without support for 5 seconds and then hold their arms upright for 5 seconds. 
Item 6. Standing up from a chair 
The child sits at a chair with a hard surface at a height that allows both feet to be resting 
flat on the ground or on a footstool. The hands are resting on the lap of the child. The 
child is asked to raise from the chair without using the hand (e.g. by placing them on 
their head).  
Item 7. Standing 
The child stands on a hard surface in a room or corridor of at least 2m wide. The resear-
cher is behind of the child to catch him/her if he falls, but so that the child cannot seek 
physical support.
The child is asked to stand straight for one minute.
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Item 8. Walking 
The child stands on a hard surface in a room or corridor of at least 2m wide. The rese-
archer is behind of the child to catch him if he falls but so that the child cannot seek 
physical support.
The child is asked to walk for 20 m at his/her usual pace. 
Item 9. Only ≥ 6years: Running
The child stands on a hard surface in a room or corridor of at least 2m wide. The rese-
archer is behind of the child to catch him if he falls but so that the child cannot seek 
physical support.
The child is asked to run or walk as fast as possible for 20 m. 
Item 10. Only ≥ 6years: Hopping on one foot 
The child stands on a hard surface in a room or corridor of at least 2m wide. The rese-
archer is behind of the child to catch him if he falls but so that the child cannot seek 
physical support.
The child is asked to hop on one leg for 10 times. One hop is take off and landing at the 
same single foot.
Item 11. Reaching 
The child sits stably in a (wheel)chair with adequate back support at a height that allows 
both feet to be resting flat on the ground or on a footstool. The table is at the height of 
the elbow or maximally halfway the height of the elbow and the shoulder in resting posi-
tion. The child is asked or encouraged to reach for a pen or a toy of approximately similar 
size and weight. The pen/toy is held in the air within arms length of the child.
Item 12. Grasping 
The child sits stably in a (wheel)chair with adequate back support at a height that allows 
both feet to be resting flat on the ground or on a footstool. The table is at the height of 
the elbow or maximally halfway the height of the elbow and the shoulder in resting posi-
tion. The child is asked or encouraged to grasp a pen or a toy of approximately similar 
size and weight from the table and to put it in his/her other hand and back. The pen is 
placed within arm length of the child. 
Item 13. Only ≥ 6 years: Rotating
The child sits stably in a (wheel)chair with adequate back support at a height that allows 
both feet to be resting flat on the ground or on a footstool. The table is at the height 
of the elbow or maximally halfway the height of the elbow and the shoulder in resting 
position. 
Rotating the pen is turning the pen around in the hand like a majorette (see instructional 
video).
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INTERPRETATION 
The score is expressed as the percentage of items which were feasible to perform. 
Asterixes (*) can be scored as well, the total score will change accordingly. E.g. if the 
parents are not able to indicate the presence of headache, the maximum score of the 
first domain changes from 103 to 73. If the child is not cooperative during the execution 
of domain 2 and 3, these items are omitted from the total score.
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Supplementary Document 10
Link to the instructional video.
https://youtu.be/WxTY-jvbFtg
Supplementary Document 11
Inter- and intra-rater and test-retest reliability for the “pilot scoring list – final 
version”. 
The pilot scoring list was adapted based on the experiences of the physicians and the 
inter- and intra-rater reliability (ICCagreement ≥ 0.7 was used as ‘acceptable’; in green). 
Adaptations of items are indicated in the “items”-column.
Item Inter-rater Test-retest Intra-rater
S1 Response to environment NV NV NV
S2 Energy 0.798 0.873 1.000
S3 Exercise tolerance 0.393 0.821 0.967
S4 Tired 0.347 0.712 1.000
S5 Depressed 0.921 0.391 1.000
S6 Epilepsy 1.000 1.000 1.000
S7 Headache 0.956 0.000 0.951
S8 Muscle pain 0.883 0.000 0.975
S9 Infections 0.271 1.00 1.000
S10 Chewing 0.837 0.632 1.000
S11 Swallowing 0.945 0.889 1.000
S12 Hearing 0.789 0.848 0.926
S13 Communicating 0.884 0.831 0.761
S14 Vomiting 0.642 NV NV
S15 GE reflux 0.642 0.774 0.873
S16 Constipation 0.974 0.774 1.000
S17 Diarrhoea 0.761 NV NV
S18.1 Continence (day) 0.761 0.774 1.000
S18.2 Continence (night) 0.761 1.000 1.000
S19.1 Aggression 0.761 1.000 1.000
S19.2 Routine 0.517 1.000 0.774
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S19.3 Fixation themes/objects 0.602 0.533 1.000
S19.4 Sleep pattern 0.364 1.000 0.741
S19.5 Imaginative play NV 0.741 NV
PE1 Growth 0.671 NV
PE2 Weight 0.046 NV
PE3 Development 0.739 0.906
PE4 Alertness NV NV
PE5 Breathing pattern 0.834 1.000
PE6 Dysarthria 0.893 0.979
PE7 Eye movement NV NV
PE8 Strabismus 0.460 0.437
PE9 Ptosis 0.342 1.000
PE10 Vision 0.750 0.889
PE11 Hypotonia 0.102
PE12 Muscle strength (proximal) 0.328
PE13 Muscle strength (distal) 0.375
PE14 Hypokinesia 0.518 0.911
PE15 Abnormal movements 0.382 0.926
PE16 Ataxia 0.569 0.962
PE17 Tremor 0.030 1.000
PE18 Pyramidal signs 0.071
PE19 Hypertonia NV
PE20.1 Reflexes 0.125 NV
PE20.2 Hyperreflexia 0.000 NV
PE21.1 Vibration 0.186 NV
PE21.2 Subtle touch NV NV
PE21.3 Cold feet NV
PE21.4 Cold shins 0.000
FT1 Communication 0.800 1.000
FT2 Head control 0.000 NV
FT3 Rolling over 0.913 NV
FT4 Sitting up 0.250 1.000
FT5 Sitting NV 0.710
FT6 Standing up 0.896 1.000
FT7 Standing 0.967 0.951
FT8 Walking 0.965 0.979
FT9 Running 0.825 0.784
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FT10 Hopping 0.883 0.916
FT11 Reaching 0.325 0.625
FT12 Grasping 0.365 0.625
FT13 Rotating 0.850 0.962
minor revision ICC agreement ≥ 0.70
major revision ICC agreement ≤0.30
removed NV = no variance
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M
ain clinical features
Feasibility 
total
Feasibility 
of appli-
cable item
s
NPM
DS-S1
NPM
DS-S2
NPM
DS-S3
NPM
DS-
total
PEDI selfcare
PEDI m
obility
M
icrocephaly, dysm
orhphism
s, failure to thrive, tired, 
exercise intolerance
85
96
6
0
10
16
49
55
Pyram
idal syndrom
e, dystonia, rigidity
81
93
11
1
15
27
24
21
Psychiatric, dyskinetic
100
100
8
0
10
18
70
54
Exercise intolerance
100
100
2
5
2
9
73
59
CPEO
, deafness, short stature, retinitis pigm
entosa
98
98
6
3
10
19
73
59
Ataxia, dystonia, cognitive im
parim
ent, dysphagia
95
96
9
0
17
26
52
35
Ataxia, dystonia, cognitive im
parim
ent, dysphagia, 
dysarthria
96
97
16
0
19
35
13
1
Cerebellar ataxia, cortical visual im
pairm
ent, learning 
disabilities
98
98
5
5
9
19
70
49
Dystonia, cortical visual im
parim
ent, orom
otor dysfunc-
tion, sever global developm
ental delay
80
91
0
2
1
3
71
57
M
yopathy, dystonia, neuropathy, respiratory failure, 
orom
otor dysfunction, learning diffi
culties
85
86
18
2
14
34
0
0
Cerebellar ataxia 
87
96
16
5
22
43
5
0
Severe developm
ental delay, severe failure to thrive, 
visual im
pairm
ent, interm
ittent dystonia, epilepsy
91
97
14
3
15
32
4
2
An episode resem
bling ADEM
, later basal ganglia 
infarcts, neuropathy, epilepsy
97
98
6
4
9
19
73
59
Cognitive regression, intractable epilepsy, visual im
pair-
m
ent, m
ood sw
ing
91
99
0
0
6
6
73
58
Deafness and ataxia
99
99
9
1
5
15
67
41
EPC, acute liver failure, FTT
84
93
14
6
9
29
2
3
Regression, infantile spasm
s, FTT
84
96
9
9
8
26
2
3
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Supplementary Document 12
Patient characteristics for the international field testing.
Patient characteristics, including biochem
ical and – if know
n – genetic diagnosis. The IPM
DS total and sub dom
ain scores are given, as 
w
ell as subjective disease severity as rated by parents and by the physicians (m
ean), the NPM
DS total score and sub dom
ain scores and 
the PEDI total and sub dom
ain scores.
Centre
Patiënt
G
ender
Age 
(years)
Ethnicity
Age at 
diagnosis
Syndrom
e
Biochem
ical defect
G
enetic defect
R
1
F
7
Dutch
2
Leigh syndrom
e
C
om
plex V deficiency
m
.9155A
>G
R
2
F
11
Dutch
8
Leigh syndrom
e
C
om
plex I deficiency
N
D
U
FS7
R
3
M
13
Dutch
3
Leigh syndrom
e
M
TFM
T
R
4
M
14
Dutch
12
Alper's syndrom
e
P
O
LG
M
u
1
M
13
G
erm
an
10
Kearns Sayre syndrom
e
single m
tD
N
A
 deletion
M
u
2
F
16
G
erm
an
2.5
Leigh syndrom
e
C
om
plex IV deficiency
S
U
R
F1
M
u
3
F
14
G
erm
an
0.7
Leigh syndrom
e
C
om
plex IV deficiency
S
U
R
F1
HK
1
M
16
Chinese
11
M
ELAS
C
om
plex I deficiency
m
.13513G
>A
HK
2
F
3
Chinese
2.8
C
om
plex II and III deficiency (C
oQ
10 deficiency)
Pending
HK
3
M
9
Chinese
2.9
Leigh syndrom
e
C
om
plex IV deficiency
S
U
R
F1
HK
4
F
8
Chinese
7
C
om
plex IV deficiency
Pending
P
1
M
2
Asian
2
C
om
plex I deficiency
Pending
P
2
M
12
African
6
C
om
plex III deficiency
Pending
P
3
M
12
European
10
C
om
plex I deficiency
Pending
P
4
M
15
European
6
C
om
plex III deficiency
Pending
C
1
F
2,2
Caucasian
1
Alper's syndrom
e
N/A
P
O
LG
C
2
F
1,6
Caucasian
0.7
Leigh syndrom
e
N/A
N
D
U
FS
8
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PEDI social
PEDI ass 
selfcare
PEDI ass 
m
obility
PEDI ass 
social
Parents 
- general 
disease 
severity
Parents - 
functional 
lim
itations
G
eneral 
disease 
severity 
(m
ean)
M
ito disease 
severity 
(m
ean)
Abnorm
a-
lities at PE 
(m
ean)
Severity of 
functional 
lim
itations 
(m
ean)
M
ild-m
ode-
rate-severe 
(m
edian)
60
29
32
23
7
7
7
7
7
7
2
65
20
9
8
8
9
8
8
9
3
52
40
35
25
6
7
5
6
4
6
2
65
40
35
25
2
2
4
4
2
3
1
65
40
35
24
7
6
5
7
4
4
2
55
19
19
17
3
3
8
7
7
8
3
52
2
0
10
4
5
9
9
9
9
3
56
37
27
15
6
8
5
5
4
4
2
60
38
32
24
0
0
1
1
1
0
1
0
0
0
0
9
10
9
9
9
10
3
13
1
0
2
10
10
10
10
10
10
3
2
0
0
0
8
10
10
10
10
10
3
65
40
35
25
6
7
9
9
9
10
3
65
40
35
25
4
3
5
5
5
5
2
65
35
18
25
8
8
8
7
8
8
3
3
0
0
0
7
9
8
8
8
8
3
3
0
0
0
8
9
8
7
7
8
3
A
D
EM
 = acute dissem
inated encephalom
yelitis; C
 = C
hildrens’ H
ospital of P
hiladelphia; C
P
EO
 = chronic progressive external ophthalm
oplegia; EP
C
 = epilepsia partialis continua; F = fem
ale; FTT = 
failure to thrive; H
K
 = the U
niversity of H
ong K
ong; M
 = m
ale; M
ELA
S
 = m
itochondrial encephalopathy w
ith lactic acidosis and stroke-like episodes; M
u = Ludw
ig M
axim
ilians U
niversität M
ünchen; N
/a 
= not assessed; N
P
M
D
S
 = N
ew
castle P
aediatric M
itochondrial D
isease S
cale; P
 = U
niversity of P
retoria; P
ED
I = P
aediatric Evaluation of D
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Supplementary Document 13
Rater characteristics for the international field testing.
Centre Rater Year of gradu-
ation from 
medical school
Highest education Years of 
experience in 
mitochondrial 
field
Time spent with 
mitochondrial 
patients per 
month (hours)
R 1 2003 Paediatric Neurology 0 1
R 2 2003 Neurology 0.5 0
R 3 1981 Neurology 25 16
R 4 2005 Neurology 0 0
Mu 1 2005 Neurology 1 32
Mu 2 2005 Neurology 5 32
Mu 3 2003 Paediatric Neurology 11 46
Mu 4 1990 Neurology 23 46
HK 1 1995 Paediatric Neurology 10 10
HK 2 1979 Paediatric Neurology, professor 30 2
HK 3 2006 Paedaitric Neurology trainee 2 3
P 1 1989 Paediatric Neurology 10 7.5
P 2 2002 Paediatrics 6 5
P 3 1989 Paediatric Neurology 4 20
P 4 1992 Paediatric Neurology 17 20
C 1 2000 Genetics attending 12 32
C 2 1996 Neurology attending 7 36
C 3 2006 Neurology attending 4 4
C 4 2010 Clinical Genetics fellow 2 4
C = Childrens’ Hospital of Philadelphia; HK = the University of Hong Kong; Mu = Ludwig Maximilians Universität München; 
P = University of Pretoria; R = ErasmusMC Rotterdam
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ICC-agreement
2.03 Alertness NV
2.05 Dysarthria 0.769
2.06 Ptosis NV
2.07 Strabismus NV
2.08 Eye movements 0.000
2.09 Nystagmus 1.000
2.13 Hypokinesia 1.000
2.14 Abnormal movements 0.848
2.15 Ataxia 0.100
2.16 Tremor NV
2.17 Reflexes 0.571
2.18 Hypertonia 0.897
2.19 Hypotonia NV
2.20 Rigitidy 0.935
NV = no variance
ICC-agreement
3.01 Communicating NV
3.02 Head control NV
3.03 Rolling over NV
3.04 Sitting up -0.154
3.05 Sitting up NV
3.06 Standing up 0.956
3.07 Standing 0.964
3.08 Walking 0.981
3.09 Running 0.968 x
3.10 Hopping 0.971 x
3.11 Reaching 0.833
3.12 Grasping 0.520
3.13 Rotating 0.938 x
X = only above 6 years; NV = no variance
Supplementary Document 14
Intra-rater reliability for the IPMDS.
Intra-rater reliability (ICCagreement) per item of the IPMDS for two physicians scoring their own 
videotaped consultation. Items with an ICCagreement ≥ 0.7 (good agreement) are marked in 
green; ≤0.3 (poor agreement) marked in blue. The items not suitable for video rating were 
removed. 
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Supplementary Document 15
Test-retest reliability for the IPMDS.
Test-retest reliability (ICCagreement) per item of Domain 1 of the IPMDS for restest by the 
same rater by telephone and by a different rater (nurse specialist). Items with an ICCagree-
ment ≥ 0.7 (good agreement) are marked in green; ≤0.3 (poor agreement) marked in blue. 
Same rater (n = 4) Different rater
(n = 4)
1.01 Response to environment (n = 4) 0.571
1.02 Exercise capacity 1.000 0.451
1.03 Walking distance 1.000 1.000
1.04 Tiredness 1.000 0.348
1.05 Depressed NV 0.000
1.06 Epilepsy 1.000 0.000
1.07 Headache NV 0.727
1.08 Muscle pain NV 0.923
1.09 Infections NV -0.465
1.10 Chewing 1.000 0.979
1.11 Swallowing 1.000 1.000
1.12 Hearing NV NV
1.13 Communicating 1.000 0.211
1.14 Vomiting 1.000 0.960
1.15 Gastroesophageal reflux NV 0.800
1.16 Constipation 1.000 0.571
1.17 Diarrhoea NV NV
1.18 Cognitive functioning 1.000 0.000
1.19 Behavioural problems NV NV
1.20 Autistic features 1.000 0.800
1.21 Breathing subjective 1.000 1.000
1.22a Continence day 1.000 NV
1.22b Continence night 1.000 1.000
1.23a Strabismus when tired NV
1.23b Ptosis when tired 0.571
1.23c Dysarthria when tired NV
NV = no variance
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The aim of this thesis was to contribute to the knowledge on outcome measures in 
paediatric mitochondrial disease. This knowledge is essential to make rational deci-
sions on which instruments to use in future clinical studies. This aim led to the following 
research goals: i) explore which symptoms and disabilities associated with mitochondrial 
disease should be measured in clinical trials from a patients’ and doctors’ perspective; 
ii) systematically select instruments from literature that could be used to cover these 
most important symptoms and disabilities; iii) validate these instruments in patients with 
mitochondrial disorders; and iv) develop new instruments for domains, which seem 
important but are not covered by instruments found during the systematic review.
Here, I will first elaborate on the methodology used to select the outcome measures 
and study populations for our validation studies. Subsequently, I will critically review the 
results of the validation studies and use these results to make recommendations on 
which instruments seem most promising. Finally, I will give suggestions to improve the 
quality of the selection process of outcome measures for future clinical trials in these 
rare disorders, as well as some other recommendations to improve the quality of such 
trials.
Approach to the validation of outcome measures
In blockbuster disease clinical trials, in for example cardiovascular disease or cancer, 
time-to-event (relapse, stroke, myocardial infarction, death), histological results or radio-
logical results are often used as end points.1-3 Since at this time no markers for mito-
chondrial dysfunction are known that correlate with disease progression4 (and Chapter 
5, 10 and 11) and studies using time-to-event as their primary end point require the 
inclusion of large populations, the orphan disease field is faced with specific difficulties 
as it comes to the selection of outcome measures.5 Since the number of patients to 
be included in a clinical trial (sample size) depends on the size of the effect relative to 
the precision of the measurement, either large treatment effects or sensitive and reli-
able outcome measures are needed when only a small amount of patients is eligible 
to participate in the study. Especially since therapies are expected to slow disease 
progression rather than reverse morbidity,6,7 there is a huge challenge to identify instru-
ments able to reliably quantify more subtle changes in for example strength, gait, and 
endurance. 
Developing outcome measures for the paediatric population is challenging for many 
more reasons. Not only are children developing and growing (requiring age-specific 
tests and the use of age- and size matched reference values), their understanding and 
enthusiasm for and cooperation during the test may highly influence the test results. 
The feasibility of measuring disease progression in severely mentally disabled children, 
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whom are sometimes not even able to communicate effectively with their environment, 
let alone respond to an instruction, is limited. Since virtually all functional tests require 
the child to show the best (s)he can do, even children having milder mental disabilities 
might not show consistent results because of attention deficit and difficulties under-
standing the relevance of the tests. The measured results are therefore not only depen-
dent on the stage of disease or grade of disability, but also on age, gender, intellectual 
functions, environment and personal factors.
Selection of outcome measures 
In part I of this thesis I aimed to select clinically relevant and robust outcome measures 
for future validation studies in children with mitochondrial disease. 
Since this had never been done for children with mitochondrial disease, we used the 
experience from the neuromuscular field and cerebral palsy (CP) fields as an example. 
Both fields have a long history in measuring the effects of interventions on functional 
status. In the early 70’s, the first study with steroids in boys with Duchenne muscular 
dystrophy (DMD) was performed.8 At that time, only subjective and unstandardised 
activity assessment and strength measurements were available to evaluate the effect 
of treatment. Since this was felt to hamper the interpretation of the study results, the 
field quickly started with the development of standardised protocols including func-
tional tests9-12 and first optimisations in methodology.13,14 Since then, many clinical 
studies investigating natural history and therapeutic interventions using different sets of 
outcome measures and populations have been performed. In 2011, the experience of 
eight centres, representing the longitudinal natural history data as well as experiences 
with the feasibility and reliability of various outcome measures in nearly 1,900 Duchenne 
patients over a 20-year time period, was presented at an international expert meeting.15 
These results were used to reach consensus for age-appropriate clinical outcome 
measures for clinical trials in boys with DMD.15 To select the most valuable outcome 
measures in an iterative process, the neuromuscular community plies the following 
steps:16 i) identification of the existing instruments; ii) choosing the optimal outcome 
measure(s) which is (are) both widely applicable and measures disease specific, clini-
cally relevant (functional) capacities; iii) determine the minimal important difference; iv) 
determine the statistical properties in the disease population; v) confirm acceptance 
of th outcome measures by the regulatory authorities; and vi) listen to patients’ and 
parents’ experiences of the impact of the changes in functional abilities on their daily 
life. 
In the CP field, patients and their caretakers were asked to rate the symptoms and 
limitations they would like to change from a much earlier stage.17,18 Since the limitations 
caused by CP range widely and most interventions aim at targeting a specific symptom 
such as spasticity, the available instruments cover a broad pallet of body functions and 
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activities.19 Several reviews have studied their psychometric properties20-24 as well as 
the construct measured.25 Although these reviews facilitate the selection of outcome 
measures targeted on a specific research question, consensus on which outcome 
measure to use for the most important domains still lacks.19,25
Our outcome measure identification project aimed at selecting psychometrically robust 
instruments measuring those aspects of the disease that are highly relevant to patients 
with mitochondrial disorders. The instruments were selected based the most burden-
some symptoms according to patients and their parents and on the results of validation 
studies in DMD and CP, which were used as a model for mitochondrial myopathy and 
mitochondrial encephalopathy, respectively. One should however keep in mind that 
despite the similarities in functional disabilities, the underlying disease pathophysiol-
ogies are completely different and this is naturally reflected in the clinical phenotype. 
Similar to mitochondrial encephalopathy, the clinical picture as well as the underlying 
pathophysiology of CP is extremely heterogeneous,26 including pyramidal syndromes, 
extrapyramidal syndromes, seizure disorders, and/or cognitive impairment.27 Even 
symptoms rated as highly burdensome by mitochondrial disease patients, such as 
speech and language problems, and behavioural problems (Chapter 2), as well as 
oromotor dysfunction, hearing and vision problems, and attention deficits, are also 
seen in CP.27 However, CP is by definition non-progressive,27 while most mitochondrial 
encephalopathies have a progressive disease course.28,29 The differences in pathophys-
iology are probably also reflected in e.g. in the aetiology of (fluctuations in) seizures30 and 
cognitive capacities and in the patterns of daily activities performed by both groups.31 
Besides, specific syndromic associations, such as the brainstem and basal ganglia 
lesions in Leigh syndrome or the stroke-like episodes in MELAS syndrome, as well as 
the multi-system nature of mitochondrial disease are not reflected in the CP-model. 
For DMD, the differences with mitochondrial myopathy are even clearer. Patients with 
DMD have a structural muscle problem, caused by (near-)absence of dystrophin, and 
thereby loss of mechanical stability during muscle contraction. This results in fragile 
muscle fibres that are prone to contraction-induced injury and progressive fibrosis.32 As 
a consequence, boys with DMD suffer from progressive muscle weakness, which has 
a more or less predictable sequence and rate if untreated.33-38 Outcome measures for 
DMD therefore mainly focused on muscle histology,39, muscle strength,10,40 and motor 
function,40,41 whereas the limitations experienced by children with mitochondrial myop-
athy are mostly related to muscle endurance or repetitive movements. Still, the results 
of psychometric studies in DMD are of value since an instrument which is not able to 
reliably measure muscle power or functional abilities in children with DMD is unlikely to 
be a good instrument for patients with mitochondrial disease. Although it is possible 
that we removed promising instruments for mitochondrial disorders because of low 
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reliability scores in DMD in Chapter 3, our personal impression during the selection 
process was that none of the discarded instruments seemed more promising than the 
instruments selected for the mitochondrial toolbox. 
Study population
In part II of this thesis I aimed to determine inclusion criteria for our validation studies, 
based on the natural disease course and clinical heterogeneity in patients with nuclear 
encoded Complex I deficiency and in carriers of the m.3243A>G mutation. For our 
biomarker validation studies, we intended to include a large population with a similar 
genetic, biochemical and/or clinical background to minimise the influence of covariates. 
For the IPMDS and the accelerometer study we aimed to include a heterogeneous 
population to maximise generalizability of the feasibility and validity results. 
The study on the natural history of nuclear encoded Complex I deficiency (Chapter 4) 
revealed that classification based on genetic defect, biochemical abnormalities, and 
clinical syndrome all led to small subgroups with still substantial clinical heterogeneity. 
Neither classification seemed superior in selecting homogeneous groups with a suffi-
cient number of patients. In Chapter 4, we even found a substantial clinical heteroge-
neity in patients with Leigh syndrome caused by nuclear encoded Complex I deficiency, 
based on the localisation of the central nervous system abnormalities, the pattern of 
multi-system involvement and the reported disabilities. A recent study in patients with 
mutations in SURF1, an assembly gene for Complex IV, stated that SURF1 patients 
have a homogeneous phenotype.42 However, based on a careful evaluation of the data 
presented in this article and other reports,43 we conclude that the clinical heterogeneity 
of SURF1 patients equals to nuclear encoded Complex I deficiency. For this reason, 
and because of the low prevalence, we chose not to perform our surrogate marker 
validations in nuclear encoded Complex I deficiency or Leigh syndrome.
Recent m.3243A>G cohort studies by our (Chapter 5) and other groups44-46 have illus-
trated the clinical heterogeneity which may be observed as a consequence of only 
one single nucleotide change in the mitochondrial DNA. We were able to recruit a total 
number of 82 carriers for this study within the first year and this number has increased 
to ~150 in 2014. Because of the large number of patients in which disease severity was 
assessed as part of the cohort study, we chose to validate our candidate surrogate 
measures in the cohort of m.3243A>G carriers. The availability of such a large geneti-
cally homogeneous cohort with known clinical phenotype outweighs the drawbacks of 
the (well-characterised) clinical heterogeneity. 
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Validation Studies
In Chapter 3, we composed a mitochondrial toolbox of promising outcome measures 
based on the most burdensome complaints experienced by patients and their parents 
(Chapter 2) and the psychometric results in e.g. CP and DMD. This toolbox has been 
used as a starting point for the validation studies in part III of this thesis, which aimed 
to obtain experience with outcome measures in patients with mitochondrial disorders.
Several validation studies have been completed and included in this thesis. Although 
only very small groups with heterogenous phenotypes (children) or genetically homo-
geneous and clinically heterogenous (adults) populations were included and generaliz-
ability may be limited, the results of these validation studies have given an indication on 
which instruments are more promising compared to others. Here, I will elaborate further 
on the results of these validation studies.
Functional outcome measures
Since tiredness and lack of energy were among the most burdensome symptoms 
according to patients and their parents, we sought for methods to quantify tiredness 
among the wide spectrum of children with mitochondrial disease. Since full capacity 
measured in a laboratory situation is highly influenced by personal factors such as 
motivation or anxiety and does not (always) reflect the disabilities the child experiences 
in daily life (e.g. sustained or repetitive movements), we aimed to measure tiredness 
in the patient’s home situation using accelerometry (Chapter 6). We hypothesised that 
in children with mitochondrial disorders, the amount of physical activity reflects the 
exercise tolerance and the amount of energy the child is able to spend during the 
day. We expected a wide variability in activity during the day,47,48 but hypothesised that 
the maximum peak-intensity and the total intensity of physical activity would be quite 
stable over the days. Seventeen children with mitochondrial disease and sixteen age- 
and gender-matched controls were included in this study. We found that patients had 
a lower peak intensity and that patients were resting more compared to their peers. 
These results seem to be generalizable, since children with widely variable symptoms 
and disabilities were included. In four patients and four healthy controls, the results of 
the retest in summer were not significantly different from the results in spring. When 
the technical issues we encountered during our validation study are addressed and 
the measurement protocol has been standardised to limit the effect of covariates, 
measuring daily physical activity using accelerometry may be of great importance in 
objectifying improvements in subjective observations of the patient such as feeling 
better and more energetic. 
Exercise tests are obviously more closely related to the exercise capacity than daily 
physical activity. Since it is known that children – and especially those with disabilities 
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- rarely engage in maximal exercise,49 and maximal and submaximal exercise capacity 
are closely related in healthy individuals,50-52 we chose to evaluate a test for submax-
imal exercise capacity: the assisted 6-minute cycling test for arms and legs (A6MCT; 
Chapter 8). The validation study showed that the A6MCT seems to be feasible in chil-
dren with OXPHOS dysfunction and a developmental age above approximately 4 years, 
without severe behavioural problems. This age-range is similar to the age at which the 
6-minute walking test (6MWT) is used,53 though the rate of completion of the 6MWT 
is known to rise dramatically after the age of 5 years.54 The A6MCT was feasible in 
seven out of nine children, but none of the children included in our study seemed to 
need the assistance provided by the bicycle, as shown by the low number of abnormal 
results, in contrast to children with neuromuscular disease. Although the test was orig-
inally developed to replace the 6MWT in non-ambulatory children or children who are 
about to lose their ambulancy, the study design dictated that only ambulatory children 
could be included. Therefore, no solid conclusions about the feasibility and validity in 
non-ambulatory patients or patients with less muscle power can be drawn. Since only 
very little children with mitochondrial disease are both fully non-ambulatory and able to 
reliably complete a 6-minute task, confirming the reliability of the 6MWT in ambulatory 
children with mitochondrial disease who have mild to severe intellectual disabilities has 
higher priority.55 
General mitochondrial disease severity
Since some therapeutic effects are not known prior to the intervention, a broad 
screening instrument rating virtually all aspects of mitochondrial disease severity was 
developed: the International Paediatric Mitochondrial Disease Scale (IPMDS; Chapter 
7). After a pilot reliability study involving eight patients and four raters, this scale was 
optimised and validated by 19 raters in 17 children with variable ages and pheno-
types at five mitochondrial centres across the globe. IPMDS execution was feasible in 
all children, although both parents and physicians experienced difficulties in applying 
the IPMDS to toddlers, which was reflected in the inter-rater reliability of the second 
domain, but not in the first and third domain or in the number of items completed. The 
validation study showed that the IPMDS has good construct validity and a good reli-
ability for most items. Excellent inter-rater reliability was found for the items within the 
functional assessment part and poor inter-rater reliability was found for 16 items (26%), 
mostly those included in the physical examination. More experience with the IPMDS 
across different age groups and mitochondrial phenotypes as well as knowledge about 
the minimal clinically important difference has to be gathered to facilitate the successful 
use of the IPMDS in future clinical studies. 
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Surrogate markers
Since all above-mentioned functional measures are subject to patient bias (including 
e.g. voluntary effort and report bias), measuring disturbances of physiology may seem 
more objective and reliable. Biomarkers or surrogate measures are generally quick and 
easy to measure, objective, reliable, non-invasive, and possibly applicable to the full 
spectrum of patients with mitochondrial dysfunction.56 Besides, biomarkers are not 
dependent of voluntary effort and can be measured reliably in severely affected patients 
of any age. 
To date, none of the existing biomarkers for mitochondrial disease have been shown to 
correlate closely with a clinical outcome in any of the high-quality intervention studies.57 
In Chapter 10 and 11, we have evaluated the value of two potential new biomarkers 
for mitochondrial disease: Fibroblast Growth Factor 21 (FGF21) and growth and differ-
entiation factor 15 (GDF15). In a large cohort of m.3243A>G carriers, we found only a 
moderate correlation between the concentration of both biomarkers and clinical disease 
severity, but neither of the two biomarkers was able to predict or monitor disease 
progression during follow-up. Because of the lack of correlation with disease progres-
sion, we could not yet recommend the use of FGF21 and GDF15 as an end point in 
clinical trials in m.3243A>G carriers. However, since m.3243A>G carriers only show 
minimal disease progression over the period of measurement and disease progression 
was measured using a clinical and partly subjective scale, it might still be of value to 
investigate the responsiveness of GDF15 and FGF21 during therapeutic interventions. 
Two-dimensional speckle-tracking echocardiography (2DSTE; Chapter 9) was validated 
in our cohort of m.3243A>G carriers using data obtained from clinical care. Strain 
analysis was feasible in 90% of the images for global longitudinal strain (GLS). GLS 
was abnormal in 53 – 68% of cases (variation depending on reference values used). 
Drawing solid conclusions on the responsiveness of 2DSTE in m.3243A>G carriers was 
not yet possible because no structured clinical follow-up assessment was performed. 
The data for this retrospective pilot study were collected as part of routine care (using 
a standardised imaging protocol) and only 77% of the patients were suitable for the 
assessment of longitudinal myocardial strain using 2DSTE. Since these numbers are 
probably higher in highly standardised prospective studies, we recommend testing the 
feasibility and responsiveness of GLS in more detail in a prospective (intervention) study. 
Since abnormalities in myocardial deformation are frequently observed in patients with 
mitochondrial disease59-61 and the 2DSTE method is a widely available and non-inva-
sive method to quantify the performance of a non-voluntary muscle, global longitu-
dinal strain is a promising end point for future clinical trials. To increase reliability of the 
results, the images should be analysed by two independent and experienced raters 
not aware of the condition and the treatment status of the carrier and efforts should be 
taken to standardise e.g. medication intake and resting conditions at the time of the 
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echocardiogram. Although the clinical relevance of subtle improvement in global longi-
tudinal strain is not yet known, we hypothesised that an improvement in myocardial 
deformation reflects a decreased cardiomyopathy-associated morbidity and mortality.
What outcome measure to use in future clinical trials?
The selection of appropriate outcome measures depends on many factors including 
the research goal, the type of the intervention, and the inclusion criteria (including age 
and mental capacities and functional abilities of in the intended patient group).25 While 
early proof-of-principle studies would prefer to study a more narrowly defined popula-
tion using highly detailed end points, larger trials require a larger population and thus 
more generally applicable outcome measures as to not render recruitment to a chal-
lenge.16 Having seen over ~50 children and ~150 adults with mitochondrial disease in 
a structured program, either as part of clinical research or clinical care, we’ve begun to 
appreciate which tests might be useful and which instruments are certainly not. Here, 
I will elaborate further on which classes of instruments now look more promising and 
are of higher priority.
Generic or disease/symptom specific instruments?
Concepts measured can be split roughly into generic (wellbeing, functioning) or 
disease-specific (symptom) aspects of the disease.62 Since the spectrum of mitochon-
drial disorders is so heterogeneous, a non-categorical approach, addressing limita-
tions in daily functioning seen as common manifestations of impaired health rather 
than specific to particular aetiologies, may suit best. We have applied this approach 
in a broader perspective using the ICF-CY to determine the domains to be included 
in our outcome measure inventory. Such a ‘one-size-fits-all’ approach increases the 
number of patients for which the instrument is relevant. However, in order to detect 
subtle, but meaningful changes in disease-specific symptoms by a generic instrument, 
large numbers of participants are required, especially in heterogeneous populations.16 
Two possible solutions for this dilemma include combining general instruments with 
disease-specific and symptom-specific instruments and the selection of a more homo-
geneous population for a clinical trial. The combination of generic and symptoms-spe-
cific outcome measures allows the inclusion of a broad clinical spectrum based on the 
relevance of the generic instrument, without losing the sensitivity of the organ-specific 
outcome measures for post-hoc analyses. The second approach may comprise the 
inclusion of a clinically homogeneous mitochondrial syndrome, such as Leber’s Hered-
itary Optic Neuropathy. For these disorders, more targeted sets of outcome measures 
can be defined, although the prevalence of many of these disorder will make recruit-
ment challenging and requires international collaborations (with its own challenges). 
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I suggest the use of a combination of generic instruments and a broad pallet of symp-
tom-specific instruments in early phases of drug testing, to evaluate the effect of the 
drug both on in-depth organ function and on universal aspects such as functioning 
or quality of life. In subsequent efficacy studies in a more homogenous population, a 
smaller set of outcome measures may be applied, selected based on earlier trial results 
and adapted to the paediatric population.63
Functional or surrogate measures?
Since all functional outcome measures are to some extent subjective instruments, 
either to the patient, his parents or to the investigator, one may feel a demand for more 
objective outcome measures that can be assessed using more reliable and unbiased 
assays or devices. These so-called surrogate end points are easy to measure variables 
that give an indirect indication of the toxicity or therapeutic benefit of a compound. 
Although surrogate end points have many advantages, such as a reduction of sample 
size and the possibility to indicate changes in biochemical processes that would be 
unethical to measure otherwise, drawbacks are numerous. 
First and foremost, a change in a surrogate end point does not necessarily reflect a clin-
ically meaningful effect of the treatment to the patient. In previous studies in progressive 
neuromuscular disorders, clinically relevant changes in motor function are not always 
equally reflected by changes in muscle power.64,65 Moreover, improvements spasticity, 
joint contractures, gait dysfunction and bone displacements may not be reflected in 
functional abilities.66 In mitochondrial disorders, examples include the lack of correlation 
between e.g. Complex I activity and the severity of the clinical phenotype (Chapter 4), the 
disappearance of lactate peaks on magnetic resonance spectroscopy during disease 
progression,4 and the lack of meaningful correlation between changes in biomarkers 
FGF21 and GDF15 and disease progression (Chapter 10 and 11). The current view is 
that only functional outcome measures are good indicators of the aspects of function 
that reflect everyday activities.16 
The second drawback of surrogate end points is that technical problems may affect the 
measurements. As shown by the accelerometer and 2DSTE study, instruments should 
be also tested in the intended population, since some seemingly easy tests may not be 
feasible in for example severely disabled children. Besides, fluctuations due to seasonal 
variation, physiological maturation and development, diurnal rhythm, hormonal cycle, 
food intake, exercise and local laboratory variations (measurement variability, storage, 
timing) should be mapped in great detail prior to using it in a clinical trial. 
So, although surrogate outcome measures may serve as reliable and unbiased indica-
tions of proof of concept, their reflection of the final goal of the treatment, namely to 
improve the functional abilities or survival of the patient, should be established before 
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using it in efficacy studies.67 Only sensitive and responsive biomarkers, closely related 
to a valid clinical end point, may suit as a surrogate end point. Moreover, changes 
in surrogate end points should always be supported by changes in clinically relevant 
parameters.
Capacity or performance?
When choosing a functional instrument, it is important to distinguish between instru-
ments measuring ((sub)maximal) capacity and those measuring the performance in 
daily life. The capacity is the ability to perform a certain task in a laboratory environ-
ment (e.g. on a level floor), while performance describes what an individual can do and 
does in his own environment on a daily basis (with both barriers and available aids and 
help).68 Both constructs have their own advantages and disadvantages. For example, 
motor performance levels only partly reflect the motor capacities of the child,68 and 
contextual factors, such as the physical and social environment and personal factors 
(anxiety, motivation) are likely to play a significant role. On the other hand, a laboratory 
situation in which a patient is encouraged to make a single maximum effort in a clinical 
environment by a relative stranger, is likely not to fully reflect the disabilities experienced 
in daily life. 
Based on the results of our validation studies, including both submaximal exercise 
capacity tests and performance tests, I sugest including performance tests rather than 
capacity tests for patients with limited ability to follow instructions. For patients with 
more abilities, I suggest validating submaximal exercise tests, such as the 6MWT. 
Patient or clinician reported?
Both the Food and Drug Administration (FDA) and the World Health Organization (WHO) 
support the inclusion of patient-reported outcome measures to describe the patient’s 
perspective on the effectiveness of the drug.62,69 Health related quality of life (HRQOL), 
either generic or disease-specific,70 is the most frequently used patient reported 
outcome measure. HRQOL is known to be only weakly to moderately correlated to 
physiological and functional parameters,71-73 suggesting both that HRQOL instruments 
provide a unique perspective on the outcome of treatment but also that the universally 
applicable HRQOL questionnaires are influenced by many more factors than disease 
severity alone. Although measuring HRQOL seems like an art rather than science 
compared to measuring blood pressure, most HRQOL questionnaires show better reli-
ability than diastolic blood pressure.74 Nonetheless, since the paediatric field is highly 
dependent on proxy-report, and parents experience the child’s quality of life different 
than the child does,36,38,75,76 the validity of patient reported outcomes for this population 
seems limited. 
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Of course, the main question for the subjects included in a clinical trial is: ‘In your 
opinion, does your treatment (or placebo) work? And how do you feel different?’. In my 
opinion, we should keep asking that question, especially in early phase drug testing, 
to be able to select outcome measures that test the changes reported by the patients. 
Patient reported outcome measures should only be included in a clinical trial after crit-
ical evaluation of clinical relevance of the content and reliability.
Recommendations
Since different tools will provide unique and relevant information, it is expected that 
the inclusion of more instruments in the trial will be needed to gather sufficient infor-
mation on the clinical condition of the patient. Naturally, the size of the set of outcome 
measures and the sequence of the tests should be adapted to the abilities and energy 
level of the patient. One should also realise that many tests are confronting to patients 
and their parents and therefore ‘less is more’. 
With the current knowledge, I would recommend the accelerometer as one of the main 
outcome measures in future clinical trials. This outcome measure seems most widely 
applicable since it measures a complaint relevant to a large proportion of children and 
does not require the child to follow specific instructions. Moreover, since the construct 
measured is closely related to the pathophysiological process that is reversed by the 
treatment, the end point is likely to respond to treatment effects. Before accelerometry 
can be used in clinical trials though, the hardware problems (i.e. battery of the devices) and 
the analyses need to be optimised. In parallel, patients and parents should be involved in 
defining the primary outcome and minimal important difference for this end point. 
As secondary outcome measures, I propose (Box 1) the IPMDS, to assess general 
mitochondrial disease severity and screen for symptom-specific improvements, and 
2DSTE, to objectively measure the function of a non-voluntary muscle. Since the Gross 
Motor Function Measure (GMFM) was feasible in all children included in the acceler-
ometer study, I would suggest to monitor changes in gross motor abilities using the 
GMFM. The Paediatric Evaluation of Disability Inventory (PEDI) was feasible in all chil-
dren seen both in the accelerometer study and in the IPMDS study, but since the PEDI 
has a significant ceiling effect in children with more abilities, I would only suggest this 
test only in more severely affected children. As a formal endurance test, I suggest the 
6MWT, since most of the children who are able to follow instructions will be ambulatory. 
The functional abilities tests used as part of the A6MCT validation could be useful, but 
should be highly standardised and tailored to the population which will be included in 
the clinical trial. For the children in the A6MCT study (with a high level of abilities), we 
sometimes felt as if the results were dependent on the reaction time of the rater, instead 
of the abilities of the child. 
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Several other tests included in our studies had lower suitability to paediatric mito-
chondrial disease compared to the above-mentioned tests. The Movement Disorder 
Childhood Rating Scale77,78 was tested during the pilot study of the accelerometer. In 
our opinion, the test was not suitable for mitochondrial disorders, since the score on 
many items (e.g. handwriting, walking) was mostly affected by symptoms other than 
the movement disorder. Moreover, it is known that the inter-rater reliability of assessing 
Box 1: Recommended tests for future clinical trials in paediatric mitochondrial disease* 
Test Domain Prerequisites
Accelerometer Physical activity Solve hardware problems 
Define more detailed primary outcome 
Define minimal clinically important difference 
IPMDS General mitochondrial disease severity Define minimal clinically important difference 
Improve inter-rater reliability for Domain 2
2DSTE (global longitudinal strain) Myocardial deformation Assess feasibility in a prospective, highly-standar-dised study
Determined by 2 independent raters not aware of 
the clinical condition of the subject
Validate in children
Standardise medication intake and resting 
conditions
Define minimal clinically important difference 
GMFM Gross motor function Test inter- and intrarater reliability, especially in children not able to follow instructions
Define minimal clinically important difference 
PEDI Functional capabilities and performance Only for severely affected children
Determine test-retest and inter-rater reliability
6MWT Submaximal exercise capacity Determine test-retest reliability and learning effect
Shorten if possible
Define minimal clinically important difference 
Timed function tests (Speed of) functional abilities Tailor to targeted population
Increase level of standardisation
  Define minimal clinically important difference 
Tests we cannot recommend (yet) include: fibroblast growth factor 21 (FGF21); growth and differentiation factor 15 (GDF15); 
Movement Disorder Childhood Rating Scale, Modified Tardieu test for spasticity, Motor Function Measure (MFM).
2DSTE = 2-dimensional speckle tracking echoardiography; 6MWT = 6 minute walking test; GMFM = Gross Motor Function 
Measure; IPMDS = International Paediatric Mitochondrial Disease Scale; PEDI = Pediatric Evaluation of Disability Inventory
* Based on studies performed in this thesis
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movement disorders is rather low.79 The Modified Tardieu test for spasticity,80 used as 
part of the accelerometer study, had good face validity but seemed to be quite situa-
tion- and rater-dependent. Especially since an improvement in spasticity is not always 
reflected in the functional abilities,66 I don’t recommend this test as a clinical end point 
for future clinical trials. The Motor Function Measure (MFM) was included in the A6MCT 
study. For this test, some of the items seemed highly relevant, but since many of the 
items were normal in most children, we don’t recommend this test for children with 
mitochondrial myopathy. Some of the clinically relevant items of the MFM were included 
in the functional domain of the IPMDS. 
A selection of the above mentioned tests, tailored to the population which is included 
in the study, may be complemented with surrogate markers and functional outcome 
measures (where indicated adapted for the paediatric population) selected from patient 
reports in earlier phase clinical trials. Since all of the above mentioned tests are, to a 
more or lesser extent, burdensome to patients and subject to either patient, parent 
or rater bias, I encourage the continuation of biomarker studies, to detect biomarkers 
correlating with clinically relevant organ functions and abilities.


Future prospects 
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Substantial progress has been made since this project started in 2010. Not only do we 
have more feeling for which outcome measures seem most robust, also several other 
initiatives focussing on the selection of outcome measures in mitochondrial disease 
have arisen, including the Common Data Elements for mitochondrial disease project 
from the National Institute of Health and a multidisciplinary workshop on biomarkers 
and outcome measures in Hinxton, United Kingdom. Beside the selection of outcome 
measures, many other challenges remain in designing a scientifically robust clinical trial 
protocol, including the selection of inclusion criteria and the choice of a primary and 
secondary outcome measures. 
Future Studies On Outcome Measures In Paediatric Mitochondrial Disease
Ideally, the selection of a test for use in a clinical trial is based on the experimental data 
on the test characteristics (e.g. feasibility, reliability, responsiveness and minimal impor-
tant change) in the considered study population. As part of the ‘Towards the Harmo-
nisation of Outcome Measures for Children with Mitochondrial Disease’-project, we’ve 
designed the SO-MITO (Selecting Outcome measures for Mitochondrial disease) study 
(MREC nr NL.47373.091.13). 
The SO-MITO study
The SO-MITO study measures the clinical relevance, feasibility, reliability, validity, 
responsiveness, and minimum important change of a set of promising instruments 
from our toolbox in children with mitochondrial disease. Inter- and intrarater reliabi-
lity are tested by assessing the patient with two blinded investigators and by making 
a video of the patient to be rated again by one of the investigators later. Test-retest 
reliability is assessed by asking the patient to perform the same tests within a limited 
time frame, two weeks later (if the patient is not feeling well or the disease seems not 
stable, this part of the protocol is postponed beyond the last visit). Validity is assessed 
by correlating tests measuring the same concepts, or by correlating with the patients’ 
or rater’s opinion about the concept measured (e.g. a VAS scale for general disease 
severity for patients or for motor abilities or muscle power for raters). Feasibility, clinical 
relevance and face validity are assessed during these study procedures. Responsive-
ness is tested by one of the raters at the time the intended clinical trial would finish. 
Since responsiveness requires the disease to change and there’s no effective treat-
ment available yet, responsiveness relies on the fluctuating disease course (both in a 
positive and negative direction) seen in many patients. Another suggestion would be 
to combine this study with an intervention study, e.g. aerobic training to prevent secon-
dary disuse.81 However, since most children are already under such a treatment and 
the burden of participation will be higher, this may not be desirable. Since knowing the 
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minimum important difference is essential before designing future clinical trials (e.g. for 
choosing the most responsive outcome measure and to determine the sample size), 
no effort should be spared to determine this parameter. The minimal clinically important 
difference can be assessed by for example assessing which changes patients and 
parents experienced as relevant compared to the previous assessment in a prospec-
tive natural history study or by statistically-based approached, although the latter do 
not take into account the patients’ perspective.34 To tailor the SO-MITO study protocol 
to the to-design clinical trial, the protocol should be adapted to include the proposed 
study population and having the same length of time that will be used in the trial in order 
to assess the spectrum of possible changes in time.16 Although the burden of this study 
to patients, investigators and financial resources seems limited, the burden associated 
with the execution such as study before the start of a clinical trial (which is preferably in 
the same patient population) may still be too burdensome to patients and their families. 
To gather similar data in a more efficient way, many aspects of the above mentioned 
protocol may be integrated in a early phase clinical trial. Examples of protocol adap-
tations include: i) repeated baseline measurements to assess test-retest reliability and 
learning effects; ii) blinded assessment by two assessors and videotaping for rater-de-
pendent tests in this kind of tests; iii) asking patients about their experience with the 
individual tests within the study protocol; and iv) asking patients to rate relevant changes 
in specific disease aspects or functional abilities to determine the minimum important 
difference. These adaptations will provide highly relevant information for future studies, 
but again may be an extra burden to patients already in a strenuous research protocol. 
Another option is the use of outcome measures as part of clinical care. Although stan-
dardisation will be suboptimal, the raters will have a good feeling about which tests 
are feasible, reliable, valid and responsive. This may also form the basis on which 
outcome measures are selected for more intensive protocols such as the above menti-
oned SO-MITO study. In Nijmegen, we’ve been running the so-called ‘MitoRoute’ since 
2014. In this intensive screening programme, about 40 different tests are used. We are 
currently analysing the results of the first 50 patients.
Optimisation of outcome measures
It is likely that some tests seem ready to be in- or excluded in future studies, while 
others will have to be optimised to be feasible or more widely applicable to the intended 
population. Here, I will give some suggestions for adaptations of available tests, for 
newly to develop tests and of new approaches to define end points in intervention 
studies. Obviously, these tests will have to be validated and if indicated undergo a 
second optimisation round before they can be used to determine treatment effects. 
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The 6-minute chewing test is a new instrument under development by our speech and 
language therapists. Since it has been developed based on the observation that many 
children with mitochondrial disease were not able to sustain chewing for the full duration 
of a meal, this is a good example of a clinically relevant outcome measure. The duration 
of this test is again 6 minutes. The first results of this test show that children only deviate 
from normal within the last minutes. This is not the case for the 6MWT and the A6MCT, 
which were completed at a stable pace (Chapter 7). Since it is known that children with 
attention problems have difficulties completing the full 6MWT,53 I suggest to test the validity 
of a 1-minute or 3-minute version of the A6MCT and 6MWT.82 Besides, a training session 
before the start of the study should be considered, since a test-retest study of the 6MWT 
in patients with Down syndrome showed a substantial learning effect.55 Moreover, one 
should take into account that, since children are growing and developing, motor abilities 
and muscle power are expected to be higher during follow-up. On the other hand, some 
child may fully lose the ability to perform the test during disease progression. Therefore, the 
result of these tests should be expressed as a z-score (normalised for height or age) or as 
velocity, instead of a distance or a time. 
Developing an entirely new rating scale for motor function abilities in children for 
mitochondrial disorders, as has been done multiple times for DMD,83,84 is complicated by 
the phenotypic heterogeneity of mitochondrial disorders. Separate scales for children with 
mitochondrial myopathy and mitochondrial encephalopathy may be suggested, although 
the need for a new functional scale for mitochondrial encephalopathy is low since the 
GMFM seems a solid test for this patient group. Except for the Childhood Myositis Assess-
ment Scale,85 I am not aware of any functional childhood scale testing muscle endurance. 
Although the Childhood Myositis Assessment Scale showed good psychometric proper-
ties85,86 and measures an important aspect of mitochondrial myopathy, there is an impor-
tant ceiling effect and children need to be cooperative and motivated to complete the test. 
Other suggestions for newly to develop scales include a paediatric mitochondrial disease 
quality of life scale, analogous to the adult scale,87 where possible with limited proxy-report.
Other possible adaptations include goal attainment scaling, an  individualised outcome 
measures to evaluate the achievement of pre-specified domain and goals (e.g. ‘ I would 
like to eat without the assistance of my caretakers. I rate my improvement a 3 when I am 
able to eat fully independently, a 2 when I need assistance with soup, a 1 if I’m able to 
complete at least 50% of my meal without assistance and a 0 if I don’t improve at all.’) or 
combinations of instruments or summed items which can be used as a single end point. 
Judging treatment effects based on pre-defined changes in a set of personalised outcome 
measures facilitates the inclusion of larger, more heterogeneous populations into the study, 
without losing the ability to detect small but relevant treatment effects. These personalised 
adaptations may be extremely relevant in these complex multi-system disorders.
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Selection of outcome measures
After completion of the above mentioned studies, a set of outcome measures can be 
selected, based on the psychometric properties, relevance and burden to the patient, 
and feasibility in multi-centre studies (Box 2).16,69,88,89
Box 2: The ideal outcome measure…
…reflects a clinically relevant outcome or change in disease severity
…has been validated for the specific study protocol (i.e. study population, 
    time to second measurement)
…has acceptable test–retest reliability 
…is sensitive to change
…has an acceptable patient burden 
…serves a broad age group
…assesses a large range of abilities
…is relevant to the largest possible phenotypic spectrum
…has little cultural bias 
…has little (or a known and stable) practice effect
…is not highly dependent on voluntary effort
…has natural history data available for intended population
…is easy to execute with a limited amount of training
Preferably, the choice for a specific (set of) outcome measure(s) is not made by a single 
doctor or research team, but by a team of key opinion leaders consisting of doctors, 
methodologists, regulators, industry representatives and patient - and parent repre-
sentatives from various institutions, using a clear pre-defined protocol based on which 
decisions will be made.90 
Since the low prevalence of mitochondrial disorder will probably require multi-centre, 
multi-national trials, involving international experts in an early stage is of main impor-
tance. When executing such an international trial, differences between sites should be 
minimised despite e.g. the large number of evaluators and language differences.91 
Therefore, special care should be taken to guarantee training for all raters and to test 
and diminish inter-rater reliability. If patients are too scattered around the world, one 
might think of relocating patients and their families to the study site or of a combination 
of centralised pre- and post treatment evaluations in combination with assessments 
which can be performed using telemedicine or devices to quantify functional abilities.92 
International agreement on which outcome measures to use for specific populations is 
also indicated for the collaboration in natural history studies. More and more patients 
are diagnosed with genetic defects associated with mitochondrial disease. As illus-
trated in our study in nuclear encoded Complex I deficiency, there is a wide hetero-
geneity between patients with the same gene defects. The standardised evaluation of 
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these patients in natural history studies using clinically relevant outcome measures will 
provide both information for interpreting clinical trials as for communicating the prog-
nosis in relevant terms to patients and families. 
Clinical Trial Design In Paediatric Mitochondrial Disease
The selection of outcome measures is just one of the aspects of designing a clinical 
trial. As for the selection of outcome measures, the selection of a study population 
and study design is highly dependent on the research question. For this discussion, 
I assume that a non-specific improvement in disease severity, energy levels en motor 
functioning is expected after application of the drug. 
Study population
To draw correct conclusions about the efficacy of treatment with a low number 
of patients (small sample size), the variance between subjects should be as low as 
possible. In other words, we would like to include a homogeneous cohort of patients, 
with similar genotype and phenotype, similar disease stage, similar organs involved 
and similar expected effect of treatment, without the use of other medication, liver- of 
kidney failure (one of the recommendations in Chapter 1). Phenotypically homogeneous 
mitochondrial syndromes with an acceptable prevalence (e.g. Leber’s Hereditary Optic 
Neuropathy) are rare and none of these syndromes is paediatric. Moreover, because 
of the previously described challenge of selecting end points for children who are not 
able to communicate effectively or to follow instructions, I suggest that efficacy of drugs 
should be studied primarily in adults with mitochondrial disease. Since children are no 
small adults, the administration of drugs to children requires separate studies on formu-
lation, pharmacokinetics and therapeutic effects. Although the efficacy of the drug is 
already proven when these paediatric studies are conducted, the quality of the study 
should still be sufficient to prove the drug’s pharmacokinetics, safety and efficacy. To 
improve the quality of the efficacy study, I will make some recommendations regarding 
the study population. 
Some rare, more or less homogeneous paediatric mitochondrial syndromes exist, such 
as Barth syndrome, a mitochondrial membrane disorder caused by a mutation in the 
TAZ gene. Barth syndrome seems to have a reasonably homogeneous phenotype with 
skeletal muscle weakness, cardiomyopathy, neutropenia, and growth delay.93-97 Since 
Barth syndrome is a mitochondrial membrane disorders, the OXPHOS dysfunction may 
be classified as secondary to the membrane disruption. Kearns Sayre syndrome is 
another more or less homogeneous mitochondrial syndrome characterised by opht-
halmoparesis, pigmentary retinopathy, deafness, muscle weakness, ataxia, and cardiac 
conduction block.98 The progression of the disease seems to be fairly stable.99 The fact 
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that this syndrome affects mostly mentally-competent children and adolescents facili-
tates the feasibility and the ethical acceptability of the study, although a separate study 
will have to be performed in neonates, infants and young children.
Another option is to include all children within a certain age group with mitochond-
rial disorders, regardless of their genetic or biochemical diagnosis, but with very strict 
clinical inclusion criteria. Examples of these would be for example: a stable disease 
course in the past year; able to follow instructions such as hopping on one leg or rota-
ting a pen in the hand; a 6MWT between the 5th and 10th percentile for age or height; 
and/or a GMFM score between 15 and 25%. 
Although measuring reliably in children is challenging, treatment effects may be expected 
to be even larger compared to adults because of higher neuroplasticity.27 Especially in 
children, effects and side effects should be monitored closely after approval of the drug, 
to select patient groups in which the balance between effect and side effects is nega-
tive, not only to reduce the pressure on the financial resources100 but also since long 
term effects of drugs are mostly poorly characterised.
Study design
Since the classical randomised controlled clinical trials generally require large numbers 
of patients, especially in heterogeneous populations, several alternative trial designs 
are available.101-103 
The use of a cross-over design, stepped-wedge, or a n-of-1 trial minimises variance 
and confounding and guarantees exposure to active treatment, which facilitates recruit-
ment of patients. In all three designs, the patient undergoes both active treatment and 
placebo treatment and is used as its own control. Whereas cross-over and stepped 
wedge studies aim to determine the efficacy of a drug, an n-of-1 study aims to deter-
mine the effect of a drug within a single subject. The results of multiple n-of-1 studies can 
be used in a meta-analysis.103 Cross-over, stepped wedge, and n-of-1 designs can only 
be applied if the disease status is expected to be similar between the start of the first 
and the second treatment phase, they can only be applied in clinically stable paediatric 
mitochondrial disorders. Moreover, if the duration of the intervention and the wash-out 
period are short and no long-term effects of treatment are expected (i.e. minimal carry-
over effect), the cross-over design and n-of-1 trial designs may be of great value when 
confirming drug efficacy in mitochondrial disease. Where feasible, larger and phenotypi-
cally homogeneous cohorts can be analysed in cross-over studies. Chosing the metho-
dodlogically less solid stepped wedge design is only acceptable if substantial long-term 
effects of treatment (carry-over) are expected. In rare mitochondrial syndromes or those 
with a heterogeneous phenotype, n-of-1 trials are most suitable. In both cases, patients 
with an obviously oscillating disease course should be excluded.
429
When choosing any of these designs, several other methodological issues should be 
covered. First of all, the sequence of the placebo and the active treatment phases should 
be randomised to correct for confounders such as seasonal influences and (unexpected) 
learning effects. In case of group comparisons, such as in a cross-over study, randomi-
sation should be stratified based on predefined criteria, in order to create comparable 
groups. Secondly, since all of the above mentioned study designs are subject to report 
bias, blinding of both investigators and patients is of great importance, especially in case 
of subjective end points. Thirdly, the end points used in these trials should be harmonized 
over individuals and/or groups to be able to draw conclusions about the overall efficacy 
of the drug. Finally, since the outcome measure is applied multiple times within the same 
subject, the instruments should be tested for learning processes, which is expected to be 
the case for e.g. the A6MCT and the 6MWT. 
Another adaptive trial design is the Bayesian trial design, which provides more clinically 
intuitive results. In contrast to the confidence intervals and p-values provided by the 
frequentist designs, this design provides probabilities that a predefined change occurs 
(e.g. the chance of a 10% higher GMFM after 4 weeks of active treatment compared to 
placebo is 23%). Although this design might still be unfamiliar to regulatory authorities and 
collaborators, its flexible design and required smaller samples sizes provides promising 
design for phase 3 trials. 
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Conclusion
The field of clinical mitochondrial medicine has been gaining momentum in the past 
decade. We have accomplished that it is now widely accepted that patients shouldn’t be 
bothered by low-quality studies. The responsibility of the international expert centres is now 
to set guidelines for high quality studies and to facilitate improvements in trial design, e.g. 
by harmonizing outcome measures. Naturally, the decision on which end points to use for 
natural history studies and clinical trials should be guided by the research question and 
taken by an expert panel and based on data obtained from experiments such as those in 
this thesis.
For drug trials in the near future, I would suggest to determine the efficacy of the drug 
in adults with mitochondrial disease first, followed by a high-quality paediatric study. To 
determine the efficacy of a drug in children, I would suggest either a randomised, place-
bo-controlled, double-blinded Bayesian design in all children with mitochondrial disease 
or a randomised, placebo-controlled, double-blinded cross-over study in a more homo-
geneous and clinically stable cohort of children. The efficacy can be determined either by 
the minimal important difference in a primary outcome measure or by pre-defined changes 
in a personalised set of end points. Both approaches require more experience with outcome 
measures in children with mitochondrial disorders, which is still an important topic of our 
ongoing research.
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The aim of this thesis was to contribute to the knowledge on which outcome measures 
should be used in future clinical trials in children with mitochondrial disorders. This led 
to the following research goals: i) to explore which the symptoms and disabilities asso-
ciated with mitochondrial disease should be measured in clinical trials from a patients’ 
and from a doctors’ perspective; ii) to systematically select instruments from literature 
that could be used to cover these symptoms and disabilities; iii) to validate these instru-
ments in patients with mitochondrial disorders; and iv) to develop new instruments 
for domains, which seem important but are not covered. This thesis started with a 
general introduction into mitochondria, mitochondrial disease and mitochondrial medi-
cine including the methodological challenges associated with the testing of potential 
medicines in this group of disorders.
Studying interventions in mitochondrial disorders: past, present and future
Part I of this thesis focused on the methodological quality of pharmacological inter-
vention studies performed in patients with mitochondrial disorders and the selection of 
clinically relevant and robust outcome measures for children with mitochondrial disease 
from literature.
 
Chapter 1 critically reviewed the existing literature on treatment studies in mitochon-
drial disease. Although a large number of studies (1,039) were found, only 35 of them 
included more than five patients. When the methodological quality of these studies 
was rated, only 4 out of 35 studies had high-quality design. None of these high-quality 
studies had a positive outcome. Maybe even more worrying, many poor-design studies 
reported a positive influence of treatment on a non-predefined biomarker of unclear 
clinical significance, suggesting reporting of positive studies only. On the other hand, 
over the years, there was a promising trend towards higher-quality studies. Based on 
these results, recommendations for future studies in mitochondrial disease were formu-
lated, including the use of validated, clinically meaningful and pre-specified primary 
end points and the development of biomarkers that are indicative of clinically relevant 
outcomes. 
Chapter 2 laid the groundwork for our subsequent studies. Using a questionnaire 
which was sent to all children seen in the Nijmegen Centre for Mitochondrial Disorders, 
we have made an inventory of the most burdensome complaints in of patients and their 
caretakers. In the 78 patients and caretakers who filled out the questionnaire, we found 
a high prevalence of tiredness and lack of energy, developmental delay, hypotonia, and 
balance problems. The most burdensome complaints reported by the cohort overall 
were tiredness, lack of energy, muscle weakness, speech and language problems, and 
epilepsy (as rated by children) as well as developmental delay and behavioural problems 
(mentioned by the parents). When the most burdensome complaints were rated only in 
the patients in which the symptom was present, epilepsy, hearing loss, depression, and 
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headache were amongst the most burdensome complaints for children. Strikingly, of 
the parents with a child with behavioural problems, 60% reported this symptom among 
their 3 most burdensome complaints, compared to 39% for epilepsy (rank number 2). 
When the treating physicians were asked which symptoms they estimated to be most 
burdensome to children with mitochondrial disorders and their parents, most paediatri-
cians correctly mentioned fatigue, developmental delay, and muscle weakness, but the 
impact of e.g. speech and language problems and behavioural problems was underes-
timated. For this reason, we recommend to involve a sounding board of patients and/
or caretakers in the development of clinical trial protocol design. After all, from a patient 
perspective, only they will know the feasibility of the protocol as well as the clinical rele-
vance of the end point used. 
The complaints and symptoms rated as most burdensome in Chapter 2 were used in 
Chapter 3 to select outcome measures. By systematic review of the published liter-
ature we made an inventory of the existing instruments. Subsequently, by using the 
experience in clinically similar disorders such as neuromuscular disorders and cere-
bral palsy, we indicated the psychometric properties of the available test. Finally, using 
strict criteria adopted by the Food and Drug Administration, we composed a toolbox 
consisting of 33 instruments with good face validity. Part of these instruments are clin-
ically tested in Part III. 
Natural disease course 
Part II of this thesis described the natural history of two groups of patients with mito-
chondrial disorders: those with a mutation in one of the nuclear genes leading to 
Complex I deficiency, and those with a mutation in mitochondrial DNA, the m.3243A>G 
mutation. One of the main goals was to make a rational choice on which population to 
include in the outcome measure validation studies. 
In Chapter 4, the disease course of 130 patients with a nuclear encoded Complex 
I deficiency was described. Although these patients have some clinical features in 
common (they usually present within the first year of their lives with failure to thrive and 
severe neurological disease), the heterogeneity is striking. Many patients with Complex 
I deficiency and Leigh syndrome are described, but the course of the disease and the 
involvement of organs other than the brain is unpredictable and heterogeneous. Even 
within the same family, the clinical and biochemical phenotype may vary widely. This 
review showed that there is huge phenotypical heterogeneity within patients with the 
same genetic condition, in patients with the same biochemical condition and in patients 
with the same clinical syndrome. Therefore, we could not suggest a homogeneous 
population to perform our validation studies in. 
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Chapter 5 studied 82 m.3243A>G carriers, a genetically homogeneous, but biochem-
ically and clinically heterogeneous population. Although the m.3243A>G mutation was 
previously known as the MELAS (mitochondrial encephalopathy lactic acidosis and 
stroke-like episodes) mutation, we only detected three patients with MELAS syndrome 
in our cohort. The vast majority of the carriers (68%) suffered from Maternally inherited 
diabetes and deafness (MIDD), either or not in combination with muscle complaints 
or multi-organ involvement. This study again showed a huge clinical variability in 
m.3243A>G carriers. However, since such a high number of patients are available (we 
currently have ~150 carriers in our cohort), we have used this cohort for our surrogate 
marker validation studies. 
Validation studies
Part III aimed to test several of the outcome measures selected in Chapter 3 in patients 
with mitochondrial disorders.
In Chapter 6 we’ve tested the feasibility of the accelerometer, a device able to measure 
acceleration in a 3 dimensional plane. We asked 17 patients and 16 healthy controls to 
wear accelerometers on the upper and lower arm, the trunk and the upper leg during 
two weekend days at home. We found that children with a mitochondrial disease take 
more rest and have a lower peak intensity of movement, compared to age- and gender 
matched controls. When four patients and four healthy controls were tested again in 
a different season with different weather, similar results were obtained (good test-re-
test reliability). Since tiredness and lack of energy are among the most burdensome 
symptoms for patients and accelerometry is an objective and universally applicable 
measurement in a home instead of a laboratory situation, we think this is a promising 
and highly clinically relevant outcome measure for heterogeneous cohorts of children 
with mitochondrial disease. However, technical issues such as hardware failures, the 
labour intensity of the analyses and the correction for wheelchair movement need to be 
addressed before being applied in a clinical trial setting. Moreover, the study protocol 
should limit the external factors influencing the activity of the child during the measured 
weekend. 
Since the scale which was available to rate general mitochondrial disease severity was 
not designed to monitor disease severity during intervention studies, we developed 
a new general Mitochondrial Disease Scale for children in Chapter 7. This score, the 
International Paediatric Mitochondrial Disease Scale (IPMDS), was designed and vali-
dated in collaboration with various international colleagues. The final questionnaire 
consisted of three domains: i) complaints and symptoms; ii) physical examination and 
iii) functional tests. The test was feasible, reliable and valid in a highly heterogeneous 
population of 17 children of various ages with mild, moderate and severe disease and 
functional disabilities from five centres around the world. In young children, the raters 
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experienced some difficulties in ‘translating’ the questions, but this did not hamper 
reliability. More studies have to be executed to know from which age the IPMDS is 
applicable. Because of the enormous heterogeneity in clinical phenotype, we expect 
that measures for general mitochondrial disease severity may be more generally appli-
cable than symptom specific measures. Therefore, the IPMDS may be of use (as a 
secondary outcome measure) in future clinical trials. Although the inter-rater variability 
of the IPMDS is good, I would suggest depending on one or two well-trained raters only. 
The 6-minute walking test (6MWT) is a widely used functional outcome measure for chil-
dren with neuromuscular disease. In Chapter 8 we’ve tested an alternative for this test, 
namely the (motor-)assisted 6-minute cycling test (A6MCT), in nine ambulatory children 
with OXPHOS dysfunction. Two children were not able to complete the test because 
of difficulties understanding the test, behavioural problems and/or attention deficit. For 
another two patients, face validity was low because the stability of the bicycle seemed 
to be the limiting factor in the number of revolutions made (due to a lack of coordination 
and relative high strength). Based on these results, we concluded that the A6MCT is 
not useful for ambulatory children with OXPHOS dysfunction. Because the test showed 
good face validity in children with more severe muscle weakness and the A6MCT with 
the legs correlate do the 6MWT, we still think this is a promising outcome for the small 
population of non-ambulatory children who are able to complete a 6-minute task. 
Chapter 9 assessed the feasibility and validity of 2-dimensional speckle tracking 
echocardiography (2DSTE) in 30 adult m.3243A>G carriers of which two subsequent 
echocardiograms were available. In 60 echocardiograms obtained as part of clinical 
care, the deformation of the myocardium was assessed using 2DSTE. Speckle tracking 
was feasible in 90% for longitudinal strain and for 57% in circumferential strain and 
radial strain. Circumferential and radial strain showed low face validity (low number of 
high quality images; suboptimal tracking) and were therefore rejected for further anal-
ysis. Global longitudinal strain had good face validity and was abnormal in 53 – 68% 
(depending on reference values used) of all carriers. Twenty-three (77%) patients could 
be included in the follow-up study. The difference between the first and the second 
global longitudinal strain measurement exceeded the measurement variance in 39% of 
the cases with time-intervals varying between 1.2 and 3.0 years. Based on these data, 
we concluded that 2DSTE is a promising outcome measure for future clinical studies 
and that 2DSTE should be tested in more detail in a prospective (intervention) study.
In Chapter 10, the value of fibroblast growth factor 21 (FGF21) as a surrogate measure 
for mitochondrial disease severity was tested in a cohort of 99 adult m.3243A>G 
carriers. Although there was a moderate correlation between FGF21 and general mito-
chondrial disease severity, a correlation between the change of FGF21 and the change 
in general mitochondrial disease severity over time lacked. Therefore, we decided that 
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this biomarker can not be used to monitor disease progression in m.3243A>G carriers. 
In Chapter 11, we came to the same conclusion for Growth and Differentiation Factor 
15 (GDF15). Since GDF15 was previously described as a biomarker for cardiac disease, 
we also evaluated the correlation between the concentration of GDF15 and myocardial 
deformation (measured by the same method as described in Chapter 9). Although 
GDF15 cannot be used as a biomarker for general mitochondrial disease severity, the 
moderate correlation between the concentration of GDF15 and myocardial deformation 
might suggest that it can be used as a biomarker for mitochondrial cardiomyopathy. 
Final remarks
This thesis concluded with a general discussion including future perspectives. Although 
we cannot draw solid conclusions on which end points to use in future clinical trials, I 
make some cautious recommendations on which outcome measures to use in future 
clinical trials as well as on clinical trial design. First of all, I recommend to confirm the 
efficacy of a drug in adult patients with mitochondrial disease, before a high-quality 
study evaluating the efficacy, safety and pharmacokinetics in the paediatric popula-
tion is initiated. For the paediatric trial, I would recommend either a randomised, 
placebo-controlled, double-blinded Bayesian design in all children with mitochondrial 
disease or a randomised, placebo-controlled, double-blinded cross-over study in a 
more homogeneous and clinically stable cohort of children. As end points for clinical 
trials in paediatric mitochondrial disease, I recommend further optimisation and eval-
uation of the accelerometer, the IPMDS, the Gross Motor Function Measure (GMFM), 
2DSTE, the Pediatric Evaluation of Disability Inventory (PEDI), the 6MWT, and the timed 
function tests. These studies are currently ongoing. 
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In deze samenvatting geef ik eerst een korte inleiding over mitochondriële ziekten en 
waarom het zo noodzakelijk is een medicijn voor deze aandoeningen te ontwikkelen. 
Vervolgens zal ik toelichten welke uitdagingen zich voordoen als het effect van een 
potentieel medicijn getest wordt. Ten slotte zal ik toelichten wat dit proefschrift bijdraagt 
aan onze kennis met betrekking tot het testen van potentiële medicijnen in deze groep 
patiënten.
Mitochondriële ziekten worden ook wel energiestofwisselingsziekten genoemd. Voor 
bijna alle processen die in ons lichaam plaatsvinden is energie nodig. Deze energie 
wordt aangeleverd via voedingsstoffen zoals koolhydraten, vetten en eiwitten en door 
de cellen omgezet in chemische energie waar de cel wat mee kan. Deze chemische 
energie wordt ook wel adenosine trifosfaat (ATP) genoemd. ATP wordt gemaakt in de 
energiefabrieken van de cel, de mitochondriën. ATP wordt niet alleen gebruikt om te 
bewegen en te functioneren, maar ook om de cellen in ons lichaam te onderhouden. 
Een mens zet ongeveer zijn eigen lichaamsgewicht in ATP om per dag! Mitochondriën 
zijn onderdelen van de cel, naast bijvoorbeeld de celkern en de eiwit producerende 
organellen. De mitochondrieën leveren de energie voor de andere celonderdelen om 
goed te kunnen functioneren. Het aantal mitochondrieën per cel varieert, afhankelijk 
van de energiebehoefte van de cel: de hersenen, het hart, de lever en de skeletspieren 
bevatten veel mitochondrieën, terwijl de huid er veel minder bevat. De meeste lichaam-
scellen bevatten ongeveer 500 tot 2000 mitochondrieën. 
Een mitochondrion bestaat uit twee membranen die door een ruimte zijn gescheiden 
(Figuur 1). Rondom deze membranen kunnen drie compartimenten onderscheiden 
worden: de binnenkant van het mitochondrion (matrix), de buitenkant van het mitochon-
drion (de vloeistof in de cel, het cytosol of cytoplasma) en ruimte tussen de membranen 
(de tussen-membraan ruimte). Het binnenmembraan heeft uitstulpingen naar binnen 
waardoor het sterk geplooid is. Hierdoor heeft het een groot oppervak, wat van groot 
belang is voor de energieproductie die hier plaats vindt. 
Figuur 1. 
Een artist impression van een mitochondrion met een dubbele membraan, waarvan de binnenste 
geplooid is. 
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Figuur 2. 
In een cel zitten vele mitochondriën. Op de binnenmembraan van de mitochondriën zitten de eiwitcom-
plexen die energie maken. 
Lichaamscellen hebben de in de mitochondrieën geproduceerde energie nodig om 
goed te kunnen functioneren. Als een van de eiwitcomplexen niet goed werkt ontstaat 
er een energietekort, waardoor cellen en organen onvoldoende kunnen functioneren. 
Meestal wordt het niet goed functioneren van een eiwitcomplex veroorzaakt door een 
genetische afwijking. Deze worden meestal óf van beide ouders geërfd (autosomaal 
recessief) óf alleen van de moeder (mitochondriële overerving; tijdens de bevruchting 
worden de mitochondrieën van de vader verwijderd). De eerstgenoemde DNA foutjes 
verdelen zich gelijk over het hele lichaam. De DNA fouten van de moeder kunnen in 
wisselende percentages (heteroplasmie) per cel aanwezig zijn. 
Patiënten met een verminderd vermogen om energie te produceren, een mitochondriële 
ziekte, hebben meestal klachten van de organen die het meest energie verbruiken, 
Het produceren van energie is een ingewikkeld proces dat begint met het afbreken 
van voedingsstoffen zoals koolhydraten, vetten en eiwitten in kleine stukjes. Tijdens de 
afbraak wordt acetyl-coA geproduceerd, waaraan in de citroenzuurcyclus energierijke 
elektronen worden onttrokken. Deze elektronen worden door een vijftal grote eiwit-
complexen (Complex 1 tot 5 (I-V); Figuur 2) op de mitochondriële binnenmembraan 
omgezet in ATP. 
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zoals de hersenen, het hart, de ogen, de lever en de skeletspieren (Figuur 3). De 
uitingsvormen van deze ziekten kunnen extreem verschillend (heterogeen) zijn, niet 
alleen tussen patiënten, maar ook binnen één patiënt gedurende zijn leven. Aankomend 
artsen wordt geleerd dat ze moeten denken aan een mitochondriële aandoening bij 
‘elk onverklaard symptoom, van elk orgaan, op elke leeftijd, met iedere vorm van over-
erving’. De oorzaak voor deze grote verschillen is nog niet helemaal duidelijk.
Kinderen zijn vaak het meest ernstig aangedaan. Sommige kinderen overlijden als ze 
pas geboren zijn, anderen zijn ernstig geestelijk en lichamelijk gehandicapt. Er zijn ook 
kinderen die normaal presteren op school, maar zich slecht in kunnen spannen. De 
ziekte kan zich ook op latere leeftijd openbaren en heeft dan meestal een milder beloop.
Er is op dit moment nog geen behandeling voor deze patiënten, maar er zijn wel een 
groot aantal studies in patiënten uitgevoerd. Echter, als je deze studies op een rijtje zet 
(Hoofdstuk 1), blijken slechts 12 van de meer dan 1000 studies op een wetenschap-
pelijk acceptabele manier te zijn uitgevoerd, waarvan er slechts 4 aan de hoogste stan-
daarden voldoen! De meeste studies voldeden niet aan de juiste methodologie (geran-
Figuur 3. 
Overzicht van de organen die het meest frequent zijn aangedaan bij patiënten met mitochondriële 
ziekten. Van boven naar beneden: de hersenen, de ogen, het hart, de lever, de maag en darmen, de spieren 
en de zenuwen. 
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domiseerde gecontroleerde studies), hadden een hoge mate van bevooroordeeldheid 
(bias) of waren maar in een handvol patiënten uitgevoerd.
 
Een belangrijk aspect van het goed uitvoeren van een klinische studie is het selecteren 
van uitkomstmaten. Uitkomstmaten zijn de tests die de onderzoekers uitvoeren om 
het effect van de behandeling te beoordelen. Voorbeelden van uitkomstmaten zijn 
vragenlijsten, bloedtesten, conditietesten of beeldvorming. Het is belangrijk dat deze 
uitkomstmaten betrouwbaar en valide zijn. Immers, als je uitkomstmaat onafhankelijk 
van het ziekteproces verschillende waarden aanneemt, is het lastig te bepalen welk 
effect bepaald werd door het geteste medicijn. 
In dit proefschrift heb ik op een wetenschappelijke en systematische manier bestudeerd 
welke uitkomstmaten geschikt zouden kunnen zijn voor het meten van het effect van 
therapie bij kinderen met een mitochondriële ziekte. Hiervoor ging ik eerst na welke 
klachten patiënten ervaren en welke klachten zij als meest belangrijk beschouwen 
(Hoofdstuk 2). De meest belastende klachten bleken vermoeidheid, gedragsstoor-
nissen, moeite met spreken, epilepsie en spierzwakte. Ook rapporteerden ouders dat 
hun kinderen erg veel beperking in het functioneren in het dagelijks leven ervaren. Een 
opvallende bevinding van deze studie was dat als de behandelend artsen gevraagd 
werden welke klachten zij dachten dat ouders en patiënten het meest belastend zouden 
vinden, dit niet volledig overeen kwam met de klachten die als meest belastend werden 
gerapporteerd. 
Naast een inventarisatie van de gerapporteerde klachten van de kinderen die wij 
vervolgen, werd ook het natuurlijk verloop van de klachten in twee verschillende 
groepen patiënten onderzocht. In patiënten met een mutatie in een van de kern genen 
die zorgen voor een verminderde werking van het eerste complex van de oxidatieve 
fosforylering, zagen wij dat patiënten ontzettend van elkaar verschillen (Hoofdstuk 
4), en dat zelfs binnen families met dezelfde genetisch afwijking totaal verschillende 
klachten kunnen voorkomen. Wij concluderen in dit overzichtsartikel dat er niet alleen 
binnen patiënten met hetzelfde genetische en biochemische defect, maar ook binnen 
patiënten met hetzelfde klinische syndroom een enorme variabiliteit is. Het gebruiken 
van een van deze indelingen om vergelijkbare groepen samen te stellen is dus van 
weinig belang. Daarom kozen wij ervoor om alle kinderen met mitochondriële aandoe-
ningen mee te laten doen aan onze validatie studies.
Ook bij patiënten met de meest voorkomende mutatie in het mitochondriële DNA (de 
m.3243A>G mutatie) zagen wij een enorme variatie in betrokken organen en ernst van 
de klachten en beperkingen (Hoofdstuk 5). Echter, aangezien het aantal dragers van de 
m.3243A>G mutatie zo groot was, leek dit toch een van de meest geschikte populaties 
om onze studies in te doen.
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Met in ons achterhoofd de klachten die voor patiënten het meest belangrijk waren en 
daarnaast de klachten die in studies in het natuurlijk beloop veel bleken voor te komen, 
keek ik welke instrumenten er op dat moment beschikbaar waren voor het meten van 
de eerder gevonden klachten (Hoofdstuk 3). Hierbij heb ik me met name gericht op 
die instrumenten die een klacht meten die relevant is voor de patiënt, zoals uithoud-
ingsvermogen, motorische capaciteiten, zelfverzorging en kwaliteit van leven. Omdat 
er binnen het onderzoek naar mitochondriële ziekten nog weinig aandacht besteed 
was aan dit onderwerp, hebben wij hierbij gekeken naar de resultaten in andere ziekten 
zoals Duchenne spierdystrofie of aangeboren hersenbeschadiging. 
De hierboven geselecteerde uitkomstmaten, zoals een ondersteunde fietstest en een 
bewegingsmeter, heb ik vervolgens getest in patiënten met mitochondriële ziekten 
(Hoofdstuk 6-11). Hierbij keek ik naar de haalbaarheid in de beoogde patiëntenpopu-
latie, de betrouwbaarheid en de relevantie van de test voor de patiënt.
Wij vroegen 17 kinderen met een mitochondriële ziekte tijdens een weekend een aantal 
bewegingsdetectoren te dragen (Hoofdstuk 6). Voor de meeste kinderen was het 
haalbaar de meters gedurende het hele weekend te dragen. Vergeleken met de 16 
gezonde kinderen van dezelfde leeftijd en hetzelfde geslacht die wij gemeten hebben, 
bewogen kinderen met mitochondriële ziekten minder, hadden zij minder hoge pieken 
in hun bewegingspatroon en namen zij meer rust. Voordat de bewegingsdetectoren 
gebruikt kunnen worden in toekomstige studies, moeten er echter nog wel een aantal 
technische problemen worden opgelost. Daarnaast moeten externe factoren die het 
bewegingspatroon van het kind beïnvloeden tijdens het meten zoveel mogelijk worden 
uitgeschakeld.
Omdat er geen maat is om de algemene ziekte-ernst van kinderen met een mito-
chondriële ziekte te vervolgen in studies waarbij het effect van een medicijn getest 
wordt, ontwikkelden wij hiervoor een meetinstrument (Hoofdstuk 7). Deze vragenlijst, 
de IPMDS, werd ontwikkeld en getest in samenwerking met internationale collega’s 
en bestaat uit 3 onderdelen: de klachten van de patiënt, het lichamelijk onderzoek 
en de functionele mogelijkheden van de patiënt. Bij de studie door 15 internationale 
collega’s bleek dat de IPMDS haalbaar, betrouwbaar en valide leek in een heterogene 
groep met 17 kinderen van verschillende leeftijden en met verschillende aandoeningen 
en maten van beperking. Ook jonge kinderen konden betrouwbaar gemeten worden, 
al moeten we nog wel onderzoeken vanaf welke leeftijd de IPMDS goed lijkt te meten. 
Aangezien er weinig testen zijn die bij alle kinderen haalbaar zijn en een klinisch rele-
vante beperking of symptoom meten, lijkt algemene ziekte-ernst een veelbelovende 
uitkomstmaat. Gezien de goede meeteigenschappen van de IPMDS kan deze goed 
voor dat doel gebruikt worden. 
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Ik testte ook een ondersteunde fietstest, waarbij kinderen gevraagd werden om 
gedurende 6 minuten zo veel mogelijk rondjes te maken met hun armen of benen 
(Hoofdstuk 8). Hieruit bleek dat als de kinderen nog goed in staat waren om 6 minuten 
te lopen, deze test minder geschikt leek. Ook was de test niet haalbaar in kinderen met 
een ernstige ontwikkelingsachterstand, gedragsproblemen of concentratieproblemen. 
Aangezien er maar weinig kinderen zijn die te zwak zijn om 6 minuten te lopen, maar 
zich wel gedurende 6 minuten in kunnen zetten voor een fietstest, heeft het testen van 
de ondersteunde fietstest niet de hoogste prioriteit.
Ten slotte deed ik twee onderzoeken in volwassen dragers van de m.3243A>G mutatie. 
Wij analyseerden hartecho’s met een techniek waarbij de vervorming van de hartspier 
uitgedrukt kan worden in een getal (Hoofdstuk 9). Hieruit bleek dat meer dan de helft 
van de dragers een afwijkende vervorming van de hartspier had. Toen wij de vervorming 
van de hartspier na enige tijd weer hebben gemeten, leken wij ook in staat veran-
deringen op te merken. Dit zal echter nog bevestigd moeten worden in grotere studies. 
Ik testte bij deze dragers ook twee biomarkers (Hoofdstuk 10 en 11), stoffen die in het 
bloed gemeten kunnen worden en waarvan gedacht werd dat zij iets zeggen over de 
aanwezigheid en de ernst van de ziekte. Aangezien de spreiding van de concentratie 
van de biomarkers niet veel leek te zeggen over de ernst van de ziekte, concludeerde 
ik dat deze nog niet gebruikt kunnen worden als uitkomstmaat.
Ik sluit af met een discussie van de onderzoeksresultaten, waarbij ik ook naar de 
toekomst kijk. Hierin doe ik aanbevelingen voor het gebruik van uitkomstmaten in 
toekomstige studies en schuif ik voorzichtig een aantal tests naar voren waarvan ik 
denk dat ze het verloop van de ziekte het best in kaart zullen brengen. Daarnaast doe 
ik de aanbeveling om medicijnen in volwassenen te testen, alvorens het effect van deze 
medicatie op kinderen te bepalen.
Met het onderzoek gepresenteerd in dit proefschrift hoop ik een aanzet gegeven te 
hebben tot het verbeteren van de kwaliteit van klinische studies in kinderen met een 
mitochondriële ziekte. Door het onderzoeken van de uitkomstmaten voordat er een 
studie uitgevoerd wordt, hopen we te voorkomen dat studies worden uitgevoerd 
waarvan van tevoren al gezegd had kunnen worden dat de resultaten niet waardevol 
zullen zijn. 
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Het zit erop! Een mooie en dynamische periode waarin ik veel geleerd heb en veel 
interessante en leuke mensen ontmoet heb. Ik wil iedereen dan ook bedanken voor 
deze mooie tijd, zowel degenen met wie ik samen heb mogen werken, als degenen die 
me daarbuiten weer de energie en motivatie gaven om er weer vol tegenaan te gaan. 
Prof. Dr. J.A.M. Smeitink, Beste Jan. Om kansen te grijpen moet je ze wel eerst krijgen. 
Ik ben dankbaar voor de zichtbare lol die je eruit haalt om de jongere generatie kansen 
te geven en te laten groeien. Bedankt ook voor het vertrouwen dat ik mijn originele 
AGIKO-project idee een eigen richting mocht geven en voor de vrijheid m’n ideeën uit 
te werken tot projecten. Ook in minder plezierige periodes was je flexibel en dacht je 
mee over nieuwe kansen, welke uiteindelijk denk ik goed gaan uitpakken. Je bevlogen-
heid heeft me echt gestimuleerd om ook het uiterste uit mezelf te halen! Ik hoop dat je 
binnenkort een medicijn kunt afleveren dat wel werkt.
Dr. I.J.M. de Groot, Beste Imelda, wat fijn dat jij mijn co-promotor was! Jouw combi-
natie van klinisch inzicht en contacten met bewegingswetenschappers hebben onder 
andere tot ons mooie accelerometer project geleid. Maar ook je kritische commentaren 
op protocollen en manuscripten heb ik erg gewaardeerd; je wist altijd de vinger op de 
zere plek te leggen, wat de kwaliteit van de stukken echt ten goede is gekomen. Ik 
hoop dat we nog vele jaren kunnen samenwerken!
Leden van de manuscriptcommissie, Geachte prof. dr. F.G.M. Russel en prof. dr. J.P.H. 
Drenth, hartelijk dank dat ik mijn proefschrift ter beoordeling aan u mocht voorleggen. 
Dear professor P.F. Chinnery, thank you for your time spent in judging my thesis and the 
effort of coming to Nijmegen for my defence (and King’s Day). 
Ook wil ik de patiënten bedanken die vrijwillig hun spaarzame energie investeerden voor 
de medische wetenschap: bedankt jongens en meiden dat jullie mee wilden doen aan 
de fietstest, de IPMDS en het onderzoek met de bewegingsdetector! Ik hoop dat we 
snel een medicijn vinden dat jullie meer energie zal geven om te spelen, te leven en jullie 
toekomstdromen waar te maken. Beste ouders, dank ook voor de tijd dus jullie wilden 
investeren in wéér een ziekenhuisbezoek. Nu ik zelf moeder ben van een kleintje met 
bijna onbeperkte energie kan ik me iets beter voorstellen hoe het zou moeten zijn als 
hij dat niet had. Nog een extra reden om hard door te werken aan een medicijn! Ook 
de deelnemers aan de nationale inventarisatie van m.3243A>G dragers wil ik hartelijk 
bedanken voor hun tijd en moeite. 
Ik wil ook mijn collega’s bedanken voor de prettige samenwerking, waarvan sommige 
mensen in het bijzonder. Mirian, met je betrokkenheid bij zowel individuele patiënten als 
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de opzet van de klinische trial ben je voor mij echt hét voorbeeld van een academische 
arts. Lonneke en Maaike, dank voor jullie bijdrage aan de accelerometer studie en de 
IPMDS pilot. Lotte en Lonneke, hopelijk wordt de LHON studie net zo’n succes als 
de m.3243A>G studie! Floor, leuk dat je mee wilde doen met het instructiefilmpje van 
de IPMDS! Marion, we leerden elkaar pas echt kennen in het gammele stapelbedje in 
Stockholm. Fantastisch hoe jij de PCS studie en de coördinatie van de MitoRoute op je 
hebt genomen! Annette, dank voor je vliegensvlugge antwoorden en met het versturen 
van de 143 brieven voor Hoofdstuk 2. Gera, wat goed dat we jouw versterking hebben 
aan het Mito-front. 
Professor Morava, beste Eva, zonder jouw aanstekelijke enthousiasme was ik nu zeker 
niet geweest waar ik nu ben. Miski, in 2003 liepen we samen intro, nu gaan we in 
hetzelfde veld promoveren. De lunches met jou en Thatjana, waren altijd even een 
momentje van ontspanning (en bovendien was ik dan ook weer op de hoogte van alle 
relevante roddels). Succes met de afronding van jullie proefschriften en opleidingen. 
Paul, de betrokkenheid waarmee jij het m.3243A>G cohort door de jaren heen gezien 
hebt zou wel eens het verschil zou kunnen gaan maken tijdens onze eerste trial. Heel 
veel succes met het afronden van je opleiding en proefschrift. Wing and Sheila, thanks 
for your help with the IPMDS during your traineeship in Nijmegen.  Ilse, wat ben ik blij 
dat ik je bij het begin van je derde collegejaar een sms’je gestuurd heb. Niet alleen om 
je hulp en gezelligheid tijdens de fietstesten, IPMDS studie en accelerometer pilot, maar 
ook omdat ik blij ben getuige te zijn geweest van de groei die je hebt doorgemaakt als 
arts, onderzoeker en als mens. Esmee, wat een zeldzaam goede onderzoeksstage 
heb je neergezet! Heel veel succes met je co-schappen, je wordt vast een fantastische 
dokter. Robert, je inzet getuigt van een ambitieniveau waar je ver mee gaat komen. Heel 
veel plezier in the Big Apple. Pascal, al ben je nog geen jaar betrokken bij het onder-
zoek, je voelt als volwaardig onderdeel van ons team.
Dear co-authors, thank you very much for your contribution to the articles included in 
this thesis! Merel, dankjewel voor je hulp bij het corrigeren van ons review toen ik in 
Zuid-Amerika was, daardoor heb ik onbezorgd van m’n sabbatical kunnen genieten. 
Leuk ook om ‘jouw’ fietstest in onze populatie te proberen! Snel een keer samen thee 
doen? Arjen, Kenneth en Hans, jullie technische/Matlab ondersteuning op gelegen en 
minder gelegen momenten was onmisbaar voor het accelerometer project. Doorlène, ik 
heb ongelofelijk veel bewondering hoe je tussen je behandelingen door het biomarker 
onderzoek toch in eigen hand hebt weten te houden. Anjo, fijn dat je de patiënten voor 
de accelerometer studie accelerometer studie voor ons wilde beoordelen. Richard, 
dank voor het geduldig antwoorden van al mijn mailtjes over lijsten met patiënten 
(gelukkig wordt het nu makkelijker gemaakt dit vanuit de kliniek zelf bij te houden). 
Livia, dankjewel voor je begeleiding tijdens het exploreren van de voor mij totaal nieuwe 
wereld van de 2DSTE. Gert, respect voor je engelengeduld met de vele (extra) analyses 
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voor onze 2DSTE studie. Je spoedcursus Access die ook in mijn andere onderzoeken 
goed van pas is gekomen! Ik wil alle leden van het MitoRoute team bedanken voor 
hun enthousiaste inzet tijdens de zorg, maar daarmee ook de dataverzameling voor 
toekomstig uitkomstmaten-onderzoek. Ook de mensen van het spierlab, bedankt voor 
het analyseren van de dubbele spierbiopten voor de studie die helaas dit proefschrift 
niet gehaald heeft. Thanks also to all members the Radboud Center for Mitochondrial 
Medicine, although I couldn’t always fully understand, your blots and complexomes 
learned me a lot about basic mitochondrial medicine.
Kees en Maroeska, dank voor jullie vertrouwen dat ik aan de opleiding tot klinisch farma-
coloog kon beginnen, ondanks dat ik niet aan het standaard profiel voldoe. Charlotte, 
Wim, Simone, Marysia, Adi, Sofie, Jenneke, Marjolein en de andere ‘opleidelingen’, 
dank voor de gezelligheid en interactie op de dinsdag. Dat maakt de opleiding levendig! 
Kinderartsen uit het CWZ, bedankt voor de tijd dat ik klinische ervaring bij jullie op heb 
mogen doen. Het was wat korter dan gepland, maar ik heb veel geleerd, over de prak-
tijk, maar vooral ook over mezelf. 
Niet alleen de mensen in het ziekenhuis verdienen een dankwoordje, misschien juist de 
mensen buiten het ziekenhuis die mijn blikversmalling overleefd hebben.
Union Dames 5, na een dag achter de computer was het altijd heerlijk om achter een 
balletje aan te kunnen hollen en eventuele frustraties weg te slaan. Bedankt voor de 
ontspanning en de gezelligheid elke dinsdag en zondag. Suze, Dien, An en Ing, echt 
super bijzonder dat we al sinds 2003 samen spelen en nu ook nog ‘lotgenoten’ in het 
combineren van het moederschap en alle andere ballen die hoog gehouden moeten 
worden. Die baby-date moet er nu echt maar es komen! 
Myrtille, Bianca en Inge, gezellig om samen alle fasen tijdens en na de co-schappen te 
doorlopen. Lieve Myrtille, ik ben ongelofelijk trots dat je doorgezet hebt en toch doctor 
bent geworden. Je wordt vast een fantastische gynaecoloog! Gezellig dat jullie nu om 
de hoek wonen, daar moeten we vaker gebruik van maken. Lieve Inge, leuk om zo veel 
levensfasen samen te doorlopen. Succes met de afronding van jouw boekje! Beste 
Bianca, we moeten snel weer een theetje doen!
Beste Marlies en Koen, dankjulliewel voor onze ontspannen bacchanaaltjes met veel 
vinologisch en culinair plezier. Beste Dirk, Claudia en Emme, dankjulliewel voor de 
ontspannen koppels-met-kind middagen. Na Bolivia en München nu met z’n vieren 
moeten we binnenkort maar eens wat met z’n achten ondernemen! 
Laura en John, ondanks de afstand voelen jullie toch altijd dichtbij. Lieve Lau, je hebt al 
m’n dipjes en euforische momenten van dichtbij mee mogen maken. Ook als we elkaar 
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even niet zien, ben je er voor mijn gevoel altijd. Ik zou niet weten wat ik zonder je zou 
moeten. Dankjewel dat je ook nu weer aan mijn zijde staat. Beste John, dankjewel dat 
je zo goed voor m’n beste vriendinnetje zorgt. Binnenkort weer Zeeland, Kaatsheuvel of 
Disneyland? Lieve Joris en Sophia, wat een vrolijk stel zijn jullie! Ik gun jullie als jullie groot 
zijn een vriendje of vriendinnetje die net zo lief is als jullie moeder (en vader natuurlijk).
Lieve Marij en Harrie, dank voor al jullie steun de afgelopen jaren. De weekenden in 
Tilburg en later ook in Villa Gladiola Nova waren altijd een welkome afwisseling op 
het drukke leven op het werk. Harrie, zonder jou was het niet mogelijk geweest om in 
ons paleisje te wonen, waar we de rust vinden om hard te kunnen werken. Marij, hoe 
fijn is het om een tweede moeder te hebben die er zichtbaar van geniet om voor ons 
gezinnetje te zorgen! Een ding is zeker: dit boekwerk was er nog niet geweest zonder 
jullie hulp!
Erik en Nienke, jullie hebben heel wat te verduren gehad met die ingewikkelde 
gesprekken over geneeskunde tijdens de kerstdiners. Broertje, ook al zien we elkaar 
niet zo vaak, we weten dat we er op de belangrijke momenten voor elkaar zijn. Zo ook 
vandaag weer. Dankjewel dat je mijn paranimf wil zijn! Ik hoop dat we er nog veel mooie 
momenten mogen delen. Schoonzusje, bedankt dat je mijn kleine broertje gelukkig 
maakt! Tebbe, lieve rouwdouwer, woef!
Pap en mam, jullie waren altijd geïnteresseerd in waar ik mee bezig was, ook al werd 
het soms een beetje veel jargon en afkortingen in huis als Dennis en ik langs kwamen. 
Pap, ondanks dat je me altijd ontraden hebt dokter te worden, denk ik dat – via wat 
omwegen - ik toch m’n plek en uitdaging gevonden heb. Dat eigenwijze karakter heb 
ik ook niet van een vreemde, hè? Mam, dankjewel voor je interesse in mijn wel en wee 
en de ontspannen momentjes, eerst in de stad en nu bij ons thuis aan de eettafel. Pap, 
mam, dit proefschrift is de kroon op jullie opvoeding waarin ik altijd mocht ontdekken 
en zelluf mocht doen en waar nieuwsgierigheid, doorzettingsvermogen en een kritische 
houding gestimuleerd werden. Hopelijk kan ik de volgende generatie Vriensjes ook de 
autonome opvoeding geven die ik van jullie kreeg.
Dennis, Lief Aapje, dank voor je hulp als co-auteur en statistiekleraar, al was dat niet je 
belangrijkste bijdrage. Ik ben echt gegroeid door je stimulans het uiterste uit mezelf te 
halen en buiten mijn comfortzone te treden. Met de Argentijnse tango heb je me hele-
maal bewezen dat dingen die je niet kunt ook heel leuk kunnen zijn! Bovendien: waar 
vind je iemand die het ook een goed idee vindt om 5 dagen op een boot te zitten om 
pinguïns en orka’s in het wild te zien, zwanger-en-wel midden in de nacht af te dalen in 
de krater van een actieve vulkaan, 5 uur om te rijden om tenminste sámen in de file te 
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staan en om met een baby van 4 maanden rond te reizen in Zuid-Afrika? Er is een hoop 
veranderd de afgelopen jaren…en ik zou nooit meer anders willen! 
Lieve Thijntje, jouw nieuwsgierigheid, ondernemingsdrang, vrolijkheid en energie geven 
elke dag kleur. Wat ben ik blij dat jij er bent!

List Of Publications
and Curriculum Vitae
465
Peer Reviewed Original Articles
Koene S, Timmermans J, Weijers G, de Laat P, de Korte CL, Smeitink JAM, Janssen 
MCH, Kapusta L. Is 2D speckle tracking echocardiography useful in detecting and 
monitoring myocardial dysfunction in adult m.3243A>G carriers? – a retrospective 
pilot study. Submitted
Koene S, Hendriks J, Dirks I, de Boer L, de Vries MC, Janssen MCH, Smuts I, Fung 
CW, Wong VCN, de Coo IFM, Vill K, Klopstock T, Falk M, McCormick EM, McFarland R, 
Hendriks JCM, de Groot IJM, Smeitink JAM. The International Paediatric Mitochondrial 
Disease Scale. Submitted
Koene S, Dirks I, van Mierlo E, de Vries PR, Janssen AJWM, Hendriks JCM, Smeitink 
JAM, Bergsma A, Essers HJMN, Meijer K, de Groot IJM. The value of using 3D accel-
erometry in estimating daily physical activity in children with mitochondrial disease. 
Submitted
Verhaak CM, de Laat P, Koene S, Tibosch M, Rodenburg RJT, Knoop H, Janssen 
MCH, Smeitink J. Quality of life, fatigue and mental health in patients with the 
m.3243A>G mutation correlates with genetic characteristics and disease manifestation. 
Orphanet Journal of Rare Diseases, in press
Wong SSN, Goraj B, Fung CW, Vister J, de Boer L, Koene S, Smeitink J. The Nijmegen 
Centre for Mitochondrial Disorders Paediatric Mitochondrial Disorder MRI Score. 
Submitted 
Dirks I, Koene S, Verbruggen R, Smeitink JAM, Jansen M, de Groot IJM. The assisted 
6-minute cycling test: an exploratory study in children. Conditionally accepted for publi-
cation by Muscle & Nerve
Koene S, de Laat P, van Tienoven DH, Vriens D, Sweep FCGJ, Timmersmans J, 
Kapusta L, Janssen MCH, Smeitink JAM. Serum GDF15 levels correlate to mitochon-
drial disease severity and myocardial strain, but not to disease progression in adult 
m.3243A>G carriers. JIMD Reports Epub May 13 2015 
Dirks I, Koene S, Verbruggen R, Smeitink JAM, Jansen M, de Groot IJM. An Exploring 
study of the psychometric properties of the Assisted 6-Minute Cycling Test in Children 
with Neuromuscular and Mitochondrial Disorders. Submitted for publication
466
List of Publications
Koene S, de Laat P, van Tienoven DH, Vriens D, Sweep FCGJ, Timmersmans J, 
Kapusta L, Janssen MCH, Smeitink JAM. Serum GDF15 levels correlate to mitochon-
drial disease severity and myocardial strain, but not to disease progression in adult 
m.3243A>G carriers. JIMD Reports 2015;24:69-81.
Koene S, de Laat P, Vriens D, van Tienoven DH, Brandt AM, Sweep FCGJ, Borm G, 
Janssen MCH, Smeitink JAM. Serum Fibroblast Growth Factor 21 (FGF-21) levels in 
adult m.3243A>G carriers: clinical implications. Neurology. 2014 Jul 8;83(2):125-33.
Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, Hirano M, 
Zeviani M, BIndoff LA, Wai Man PY, Hanna M, Varelli V, McFarland R, Majamaa K, 
Turnbull DM, Smeitink J, Chinnery PF. New treatments for mitochondrial disease: no 
time to drop our standards. Nat Rev Neurol. 2013 Aug;9(8):474-81.
Koene S, Wortmann SB, de Vries MC, Jonckheere AI, Morava E, de Groot IJM, 
Smeitink JAM. Developing outcome measures for paediatric mitochondrial disorders: 
which complaints and limitations are most burdensome to patients and their parents? 
Mitochondrion, 2013 Jan;13(1):15-24.
de Laat P, Koene S, vd Heuvel LPWJ, Rodenburg RJT, Janssen MCH, Smeitink JAM. 
Inheritance of the m.3243A>G mutation. J Inherit Metab Dis Reports, 2013;8:47-50.
de Laat P, Koene S, vd Heuvel LPWJ, Rodenburg RJT, Janssen MCH, Smeitink JAM. 
Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families 
carrying the m.3243A>G mutation. J Inherit Metab Dis 2012 Nov;35(6):1059-69.
Morava E, Gardeitchik T, Kozicz TL, de Boer L, Koene S, de Vries MC, McFarland R, 
Roobol T, Rodenburg RJT, Verhaak CM. Depressive behaviour in children diagnosed 
with mitochondrial disorder, Mitochondrion 2010 Aug;10(5):528-33
Peer Reviewed Review Articles
Koopman WJH, Beyrath J, Fung CW, Koene S, Rodenburg R, Willems PHGM, 
Smeitink JAM. Pathophysiology of OXPHOS-related disorders in children: Towards 
development of clinically relevant treatment strategies. EMBO Mol. Med, in press.
Fung CW, Koene S, Willems, PHGM, Koopman WJH, Smeitink JAM. Emerging roles 
of mitochondrial translation, coenzyme Q biosynthesis, membrane homeostasis and 
quality control in mitochondrial oxidative phosphorylation: clinical phenotypes, diag-
nostic signatures and treatment strategies. Submitted
467
Koene S, Jansen M, Verhaak CM, de Vrueh RLA, de Groot, IJM, Smeitink JAM. 
Towards harmoisation of Outcome Measures in Children with Mitochondrial Disorders. 
Dev Med Child Neurol. 2013 Aug;55(8):698-706.
Koene S, Rodenburg RJ, van der Knaap MS, Willemsen MAAP, Sperl W, Laugel 
V, Ostergaard E, Tarnopolsky M, Martin MA, Nesbitt V, Fletcher J, Edvardson S, 
Procaccio V, van den Heuvel LPWJ, Smeitink JAM. Natural disease course and geno-
type-phenotype correlations in Complex I deficiency: what we learned from the more 
than 130 known cases. J Inherit Metab Dis. 2012 Sep;35(5):737-47
Koene S, Smeitink JAM. Metabolic manipulation. J Inherit Metab Dis. 2011 
Apr;34(2):315-25
Breuer ME, Koopman WJ, Koene S, Nooteboom M, Rodenburg, RJT, Willems, PJ, 
Smeitink JAM. The role of OXPHOS dysfunction in the development of neurologic 
disease. Neurobiology of Disease 2013 Mar;51:27-34.
Koene S, Willems PHGM, Roestenberg P, Koopman WJH, Smeitink JAM. 
Mouse models for mitochondrial complex I deficiency, J Inherit Metab Dis. 2011 
Apr;34(2):293-307
Koene S, Smeitink JAM. Mitochondrial medicine, entering the era of treatment, J 
Intern Med. 2009; 265(2):193-209. 
Peer Reviewed Case Reports and Case Series
Koene S, Matthyssens L, Buzing C. Een zuigeling met twee huiddefecten ter plaatse 
van de kleine fontanel. Praktische Paediatrie; June 2013; 92, 
Koene S, Rodenburg R, Peters G, de Groot I, Verhaak C, Kapusta L, Smeitink JAM, 
Morava E. Muscle pain, fatigue and hypothermia at night in association with mito-
chondrial dysfunction, Journal of Paediatric Neurology, 2009, 1304-2580
Koene, S, Kozicz, TL, Rodenburg RJT, Verhaak C, de Vries MC, van den Heuvel 
LPWJ, Smeitink JAM, Morava E. Major depression in adolescent children consecu-
tively diagnosed with mitochondrial disorder, J Affect Disord.;114(1-3):327-32. 2009
Koene, S, Kluijtmans L, Wevers R, Pasch M, Mock D, Morava E. Biotin-sensitive 
3-methylcrotonylglycinuria in a patient with severe growth delay, ectodermal abnor-
malities, neonatal progerioid appearance and developmental delay. Clin Dysmorphol.; 
17(3):195-8 2008
468
List of Publications
Other Publications
Koene S, Smeitink J. Mitochondrial Medicine. Editorial. J Inherit Metab Dis. 2011 
Apr;34(2):247-8
Vogel RO, Koene S, Smeitink JAM. Complex I. Book Chapter in Scriver, the Online 
Metabolic and Genetic Basis of Inherited disease. http://www.ommbid.com; McGraw 
Hill Publications.
Books
Mitochondrial Medicine – a clinical guideline, Saskia Koene and Jan Smeitink; ISBN 
978.90.81.773. First press 2011, second press 2013.
 

Curriculum Vitae

472
Curriculum Vitae
Curriculum Vitae
Saskia Koene was born on the 19th of May 1984 in Weert, the Netherlands. She grew 
up in Wageningen. After her graduation, she started her medical training at the Radboud 
University in Nijmegen. During her medical training she was involved in various commit-
tees of the Medical Faculty Students Association Nijmegen (MFVN) and the Nijmegen 
Students Hockey Association (NSHC) Apeliotes, was quaestor of the 11th lustrum of 
the MFVN (2007) and was the praeses of NSHC Apeliotes (2004 – 2005).
Saskia started her research career as a student-researcher under supervision of Eva 
Morava, MD, PhD in 2007. They wrote her first two papers together and set up the 
excellent student trajectory, in which young students get the opportunity to participate 
in scientific research. After one year, Jan Smeitink, MD, PhD, MAE, took on the super-
vision and they laid the foundations for her PhD project and published three literature 
reviews during Saskia’s internships. Her final internship was at Great Ormond Street 
Hospital in London under supervision of P.E. Clayton, MD, PhD and A. Male, MD, PhD. 
In 2010, she started a PhD project on the treatment of mitochondrial diseases at the 
Nijmegen Centre for Mitochondrial Disorders, still under supervision of Jan Smeitink. 
Her PhD trajectory was funded with an Qualified Doctor Training to become a Clinical 
Researcher (AGIKO) grant by Netherlands Organisation for Health Research and Devel-
opement (ZonMW). When the focus on outcome measures became more clear, Imelda 
de Groot, MD, PhD agreed to be a co-supervisor. For her studies, Saskia received 
financial support from the Tjallingh Roorda foundation, Stofwisselkracht and the Rare 
Disease Foundation. She was invited to present her work in several lectures on national 
and international conferences. Saskia was also part of the National Institute of Health 
(NIH) working group on common data elements for mitochondrial disease. To create 
more awareness and understanding of mitochondrial diseases, she wrote the booklet 
‘Mitochondrial Medicine - a clinical guideline’ together with Jan Smeitink. During her 
PhD trajectory, she also followed 9 months of clinical training in paediatrics in the Cani-
sius Wilhelmina hospital under supervision of Ben Semmekrot, MD, PhD. 
Since January 2015, she has started her training in clinical pharmacology with a focus on 
orphan drugs trial design, under supervision of Kees Kramers, MD, PhD and Maroeska 
te Loo, MD, PhD. Besides, she is continuing her research on outcome measures in 
mitochondrial disease. 
Saskia resides with Dennis in Nijmegen and they have a son, Thijn (12-10-2014). 
They’re expecting their second child in July 2016. She likes to travel the world with her 
family and to play field hockey.
